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Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of
the central nervous system, characterised by acute memory loss and
behavioural symptoms. The AD brain is characterized by the presence of senile
amyloid plaques associated with degenerating neurites and inflammatory
processes. The major protein component of these amyloid deposits is the
amyloid beta (Aβ) protein. The Aβ protein is a 40 or 42 amino acid cleavage
product of APP (Amyloid Precursor Protein) which is produced in low levels in
the normal ageing brain. Although senile amyloid plaques is the major
pathological hallmark of AD brains, accumulating evidence has been presented
to show that increased levels of soluble forms of Aβ42 correlate with the clinical
manifestations and severity of the disease. Increased accumulation (both
intracellular and extracellular) and toxicity of Aβ42 peptide in the brain play
pivotal roles in neurodegeneration and loss of memory functions in the AD
brain. Therefore reducing the toxicity of Aβ42 and increasing its clearance from
the brain has been considered to be main targets for AD therapeutics.
The search for a disease modifying therapy for AD has been very difficult
with the majority of agents failing in later stages of clinical trials. The incomplete
understanding of drug-target mechanisms and the lack of high-throughput
screening systems for identifying selective target based drugs have been some
of the main issues expressed for the failure of AD drugs. Yeast offer a simple
eukaryotic model for studying pathological mechanisms and compared to other
models there is availability of various experimental tools applicable for high
throughput analysis of protein-protein, gene-gene and gene-protein interactions
and associated cellular functions. It can also offer a versatile model for initial
screening in drug development for various human diseases, including AD.
Yeast models have been utilised for studying AD related proteins including APP
and its processing enzymes (secretases) and tau phosphorylation.
The broad aims of this work were to develop yeast models for studying
toxicity of oligomeric Aβ42 peptide and investigate intracellular accumulation of
aggregated Aβ42. Furthermore, these models were utilized for examining
III

compounds which modulate Aβ42 structure/toxicity or promote its clearance
from cells.
Extracellular treatment of oligomeric Aβ42 was used for studying toxicity
in yeast. The uptake of extracellularly added Aβ42 peptide by yeast and its
localisation indicated that oligomeric Aβ42 mediated cell death was associated
with binding to the plasma membrane. It was shown that oligomeric Aβ42
inhibited the plasma membrane H+ATPase activity which may be one important
mechanism of oligomer Aβ42 mediated cell death in yeast. Further, this yeast
model was utilized for investigating the effects of dairy peptides on Aβ42
oligomerization and toxicity. It was shown that suppression of Aβ42
oligomerization lead to concomitant reduction in the toxic effects of Aβ42 in both
yeast and neuronal cells. In addition, studies in yeast showed that the
recombinant oligomer forming MBP-Aβ42 fusion protein (representing a more
stable form of oligomeric Aβ42) was toxic which was further validated in
neuronal cells. Overall, these studies established the use of yeast as a model
for studying oligomer Aβ42 toxicity.
Cells expressing green fluorescent protein tagged Aβ42 (GFP-Aβ42) as
a fusion protein was used for investigating intracellular accumulation of Aβ.
Yeast cells expressing GFP-Aβ42 showed punctate fluorescence and reduced
levels of expression suggesting that it is sequestered into vesicles which are
targeted for degradation. Further investigation revealed a key role for
intracellular degradation pathways such as the autophagy in this process and
enhancing this pathway was shown to reduce levels of GFP-Aβ42 aggregates.
Further, findings presented in this thesis also provided a novel mechanism of
action for a drug latrepirdine that has shown promise in AD trials. In yeast,
latrepirdine was shown to enhance autophagy and promote the clearance of
GFP-Aβ42. Further, preliminary data from an in vivo mouse model showed that
latrepirdine reduced peripheral levels of injected Aβ42 and promoted uptake
into liver, providing further evidence for a role of latrepirdine in enhancing Aβ
clearance.
Overall, the findings presented in this thesis have highlighted the
application of yeast models for investigating drug mechanisms and developing
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high-throughput methods for screening. Reducing oligomer Aβ toxicity and
enhancing its clearance in the brain are much sought after targets for
therapeutic interventions in AD. The use of the yeast models presented in this
work can therefore provide a greater scope for the search of novel AD drugs.
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Chapter 1
Introduction
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1.1

Alzheimer’s disease – Background

Alzheimer's disease (AD) is a progressive neurodegenerative disease of the
central nervous system and comprises approximately 80% of all dementia
cases in the elderly (Terry, 2006). Dementia is posing escalating societal and
financial burdens especially with the ageing generation. In 2007, 29.8 million
people worldwide had dementia, with this number expected to exceed 100
million by 2050 unless a cure or prevention is found. In 2005, the total
worldwide societal cost of dementia was estimated to be US$315.4 billion
including US$105 billion for care for a dementia population of 29.3 million in that
year. In Australia, AD is the second major cause of disability burden which
exerts an immense toll on the sufferers and care givers. It is currently estimated
that approximately 250,000 people are suffering from dementia in Australia and
the figure is predicted to almost quadruple by 2050 (Brookmeyer et al., 2007;
Ziegler-Graham et al., 2008). The cost of AD is predicted to increase from about
1% of GDP (gross domestic product) to more than 3% of GDP in the coming
decades (Access Economics 2003) representing a major burden to the health
care system.

1.2

Prevalence of AD

AD is the major cause of dementia worldwide with vascular dementia and
other neurodegenerative diseases such as Pick‟s disease, Parkinson‟s disease,
Frontotemporal dementia and diffuse Lewy-body dementia making up the
majority of the remaining cases (Aronson et al., 1991; Brookmeyer et al., 2007;
Ferri et al., 2005). The incidence of AD differs depending on the diagnostic
criteria used, the age of the population surveyed, and other factors, including
geography and ethnicity. Although AD is recognized as a major health crisis in
developed countries, its impact in developing countries is expected to be much
more severe (Brookmeyer et al., 2007; Ferri et al., 2005). Age is the major risk
factor for sporadic AD cases with a prevalence of approximately 5% among
those 65-69 years of age and increases with age to 40-50% among persons 95
years of age and over. Early-onset and genetic predisposition factors leading to
2

AD (mutations in APP, PS1, PS2) are comparatively less prevalent and
contribute to approximately 5% of the total AD cases (Hy and Keller, 2000;
Koedam et al., 2010; Koedam et al., 2008).

1.3

Clinical Manifestations and Diagnosis of the Disease

AD leads to a progressive deterioration of cognitive function starting with
loss of memory and judgement and eventually resulting in complete inability to
independently function in basic daily activities. The preclinical stage of AD is
inconspicuous and there are no reliable and valid symptomatic markers which
would allow an early diagnosis before the manifestation of irreversible loss of
memory. Clinical diagnosis of AD is more likely to be accurate only in the late
stages of severe cognitive impairment as other dementias have common
overlapping features. In the mild dementia stage, difficulties with declarative
memory are usually prominent, with less profound effects on daily activities. In
the moderate dementia stage, other cognitive domains are noticeably affected
including disturbances of thought, perception and behaviour. The patient is
completely dependent on the care-giver during the late stage of illness.
However, following clinical diagnosis of AD, life expectancy of the patient is
significantly reduced (Forstl and Kurz, 1999; Reisberg et al., 1987).

Identifying the disease at a clinical stage when the pathological damage is
not too severe to prevent functional recovery, or stabilization, is a major issue of
current research. Strategies for clinical diagnosis of AD include evaluation of a
detailed history of the type and course of symptoms combined with a battery of
neuropsychological assessments. In addition, imaging techniques such as
magnetic resonance imaging (MRI), computed tomography (CT) scans and
positron emission tomography (PET) are also currently being used in the
differentiation of the various forms of dementia (Karow et al., 2010). Since the
advent of these techniques, significant cognitive deficits may be detectable
before the typical cognitive, behavioral, and social criteria of AD caused
dementia are met (Howieson et al., 1997; Jacobs et al., 1995; Linn et al., 1995;
Masur et al., 1994; Storandt et al., 2006; Tierney et al., 2005). However, there is
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still a high degree of variability between these studies, and analytical techniques
need to be standardised. One major challenge for AD diagnosis and specific
biomarker discovery is the substantial overlap of major brain pathologies. The
indefinite relation between the amount of Aβ and tau pathology, the large
overlap of AD, synucleinopathies, and cerebrovascular pathologies are
problematic when interpreting a biomarker profile in individual patients. Exact
methods and thresholds for specific biomarkers in AD diagnosis are currently
not well defined. Establishing a model with characterized definitions of
diagnostic thresholds for specific biomarkers need to be incorporated.
Additionally, the model needs to be validated and calibrated (Dubois et al.,
2007).

1.4

Structural changes in the AD brain

Structural changes in the brain during aging are complex and not well
understood. Neurons maintain homeostatic control of essential brain functions,
including gene expression, synaptic transmission, and metabolic regulation.
During aging, there is a reduction in the complexity of dendrites and a host of
other subtle changes within the cortex that includes alterations in receptors, loss
of spines and myelin dystrophy, as well as alterations in synaptic transmission
which are observed in the neurons. It is suggested that these multiple
alterations in the brain may correspond to the age-related neuronal dysfunction
and decline in cognitive function. However in AD, where age is the major risk
factor, studies have demonstrated that neuronal losses in cortical and
hippocampal regions are more severe and possibly caused by distinct
pathological processes (Hof et al., 1997; Morrison and Hof, 2002; West et al.,
1994; West et al., 2004).

The post-mortem AD brain is considerably atrophied with enlarged ventricles
and extensive neuronal loss in the cortex and hippocampus compared to a
normal aged brain (Figure 1). Significant neuron and synapse loss in specific
brain regions is observed in the AD brain (Hof and Morrison, 2004; Hof et al.,
1997; West et al., 1994; West et al., 2004). Unlike in the normal aging brain,
4

neuronal loss is extensive in the neocortical and entorhinal regions of the AD
brain, accompanied by an approximate 45% decline in neocortical synapses
(Terry et al., 1991; Terry et al., 1981). An average neuronal cell loss of 68% in
the CA1 region of the hippocampus region of AD patients is observed compared
to age matched controls (West et al., 1994). Also, a significant reduction in
spine density and decrease in overall dendritic area in AD patients was
observed (Einstein et al., 1994; Ferrer and Gullotta, 1990; Moolman et al.,
2004)..
A

B

Figure 1: Representation of post mortem brain cross-section of (A) healthy
control and (B) AD patient. Differential characteristics are shown in the image.
The AD brain is featured by severely enlarged ventricles and shrinkage of the
5

cerebral cortical and hippocampal regions, which are responsible for memory
and cognitive functions.
1.5

Pathological lesions in the AD brain

Accompanying the selective damage in brain regions, distinguished
abnormal fibrous protein deposits are observed within the brains of AD patients
which

include

the

extracellular

senile

amyloid

plaques,

intraneuronal

neurofibrillary tangles (NFTs) and amyloid deposits in the walls of cerebral
blood vessels (cerebral amyloid angiopathy) (Figure 2). Amyloid deposition and
NFTs are also found in the neocortical, hippocampal, and entorhinal regions of
cognitively normal elderly people, although in fewer numbers and considered to
be largely non-pathogenic (Arriagada et al., 1992; Goldman et al., 2001; Kazee
and Johnson, 1998; Price et al., 1991) although it could be argued that these
individuals have the pre-clinical form of the disease and had they lived longer
would have exhibited clinical symptoms. In AD, however, the robust number of
plaques and NFTs is associated with dystrophic neurites and synaptic loss and
show increased distribution in specific regions of the brain (Braak and Braak,
1991; Price et al., 1991).

1.5.1 Senile amyloid plaques

The senile plaques in the AD brain consist of a central core of amyloid
deposits surrounded by dystrophic neurites together with reactive microglia and
astrocytes (Ma et al., 2010a; McGeer et al., 1994; Yasuhara et al., 1994). The
amyloid core is composed of straight, unbranching fibrils of 8-10nm diameter,
and display strong affinity to Congo red staining and resistance to proteolysis.
These properties are representative of a predominant cross-β sheet structure of
the polypeptide constituents of the plaque (Goedert and Spillantini, 2006).
The amyloid-β-protein (Aβ) has been found to be the main protein
component in the nucleating core of the senile plaques which is also the same
protein originally isolated from cerebral blood vessels (Glenner and Wong,
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1984a; Glenner and Wong, 1984b; Masters et al., 1985a; Masters et al.,
1985b). In addition to Aβ, other proteins accumulate within senile plaques,
including apolipoprotein E (ApoE), α2-macroglobulin, interleukins, components
of the complement system, α2-macroglobulin receptor, low-density lipoprotein
receptor-related protein, collagenous Alzheimer amyloid component (Griffin et
al., 1989; McGeer et al., 1989; McGeer et al., 1994; Namba et al., 1991;
Strauss et al., 1992; Thal et al., 1997). In addition to the insoluble senile
plaques, plaques of a more diffuse nature are also observed in the brain. In
contrast, the diffuse plaques show no association with abnormal neurites or
reactive glial cells and have few or no amyloid fibrils content. It is suggested
that diffuse plaques are an early stage of plaque formation (Goedert and
Spillantini, 2006). In AD, diffuse plaques are usually more abundant and
widespread throughout the CNS than typical senile plaques. However,
substantial amounts of these diffuse types of Aβ deposits are found in the limbic
and associated cortices in many healthy older humans (Dickson, 1997).

1.5.2

Neurofibrillary tangles

The dystrophic neurites surrounding the amyloid core of the senile plaques
contain paired helical filaments (PHFs) which are pairs of filaments (10nm in
diameter) strung into a left-handed helical structure (~80nm in diameter). These
PHFs constitute the main structural element of the neurofibrillary tangles
(NFTs). The NFTs comprise of hyperphosphorylated tau, a protein involved in
microtubule assembly and stabilization (Brion et al., 1985; Delacourte and
Defossez, 1986; Ihara et al., 1986; Iqbal et al., 1986). In the human brain, six
tau isoforms are produced from a single gene via alternative mRNA splicing
(Goedert et al., 1989). Based on the number of microtubule-binding repeats, the
isoforms are classified into two groups (three and four repeats: 3R, 4R
respectively). The nature of N-terminal inserts distinguishes the three isoforms
in each group. In tau filaments isolated from AD brains, similar levels of 3R and
4R isoforms are expressed which are present in similar proportions to those in
normal brains. Filamentous tau deposits are also found in a number of other
neurodegenerative diseases, including progressive supranuclear palsy (PSP),
7

corticobasal degeneration (CBD), Pick‟s disease, argyrophilic grain disease
(AGD), and Guam Parkinson dementia (GPD) [reviewed in (Lee et al., 2001)].
Hyperphosphorylation of tau leading to the disintegration of microtubules and
abnormal accumulation of tau proteins is common to these diseases and is
thought to be associated with toxicity (Avila, 2006). However the absence of
beta amyloid pathology distinguishes a majority of these diseases from AD.

The comparative relevance of these lesions in the pathogenesis of AD is
controversial. It has been widely acknowledged that senile plaques are a better
representative of AD pathology compared to NFTs (Terry et al., 1987).
Therefore, quantification of senile plaques, rather than of NFTs, forms the basis
of current post-mortem diagnostic criteria for AD (Khachaturian, 1985; Mirra et
al., 1991). Although senile plaques are widespread in the AD brain, they are a
poor indicator of cognitive decline and disease severity. Growing evidence has
indicated that the soluble oligomeric forms of Aβ are responsible for the loss of
memory functions in AD and a better correlate than plaques, of cognitive
decline and disease severity (Fonte et al., 2001; Lue et al., 1999; McLean et al.,
1999). The role of Aβ in neurodegeneration and cellular dysfunction in the AD
brain is discussed further.

8

Figure 2: AD pathological hallmarks (A) Senile plaques (SPs) indicated by
dense cores and radially oriented dystrophic neurites in entorhinal cortex. (B) A
typical neurofibrillary tangle in CA3. (C) Aβ protein immunohistochemistry
demonstrates frequent plaques in posterior cingulate cortex, accompanied by
cerebral

amyloid

angiopathy.

(D)

Immunohistochemical

stains

for

hyperphosphorylated tau show aggregation in NFTs and cortical dystrophic
neurites.

Scale

bars

indicate

50µm.

(Image

courtesy:

http://knol.google.com/k/lara/alzheimer-s-disease/Ing3X-NE/g1JpHQ).

1.6

Role of Aβ in Neurodegeneration

Although Aβ containing senile plaques are seen associated with dystrophic
neurites and reactive microglia, they are poorly correlated with the clinical
manifestations of the disease. Moreover, the quantitative correlations between
manual microscopic counts of amyloid plaques in post-mortem brain sections
and the severity of cognitive decline measured by neuropsychological tests are
fraught with methodological challenges. Counting plaques in two-dimensional
brain sections provides an inaccurate measure of Aβ load in the brain and is
likely to miss other small and heterogeneous Aβ-assembly forms. Specific Aβ
enzyme-linked-immunosorbent assays (ELISAs) coupled with western blotting
and mass spectrometry analysis has enabled a more sensitive and
comprehensive qualitative and quantitative assessment of Aβ forms in the brain.
Using these techniques, studies have identified that levels of soluble Aβ
correlate much better with the degree of cognitive deficits than plaque counts
(Fonte et al., 2001; Lue et al., 1999; McLean et al., 1999). Also the fact that
fibrillar amyloid plaques (~20–120-μm diameter) present much less Aβ surface
area to neuronal membranes compared to small diffusible forms of Aβ, indicates
that soluble assembly forms are better candidates for inducing neuronal
dysfunction than plaques containing amyloid fibrils (Haass and Selkoe, 2007).
Furthermore, „amyloid‟ structuring of proteins is thought to be a detoxification
strategy to mask the promiscuous surface of the toxic oligomeric building blocks
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(Carrell et al., 2008). Studies have also identified novel biological functions for
amyloidogenic protein fibrils in bacteria, fungi and even mammals (Kelly and
Balch, 2003).Supporting evidence from a range of studies in several
neurodegenerative diseases including AD, Huntington‟s disease, Parkinson‟s
disease, prion diseases and many other amyloidosis point to soluble protein
oligomers in the brain as an indicator of cognitive decline rather than the
insoluble fibrillar deposits (Ferreira et al., 2007; Glabe and Kayed, 2006; Popik
et al., 1999). It is also indicated that oligomeric and fibrillar assemblies maybe
formed via distinct mechanisms, possibly mediated by external factors (binding
ligands including other proteins, metals, lipids etc) [reviewed in (Bharadwaj et
al., 2009)].

1.6.1

Oligomeric forms of natural and synthetic derived Aβ

Amyloid β-protein (Aβ) is a proteolytic product of its larger parent protein, the
Amyloid precursor protein and is found in the brains and cerebrospinal fluid
(CSF) of both healthy normal individuals and those with AD (Citron et al., 1992;
Haass et al., 1992 ; Ida et al., 1996; Vigo-Pelfrey et al., 1993; Walsh et al.,
2000). Numerous isoforms of Aβ (Aβ1-42, Aβ4-42, Aβ1-40 and the 3pyroglutamate derivate of Aβ3-42 (pGluAβ3-42) constituting ~80% of total
species) have been detected in the brains of healthy, sporadic and familial AD
subjects. However the AD brain (both sporadic and familial cases) exhibit
markedly increased levels of the Aβ42 isoform. Distinct regional specific
differences are observed with the hippocampus exhibiting heavy A deposition
compared to the cerebellum which results in memory impairment (Portelius et
al., 2010; Portelius et al., 2009; Tekirian, 2001). Neurodegeneration in AD is
believed to be caused by self association of the Aβ42 molecules into toxic
isoforms due to its increased accumulation in the brain (Busciglio et al., 1992;
Geula et al., 1998; Pike et al., 1991a, b), and studies have clearly demonstrated
that aggregation of Aβ42 is essential for toxicity.
Reports indicate soluble oligomeric Aβ as an indicator of the scale of
cognitive deficits in AD (Cleary et al., 2005). In general, soluble oligomers are
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defined as Aβ assemblies that are not pelleted from physiological fluids by high
speed (>100,000g) centrifugation (Lue et al., 1999; McLean et al., 1999).
Oligomeric assemblies have been isolated from post-mortem AD brains, and
their presence correlated with memory loss (Cleary et al., 2005; Gong et al.,
2003). Intracellular and secreted soluble dimeric and trimeric oligomers have
been described in cultured cells (Podlisny et al., 1995; Walsh et al., 2000).
SDS-stable oligomers of varying sizes have also been detected in APP
transgenic mouse brain and human brain (Enya et al., 1999; Funato et al.,
1999; Kawarabayashi et al., 2004; Lesne et al., 2006; Roher et al., 1996). Such
natural Aβ oligomers can be resistant not only to SDS but also to the Aβdegrading enzymes like insulin degrading enzyme (IDE), which can only digest
monomeric Aβ (Walsh et al., 2002a). The presence of similar SDS-stable
dimers and trimers in the soluble fraction of human brain and in extracts of
amyloid plaques suggest that these SDS stable low n-oligomers (dimers and
trimers) of Aβ are the basic building blocks of insoluble amyloid deposits and
could be the earliest mediators of neuronal dysfunction.(Lesne et al., 2006))
reported that a unique and novel Aβ isoform (Aβ*56: 56-kD soluble Aβ42
assembly, dodecamer) as the key neurotoxic Aβ42 isoform responsible for
cognitive decline in APP overexpressing Tg2576 mice, based on its stability,
abundance and occurrence during memory decline. However, a more recent
study (Shankar et al., 2008) identified Aβ dimers from the soluble extract of AD
cerebral cortex tissues. This report specifically attributed Aβ dimers to the loss
of long-term potentiation (LTP), enhanced long-term depression, reduced
dendritic spine density in normal rodent hippocampus and memory disruption of
a learned behaviour in normal rats. Importantly this study showed that insoluble
amyloid plaque isolated from AD cortex did not impair LTP. However Aβ dimers
released from the plaques following solubilisation (TBS, SDS, formic acid)
showed neurotoxic properties similar to the soluble Aβ extracts, suggesting that
plaque cores are largely inactive but can sequester toxic Aβ forms. Both the
Lesne et al and Shankar et al studies identify different toxic Aβ species (dimer
or Aβ*56), which might reflect the species differences (mouse and human
respectively) and also the Aβ detection techniques employed. It is also
suggested that an array of soluble oligomeric Aβ species (ranging from dimers
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to dodecamers) may have similar neurotoxic properties associated with memory
impairment in AD.
A substantial amount of structural and functional information of Aβ comes
from studies using Aβ produced by solid phase peptide synthesis (SPPS).
Similar to naturally derived forms, Aβ42 solutions prepared from synthetic
lyophilized peptides have shown to form multiple forms ranging from
monomeric, oligomeric, fibrillar and many more other multimeric structures and
show neurotoxic properties. A large body of literature describes many types of
assembly forms of synthetic Aβ, including protofibrils (PFs), annular structures,
paranuclei, Aβ-derived diffusible ligands (ADDLs), globulomers and amyloid
fibrils [reviewed in (Bharadwaj et al., 2009)].
Although synthetic Aβ has been widely used for variety of experimental
purposes, the preparation and handling of the peptide solutions have not been
very straightforward. In addition to the heterogeneous and variable nature of
Aβ42 peptide, substantial compositional variation in Aβ produced by SPPS
resulting in experimental irreproducibility has been reported (Howlett et al.,
1995; Simmons et al., 1994; Soto et al., 1995a; Soto et al., 1995b). Most
lyophilized peptides contain salts which can complicate the initial solvation and
preparation of peptide stock solutions. In addition, these non-peptide
substances can alter the biophysical and biological behaviour of the peptide.
Preparation of a homogenous Aβ solution is quintessential; but Aβ can form
many different forms in aqueous state and the equilibrium and stability among
these assemblies are not entirely understood. Some controversy exists as to
the actual state of aggregate-free starting preparations. Chaotropic agents
([DMSO]), organic acids (TFA), organic solvents (trifluoroethanol [TFE] and
hexafluoroisopropanol [HFIP]), and sodium hydroxide (NaOH) all have been
used to solubilise and disaggregate lyophilized Aβ peptide (Teplow, 2006).
Causes of irreproducibility may include the aggregation state of the peptide in
the solid state (Fezoui et al., 2000) and immediately after reconstitution. There
are also some early studies regarding the variable behaviour of different peptide
stocks (Brining, 1997; May et al., 1992). Currently, a range of carefully
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optimized protocols for preparation of Aβ42 oligomers from synthetic lyophilized
stocks are available (Stine et al., 2010; Teplow, 2006).

1.6.2

Potential mechanisms of Aβ mediated toxicity

Over the past two decades extensive work on understanding the mechanism
of Aβ toxicity has been undertaken. Although Aβ is largely secreted from the
cell surface, it can be present in many cellular compartments. Consequently Aβ
has been found to be associated with disruption of several cellular functions
including mitochondrial activity (Butterfield et al., 2001 ; Dyrks et al., 1992;
Lustbader et al., 2004a; Palmblad et al., 2002), oxidative stress (Butterfield et
al., 2001 ; Martins et al., 1986), receptor mediated functions (Bhaskar et al.,
2009; Fuentealba et al., 2004; Pereira et al., 2004; Wei et al., 2002 ; Yaar et al.,
1997), disruption of Ca2+ homeostasis (Hartmann et al., 1994; Mattson et al.,
1993), membrane depolarization and disorder (Müller et al., 2001; Verdier et al.,
2004) and microglial activation (Giulian et al., 1996). Some of the well known
mechanisms of Aβ induced toxicity will be discussed here.

1.6.2.1

Mitochondrial dysfunction

The central nervous system (CNS) has a high metabolic rate, as it
consumes about 20% of oxygen inspired, even though it accounts for only 2%
of the body weight (Silver and Erecinska, 1998). This large metabolic demand is
because neurons are highly differentiated cells that need huge amounts of
adenosine tri-phosphate (ATP) for maintenance of ionic gradients across the
cell membranes and for neurotransmission. Since most neuronal ATP is
generated by oxidative metabolism, neurons critically depend on mitochondrial
function and oxygen supply (Ames, 2000; Erecinska et al., 2004). Conversely,
neuronal function and survival are very sensitive to mitochondrial dysfunction
(Fiskum et al., 1999; Nicholls and Budd, 2000).
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Growing evidence indicates that mitochondrial dysfunction may be an
important factor in AD pathogenesis. The AD brain is featured by altered
glucose metabolism, mitochondrial activity and morphology (Baloyannis et al.,
2004; Bubber et al., 2005; Duara et al., 1986; Haxby et al., 1986), and an
overall decrease in the number of mitochondria within vulnerable neurons (Hirai
et al., 2001). Studies have reported an intracellular interaction between Aβ and
ABAD (Aβ binding alcohol dehydrogenase). It was shown that Aβ accumulated
in the mitochondria of AD brain and altered the enzyme‟s active site and
prevented native dehydrogenase activity (Caspersen et al., 2005; Lustbader et
al., 2004b). These studies therefore provided evidence for the presence of a
mitochondrial pool of Aβ within the AD brain that also had the capacity to disrupt
normal mitochondrial functionality. Other groups also provide evidence for Aβ
accumulation in mitochondria within the brains of AD patients, rodent models,
and neuronal cells over expressing APP (Caspersen et al., 2005; Crouch et al.,
2005; Manczak et al., 2006). There is evidence that APP and γ-secretase
components are present in the mitochondria, indicating that Aβ could be
generated within mitochondria (Anandatheerthavarada et al., 2003; Devi et al.,
2006; Hansson et al., 2004). Alternatively, Aβ may accumulate in the
mitochondria due to decreased capacity to regulate Aβ levels. It has been
shown that the human mitochondrial metallo-protease PreP (presequence
protease) is capable of degrading Aβ (Falkevall et al., 2006; Stahl et al., 2002).
Whether a decline in the PreP activity is related to intracellular Aβ accumulation
or toxicity remains to be determined.

Several studies have shown that direct exposure of isolated mitochondria to
Aβ significantly impairs functionality of the mitochondrial electron transport
chain which is essential for the cell‟s energy requirement (Casley et al., 2002;
Crouch et al., 2005). Aβ has been shown to inhibit the COX (cyclooxygenase)
activity in vitro supported by reports that COX activity was decreased in the AD
brain (Chagnon et al., 1995; Mutisya et al., 1994). Aβ treatment has also been
shown to decrease mitochondrial membrane potential and respiration rates,
induce mitochondrial swelling, cytochrome c release, transition pore opening,
and mitochondrial ROS output [reviewed in (Crouch et al., 2008)]. Most of the
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Aβ related effects on mitochondria can contribute to neuronal dysfunction and
pathology in the AD brain. Aβ induced mitochondrial dysfunction is closely
associated with oxidative stress, which is considered a key feature in the
pathogenesis of AD.

1.6.2.2

Oxidative stress

Oxidative stress has been implicated as a major cause of neurotoxicity in a
number of neurodegenerative disorders including AD, and there is strong
evidence linking oxidative stress to Aβ. Oxidative stress occurs when free
radical production exceeds antioxidant defence systems, thereby leading to
oxidative damage to cellular components. Most free radicals within a cell
originate from reactive oxygen species (ROS) produced via the oxidative
phosphorylation within the mitochondria. As described above the CNS
consumes 20% of the total oxygen and therefore generates high levels of ROS.
The brain is rich in unsaturated fatty acids and comprised mostly of post-mitotic
tissue with limited regenerative capacity and a relatively poor antioxidant
system (Cooper and Kristal, 1997) which makes it particularly vulnerable to
oxidative stress. An initial report by Martins et al (Martins et al., 1986) described
an increase in activity of enzymes from the hexose monophosphate pathways in
post-mortem AD brain samples compared to age-matched controls, reflecting
the increased oxidative stress in the AD brain. Several reports following have
shown extensive oxidative damage in AD, including lipid peroxidation
(Butterfield et al., 2002; Sayre et al., 1997), oxidized proteins (Bissette et al.,
1991; Smith et al., 1991) nucleic acid damage (Gabbita et al., 1998; Lovell et
al., 1999) and advanced glycation end products (AGE) (Markesbery and Lovell,
1998; Perry et al., 2003).

Oxidative damage in AD may be a direct result of Aβ peptide accumulation.
The senile amyloid plaques in the AD brain are associated with oxidative
markers, mainly lipid peroxidation (Lovell et al., 1995; Mecocci et al., 1994). As
discussed above, Aβ mediated oxidative stress could be a result of the inhibition
of mitochondrial function. Alternatively, oxidative stress may involve direct
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production of ROS by Aβ. Aβ can cause neurotoxicity by production of ROS
(Behl et al., 1994). One of the widely known mechanisms of Aβ induced ROS is
via interaction with metals, mainly copper (Cu) (Curtain et al., 2001; Dong et al.,
2003). Aβ-Cu generated H2O2 can result in oxidative damage of lipids and
intracellular proteins. Aβ-metal interactions are also known to exacerbate
aggregation and potentiate toxicity in neuronal cells, which can be rescued by
catalase (Atwood et al., 2004; Barnham et al., 2004). Furthermore, neurons
depleted of essential antioxidants such as glutathione are more susceptible to
Aβ-Cu mediated toxicity (White et al., 1999). Overall, these studies indicate that
Aβ mediated generation of free radicals is possibly involved in the neuronal cell
death in AD. However reactive oxygen species (ROS) generation could also be
a result of tissue injury, and it is unclear whether this is a primary or secondary
event of Aβ mediated toxicity to cells in AD.

In addition to oxidative stress and mitochondrial stress many other
mechanisms of toxicity have been identified [review in (Harkany et al., 2000)].
Since Aβ has been shown to induce a variety of toxic effects in cells, it is
unclear whether the neurodegeneration and cognitive deficits observed in AD
are caused by disruption/loss of a particular cellular function or a collective
contribution of several toxic outcomes. Also different isoforms of Aβ
(predominantly fibrillar and oligomeric forms) have been shown to be toxic in
distinct pathways (Dahlgren et al., 2002). While Aβ42 may have been shown to
induce a variety of pathological events in the cell, it is possible that some of
them are not associated with the disease symptoms. Also, it is argued that the
high concentrations of Aβ peptide used in some studies may not represent the
actual levels that may be present at any point of time in the AD brain. And most
importantly, increased levels of soluble protein oligomers and synaptic loss in
the AD brain have been established as the main indicators of cognitive decline
rather than the insoluble fibrillar deposits. Therefore the role of Aβ in disrupting
synaptic function and promoting dendrite loss has gained much interest in
recent years.
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1.6.2.3

Synaptic toxicity

Memory impairment in AD is categorized by the loss of ability to form and
retain new episodic memories. Cognitive impairment is often attributed to
synaptic dysfunction and neuronal cell loss particularly in the cells
interconnecting the hippocampal formation with the associating structures
crucial for memory (Davies et al., 1987 ; Hyman et al., 1984). Depleted
neurotransmitters (Hyman et al., 1984), synaptic connections (Small et al.,
2001; Whitehouse et al., 1982) and quantitative correlations of postmortem
cytopathology with cognitive deficits indicate that synaptic loss is more robustly
correlated than the extent of cortical gliosis (Davies et al., 1987 ). An intensively
studied electrophysiological correlate of learning and memory is long-term
potentiation (LTP). LTP is a long-lasting enhancement in signal transmission
between neurons using repetitive and synchronous high frequency electrical
stimulation. It is an important phenomena underlying synaptic plasticity. As
memories are thought to be determined by modification of synaptic strength,
LTP is considered as one of the major cellular mechanisms that underlies
learning and memory (Bliss and Collingridge, 1993; Cooke and Bliss, 2006).
Several reports provide evidence that naturally secreted low-n Aβ oligomers
(Walsh et al., 2002a) and synthetically derived oligomeric Aβ42 (Lambert et al.,
1998) can inhibit the maintenance of hippocampal LTP. This effect has been
shown by treatment of hippocampal slices (Townsend et al., 2006) or by in vivo
microinjections in living rats (Walsh et al., 2002a), and can be specifically
neutralized by anti-Aβ antibodies in vivo (Klyubin et al., 2005). Reports indicate
that the induction of long term synaptic depression (LTD) affects hippocampal
plasticity and results in decreased dendritic spine volume (Nagerl et al., 2004;
Zhou et al., 2004). Although it is established that soluble Aβ oligomers can
inhibit LTP in the hippocampus, the effects of Aβ on the induction of LTD are
not well understood. Some reports show Aβ42 peptides to induce LTD in CA1 in
vivo (Cheng et al., 2009; Kim et al., 2001b; Li et al., 2009), whereas other
studies show no effect on LTD (Raymond et al., 2003; Wang et al., 2004).
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The biochemical mechanism by which soluble oligomers bind to synaptic
plasma membranes and interfere with signalling molecules that are required for
synaptic plasticity is unclear. Aβ oligomers can interact with membranes to
induce structural changes (Kremer et al., 2000), create ion pores (Demuro et
al., 2005; Kremer et al., 2000), enhance membrane permeability or ion
conductance (Kayed et al., 2004), modulate a wide array of ion channels
(Demuro et al., 2010), and osmotic flux (Demuro et al., 2010; Mattson and
Chan, 2003). Several studies have implicated disrupted cellular homeostasis to
neuritic dystrophia and blockage of intra neuronal signalling essential for
cognitive functions (De Fusco et al., 2003; Lingrel et al., 2007; Moseley et al.,
2007). The role of cation transporters has been previously reported in AD.
Decreased Na+/K+ ATPase activity was observed in APP (Amyloid precursor
protein) +PS1 (Presenilin 1) double transgenic mice (Dickey et al., 2005) and
Aβ causes inhibition of Cl-, Na+/K+ ATPase in neuronal cell cultures (Bores et
al., 1998; Mark et al., 1995; Yagyu et al., 2001). Interestingly, a recent study
showed that neuronal electrical activity stimulated BACE (β-secretase) and
therefore increased Aβ production, and the resulting increased levels of Aβ
depressed synaptic transmission (Kamenetz et al., 2003). Moreover, synaptic
activity in APP transgenic mice was correlated with the interstitial fluid Aβ
concentrations (Cirrito et al., 2005).
It is suggested that soluble Aβ oligomers may interfere with signalling
pathways downstream of certain NMDA (N-methyl-d-aspartate), metabotropic
glutamate

(mGluR)

or

AMPA

(α-amino-3-hydroxy-5-methyl-4-isoxazole)

receptors at synaptic plasma membranes (Snyder et al., 2005). It has also been
shown that oligomeric Aβ can interfere indirectly with LTP through an inhibition
of ubiquitin C-terminal hydrolase (UCH) (Gong et al., 2006). In addition to
extracellular Aβ, studies indicate that aberrant accumulation of Aβ within
neurons could also be involved in synaptic dysfunction. Aβ accumulation is
most prominent in distal neurites and synapses in the brains of AD transgenic
mice (Takahashi et al., 2002). Since accumulating Aβ42 in endosomes are
known to reside near synapses (Cooney et al., 2002), altered function of these
18

organelles (Nixon et al, 2007) might lead to disruption of axonal transport and
synaptic dysfunction.
It has been shown that intracellular accumulation of Aβ and soluble Aβ
oligomers can induce synaptic dysfunction and dendrite loss (Figure 3).
However, the molecular mechanisms that underlie the loss of synapses and
ensuing decline in memory related functions caused by Aβ are complex.
Neurodegeneration in AD is specific to particular regions of the brain, but it is
still not clear what makes the particular subset of neurons and their processes

Dendrite

Axon terminal

more vulnerable to the effects of Aβ toxicity.

Aβ accumulating in
endosomes

Synaptic vesicle

Ca+ channel

Neurotransmitter
Receptor

Aβ Oligomer

Neurotransmitter

Figure 3: Aβ causes synaptic dysfunction
Extracellular Aβ oligomers can mediate synaptic dysfunction via the
neurotransmitter receptors (NMDA, mGluR, AMPA) on the synaptic plasma
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membranes. Intracellular accumulation of Aβ in endosomes may disrupt axonal
transport or affect dendrites can also be a cause of synaptic loss in AD.

1.6.3

Neurotrophic effects of Aβ

Although the toxic effects of Aβ peptide in mature neurons is well
established, some early reports have demonstrated its neurotrophic effects in
neurons. C-terminal truncated Aβ [Aβ (1-28)] peptide was shown to enhance
survival in embryonic hippocampal cells (Whitson et al., 1989). In the same
year, (Yankner et al., 1990) showed that the Aβ (1-40) was neurotrophic to
undifferentiated hippocampal neurons at low concentrations and neurotoxic to
mature neurons at higher concentrations. However, in differentiated neurons,
Aβ (1-40) protein caused cell loss and shrinkage of dendritic processes, which
is a widely observed phenomenon with Aβ induced neurotoxicity. Low
concentrations of Aβ have also shown to promote neurite outgrowth (Koo et al.,
1993) and stimulate tyrosine phosphorylation /phosphatidylinositol-3-kinase
activity (Luo et al., 1996a; Luo et al., 1996b) in neuronal cells under low serum
conditions. Aβ also exhibits anti-apoptotic properties in serum deprived
conditions and anti-oxidant properties [reviewed in (Atwood et al., 2003)].
Although largely neglected and poorly characterized, the trophic actions of Aβ
reported in these studies may be related to the physiological role of the APP in
neuronal development process and even AD pathology. It is even suggested
that Aβ production may be linked to a regenerative response of the brain elicited
in an attempt to ameliorate the degeneration and neuronal injury associated
with AD.
Along similar lines, recent evidences support the notion that abnormal
activation of cell cycle events in regions susceptible to neurodegeneration in the
AD brain (Husseman et al., 2000; Yang et al., 2003). Increased levels of cell
cycle proteins (Cdc2, cyclin B, activated cdc25A) (Ding et al., 2000; Vincent et
al., 2001) and mitotic signalling phosphoepitopes (p-eIF4E, p-mTOR and p-4EBP1. p-PKR and p-eIF2α) (Chang et al., 2002; Li et al., 2005; Li et al., 2004)
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have been observed in the AD brain. A number of studies also show that Aβ42
treatment (both fibrillar and oligomer) can induce neuronal cell cycle events via
mTOR/MAP kinase cell proliferation pathways in neurons (Bhaskar et al., 2009;
Frasca et al., 2004; Malik et al., 2008; Varvel et al., 2008; Wu et al., 2000). In
contrast to Aβ‟s neurotrophic effects shown in previous reports, these studies
suggest that cell cycle events induced by Aβ are associated with
neurodegeneration and cell death. It is possible that neurons have different
response patterns to Aβ treatment depending on their cell cycle and availability
of neurotrophic factors, which also may explain the selective susceptibility of a
particular subset of neuronal population to Aβ mediated toxicity in late onset
AD.
The studies on Aβ clearly indicate its pivotal role in neurodegeneration in the
AD brain, although the exact role of Aβ in AD pathology and loss of cognitive
functions are not completely understood. Besides the physical evidence, the
critical role of Aβ in AD is strongly supported by the genetic risk factors
associated with the onset of the disease.

1.7

Genetic risk factors of AD

There is a large amount of data about potential risk factors for AD. The
major risk factors include age, genetics, and head injury. Many other risk factors
have also been identified including hormonal levels, cognitive reserve
(education and occupation), physical activity and exercise, midlife obesity,
alcohol intake and medical conditions like stroke, diabetes, hypertension, and
hypercholesterolaemia. However, there is insufficient overall evidence from
epidemiological studies to support any association of lifestyle factors or medical
conditions to the risk of AD caused dementia (Verghese et al., 2011). Age
represents the major risk factor for AD with 4 allele of the apolipoprotein E
gene also playing a key role (60-80% of attributed risk) (Lambert and Amouyel,
2011) which are discussed below.
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1.7.1

Early Onset (Familial) AD

AD incidence increases exponentially with every 5 years of age, such that
about 5% of people aged 65 have AD, whereas greater than 20% of people
over 80 have AD (Brookmeyer et al., 2007). Based on the age at onset, the
major types of AD are differentiated into the early-onset forms (less than
age65), and late-onset forms (greater than age of 65). The early-onset AD
(EOAD) have a clear family history of AD and are caused by autosomal
dominant mutations in the genes encoding APP, presenilin-1(PSEN1), and
presenilin-2 (PSEN2) (Levy-Lahad et al., 1995; Rogaev et al., 1995; Sherrington
et al., 1995). A common feature of these EOAD mutations is change in APP
metabolism leading to increased production or stability of the Aβ peptide
secreted. While EOAD accounts for only a small fraction (~5%) of the total AD
cases, it has presented a useful model for studying the fundamental aspects of
the disorder.

1.7.2

Late onset (Sporadic) AD

The more common sporadic cases (late onset AD: LOAD) usually start
manifesting symptoms after the age of 65. The 4 allele of the Apolipoprotein E
(APOE) gene is long known to be a major genetic risk factor for the late onset
AD cases and many studies have reported and confirmed the association of this
allele with the disease (Farrer et al., 1997; Laws et al., 2003). In the past two
decades several candidate genes apart from APOE have been idenified as risk
factors for LOAD (~ 660), although with poor correlations in significantly larger
cohorts (the Alzgene database) (Bertram et al., 2007).

The major function of the apoE is to mediate the clearance of lipoproteins by
interacting with the low-density lipoprotein (LDL) family of receptors in liver cell
(Beisiegel et al., 1989). ApoE-containing lipoproteins initially bind to cell surface
heparin-sulphate proteoglycans, and are subsequently transferred to the LDL
receptor-like protein (LRP) or LDL receptor for endocytosis via clathrin coated
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vesicles (Havel, 1998; Ji et al., 1993). Studies also suggest an important role for
apoE in the uptake and redistribution of cholesterol within the CNS (Holtzman et
al., 1995; Pitas et al., 1987; Roheim et al., 1979).

1.7.3

The role of APOE in AD

ApoE is comprised of 299 amino acids, and exists as three major isoforms
namely: apoE ε2, apoE ε3 and apoE ε4 (Rall et al., 1982; Zannis and Breslow,
1982). The APOE ε3 allele is present in 50–90% of people in all populations,
whereas APOE ε4 is present in 5–35% and APOE ε2 in 1–5% of people
(Verghese et al., 2011). Risk of AD is associated with APOE ε4. The APOE ε4
allele is present in about 50% of patients who have late-onset disease,
compared with 20–25% of controls (Saunders, 2000; Saunders et al., 1993).
The presence of one copy of the APOE ε4 allele increases risk of AD by about 3
times and two copies increases risk about 12 times. Furthermore, in patients
with late-onset disease, the presence of APOE ε4 leads to an earlier age of
onset compared with non-carriers (Corder et al., 1993). The APOE ε4 allele
steadily increases risk with age, exerting its greatest effect on AD between the
ages of 60 and 79 years, and decreasing thereafter (Farrer et al., 1997).
Additionally, the APOE ε4 allele is associated with more rapid memory decline
in

non-demented

individuals

and

preclinical

memory

impairment

in

asymptomatic middle aged individuals (Caselli et al., 2001; Deary et al., 2002;
Flory et al., 2000). Epidemiological studies from various populations have
confirmed the increased frequency of APOE ε4 in patients with late-onset AD
compared with non-carriers, however the frequency varies between different
ethnic groups (Roses, 1996). Although APOE alleles alter the onset of the
disease, controversy exists about whether they are associated with the rate of
progression of cognitive decline in AD after its onset (Corder et al., 1995a;
Corder et al., 1995b). The role of APOE in the predisposition to AD is well
established, but the association of APOE with rate of disease progression is not
completely understood (Hone et al., 2003; Laws et al., 2003). Evidence strongly
supports the notion that apoE plays a key role with the regulation of both
23

extracellular and intracellular Aβ clearance in the brain (Kim et al., 2009). The
important role of apoE in Aβ clearance is discussed in a later section of this
review (Section 1.9.1).

1.7.4

Newly identified genetic risk factors

Genome wide association studies (GWAS) is a high throughput genotyping
technique for screening the whole genome for single nucleotide polymorphisms
(SNPs). In contrast to candidate gene studies, GWAS is based on a nonhypothesis driven genome wide analysis. Studies indicate that the GWAS
approach can be problematic and the significance of its findings may require
further validation (Manolio, 2010; Pearson and Manolio, 2008). Nevertheless,
recent studies performed on GWAS of ~53000 autosomal SNPs in large
european cohorts have reported association of CR1 gene (complement
component 3b/4b receptor1), clusterin gene (CLU), phophatidylinositol-binding
clathrin assembly gene (PICLAM) and bridging integrator 1 (BIN1) loci in the
risk of AD (Corneveaux et al., 2010; Harold et al., 2009; Lambert et al., 2009;
Seshadri et al., 2010). A more recent GWAS study has shown variants at
ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP to be associated with
AD (Hollingworth et al.). Although the newly identified genes do not represent a
major risk factor for incidence of AD, some of them have been attributed to roles
in lipid transport and Aβ clearance (including CLU, CR1). However, no distinct
causative roles for these genes in AD pathology have been identified so far.

Mechanisms underlying AD pathogenesis are unclear. There are several
hypotheses, but much attention has been given to the amyloid pathway of
neurodegeneration. The amyloid hypothesis proposes that accumulation of
Aβ42

and

subsequent

toxicity

as

the

key

events

responsible

for

neurodegeneration in AD (see Figure 4). Mutations in APP, PS1 and PS2 genes
causing overproduction of Aβ leading to its accumulation in the brain is an
important feature in the early onset AD cases. Although the causative roles of
genes associated with sporadic AD are still unclear, APOE and the identification
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of these new AD genetic determinants suggest that the common and late-onset
forms of the disease are associated with a defect in Aβ peptide clearance. In
addition, impaired degradation of Aβ by cellular pathways (autophagy,
proteasome), by enzymes neprilysin and insulin-degrading enzyme (Iwata et al.,
2000; Miller et al., 2003) and reduced perivascular drainage (Weller et al., 1998)
have been suggested as possible causes of Aβ accumulation in sporadic AD
brains. Also, a recent study has shown direct evidence of decreased clearance
of Aβ, but no increased production in the brains of sporadic AD patients
(Mawuenyega et al., 2010). The mechanisms involved in the production and
clearance of Aβ in the brain and their contribution to AD pathogenesis will be
discussed further.
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Figure 4: The sequence of genetic risk factors associated with the pathogenic
events leading to cognitive decline and dementia in familial and sporadic cases
of AD.

1.8

Production of Amyloid-β protein (Aβ)

Aβ is a 38-43 amino acid length peptide, formed by intramembrane
proteolysis of the amyloid precursor protein (APP) by successive action of the β
and γ secretases. APP metabolism and regulation of its processing are crucial
factors involved in the pathogenesis of AD.
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1.8.1

APP Biology

The APP molecule is an integral transmembrane glycoprotein ubiquitously
expressed in many tissues and concentrated in the synapses of neurons. The
APP gene is located on chromosome 21 in humans with three major isoforms
arising from alternative splicing known as APP695, APP751, and APP770.
APP751 and APP770 are expressed in most tissues and contain a 56 amino
acid Kunitz Protease Inhibitor (KPI) domain within their extracellular regions.
The major form in neurons is the APP695 which lacks the KPI domain. Its
primary functions are not clear, although it has been implicated as a regulator of
synaptic function (Priller et al., 2006), neural plasticity (Turner et al., 2003) and
iron export (Duce et al., 2010). Aβ is produced by cleavage of the APP protein
by enzymes termed β- and γ-secretases. Three enzymes (ADAM9, ADAM10
and

ADAM17)

belonging

to

the

ADAM

family

(a

disintegrin-

and

metalloproteinase-family enzyme) with α-secretase activity have been identified
(Allinson et al., 2003). The β-secretase enzyme has been identified as β-site
APP-cleaving enzyme 1 (BACE1), and is a type I integral membrane protein
belonging to the pepsin family of aspartyl proteases (Hussain et al., 1999; Sinha
et al., 1999; Vassar et al., 1999). The γ-secretase enzyme has been identified
as a complex of proteins composed of presenilin 1 or 2, (PS1 or PS2), nicastrin,
anterior pharynx defective homolog 1 and presenilin enhancer 2 (Edbauer et al.,
2002; Francis et al., 2002; Steiner et al., 2002; Wolfe et al., 1999a; Wolfe et al.,
1999b). In addition to the four critical components, several other factors have
been proposed as additional modulators of γ-secretase (CD147, TMP21/p23).
Although not core components, these factors have a role in modulating γsecretase activity (Krishnaswamy et al., 2009; Zhang et al., 2011).

1.8.2

APP processing pathways

The processing of APP involves two competing pathways: the nonamyloidogenic

and

amyloidogenic

pathways

(Figure

5).

In

the

non-

amyloidogenic pathway, APP is cleaved by the α-secretase at a position located
83 amino acids from the carboxyl (C) terminal, producing an amino (N) terminal
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ectodomain (sAPPα) which is secreted into the extracellular medium (Kojro and
Fahrenholz, 2005). sAPPa has an important role in neuronal plasticity/survival
and regulates neural stem cell proliferation which is important for early CNS
development (Furukawa et al., 1996; Ohsawa et al., 1999). The resulting Cterminal fragment (C83) is retained in the membrane and subsequently cleaved
by the γ-secretase, producing a short fragment termed p3 (Haass et al., 1993).
Cleavage by the α-secretase occurs within the Aβ region, thereby precluding
formation of Aβ.

The amyloidogenic pathway is a competitive cleavage pathway for APP
which leads to secretion of Aβ. The initial proteolysis is mediated by the βsecretase at a position located 99 amino acids from the C terminus, resulting in
the release of sAPPβ into the extracellular space. The 99-amino-acid C-terminal
fragment (C99) within the membrane is subsequently cleaved (between
residues 38 and 43) by the γ-secretase liberating the Aβ peptide, although the
exact site can vary.

Cleavage of C99 by γ-secretase can yield Aβ40, the

majority species, and Aβ42 (approximately 10%), the more amyloidogenic
species, as well as releasing the intracellular domain of APP (AICD). The Aβ42
variant is more hydrophobic and has an increased tendency to aggregate than
Aβ40 (Jarrett et al., 1993) and is the predominant isoform found in cerebral
plaques observed in AD brains (Younkin, 1998). Recent data has shown that
PS/γ-secretase also mediates δ-site cleavage (Aβ46) (Zhao et al., 2004) and εsite cleavage (Aβ49) (Sastre et al., 2001), suggesting a sequential cleavage
model where cleavage at the ε-site is followed by the δ-site and γ-site. The
processing of APP by secretase activity in the generation of Aβ and other APP
metabolites is expertly reviewed in (Zhang et al., 2011).

1.8.3

APP/Presenilin mutations in EOAD

Mutations in APP and components of PS1 and PS2 have been reported in
EOAD cases. A common feature of these EOAD mutations is change in APP
metabolism leading to increased production or stability of the Aβ peptide
secreted. All APP mutations have profound effects on APP processing, resulting
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in increased levels of the Aβ peptide (Citron et al., 1992; Eckman et al., 1997;
Hendriks et al., 1992; Jonghe et al., 2001). The APP mutations that cluster near
the APP γ-secretase cleavage site have been shown to shift the balance of γsecretase cleavage products towards the Aβ42 over Aβ40 species. One
common mutation in the APP gene is the Swedish mutation which leads to
increased cleavage of APP by the β-secretase (Haass et al., 1995). Some APP
mutations, such as the Arctic (E22G), Italian (E22K), and Iowa (D23N) have
shown to increase the aggregation of the secreted Aβ (Grabowski et al., 2001;
Murakami et al., 2002 ; Nilsberth et al., 2001; Tagliavini et al., 1999). Reports
have also shown loss of APP synpatotrophic functions and decreased
interaction with PS1 as a result of EOAD APP mutations (Herl et al., 2009;
Seeger et al., 2009). The vast majority of EOAD cases are associated with
mutations in the PS1 gene (>180). A large number of these mutations are
missense mutations involving substitution of a single amino acid. Others include
small deletions, insertions or splice mutations (De Strooper, 2007). Mutations in
the presenilins have been shown to affect APP metabolism causing increased
production of Aβ42 (Guo et al., 1999; Jankowsky et al., 2004). Recently, a study
has also shown that EOAD mutations in PS1 may result in impaired autophagylysosomal function (Lee et al., 2010). Overall, these studies indicate that in
addition to increased production of Aβ, EOAD mutations can also be associated
with loss of functions of the protein which may contribute to the pathology of the
disease.

In addition to the intramembrane cleavage of APP at the cell surface by
secretase complexes leading to secretion of Aβ, many studies also provide
evidence for the occurrence of intracellular Aβ in the AD brains. Growing
evidence also indicate that Aβ can accumulate intracellularly which precedes
plaque formation and may contribute to cognitive decline in AD. The possible
sources of intracellular Aβ have been discussed further.
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Figure 5: Processing of APP by α-, β-, γ-secretases by non-amyloidogenic
pathway and by amyloidogenic pathway leading to generation of Aβ peptide.

1.8.4

Intracellular sites of Aβ production

The occurrence of APP/Aβ products in intracellular compartments has been
reported. APP has been found localized in the endoplasmic reticulum (ER),
trans-Golgi network (Xu et al., 1995), endosomal, lysosomal (Kinoshita et al.,
2003) and mitochondrial membrane (Mizuguchi et al., 1992). Intracellular
accumulation of Aβ has been observed in cells expressing APPSwe (familial
APP Swedish mutation) but not wild-type APP (Martin et al., 1995). Similarly,
duplication in the APP gene has also been associated with higher levels of
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intracellular Aβ formation (Cabrejo et al., 2006; Rovelet-Lecrux et al., 2006).
Sortilin-related receptor 1 (SORL1) has been found to regulate trafficking of
APP from the plasma membrane into retromer recycling endosomes (Golde et
al., 1992). APP and BACE1 interactions have been observed within the
endosomes and is indicated as a possible site of Aβ generation (Kinoshita et al.,
2003). Importantly, genetic variants in SORL1 lead to increased APP trafficking
into these Aβ-producing endosomes, which has been linked to an increased risk
for late-onset AD (Lee et al., 2007). Also, blocking APP internalization
significantly reduced Aβ levels, demonstrating that the internalization of APP by
endocytosis is an important pathway for the generation of Aβ (Koo and
Squazzo, 1994; Perez et al., 1999). Furthermore, low-density lipoprotein (LDL)
receptor-related protein 1B (LRP1B), an LDL family member has been shown to
bind APP holoprotein at the plasma membrane thereby preventing Aβ
internalization and leading to decreased Aβ production and increased sAPPα
secretion (Cam et al., 2004). In addition to the endosome system, evidence has
been provided in support of the notion that Aβ is generated intracellularly along
the ER-Golgi secretory pathway (Busciglio et al., 1993). It has been shown that
retention of APP in the ER blocks production of Aβ40 but not Aβ42, suggesting
that Aβ42 can be produced in the ER (Lee et al., 1998; Skovronsky et al., 1998;
Wild-Bode et al., 1997). It was further shown that Aβ40 could be produced in
the trans-Golgi network (Lee et al., 1998; Skovronsky et al., 1998; Wild-Bode et
al., 1997). It is notable that intracellular Aβ42 and Aβ40 can be generated at
different sites. A number of studies also indicate that amyloidogenic processing
of APP occurs in cholesterol- and sphingolipid-enriched membrane raft
microdomains of intracellular organelles (Ehehalt et al., 2003; Riddell et al.,
2001; Vetrivel et al., 2005). Although intracellular synthesis of Aβ is evident, the
organelles/transport vesicles where Aβ is generated are not fully characterized.
A recent study showed evidence of PS1 and PS2 enriched in a compartment of
the

endoplasmic

reticulum

associated

with

mitochondria

known

as

mitochondrial associated membranes (MAM) (Area-Gomez et al., 2009). This
study indicates that presenilin components in the mitochondria may contribute
to generation of intracellular Aβ.
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In addition to being generated intracellularly, secreted Aβ in the extracellular
media can be taken up by cells and internalized into intracellular pools. Binding
to the cell surface and subsequent internalization via receptor proteins into the
cell is thought to be an important pathway for clearance of Aβ in the brain.
Different isoforms of Aβ have been shown to internalize via a variety of cell
surface receptors in neurons and also in inflammatory cells (astrocytes and
microglia). These receptors include , α7 nicotinic acetylcholine receptor
(α7nAChR) (Nagele et al., 2002), apolipoprotein E (APOE) receptors (Zerbinatti
et al., 2006), members of the low-density lipoprotein receptor (LDLR) family
(Jaeger and Pietrzik, 2008), scavenger receptor for advanced glycation end
products (RAGE) (Yan, 1996), formyl peptide receptor-like 1 (FPRL1) (Yazawa,
2001) and NMDA (N-methyl- D-aspartate) receptors (Snyder et al., 2005). As
Aβ can be generated intracellularly, secreted into the extracellular lumen and
also re-internalised (Figure 6), it is not surprising that the clearance of Aβ can
be associated with a range of mechanisms. This is discussed further below.
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Figure 6: Intracellular accumulation of Aβ
Aβ is secreted into extracellular media by secretase activity of APP localized in
the plasma membrane (1). Secreted Aβ can bind to cell surface receptors (for
example, LRP, RAGE, FPRL1, NMDA receptors and α7nAChR), and can be
internalized (2). Aβ can be produced from APP processing within the
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endoplasmic reticulum (ER) and Golgi system and in early endosomes (3).
Intracellular accumulation of Aβ is seen predominantly in the multivesicular
body and lysosomes, but also in the mitochondria, ER, Golgi and the cytosol,
where it is known to affect proteasome function (4).

1.9 Clearance mechanisms of Amyloid-β protein
Defective clearance of Aβ in the brain is implicated as one of the primary
causes of its increased accumulation and associated pathology in sporadic AD
brains. Gene polymorphisms in APOE and some of the newly identified risk
factors (CLU and CR1) suggest impaired Aβ clearance in sporadic AD cases.
Direct evidence for decreased clearance of Aβ from the CNS in the brains of AD
patients has also been provided (Mawuenyega et al., 2010). The various
clearance mechanisms and their roles in the accumulation of Aβ in the brain will
be discussed here.

1.9.1

Effect of ApoE on Aβ clearance

One of the major risk factors associated with LOAD is APOE. It is thought
that the isoform specific effects of ApoE may contribute to decreased clearance
of Aβ in the AD brain. Evidences show that ApoE alters both the transport and
metabolism of Aβ in the brain. There is no clear evidence for isoform-specific
effects on APP processing or production of Aβ (Biere et al., 1995; CedazoMinguez and Cowburn, 2001; Cedazo-Minguez et al., 2001; Irizarry et al.,
2004). Regardless, ApoE is known to play an important role in the clearance of
Aβ. ApoE-containing lipoprotein particles can modulate the cellular uptake and
degradation of Aβ by receptor-mediated endocytosis (Beffert et al., 1998,
1999a; Beffert et al., 1999b; Cole and Ard, 2000; Yamauchi et al., 2002;
Yamauchi et al., 2000). Studies have reported that lipid-associated ApoE2 and
ApoE3 formed SDS-stable complexes with Aβ to a much greater extent than
ApoE4 (Aleshkov et al., 1997; LaDu et al., 1994; Yang et al., 1997). It has been
shown that the efficiency of complex formation between lipidated ApoE and Aβ
34

follows the order of ApoE2 > ApoE3 ≫ ApoE4 (Tokuda et al., 2000). Since the
binding efficiency of ApoE isoforms to Aβ correlates inversely with the risk of
developing AD, it has been thought that ApoE2 and ApoE3 may enhance the
clearance of Aβ, compared to ApoE4.
Alternatively, ApoE may modulate Aβ removal from the brain to the systemic
circulation by transport across the blood-brain-barrier. ApoE is known to play a
very important role in mediating Aβ clearance in the periphery. Previous in vivo
data from Prof. Martins laboratory has demonstrated that Aβ is rapidly removed
from the plasma by the liver and kidney and the rate of its clearance is affected
by ApoE in C57BL/6J and APOE knockout mice (Hone et al., 2003). More
recently it was shown that APOE influences the rate at Aβ42 clearance in the
bloodstream. Both APOε4 mice and APOE knockout mice treated with lipidated
ApoE4 demonstrated increased retention of plasma Aβ42 compared to
APOε2/APOE knockout rE2 and APOε3/APOE knockout rE3 mice (Sharman et
al., 2010). ApoE3-Aβ and ApoE4-Aβ complexes were shown to be cleared out
of the brain at a significantly faster rate than ApoE4-Aβ (Bell et al., 2007; Deane
et al., 2008; Ito et al., 2007). However a study using mice expressing human
ApoE3 or ApoE4 did not show any differences in the clearance of Aβ from the
brain (Ji et al., 2001).
In addition to its isoform-specific difference in the clearance of Aβ, ApoE can
affect Aβ aggregation in vitro. One study demonstrated that all three ApoE
isoforms promoted Aβ42 fibrillization, with the effect being more enhanced with
the ApoE4 isoform and least with ApoE2 (Ma et al., 1994). Subsequently, others
also found that ApoE4 was more efficient than ApoE3 at increasing Aβ40
aggregation (Castano et al., 1995; Wisniewski et al., 1994). Overall these
findings provide evidence for the pathogenic role of ApoE4 in the decreased
clearance and also enhanced accumulation of Aβ in AD brain.
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1.9.2

Aβ degrading enzymes

Multiple enzymes within the central nervous system (CNS) also play
important roles in Aβ clearance. Such enzymes are produced by neurons or
microglia, and also expressed in the cerebral vasculature. Studies show that the
reduced Aβ-degrading activity may contribute to Aβ deposition in the brain and
in vascular system. Insulin-degrading enzyme (IDE) and neprilysin (NEP) are
identified as the main Aβ degrading enzymes expressed in neurons and in the
cerebral vasculature. Other enzymes which can degrade Aβ include endothelin
converting enzymes (ECE-1,2), plasmin, matrix metalloproteinase (MMP-2, -3
and -9) and angiotensin-converting enzyme (ACE). Reduced levels of IDE,
NEP, plasmin, plasminogen activators (uPA and tPA) and ECE-2 enzymes in
AD have been demonstrated, although the correlation of Aβ accumulation with
the activities of these enzymes are still not entirely clear. Reductions in
neprilysin, IDE and plasmin in AD have also been associated with occurrence of
APOE e4 alleles. The roles of Aβ degrading enzymes in the development of AD
pathology and their potential therapeutic benefits have been extensively studied
(reviewed in (Miners et al., 2008)), however this is not of major focus in this
review.

In addition to extracellular accumulation of Aβ, numerous reports show
evidence for intraneuronal deposition of Aβ in brains of AD patients and
transgenic animal models (LaFerla et al., 2007 ). A study has shown that
increased Aβ levels in membrane-associated and intracellular fractions isolated
from the temporal neocortex of AD patients to be more closely related to AD
symptoms than other measured Aβ species (extracellular soluble and
extracellular insoluble) (Steinerman et al., 2008). A recent study also shows
correlation of the presence of the APOE 4 allele with an increased
accumulation of intraneuronal Aβ peptides in sporadic AD brains (Christensen
et al., 2010). Intraneuronal Aβ accumulation is thought to be an early event in
AD pathogenesis and has been reported to be critical in the synaptic
dysfunction, cognitive decline and the formation of plaques in AD (Gouras et al.,
2000; Oddo et al., 2006). The autophagy-lysosome pathway and ubiquitin36

proteasome system are the main intracellular degradation pathways in cells.
Disruption of these pathways has been observed in AD brains and believed to
play important roles in Aβ mediated neurodegeneration.

1.9.3

Autophagy-Lysosome Pathway

Autophagy is a vital cellular degradation pathway involved in degradation of
long-lived, aggregated proteins and even whole organelles inside the cells.
Based on the nature and delivery of substrates for degradation autophagy can
be classified into three types: macroautophagy, microautophagy and chaperone
mediated autophagy (CMA) (Figure 7). Macroautophagy is considered to be the
main contributor to the overall autophagy in cells. It is mostly a non-specific
process conserved from yeast to mammals, which is up-regulated during stress
and nutrient starvation conditions. This process mediated through the
mammalian target of rapamycin (mTOR) kinase and regulated through
signalling cascades AMPactivated protein kinase (AMPK) or the class I
phosphatidylinositol 3-kinase (PI3K)/Akt pathways (Hay and Sonenberg, 2004;
He and Klionsky, 2009). The inhibition of mTOR initiates the formation of the
autophagosome which sequesters the cytoplasmic material for delivery into the
lysosome for degradation by acidic hydrolases (Klionsky and Emr, 2000).
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Figure 7: The different types of autophagy in eukaryotes
Macroautophagy featured by bulk degradation of cytosolic material in the
lysosome after delivery by autophagosomes. Microautophagy is a process
where bulk degradation by lysosome does not require intermediate vacuoles for
delivery. Chaperone mediated autophagy is selective degradation of a cytosolic
protein target in the lysososme by a dedicated chaperone complex.
(Adapted from Martinet et al, 2009)
1.9.3.1

Extensive accumulation of autophagic vacuoles in AD

A number of reports indicate that autophagy is minimal but constitutively
active in neurons and is essential for protein turnover and survival (Hara et al.,
2006; Komatsu et al., 2006). Autophagic vacuoles are less abundant in neurons
of the healthy brain (Cota et al., 2006; Mizushima et al., 2008; Nixon et al.,
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2005). However in the AD brain, severe abnormalities in endocytic and
autophagic pathway including extensive accumulation of autophagic vacuoles
(AVs) containing APP/Aβ products and dystrophic neurites containing these
AVs is observed (Nixon, 2007; Nixon et al., 2005). Autophagy-related pathology
has also been increasingly documented in several other neurodegenerative
diseases such as Parkinson‟s disease, Frontotemporal dementia and
transmissible spongiform encephalopathy (Anglade et al., 1997; Liberski et al.,
2008; Rudnicki et al., 2008; Yue et al., 2002; Zhou et al., 1998).

Severe autophagic pathology develops in mouse models of AD expressing
familial AD forms of APP and PS1 mutations (Cataldo et al., 2004; Chishti et al.,
2001; Yang et al., 2011; Yu et al., 2005). Accumulation of autophagy substrates
and AVs are also observed in PS1-null blastocysts and neurons of mice
conditionally depleted of PS1 (Esselens et al., 2004; Wilson et al., 2004). A
recent study has shown that the critical component of the Aβ-generating, γsecretase enzyme presenilin-1 (PS1) is required for autophagy and familial AD
causing PS1 mutations are associated with impairments in the autophagylysosome pathway. This study has identified a specific role of PS1 in the
acidification of autolysosomes/lysosomes (Lee et al., 2010). It is suggested that
loss of PS1 function can induce autophagy impairment alongside Aβ
accumulation which could account for the cell death and dysfunction observed
in AD.
1.9.3.2

Defective lysosomal proteolysis in AD

Many lines of evidence indicate that disruption of the lysosomal proteolytic
clearance forms the basis for the neuronal accumulation of AVs in the AD brain.
The AD brain is featured by AVs filled with undigested or partially digested
substrates (Nixon et al., 2005). A similar pattern of AV accumulation and
neuritic dystrophy is observed when lysosomal degradation is inhibited by
deletion of cathepsins (Felbor et al., 2002; Koike et al., 2000; Koike et al., 2005)
or by lysosomal enzyme inhibitors (Bednarski et al., 1997; Boland et al., 2008;
Ivy et al., 1989; Takeuchi and Takeuchi, 2001; Yang et al., 2008). The abnormal
autophagic-lysosomal pathology is comparable to that seen in particular
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lysosomal storage disorders (LSDs), which are also associated with
accumulation of autophagic and endosomal substrates (Nixon et al., 2008).
Importantly, some LSDs, such as GM1 and GM2 gangliosidoses, Niemann Pick
type C disease (NPC) and neuronal ceroid-lipofuscinosis (NCL) are associated
with prominent nervous system degeneration (Jeyakumar et al., 2005; Walkley,
1998, 2009). Furthermore, other similarities are also being identified between
the cellular pathologies of AD and of certain LSDs (Chevrier et al., 2010;
Eckhardt, 2010; Fukuda et al., 2006; Settembre et al., 2008). Some notably
include NFTs, increased levels of the BACE-1, Aβ deposition. A recent study
has shown that stimulating lysosomal proteolysis by deletion of an endogenous
inhibitor of lysosomal cysteine proteases (cystatin B) in AD transgenic mice,
diminishes accumulation of autophagy substrates, extracellular amyloid
deposition and ameliorates learning and memory deficits (Yang et al., 2011).
These studies establish the pathogenic significance of autophagic-lysosomal
dysfunction in AD and specifically the importance of deficient lysosomal
proteolysis. But, the exact contribution of autophagy to the clearance of
intracellular Aβ is unclear.

1.9.3.3

Enhancing Autophagy promotes Aβ clearance

Modulation of autophagy to enhance clearance of protein aggregates is
gaining interest as a therapeutic strategy in many neurodegenerative diseases
(Rubinsztein et al., 2007). Enhancing autophagy has been suggested as a
treatment strategy for HD (Ravikumar et al., 2004; Sarkar et al., 2007b; Williams
et al., 2008) and α-synucleinopathies such as Dementia with Lewy Bodies
(DLB; (Crews et al., 2010)). In mammalian AD models, activators of autophagy
have been shown to be neuroprotective and confer cognitive benefits (Hung et
al., 2009; Spilman et al., 2010). The best-characterised drug that enhances
autophagy is rapamycin. Inhibition of mTOR by rapamycin has been widely
reported to enhance clearance of aggregate-prone proteins by macroautophagy (Berger et al., 2006; Ravikumar et al., 2004; Sarkar and Rubinsztein,
2008). Small molecules which activate autophagy by 1) mTOR inhibition
(Berger et al., 2006; Ravikumar et al., 2003; Webb et al., 2003), 2) reducing
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inositol levels (Fornai et al., 2008; Sarkar et al., 2005) or by 3) Ca2+ channel
modulation (Zhang et al., 2007) have also shown to reduce aggregation in
cellular models of neurodegeneration, reduce amyloid deposition and abolish
cognitive deficits in mice models (Sarkar and Rubinsztein, 2008). Further,
derivatives of known agents shown to have benefits in AD models, such as
resveratrol, have been developed and shown to modulate mTOR signalling and
facilitate autophagy and Aβ degradation (Vingtdeux et al., 2010). A recent study
has also shown that small molecule enhancer of rapamycin (SMER28)
decreases levels of Aβ and APP-CTF via Atg5 dependent autophagy in
neuronal cells (Tian et al., 2011). Autophagy can also be regulated in an
mTOR-independent manner by drugs that reduce intracellular inositol levels,
such as lithium, valproate and carbamazepine (Sarkar and Rubinsztein, 2008).
In addition to autophagy, the proteasome is an important pathway for
maintenance of protein homeostasis in cells. It also has an important role in AD
pathology.
1.9.4

Ubiquitin-Proteasome System

The proteasome is a large protein complex that is located in the nucleus and
the cytoplasm and is essential for the degradation of ubiquitin tagged proteins.
The ubiquitin-proteasome system (UPS) is essential for maintaining a constant
balance of protein synthesis and degradation in cells and is conserved from
archaebacteria to mammals. The UPS functions constitutively and is essential
for the normal functioning of the cell. Protein clearance by the UPS occurs in
two sequential steps, an ubiquitin tagging reaction catalysed by the ubiquitin
ligase and a subsequent degradation of the tagged proteins by the proteasome
system. Unlike autophagy the UPS substrates mostly includes proteins with
short half-life and signalling functions inside the cell.

1.9.4.1

Altered proteasomal activity in the AD brain

Increasing evidence indicates that alterations in the UPS function may be
involved in AD pathogenesis. Accumulation of an ubiquitin-B mutant protein
(UBB+1) in both plaques and tangles has been observed (Mori et al., 1987;
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Morishima-Kawashima et al., 1993; Perry et al., 1987). UBB+1 is a frameshift
mutant of ubiquitin B gene and has been shown to block ubiquitin-dependent
proteolysis (Lindsten et al., 2002) and mediate Aβ-induced neurotoxicity in
neuronal cells (Song et al., 2003). Also the ubiquitin carboxy-terminal hydrolase
L1 (UCH-L1), a deubiqutinating enzyme, is oxidized and down-regulated in the
specific brain regions of AD cases (Castegna et al., 2002; Pasinetti, 2001).
Recent evidence provided a positive association for genetic polymorphisms in
an ubiquitin-like protein UBQLN1, in sporadic AD (Bertram et al., 2005). Direct
evidence of altered proteasome activity showing a selective decrease in activity
in specific regions of AD brain like the hippocampus has also been reported
(Keller et al., 2000). Together, these reports suggest a possible role for
dysfunctional UPS function in AD pathogenesis.

1.9.4.2

Aβ interacts with the proteasome

Numerous studies have reported interactions between Aβ and the
proteasome system. Both Aβ40 and Aβ42 have shown to selectively inhibit the
chymotrypsin-like activity of the 20S proteasome (Gregori et al., 1995; Gregori
et al., 1997; Oh et al., 2005). Using a cell-free proteasome activity assay,
oligomeric forms of Aβ were found to significantly decrease proteasomal activity
in a dose-dependent manner (Tseng et al., 2008). Elevated levels of an
ubiquitin-conjugating enzyme, E2-25K/Hip2 have been identified as a mediator
of Aβ neurotoxicity in primary cortical neurons (Song et al., 2003). In addition, it
has also been shown that the Aβ induced synaptic dysfunction and cognitive
deficits can be rescued via restoring proteasomal enzymatic activity by
increasing expression of UCH-L1 (Gong et al., 2006). Intraneuronal Aβ
accumulation due to decreased proteasome function has been reported in the
brains of AD transgenic models, primary neurons isolated from APP transgenic
mice and in N2A cells treated with a proteasome inhibitor (Almeida et al., 2006;
Oddo et al., 2006; Oh et al., 2005; Tseng et al., 2008).

Evidence shows that tau can be degraded by the proteasome as inhibition
using lactacystin in cell culture inhibits tau degradation (David et al., 2002;
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Tseng et al., 2008). Injection of anti-Aβ antibodies into the brains of AD
transgenic mice showed that Aβ clearance led to a significant reduction in early
tau pathology but not late aggregated tau deposits. However concomitant
injection of the anti-Aβ antibody with a proteasome inhibitor led to a reduction of
Aβ deposits but no changes in tau pathology were detected (Oddo et al., 2004).
These data indicate that the accumulation of Aβ may impair proteasome
function thus facilitating tau accumulation.

It is evident that disruption of proteasomal and autophagy-lysosomal
functions corresponds to intracellular Aβ deposition and ensuing pathology
including tau aggregation and memory impairments in AD. It is widely accepted
that

functions

of

the

proteasomal

and

autophagic

systems

become

compromised during the normal aging process contributing to benign protein
deposition in the brain. But the exact causes of the failure of these functions in
AD are unclear. Whether loss of specific functions in the cellular degradation
systems leading to pathological amyloid deposition can contribute to AD is yet
to be determined.

The literature reviewed above has presented evidence of the pathogenic
nature of Aβ in AD. The accumulation/ aggregation of Aβ and associated
toxicity have been considered as a target for therapeutic intervention for AD and
there is a number of therapeutics that have been developed. There has been
considerable progress in the development of anti-amyloid therapeutics for
clinical trials. The current strategies for drug designing and treatments
underway in AD clinical trials for targeting Aβ production, aggregation and
clearance in the brain are discussed further.

1.10

AD therapeutics

With an increasing ageing population, the need for preventative and disease
modifying treatments for AD caused dementia is critical for the future. Current
AD treatments target cognitive decline or failure and provide only minor benefits
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across the array of clinical symptoms (Omerovic et al., 2007; Tariot, 2006).
Approved AD drugs such as acetylcholine esterase (ACE) inhibitors (Aricept,
Namenda,

Exelon,

etc.)

and

N-methyl-D-aspartate

(NMDA)

receptor

antagonists (Memantine) are generally prescribed in monotherapy or in
combination. However they are expensive and most importantly, do not prevent
disease progression are of limited benefit to most patients (Jelic et al., 2006;
Raschetti et al., 2007). Other drugs are used to manage mood disorder, anxiety
and neurosis in later stages of the disease, but no treatment with a strong
disease-modifying effect is currently available.

1.10.1

Anti-amyloid therapies

The main strategies that target Aβ include 1) reducing its production by
modulating APP processing by α-, β- and γ-secretases, 2) reducing aggregation
of Aβ and 3) enhancing clearance of Aβ by immunotherapy.

1.10.1.1 Drugs to reduce Aβ production
Therapeutic strategies to reduce production of Aβ include BACE1 inhibitors,
γ-secretase

inhibitors

and

α-secretase

activators.

PPAR

(peroxisome

proliferator activator receptor) agonists like rosiglitazone and pioglitazone and
BACE1 inhibitors like CTS-21166 (Landreth et al., 2008) which reduce Aβ levels
are currently under investigation (Mangialasche et al., 2010). A range of γsecretase inhibitors (semagacestat, MK-0752, BMS-708163, PF-3084014,
begacestat), E-2012 and a subset of non-steroidal anti-inflammatory drugs
(NSAIDs) which act as γ-secretase modulators have shown to decrease Aβ
production (Tomita, 2009). Up-regulation of α-secretase activity and nonamyloidogenic cleavage of APP to decrease production of Aβ and increase
sAPPα have been shown to be neuroprotective. Many compounds have been
shown to activate α-secretase activity (Marcade et al., 2008) and some of them
are also currently being tested in patients with mild-to-moderate AD
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(Mangialasche et al., 2010). Despite showing positive results in animal models,
most drugs targeting Aβ production have failed in AD clinical trials.
Development of drugs targeting secretases is particularly challenging because
of the fact that these enzymes have a wide array of neuronal substrates and
may have undesirable long term side-effects.

Of these the type I

transmembrane protein receptor, Notch is the most pharmacologically relevant
as it has been difficult to develop specific inhibitors/modulators of Aβ42 without
affecting Notch signalling. Indeed, a phase 3 trial of Eli Lilly‟s γ-secretase
inhibitor, Semagacestat in 2,600 patients, with mild-to-moderate AD, recently
failed. In addition, cognition and the ability to complete activities of daily living
worsened with drug treatment and increased the risk of skin cancer for the
patients on the drug compared to those on placebo. These side effects were
most likely related to inhibition of Notch processing. A suitable therapeutic
window needs to be defined, through which γ-secretase activity is selectively
modulated, thereby allowing Notch and other substrates to be normally
processed while simultaneously reducing Aβ generation. Although results from
the Lily‟s recent trial has placed doubts on inhibiting γ-secretase as an effective
approach to treating AD, it does not rule out other approaches to modulating
this target. Indeed, there is a push by major pharmaceutical companies such as
Pfizer to develop Notch-sparing inhibitors (BioCentury; Bernstein Report on
Biobusiness, 23/8/10).

1.10.1.2 Drugs preventing Aβ aggregation
Evidence for the neurotoxic activity of Aβ oligomers constitutes the scientific
basis for the development of compounds that inhibit Aβ aggregation or
destabilise Aβ oligomeric species. A range of compounds targeting Aβ
aggregation have been investigated including Tramiprosate (homotaurine,
Alzhemed; a small compound that binds preferentially to soluble Aβ and
prevents fibrillisation) (Aisen et al., 2007; Gauthier et al., 2009), Clioquinol
(metal chelators which reduces Aβ-metal association: PBT1 and PBT2) (Adlard
et al., 2008; Biran et al., 2009), Scyllo-inositol (promotes dissociation of Aβ
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aggregates) (McLaurin et al., 2006) and Epigallocatechin-3-gallate (EGCG, antiaggregation properties including a range of other neuroprotective functions)
(Mandel et al., 2008). Compounds targeting Aβ aggregation have shown mixed
results in AD clinical trials. Although promising, a major challenge in designing
such compounds is to specifically target the toxic form of Aβ. Although soluble
oligomers have been identified as the main toxic species, structural information
is significantly lacking to engage target specific inhibitors. A fair amount of risk
in modulating Aβ aggregation leading to increased toxic species in the brain
may also be involved.
Inhibitors of Aβ aggregation from natural food products or dietary intake
have been of interest in AD therapeutics. Peptides with capacity for amyloid
inhibition, derived from bovine dairy sources including whey, casein and
lactoferrin, have also been reported (Bennett et al., 2009). The Colostrinin
peptide complex (proline-rich polypeptides derived from colostrums) was shown
to inhibit and disrupt β-sheets of amyloid proteins (Schuster et al., 2005) and
exert several other bioactive properties (Boldogh and Kruzel, 2008; Zimecki,
2008) that translated to proven neuroprotective bioactivity against AD
(Bilikiewicz and Gaus, 2004). Successful in vivo neuroprotective studies with
Colostrinin (Bilikiewicz and Gaus, 2004) suggest that other exogenous peptides,
perhaps dietary sources, with amyloid inhibition capacity might be also be
protective against AD.
1.10.1.3 Immunotherapy to promote Aβ clearance

Active and passive immunisations have been developed to remove soluble
and aggregated Aβ from the CNS. In a phase 2 clinical trial of AN-1972 (anti-Aβ
vaccine)

in

mild-to-moderate

AD,

some

patients

developed

aseptic

meningoencephalitis, which was attributed to cytotoxic T cells and/or
autoimmune

reactions to

AN-1972

(Gilman

et

al.,

2005). To

avoid

neuroinflammation, new vaccines that selectively target B-cell epitopes without
stimulating T cells have been developed like CAD-106, ACI-24, UB-311, ACC001 and V-950 which are currently in clinical trials (Muhs et al., 2007; Wang et
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al., 2007). Another active immunisation strategy is AFFITOPE which is based
on short peptides mimicking parts of native Aβ42 (Schneeberger et al., 2009).
Passive immunisation using monoclonal/polyclonal antibodies targeting Aβ have
been shown to reduce brain amyloid load with improvement in cognitive
functions in AD models (Wilcock and Colton, 2008). Monoclonal antibodies
currently being tested in clinical trials include bapineuzumab (humanised antiAβ monoclonal antibody), solanezumab (specific monoclonal antibody for
soluble Aβ), PF-04360365 (humanised, modified IgG2 antibody that binds to the
C terminus of Aβ40), GSK-933776, R-1450, and MABT-5102A (Salloway et al.,
2009). Passive immunisation may be more effective in the elderly than active
immunotherapy, due to reduced responsiveness to vaccines. But administration
of antibodies is time consuming and costly. Active immunotherapy is cost
effective and may guarantee constant high antibody titres. However the risk of
inflammation and possible adverse effects are of concern.

1.10.2

Latrepirdine (DimebonTM)

Several neuroprotective compounds which can enhance neurogenesis and
reduce amyloid deposition are of current interest in many neurodegenerative
diseases (Pieper et al., 2010). However their mode of action is largely
uncharacterized and poorly understood. One of them is latrepirdine (2,3,4,5tetrahydro-2,8-dimethyl-5-[2-(6-methyl 3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole),
which is an orally-available, small molecule previously approved in Russia as a
non-selective antihistamine (Bachurin et al., 2001). Latrepirdine was shown to
weakly inhibit butyrylcholinesterase and acetyl cholinesterase, block the Nmethyl-D-aspartate receptor signalling pathway, and inhibit mitochondrial
permeability transition pore opening (Bachurin et al., 2001; Grigorev et al.,
2003; Lermontova et al., 2001). Latrepirdine has also shown neuroprotective
effects in models for AD (Bachurin et al., 2001) and Huntington‟s disease. In the
initial clinical study in a Russian cohort, latrepirdine showed great promise for
improving cognition in mild-moderate AD (Doody et al., 2008). However, a
subsequent 6 month, US-Based replication (CONNECTION) trial showed no
47

benefits of the drug for AD. The exact causes for the mixed results in the AD
clinical trials were unclear. The lack of understanding of a specific mechanism
of action for latrepirdine was one of the main issues expressed for its mixed
outcomes in two different phase II AD clinical trials (Bezprozvanny, 2010;
Editorial, 2010a, b; Jones, 2010).

Interest in latrepirdine rebounded recently with the Steve McKnight paper in
Cell pointing out the similarity of the latrepirdine scaffold to that of a new,
neuroprotective class of drugs (Pieper et al., 2010). Subsequent studies have
identified more neuroprotective functions for latrepirdine including enhanced
neuronal survival (Zhang et al., 2010b), modulated Aβ secretion and
metabolism (Steele et al., 2009) and clearance of α-synuclein protein
aggregates (Wu et al., 2008; Yamashita et al., 2009). Some recent studies have
also reported latrepirdine‟s cognitive enhancing properties, although the
mechanism of action responsible for improving memory functions is still unclear
(Giorgetti et al., 2010; Vignisse et al., 2011). Currently, a longer 12 month
(CONCERT) trial for AD is still in progress and Phase 3 trial for Huntington‟s
disease is also underway.

1.10.3

Current challenges in AD therapeutics

The search for a disease modifying therapy for AD has been very difficult.
Some of the challenges that need to be addressed are 1) the heterogeneous
nature of the disease (both pathology and epidemiology), 2) lack of a reliable
diagnostic test for early detection and intervention, 3) drug delivery and ageing
factors which may influence response to treatment, 4) linear and target driven
reductionist approach in drug discovery 5) lack of high-throughput drug
screening systems, 6) incomplete understanding of the drug-target mechanism
and 7) AD drugs are targeted at a stage when brain is irreparably damaged and
therefore effective treatment is unlikely.

48

The use of disease models ranging from in vitro non-cell based systems to
transgenic animals form the basis for drug discovery and evaluation and
elucidating disease mechanisms in AD. The use of animal models and the
significance of alternative model systems in studying disease mechanisms and
drug targets have been discussed further.

1.10.4

Disease models for AD

The majority of transgenic AD animal models represent overexpression of
an EOAD associated mutation or particular fragments of human APP, to
develop AD like pathology. Hence they are of immense value to gain knowledge
about the mechanisms underlying AD pathology. AD animal models that provide
information on Aβ deposition and memory impairment are most popular in drug
testing as these attributes are considered relevant to AD pathogenesis. Apart
from single, double and triple transgenic mice (Duyckaerts et al., 2008), other
animal models used in AD research are hamsters (Hartig et al., 2007), rabbits
(Woodruff-Pak et al., 2007), guinea pigs (Arjona et al., 2002), non-human
primates (Kulstad et al., 2005), fruit flies (Ganguly et al., 2008), zebrafish
(Newman et al., 2010) and worms (Link, 1995). A difficulty with any model is its
relevance to AD and therefore extrapolation is indispensable, even in animal
models (Duff and Suleman, 2004; Duyckaerts et al., 2008). Animal models are
also very expensive, require rigorous maintenance and time-consuming, with
years being required to reproduce an ageing process. In addition, animal
models are unsuitable for high throughput screening techniques. Therefore, use
of simpler model systems like yeast, worms, flies and zebrafish for studying
disease mechanisms and map drug targets are more attractive. Yeasts are
simple eukaryotic cells and provide a greater advantage comparing other model
systems mainly due to its powerful genomic and proteomic screening methods
and availability of a range of tools for molecular level analysis. The potential
applications of yeast cell systems and models in AD research will be discussed
further.
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1.11

Yeast Models

Yeast is a unicellular eukaryotic organism and is widely known for its
applications in molecular and cellular biology studies. Yeast growth and division
can be controlled efficiently by adjusting environmental conditions. Moreover
yeast species including baker‟s yeast Saccharomyces cerevisiae and fission
yeast Schizosaccharomyces pombe are genetically tractable and greatly
amenable to modifications such as gene disruption, mutations or gene-dosage
effects. Because of these advantageous features, yeast cells have been the
model organism of choice in both fundamental and applied medical research.
For example, cell division cycle proteins (CDKs) were first identified in yeast
cells (Nurse et al., 1998). Molecular pathways and essential proteins involved in
autophagy were first identified and modelled in yeast cells (Klionsky, 2010).
Also the cellular target of rapamycin (mTOR pathway inhibitor) was first
discovered in yeast (Heitman et al., 1991).

1.11.1 Yeast genes and human disease
Yeast has been successfully used as a model for human diseases and
particularly neurodegenerative disorders characterized by protein misfolding
and aggregation (Braun et al., 2010; Winderickx et al., 2008). Comparison of
the yeast and human genomes has revealed that 31% of genes involved in
human disease have functional homologs in yeast and nearly 50% of human
genes implicated in heritable diseases have yeast homologs (Foury, 1997;
Hartwell, 2004a; Hartwell, 2004b; Koutnikova et al., 1997). In addition to
similarity in gene sequences, yeast cells demonstrate similarity in various cell
signalling and metabolic pathways. Studies have shown evidence of
morphological markers of apoptotic and necrotic cell death in yeast (Madeo et
al., 1997; Madeo et al., 1999). Yeast cells have also shown to demonstrate
pathological markers associated with human neurodegenerative diseases such
as oxidative stress, mitochondrial dysfunction and endoplasmic reticulum (ER)
stress with expression of human proteins or exogenous treatment with toxic
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agents (Eisenberg et al., 2007; Haynes et al., 2004). Intriguingly, ageing (both
chronological and replicative ageing) also show similar markers in yeast cells.
Despite the evolutionary distance, the molecular pathways involved in cell
death are highly conserved in yeast and humans (Braun et al., 2010). For
example, regulators of cell death in yeast may include apoptosis-inducing factor
(Aif1p),

metacaspase

(Yca1p),

Ndi1p

(homolog

of

AIF

homologous

mitochondrion-associated inducer of death; AMID), Bir1p (homolog of the
inhibitor of apoptosis (IAP) family), Nuc1p (homolog of endonuclease G,
EndoG), Bax inhibitor (BI-1), Nma111p (homolog of HtrA2/Omi), and Cpr3p
(homolog of cyclophilin D) (Aerts et al., 2009; Buttner et al., 2007; Eisenberg et
al., 2007; Madeo et al., 2009). It is to be noted that even though these cell death
pathways are similar between yeast and humans, replication in mammalian cell
models is essential for validation.

1.11.2

Yeast as an experimental tool for AD research

One of the most attractive advantages of yeast compared to other models is
the availability of various experimental tools applicable for high throughput
analysis of protein-protein, gene-gene and gene-protein interactions and
associated cellular functions. Such tools offer an unbiased approach for
studying the pathological functions of human disease proteins and establish
models for drug screening. Some of the notable tools may include the classical
yeast two/three-hybrid system for studying protein-protein interactions for a
range of eukaryotic proteins (Ito et al., 2001), the Saccharomyces Genome
Deletion Project (SGD) (Winzeler, 1999) which is a unique collection of knockout strains covering 96% of the yeast genome and provides a unique tool for the
functional analysis of the yeast genome (Giaever, 2002), Synthetic Genetic
Array analysis (SGA) which is a high-throughput technique for exploring lethal
or growth inhibitory genetic interactions (Tong et al., 2001) and large-scale
protein localization analysis using green fluorescent protein (GFP) tags inserted
individually at the C terminus of 6029 yeast ORFs covering 75% of the total
proteome (Huh et al., 2003). These tools present a variety of applications in AD
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research including studying drug targets/mechanisms and functional analysis of
pathological AD related proteins.
A range of yeast models for studying AD related proteins have been
developed to date (Table 1). Yeast models have been utilized for exploring APP
processing,

secretase

activities,

Aβ

oligomerization/toxicity

and

tau

phosphorylation (Figure 8). Yeast offers numerous advantages compared to
mammalian models with its relatively less complex and well characterized
biology. But, yeast also has natural limitations: they are unicellular and not
functionally linked to other cells.

Although they are primitive compared to

neurons as they lack structures like synapses, axons and dendrites and related
functions, yeast models continue to be a very valuable initial tool for
investigating cellular mechanisms involved in AD (Bharadwaj et al., 2010) which
can then be further validated in model systems.

52

Alzheimer’s Disease Pathology Yeast Model
Amyloid Precursor Protein (APP)

Expression of human APP (Le Brocque et al.,

processing

1998; Zhang et al., 1994; Zhang et al., 1997)

γ-secretase

Functional expression of human APP with
engineered γ-secretase complex (Edbauer et al.,
2004; Edbauer et al., 2003; Futai et al., 2009;
Yagishita et al., 2008)

β-secretase

Expression of human β-secretase in yeast (Luthi
et al., 2003; Middendorp et al., 2004)

C99

Processing of C99 Fragment (Sparvero et al.,
2007)

In vivo Aβ Oligomerization

Two hybrid system (Aβ linked to LexA DNA
binding domain and B42 transactivation domain
(Hughes et al., 1996)
Expression of Aβ/GFP fusion protein (Caine et al.,
2007a)
Expression of Aβ/Sup35p fusion protein
(Bagriantsev and Liebman, 2006; von der Haar et
al., 2007)

Extracellular Aβ Toxicity

Toxicity of oligomeric and fibrillar Aβ (Bharadwaj
et al., 2008)

tau phosphorylation

Expression of human tau-3R and tau-4R isoforms,
clinical mutant tau-P301L (Vandebroek et al.,
2006; Vandebroek et al., 2005)

Table 1: Yeast models developed for studying AD pathology
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Figure 8: Diagrammatic representation of engineered yeast models developed
for studying downstream pathological events in AD
(A) Cells transfected with human APP to study endogenous α-secretase activity
(B) Growth assay developed to monitor human β-secretase activity and screen
for inhibitors, (C) Reconstitution of γ-secretase components using β-gal assay,
(D) Aβ tagged to GFP to monitor localization and oligomerization, (E) Aβ42
tagged to Sup35p protein to study oligomerization,

(F) Endogenous

phosphorylation of human tau, (G) Extracellular toxicity of oligomeric and fibrillar
Aβ42. (Adapted from Bharadwaj et al., 2009)
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1.12

Hypothesis and Objectives:

AD is a very heterogeneous and a multifactorial ageing disorder of the
nervous system. Accumulation and toxicity of the Aβ protein are key mediators
of neurodegeneration in AD and a major target of interest in developing
effective

treatments.

As

described

above

yeast

have

a

number

of

characteristics that allows investigation of AD related proteins that have key
roles in AD pathogenesis and can enable the development of cell based
screening techniques for novel drug discovery and identification of essential
gene functions for Aβ clearance and protection against toxicity. This project
mainly focuses on establishing and validating a yeast model of Aβ oligomer
mediated toxicity and intracellular accumulation. Using these yeast models the
project will address the following hypotheses:



Oligomeric Aβ42 alters viability and proliferation of yeast cells.



Whey derived peptides inhibit Aβ oligomer formation and associated
toxicity.



Recombinant MBP-Aβ42 fusion protein forms oligomers and is toxic



The ubiquitin-proteasome and autophagy-lysosome intracellular
degradation pathways have a role in reducing intracellular Aβ
aggregates in yeast



Enhancing autophagy in yeast reduces levels of intracellular Aβ
aggregates



Latrepirdine enhances autophagy and reduces the levels of
intracellular Aβ aggregates in yeast.



Latrepirdine promotes A42 clearance in vivo.
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The aims of the project are as follows:
1.) Study Aβ42 toxicity and growth effects
a.) Determine toxicity and uptake of Aβ42 and a modified Aβ42 (19:34)
peptide in yeast cells.
b.)

Investigate

the

effect

of

dairy derived

peptides

on

Aβ42

oligomerization and toxicity
c.) Determine structural characteristics and toxicity of MBP-Aβ fusion
proteins
d.) Determine if Aβ42 can promote proliferation of yeast within the
stationary phase of cell growth and whether this can be blocked by
inhibition of mTOR by rapamycin.
2.) Study intracellular accumulation and degradation of Aβ42
a.) Establish a yeast model for intracellular Aβ accumulation using GFPAβ42 and GFP-Aβ42 (19:34) expressing yeast.
b.) Study cellular degradation pathways involved in clearance of GFPAβ42 inside the yeast cell using autophagy and proteasomal activity
deficient mutants.
c.) Determine if activation of autophagy by rapamycin promotes
clearance of intracellular GFP-Aβ42 in yeast.
d.) Determine if latrepirdine can stimulate autophagy and promote GFPAβ42 clearance
e.) Determine if latrepirdine influences A clearance in vivo
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Chapter 2
Materials and Methods
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2.1
2.1.1

Materials:
Yeast strains:

Strain

Genotype

Source

Candida glabrata

Candida glabrata ATCC 90030

Ass. Prof. Ian Macreadie,
RMIT University

Saccharomyces

MATα leu2 ura3 trp1 lys2 his3

cerevisiae (Kvy55) suc2- Δ9

Dr. Kuninori Suzuki,
Tokyo Institute of
Technology (Kirisako et
al., 2000)

Saccharomyces

MATα leu2 ura3 trp1 lys2 his3

Dr. Kuninori Suzuki,

cerevisiae

suc2- Δ9 Δapg8::HIS3

Tokyo Institute of

(Kvy55:atg8Δ)

Technology (Kirisako et
al., 2000)

Saccharomyces

MATa/MATα his3Δ1/his3Δ1

Dr. Gabriel Perrone

cerevisiae

leu2Δ0/leu2Δ0 LYS2/lys2Δ0

University of New South

(BY4743)

met15Δ0/MET15

Wales

ura3Δ0/ura3Δ0
Saccharomyces

MATα his3Δ1/his3Δ1

Dr. Gabriel Perrone

cerevisiae

leu2Δ0/leu2Δ0 LYS2/lys2Δ0

University of New South

(BY4743:pep4Δ)

met15Δ0/MET15

Wales

ura3Δ0/ura3Δ0 pep4Δ/pep4Δ
Saccharomyces

MATα his3Δ1/his3Δ1

Dr. Gabriel Perrone

cerevisiae

leu2Δ0/leu2Δ0 LYS2/lys2Δ0

University of New South

(BY4743:cvt1Δ)

met15Δ0/MET15

Wales

ura3Δ0/ura3Δ0 cvt1Δ/cvt1Δ
Saccharomyces

MATa ura3 his3-11,15 leu2-

Dr. Ben Distel, University

cerevisiae

3,112

of Amsterdam

(Wcg4a)

(Heinemeyer et al., 1993)

Saccharomyces

MATa ura3 his3-11,15 leu2-

Dr. Ben Distel, University

cerevisiae

3,112 pre1-1

of Amsterdam

(Wcg4a:pre1Δ)

(Heinemeyer et al., 1993)
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Saccharomyces

MATa ura3 his3-11,15 leu2-

Dr. Ben Distel, University

cerevisiae

3,112 pre1-1pre2-1

of Amsterdam

(Wcg4a:pre1-2Δ)

2.1.2

(Heinemeyer et al., 1993)

Yeast media:

1) Rich media (YEPD) contains 1% yeast extract, 2% peptone and 2% glucose
in distilled water
2) Minimal media (YNB+2% glucose) contains 0.67% yeast nitrogen base
(YNB) with 0.5% ammonium sulphate and 2% glucose in distilled water
3) Synthetic complete media (YNB complete) contains minimal media (YNB+2%
glucose) supplemented with 20mg/L each of uracil, tryptophan, adenine,
histidine and 30mg/L of leucine in distilled water.
4) Selective media (YNB+2% glucose, -selective amino acid) contains synthetic
complete media with the selected amino acid omitted from the mixture for
selective growth.
5.) Starvation media (YNB+ different carbon sources) contains 0.67% yeast
nitrogen base with 0.5% ammonium sulphate and 2% maltose or 2% glycerol or
2% ethanol or 0.1% glucose in distilled water.
6.) Nitrogen starvation media (YNB -N) contains 0.67% yeast nitrogen base
without ammonium sulphate, and 2% glucose in distilled water
For solid media, 1.7% bacto-agar was added to the liquid media composition.

2.1.3

Bacterial strains and media:

For plasmid amplification, E. coli DH5α strain (fhuA2 Δ (argF-lacZ) U169
phoA glnV44 Φ80 Δ(lacZ)M15 gyrA96 recA1 relA1 endA1 thi-1 hsdR17) was
used. For production of MBP-Aβ fusion proteins, BL21 (DE3) F- ompT hsdSB
(rB-, mB-) gal dcm (DE3) strain was used. Bacterial strains were grown in YT
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media [0.8% bacto-tryptone, 0.5% yeast extract, 0.5% sodium chloride] plus
50µg/ml ampicillin.
For solid media, 1.7% agar was added to the liquid media composition.
Yeast extract, peptone, yeast nitrogen base (YNB), bacto-tryptone and bactoagar were purchased from Difco or MP Biomedical. Amino acids were obtained
from Sigma-Aldrich.

2.1.4

Plasmids:

Expression

Plasmid vector Selective

Reference

marker
GFP

p416

URA3

(Caine et al., 2007a)

GFP-N terminal

p416

URA3

(Caine et al., 2007a)

p416

URA3

Constructed by Sonia

fusion Aβ42
GFP-N terminal
fusion Aβ42

Sankovich, CSIRO

(F19S:L34P)
GFP-N terminal

pRS306

URA3

Prof. Daniel Klionsky,

fusion Atg8p with

University of Michigan

endogenous Atg8

(Suzuki et al., 2001)

promoter
MBP-5ala

pMALc2

AmpR

(Caine et al., 2007b)

MBP-N terminal

pMALc2

AmpR

(Caine et al., 2007b)

pMALc2

AmpR

(Caine et al., 2011)

fusion Aβ42
MBP-N terminal
fusion Aβ16
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2.1.5

Mammalian cell culture reagents:

The human M17 neuroblastoma cell line was kindly provided by Dr. Kim
Wark (CSIRO, Material Sciences and Engineering, VIC, Australia). SH-SY5Y
human neuroblastoma cells and other cell culture reagents including Opti-MEM
(minimum Eagle's medium), Dulbecco‟s MEM, neurobasal media, FCS (Foetal
calf serum), horse serum, non-essential amino acids, penicillin, streptomycin,
sodium pyruvate, trypsin were purchased from Gibco, Life Technologies (USA).
Primary mouse cortical neuronal cultures were kindly provided by Dr. Giuseppe
Ciccotosto (University of Melbourne). Primary cultures were prepared under
sterile conditions as described previously (Barnham et al., 2003; Ciccotosto et
al., 2004) and approved by the local institutional animal ethics committee.
Briefly, embryonic, day 14, BL6J mouse cortices were removed, dissected free
of meninges, and dissociated in 0.025% (w/v) trypsin in phosphate buffer. The
dissociated cells were triturated using a filter-plugged fine pipette tip, pelleted,
resuspended in plating medium (DMEM, 10% FCS, 5% horse serum).
2.1.6

Reagents:

Synthetic human Aβ42 was purchased from the W. M. Keck Laboratory
(Yale University, New Haven, CT). Aβ42 with substitutions at positions [F19S]
and [L34P] [Aβ42 (19:34)] was purchased from Biomatik Corporation
(Wilmington, USA).
Mouse monoclonal antibody WO2, raised against amino acid residues 5-8 of
N-terminal Aβ sequence (Cherny et al., 1999) was kindly provided by Prof. Colin
Masters (University of Melbourne, VIC, Australia). Rabbit polyclonal antibody
raised against GFP was purchased from Abcam. Horseradish peroxidase (HRP)
conjugated anti-mouse and anti-rabbit antibodies were purchased from Abcam.
Gold-conjugated anti-mouse antibody (Ultrasmall Gold) was purchased from
Aurion (ProSciTech).
QuikChange II Site Directed Mutagenesis Kit was purchased from
Stratagene. All restriction enzymes and T4 ligase were purchased from New
England Biolabs (Beverley, MA). All were used according to the manufacturer‟s
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instructions. DNA fragment purification was by QIAquick Gel Extraction Kit and
DNA preparations by QIAprep Spin Miniprep Kit, both from Qiagen (Germany).
DNA sequencing was carried out by Micromon Sequencing Facility (Monash
University).
Oligonucleotide

primers

(for

(TCACTGGTGTTGTCCCAATTT)

GFP
and

cDNA),
GFP-R

GFP-L
(5'

-

(5'
3')

-

3')
(CGT

AAGTAGCATCACCTTCACCT) were purchased from GeneWorks, Australia.
CellSure cDNA kit was purchased from Bioline, Australia. KAPA SYBR® FAST
universal qPCR 2X mix was kindly supplied by Dr. Mark Brown (Edith Cowan
University, WA, Australia).
FM 4-64 stain [N-(3-triethylammoniumpropyl)-4-(6-(4-(diethylamino) phenyl)
hexatrienyl) pyridinium dibromide, (Cat no. T-3166)] and Fluorescein 5isothiocyanate (FITC, Cat no. F1907) were purchased from Molecular Probes,
Invitrogen. α-naphthyl phosphate disodium salt (Cat no. N7255) and D-sorbitol
(S1876) were purchased from Sigma. Rapamycin (MW: 914.17, Sigma, Cat no.
R0395) was a generous gift from Mr. Jay Steer (University of Western Australia,
WA, Australia). Latrepirdine (Dimebolin dihydrochloride MW: 392.37) was
purchased from Biotrend AG, Zurich. MTT reagent [3-(4,5-dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide] was purchased from Sigma (M5655). CytoTox
96® Cytotoxicity assay kit (G1780) and CellTiter 96® AQueous Cell
Proliferation assay (G3582) kits were purchased from Promega (NSW,
Australia).
2.1.7

Miscellaneous consumables:

Nupage Novex 4-12% Bis-Tris gels, lithium dodecyl sulfate (LDS) sample
buffer (40% glycerol 4% LDS, 0.025% phenol red, 0.025% serva blue G250,
2mM EDTA disodium, pH 7.6), MES running buffer (50mM Tris base, 50mM 3–
(N–Morpholino)propanesulfonic acid, 1mM EDTA, 0.01% SDS at pH 7.3), iBlot
western transfer kit were purchased from Invitrogen. Micro BCA protein assay
kit and 0.2µm filters dialysis cassette with a 2kDa cut-off were purchased from
Thermo scientific. 96 well microtitre plates were purchased from NuncBrand
products. 10 kDa MWCO spin column and 0.2µm filters were purchased from
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Pall Corporation (Australia). Gas permeable membrane was purchased from
Diversified Biotech Inc. Uranyl acetate, LR Whiteresin and nickel grids (200
mesh)

were

purchased

from

ProSciTech.

HRP-reactive

Enhanced

Chemiluminiscence reagent (ECL), Pharmacia S200 columns was purchased
from GE Healthcare. Complete protease inhibitor cocktail was purchased from
Roche. 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), dimethyl sulfoxide (DMSO),
polyoxyethylene

(20)

sorbitan

monolaurate

(Tween-20),

ampicillin,

glutaraldehyde, formaldehyde, adenosine triphosphate (ATP), ammonium
sulphate, glucose, maltose, ethanol, 1,4-piperazinediethanesulfonic acid
(PIPES), Magnesium chloride (MgCl2), Calcium chloride (CaCl2), potassium
chloride (KCl), ovalbumin, disodium hydrogen phosphate (Na2HPO4), potassium
dihydrogen phosphate (KH2PO4). sulphuric acid (H2S04), hydrochloric acid
(HCl), methanol, isopropanol, ethylene diamine tetraacetic acid (EDTA), acetic
acid

(Ch3COOH),

magnesium

sulphate

(MgSO4),

2-(N-

morpholino)ethanesulfonic acid (MES). isopropyl b-D-thiogalactopyranoside
(IPTG), ammonium molybdate ((NH4)6Mo7O24), sodum Nitrate (NaN3), tris(hydroxyl methyl)-methyamine (Tris), bovine serum albumin (BSA), sodium
chloride (NaCl), phenylmethylsulfonyl fluoride (PMSF), sodium orthovanadate
(Na3VO4), ascorbate were purchased from Sigma. Sodium Dodecyl sulphate
(SDS) and Coomassie G-250 were purchased from Bio-Rad (Irvine, USA).
Glycerol was purchased from ICN biomedicals. Cholesterol, triolein, oleate
cholesterol, egg yolk phosphatidylcholine were purchased from Sigma. Human
recombinant ApoE4 was purchased from Invitrogen.
2.2

Methods:

2.2.1

Protein detection and analysis:

2.2.1.1

Coomassie staining

Proteins samples containing LDS sample buffer were loaded and
electrophoretically resolved on 4-12% Bis-Tris gels at 100V in MES buffer. The
gels were then stained with Coomassie staining solution (0.2% Coomassie G250, 7.5% Acetic Acid and 50% methanol) for 2-3h. Following the staining
solution was removed and the gels were immersed in destaining solution (20%
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methanol, 10% acetic acid) till clear bands appeared. The gels were scanned
on a VersaDoc 4000MP imaging system.

2.2.1.2

Western Immunoblotting Analysis

Proteins samples containing LDS sample buffer were loaded and
electrophoretically resolved on 4-12% Bis-Tris gels at 100V in MES buffer. The
proteins were transferred from the polyacrylamide gel to a nitrocellulose
membrane using iBlot dry transfer method. Membranes were blocked in 5%
skim milk in TBS solution (50mM Tris, 150mM NaCl, pH 7.4) for 1h. Primary
antibody was diluted in TBST solution (0.5% skim milk, 0.05% Tween in TBS) at
concentrations of (1/3000 for WO2 and 1/5000 for anti-GFP). Incubation (2h at
RT) was followed by three washes with TBST. HRP conjugated secondary
antibody (anti-mouse or anti-rabbit) was diluted by 1/5000 in TBST solution and
incubated with membranes for 1h. After washing with TBST followed by TBS,
membranes were incubated for 2 min with ECL reagent. The membranes were
then developed on films which were scanned using a Bio-Rad GS800TM
calibrated densitometer. The immunoreactive bands were later quantified using
Quantity One 1-D analysis software (version 4.6.8).

2.2.1.3

Determination of protein concentration:

The Micro BCA Pierce protein assay kit was used to estimate the total
protein concentration in all samples indicated. 100µl of blanks (respective lysis
or suspension buffer) including standards and diluted samples (1/500) were
added to a 96 well microtitre plate. Freshly prepared colorimetric reagents were
added (100µl) to each sample and incubated for 30 min at 60°C. Following
incubation the absorption at 595nm was measured using the FLUOstar
OPTIMA multi-detection microplate reader. The protein concentrations in the
samples were determined by reference to the bovine serum albumin (BSA)
standard curve.
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2.2.2

Preparation and characterisation of dairy SPE products

The dairy peptide products were kindly provided by Louise Bennet (CSIRO,
Food Sciences Australia, Victoria, Australia). Dairy protein hydrolysate was
prepared from bovine whey protein isolate (Murray Goulburn, Natrapro WPI,
MG Nutritionals, Brunswick, Australia) by dispersing at 10% total protein (w/w)
in 10mM tri-ethanolamine (Sigma, USA), 10% EtOH, and maintaining at pH 7.4
throughout processing. The enzymes: Glutaminase (Daiwa Kasei K.K., Shiga,
Japan), Corolase PN-L (AB Enzymes GmbH, Darmstadt, Germany), Alcalase
(2.4L,

Novozymes,

Bagsvaerd,

Denmark)

and

Flavourzyme

(1000L,

Novozymes), were introduced in sequence, each at a final concentration of
0.5% (w/w) and incubated sequentially at 50°C for 1h.

Finally, Trypsin

(Novozymes, 0.5%, w/w) was added and incubated at 37°C for 17h before
heating at 90°C for 30 min to inactivate all enzymes.

The molecular size

fraction <8 kDa was recovered by dialysis using regenerated cellulose
membrane (6-8 kDa molecular weight cut-off, Spectrum Laboratories, Inc.,
Dominguez,

CA)

before

further

processing

by

ion

exchange

(IEX)

chromatography, using 2 columns (4.6 x 10 cm) connected in series. Column 1
was packed with cation exchange resin (SP Sepharose Big Beads, GE
Healthcare, Uppsala, Sweden) and Column 2 was packed with anion exchange
resin (Q Sepharose Big Beads, GE Healthcare). Batches of dialysate (400ml)
were loaded onto the pair of IEX columns with 400ml of eluant containing nonbinding peptides recovered. In this case, the IEX-binding fractions were not
recovered. Eluates were freeze dried and stored at -20°C. A single batch of
the total hydrolysate was used for the reported studies.

The product (containing 12.2% nitrogen) was sub-fractionated using C18
solid phase cartridges (Strata-X 33µm Polymeric Reverse Phase cartridges
(500mg/6ml, Phenomenex, California, USA). After washing with methanol and
re-equilibrating with water, sample (100mg/ml total solids in water, 5.0ml) was
loaded and non-binding solids eluted in a further 5.0ml of water (designated
Load+Void sample). Bound fractions were sequentially eluted with 5.0ml of 40%
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and 100% acetonitrile respectively (Ajax Fine Chem, NSW, Australia) and
designated SPE40, and SPE100 respectively. In some cases the bound fraction
was eluted entirely into 100% acetonitrile (SPE-total product). The ratio of solid
eluted by 40% to 100% acetonitrile was approximately 19:1. Products were
dried by evaporation under vacuum and stored at -20°C.

Amino acid analysis of the SPE-total product was conducted in duplicate
using the High Sensitivity Waters AccQTag Ultra (Milford, MA, USA) chemistry.
Results were expressed in mole percent of detectable amino acids. Tryptophan
was not detectable by this method. SPE products were analysed (5mg/ml, 20µl
injection) by reverse phase HPLC (Jupiter 5µ C18 300Å, 250 x 4.6 Phenomenex, USA) under gradient elution (mobile phase A (0.1% TFA in water,
Sigma) and B (0.1% TFA in 95% acetonitrile), using a Waters Alliance HPLC
with a flow rate of 1.0 ml/min and photo-diode array detector set at 220nm. The
gradient was programmed for 2 to 50% B over 54 mins, then 100% B for 4 mins
before re-equilibration to starting conditions. The equivalence of batches of
SPE40, SPE100 and SPE-total prepared for these studies, was routinely
verified by HPLC profiling.

2.2.3

Expression and purification of MBP-Aβ fusion proteins

The cloning, expression and purification of recombinant MBP-Aβ fusion
proteins was done as previously described (Caine et al., 2007b). Bacterial
transformants were grown in 2X YT + 50 mg/ml ampicillin + 0.2% glucose at
37°C until the OD600 reached 0.8. For induction of recombinant protein
expression, IPTG was added to a level of 0.3mM. Following overnight growth at
30oC, the cells were harvested by centrifugation, weighed and resuspended in
cold lysis buffer (50mM Tris pH 7.5, lysozyme 0.05mg/ml, Complete Protease
Inhibitor) for 30 min. This solution was then sonicated and the crude protein
extract was collected by centrifugation and purified by affinity chromatography
using an amylose column (10mm X 10mm). All chromatography procedures
were performed at 4°C. The MBP fusion proteins were eluted in 50mM Tris pH
7.5 buffer containing 10mM maltose.

After elution, the eluted peak was
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concentrated using 10 kDa MWCO spin column, sterile filtered using 0.2μM
filters and stored at 4°C. The eluted protein was checked for purity and stability
by SDS-PAGE and Western blotting using 4-12% NuPage gels in a MES
buffering system and coomassie staining as described in Section 2.2.1. Gel
filtration was performed on a superdex S200 (Pharmacia S200) column in
50mM Tris pH 8.0 at 0.5ml/min. Absorbance was monitored at 280nm.

2.2.4

Aβ peptide preparations and treatment in cells

2.2.4.1

Preparation of Aβ peptides:

Solutions of Aβ peptides were prepared according to the method of
(Bharadwaj et al., 2008) with some modifications. 0.5mg Aβ peptide was
dissolved in 500µl HFIP solution and incubated overnight at RT. The Aβ
dissolved HFIP solution was aliquoted into 5 tubes each containing 0.1mg Aβ
peptide. The HFIP was then evaporated by vacuum and the tubes containing
the peptide films were stored in the -80 freezer. Aβ peptide solutions were
prepared fresh prior to use. The 0.1mg peptide film in the tube was dissolved in
200µl sterile double-distilled water. The solution was vortexed and sonicated on
ice for 5 min followed by centrifugation for 10 min at 14000xg. The supernatant
was incubated at RT overnight which was used for the toxicity experiments. The
concentration of the Aβ solution was approximately 0.5mg/ml (~110µM). The
exact concentration was determined by measuring absorbance at 214nm. The
final concentration was calculated using the formula Aβ (M) = Abs214 x dilution
factor (DF) / 75887. All solvents used for the preparation of Aβ solutions were
filtered using 0.2µm filters and the entire procedure was performed in laminar
air flow hoods. Both Aβ42 and Aβ42 (19:34) peptide solutions were prepared as
described above.

2.2.4.2

Fluorescein isothiocyanate (FITC) labelling of Aβ peptides:

FITC labelling of Aβ peptide was done as described by manufacturer‟s
(Invitrogen, Molecular probes) instructions with slight modifications. FITC
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dissolved in DMSO (10mg/ml) was mixed with premade Aβ solution [0.5mg/ml
(~110µM)] at 1:10 (wt/wt) dye: protein ratio. The mixture was incubated at 4˚C
on a rotator for 2h. The labelled peptide solution was dialyzed in sterile doubledistilled water at 4˚C for 2h using a dialysis cassette with a 2kDa cut-off to
remove unlabelled FITC molecules. Following dialysis, the solution was
centrifuged for 10 min at 14000g and the supernatant was used for
experiments. Aβ42 and Aβ42 (19:34) were FITC labelled as described above.

2.2.4.3

Aβ treatment in Yeast cells: colony count viability assay:

Yeast cells (Candida glabrata) were stored on YEPD agar plates at 4ºC. A
single yeast colony from stock agar plates was inoculated in 5ml
YNB+2%glucose and incubated with shaking at 30ºC overnight. The overnight
culture was resuspended in fresh YNB+2%glucose to an initial cell density (OD
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking and
grown up to exponential phase (OD 1.5-2). These cultures were diluted to
~5X103 yeast cells/ml in sterile, pure water. Cells were then aliquoted into 96well microtitre plates for peptide treatments. Vehicle or peptide preparations
were added to the diluted cell suspension to required concentrations. The final
volume in each well was made up to 125μl. The microtitre plate was then sealed
with a gas permeable membrane and incubated at 30°C constantly shaken at
150rpm for time periods as indicated. Cell survival was determined by plating
aliquots of the cell suspensions onto YEPD agar plates to measure the number
of colony-forming units (CFU) after incubation at 30°C for 2 days. Cell viability
following Aβ treatment was calculated from the CFU count and represented as
percent change from vehicle treated.

2.2.4.4

Aβ treatment in M17 Neuroblastoma cells: MTT viability

assay:
The human M17 neuroblastoma cell line was maintained in Opti-MEM
medium supplemented with 10% FCS (Foetal calf serum), 0.1mM non-essential
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amino acids, 50 IU/ml penicillin, 50mg/ml streptomycin, and 1mM sodium
pyruvate, in 5% CO2 at 37˚C. Cells were seeded in 96-well tissue culture plates
at 104 cells per well and incubated for 20h. Cells maintained in serum free OptiMEM media were incubated with freshly prepared Aβ solutions for 48h at 37˚C.
Cell viability was determined using MTT toxicity assays (Robert et al., 2009).
Following Aβ treatment, cells were re-suspended in 100μl fresh Opti-MEM
media

containing

5mg/ml

MTT

[3-(4,5-dimethylthiazol-2-yl)-2,5-

diphenyltetrazolium bromide] for a 24h incubation at 37˚C. Plates were
centrifuged, the supernatant was removed and 100μl of 0.1M HCl in isopropanol
was added to each well to dissolve the MTT crystals. The absorbance was
measured at 560nm using the FLUOstar OPTIMA multi-detection microplate
reader. Cell viability following Aβ treatment was calculated from the absorption
values at 560nm and represented as percent change from vehicle treated.

2.2.4.5

Aβ treatment in SH-SY5Y human neuroblastoma cells: LDH

and MTS viability assays
The SH-SY5Y human neuroblastoma cell line was maintained in DMEM
medium supplemented with 10% FCS (Foetal calf serum), 50 IU/ml penicillin,
50mg/ml streptomycin in 5% CO2 at 37˚C as described in (Zhang et al., 2009).
For Aβ42 toxicity experiments, cells were plated in 96-well tissue culture plates
at a density of 104 cells/well in DMEM media containing 1% FCS for 20h.
Oligomeric Aβ42 (10µM) co-incubated for 20h with SPE products (0.001-0.1
mg/ml) was added to the cells and incubated for 72h at 37°C.

Lactate

dehydrogenase (LDH) released into the media as a result of Aβ42 toxicity, was
measured in cell supernatants using the CytoTox 96R Cytotoxicity assay as per
manufacturer‟s (Promega) instructions. The cells were then incubated (4h at
37C) with fresh DMEM medium containing 1% (v/v) MTS reagent and viability
was measured as per manufacturer‟s (Promega) instructions. The fluorescence
(LDH) or colorimetric (MTS) measurements were determined using a Fluostar
Optima plate reader (BMG Labtech, Victoria, Australia), and results corrected
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for reagent controls. The data were reported as the percentage standardized
change compared with sample-free controls, after correction for reagent blanks.

2.2.4.6

MBP-Aβ fusion protein treatment in primary cortical neurons:

CCK-8 assay
The mouse primary cortical cell cultures were prepared and maintained in an
incubator set at 37 °C with 5% CO2 as described before in Section 2.1.5. The
cells were allowed to mature for 6 days in culture before commencing treatment
using freshly prepared neurobasal medium plus B27 supplements minus
antioxidants. For the treatment of neuronal cultures, freshly prepared soluble
MBP-Aβ and MBP stock solutions were diluted to 30µM in neurobasal medium
and added to neuronal cells for up to 4 days in vitro.

Cell viability was

quantitated using the CCK-8 assay kit according to the manufacturer‟s
instructions (Dojindo, Maryland, USA). Briefly, the medium was replaced with
fresh neurobasal medium supplemented with B27 lacking antioxidants, and 10
% v/v CCK-8 was added to each well and incubated for 3h at 37°C in a 5% CO2
incubator. Plates were gently shaken, and a 150µl aliquot from each well was
transferred to separate wells of a 96-well plate. The colour change of each well
was determined by measuring the absorbance at 450nm using a FLUOstar
Omega (BMG LABTECH, Germany) microplate reader and background
readings of CCK-8 incubated in cell-free medium were subtracted from each
value before calculations.

The data were normalized and calculated as a

percentage of untreated vehicle control values.

2.2.5

Localization analysis of Aβ peptide treated yeast cells:

2.2.5.1

Preparation of cell extracts from Aβ treated yeast cells

Uptake of Aβ was determined by Aβ immunoblotting analysis of soluble and
insoluble membrane protein extracts of yeast cells treated with Aβ peptides.
Exponentially-growing yeast cells (Candida glabrata) in YNB+2%glucose were
treated with Aβ peptide (5µM) for 3, 6, or 20h. Following treatment, the cells
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were washed in 1XPBST (1XPBS+0.05% tween) and resuspended in 1XPBS
containing 1Xcomplete protease inhibitor cocktail (PI). For cell lysis, the mixture
was vortexed with 0.5-0.6mm diameter glass beads for 4 min with intermittent
cooling on ice and centrifuged at 14000g for 15 min. The supernatant contained
the soluble cytosolic protein fraction. The pellet was washed in 1XPBST and
resuspended in lysis buffer (1% SDS/2M urea/200mM Na2CO3) + 1XPI. The
mixture was incubated at 50°C for 20-30 min followed by centrifugation at
14000xg for 15 min. The supernatant contained the insoluble membrane
associated protein fraction (Caine et al., 2007a). The protein extracts were
analysed by Aβ western immunoblotting as described above.

2.2.5.2

Fluorescent Light Microscopy:

For studying the localization of Aβ, yeast cells were treated with FITC
labelled Aβ peptides (5µM) for 6h, washed in 1XPBST (1XPBS+0.05% tween)
and resuspended in 1XPBS. A total of 4-5µl of the suspension was loaded on a
microscopic slide for imaging using oil immersion at 100X magnification. Cells
were analysed by fluorescent microscopy using wide field optics in Olympus
BX51 Upright Microscope. Fluorescent and bright field images were taken using
Olympus DP71 digital camera. For a better resolution and co-localization
analysis, yeast cells treated with FITC-Aβ42 peptide were observed using Leica
TCS NT upright confocal microscope (Dr. Judy Callaghan, Monash Micro
Imaging). Yeast cells were treated with FITC labelled Aβ42 (5µM) for 6h,
washed in 1XPBST (1XPBS+0.05% tween) and resuspended in 1XPBS. The
cells were then incubated with lipophilic membrane stain FM4-64 (1µM) for
20min at RT, followed by further washing in 1x PBST and resuspended in 1X
PBS. A total of 4-5µL of the suspension was loaded on microscopic slide for
imaging using oil immersion at 100X magnification. Images were taken with
different fluorescent filters (red and green channels) using Olympus DP71
digital camera. Image and overlay analysis was done using Leica LASAF
imaging software.
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2.2.5.3

Transmission electron microscopy of yeast cells:

Aβ42 peptide treated yeast cells (6h) were prepared for imaging by
transmission electron microscopy according to the protocol described by
(Wright, 2000). The method involved fixation, cell wall permeabilization, ethanol
dehydration, embedding in LR White resin, sectioning, labelling and imaging.
Pre-fixation: The cells were incubated in 1X fixative (0.2M PIPES, pH 6.8,
0.2M

sorbitol,

2mM

MgCl2,

2mM

CaCl2,

0.5%

glutaraldehyde,

4%

formaldehyde) at RT for 5 min. The cells were washed in water and
resuspended in 1X fixative and incubated for 30 min at 4°C. The fixative was
removed by centrifugation and cells were resuspended in water and incubated
for 10 min. To permeabilize the cell wall, the yeast cell suspension was
incubated in 1% sodium metaperiodate for 15 min at RT. The cells were then
washed in water and resuspended in 50 mM ammonium chloride for 15 min at
room temperature for quenching of free aldehydes. Dehydration was done by
incubating the cells in a graded ethanol series (25, 50, 75, 95, and 100%
ethanol).
Embedding: The dehydrated yeast cell suspensions were embedded in LR
White resin. The ethanol dehydrated yeast pellet was suspended in 2:1
ethanol:resin and incubated in a glass vial for 1h. The resin was replaced twice
with 1:1 ethanol:resin

and incubated overnight. Following incubation the

ethanol:resin mixture was removed and replaced twice with 100% resin and
incubated for 1h. The resin was then filled into a gelatine capsule.
Thin-Sectioning: The capsules were incubated in a temperature block at
45°C for hardening. Thin sections of 80-120nm were prepared using an ultramicrotome with diamond knife (Jacinta White, CSIRO, Material Sciences
Engineering, Clayton, Australia). The thin sections were then overlayed onto
nickel grids.
Aβ Immunolabeling: The nickel grids were blocked in TBSTOem (140mM
NaCl, 3mM KCl, 0.05% Tween-20, 2% ovalbumin, 8mM Na2HPO4 and1.5mM
KH2PO4) for 15-30 min. The grids were removed from blocking buffer and
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excess liquid was removed using a piece of torn filter paper. Following the grids
were then incubated with the primary antibody (WO2, 1/1000 dilution in
TBSTOem) for 2h. Following three washes with TBSTem (140mM NaCl, 3mM
KCl, 0.05% Tween-20, 8mM Na2HPO4 and1.5mM KH2PO4) the grids were
blocked in TBSTOem for 15-30 min. Later the grids were incubated for 1h with
gold

conjugated

secondary antiserum

(anti-mouse,

1/2000

dilution

in

TBSTOem). The grids are washed in TBSTem three times. Following the grids
were submerged in 2% glutaraldehyde in TBS and incubated for 1h. The grids
are then washed in three times in TBSTem, two times in TBS and in distilled
water. The grids are then air dried and stored in a grid box.
Imaging of yeast sections using transmission electron microscope:
The grids were stained with 2% uranyl acetate for 5–15 min and washed in
water. The grids were then stained with reynolds‟ lead citrate for 5 min at RT
following another wash step. Grids were examined in a Tecnai 12 transmission
electron microscope operating at 120 keV, and images were obtained using a
Soft Imaging Systems MegaView III CCD camera.

2.2.6

Preparation of crude yeast plasma membrane fractions:

The isolation of yeast plasma membrane fractions was performed as
described by (Monk et al., 1991 ). Untreated cells were washed twice with
distilled water and resuspended in homogenization medium (2.5mM EDTA,
1mM phenylmethylsulfonyl fluoride (PMSF), and 50mM Tris, pH 7.5) with 0.50.6µm diameter glass beads. The mixture was then vortexed for 4 min with
intermittent cooling on ice and centrifuged. Immediately after cell disruption, the
homogenate was adjusted to pH 7.25 with 2M Tris. After two centrifugations at
5000g for 10 min to remove cellular debris and unbroken cells, a crude
membrane fraction was pelleted from the supernatant by centrifugation at
30000g for 1h. The crude plasma membrane fraction was pelleted from the
supernatant by centrifugation at 76000g for 1 h. The crude membranes were
washed and suspended in plasma membrane suspension buffer (20% glycerol,
1mM EDTA, 1mM PMSF and 10mM Tris, pH 7.0). The crude plasma
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membranes were snap-frozen in liquid nitrogen and transferred to -70˚C for
storage.

2.2.7

Delipidation of yeast plasma membrane fractions and sample

preparation for mass spectrometric analysis:
Crude plasma membrane fractions from cells treated with 5μM Aβ42 and
Aβ42 (19:34) were prepared as described above. Delipidation of Aβ-treated
yeast membrane fractions was done according to (Mirza et al., 2007). The
crude plasma membrane fractions were incubated in 0.75ml of chloroform on a
shaker at room temperature for 1h. To this, 0.75ml of methanol water (1:1
vol/vol) was added, and the mixture was vortexed for 10 min. The mixture was
centrifuged at 2000g for 1 min, and the chloroform layer was discarded. Another
1ml of chloroform was added to the mixture and sonicated in a bath sonicator
for 30 min. The mixture was then centrifuged at 14000g for 5 min. The
chloroform layer was discarded. To the aqueous layer 1ml acetone was added
and incubated at 4°C for 1h. The protein was recovered by centrifugation at
10000g for 15 min. The protein precipitate was dissolved in 70% acetonitrile,
0.1% TFA and analysed in an Agilent Q-TOF 6510 mass spectrometer (Bio21,
University of Melbourne, VIC, Australia).

2.2.8

Plasma membrane ATPase assays:

Yeast plasma membrane ATPase assays were performed by the
colorimetric measurement of free phosphate released by ATP hydrolysis in
microtiter plates (Monk et al., 1991 ). The basic ATPase assay medium
contained 15mM MgSO4 and 15mM ATP in 50mM MES-Tris buffer at pH 6.0
but also included 0.2mM ammonium molybdate, and 5mM NaN3 to eliminate
nonspecific phosphatase, and mitochondrial ATPase activities. The crude
plasma membrane fractions were incubated with different concentrations of
freshly prepared Aβ peptide solutions for 15-20 min, prior to addition of ATPase
assay medium. The final reaction mixture was incubated for 1h at RT, and the
75

reaction was stopped by addition of 100μl of a stop developing reagent
containing 1% SDS, 100mM ammonium molybdate, 0.6M H2S04, and 0.8%
ascorbate. After a 10 min of incubation at RT, the absorbance at 630nm was
determined. Activity was measured by subtracting the absorbance at 630nm of
the same set of sample treated with ATPase inhibitor vanadate (Na3VO4). The
amount of phosphate (Pi) liberated was estimated by reference to a linear
standard curve containing 0-100nM of H3PO4 in the reaction mixture. The
values were represented as percent activity of the vehicle treated.

2.2.9

Protein structure analysis

2.2.9.1

Dynamic light scattering of MBP and MBP-Aβ fusion proteins

Dynamic light scattering (DLS) analysis of MBP and MBP-Aβ solutions was
done by Dr. Jo Caine (CSIRO, Parkville, Australia) as described in (Caine et al.,
2011). DLS was completed using Dyna Pro Nano Star plate reader at laser
wavelength 830nm.

Both MBP and MBP-Aβ42 (~0.8mg/ml) was set up in

triplicates in a Greiner 384-well low volume glass bottom plate (approx 20 µl
working volume). Forty individual 5 second DLS collections per well were taken
at 25ºC. The hydrodynamic radius, Rh, was estimated from translation diffusion
coefficient by the Stokes–Einstein relationship. For comparison the radius of
gyration, Rg, was calculated as follows. For MBP protein the MOLREP program
(Vagin and Teplyakov, 1997) was used with the crystal structure [PDB: 4MBP]
(Quiocho et al., 1997)) and Rg was adjusted by a scaling factor of ρ=Rg/Rh=0.77
(Wilkins et al., 1999) for globular protein structures like MBP. For MBP-Aβ
fusion proteins with unknown structures the empirical relationships established
by (Wilkins et al., 1999) Rh=0.475 N0.29 nm for native proteins and Rh=0.221
N0.57 nm for highly denatured proteins, where N

is a number of protein

residues, were used. The average radii, Rav, of the MBP-Aβ fusion proteins
were also estimated from volumes occupied by the protein molecules: V = D M
10-3, where D=1.43 (nm3/Da) is the mean density of proteins (Quillin and
Matthews, 2000), M, the molecular weight in Dalton and V, the volume of the
protein in nm3.
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2.2.9.2

Circular Dichroism Spectroscopy

Aβ42 peptide solutions were prepared as described in Section 2.2.4.1. Aβ42
peptide

solutions

(0.05mg/ml;

11µM),

pre-incubated

with

different

concentrations of SPE40 and SPE100 preparations (Section 2.2.2) (final
concentrations: 005, 0.05 & 0.25 mg/ml in de-ionised water) were analysed by
Jasco J-810 CD Spectropolarimeter (JASCO Inc., Easton, MD, USA). The
mean residue ellipticities of samples were recorded across the far UV range
(190-260 nm), using a 0.1cm path-length quartz cuvette, at room temperature,
monitoring at 0.1 nm intervals. The acquisition parameters were 100 nm/min
with 1 sec response times, 1.0 nm bandwidth, and 0.1 nm data pitch, and data
sets were averaged over 3 scans. Spectra of SPE products alone at appropriate
concentrations were subtracted from respective profiles of Aβ42+SPE product,
but were otherwise unsmoothed. The instrument was calibrated with de-ionised
water. The spectra were analysed and generated using the Jasco‟s Spectra
Manager TM.
2.2.9.3

Fourier Transform Infra-Red Spectroscopy

Fourier transform infrared (FTIR) spectroscopic analysis of Aβ42+SPE
fractions were done by Rabia Sarroukh (Université Libre de Bruxelles, Belgium).
Aβ42 peptide solutions were prepared as described in Section 2.2.4.1. Aβ42
peptide solutions (0.05mg/ml; 11µM) were pre-incubated with different
concentrations of SPE40 and SPE100 preparations (Section 2.2.2) (final
concentrations: .001, 0.005, 0.01, 0.05 & 0.1 mg/ml mg/ml in de-ionised water).
Following, IR spectra of the solutions were recorded using a Equinox 55
infrared spectrophotometer (Bruker Optics, Ettlingen, Germany) placed in a
thermoregulated room (21°C) and equipped with a liquid N2-refrigerated
mercury-cadmium-telluride detector. Fourier self-deconvolution was applied to
increase the resolution of spectra in the amide I region, which is that most
sensitive to protein secondary structure. The FTIR data were preprocessed as
described in (Goormaghtigh et al., 1999). Briefly, the water vapor contribution
was subtracted with 1956-1935 cm-1 as the reference peak, and then the spectra
were baseline-corrected and normalized for equal area between 1700-1500
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cm−1. The spectra were finally smoothed at a final resolution of 4 cm −1 by
apodization of their Fourier transform using a Gaussian peak shape (full width
at half height of 13.33 cm-1) and self-deconvolution was carried out using a
Lorentzian peak shape (full width at half height of 20 cm -1). The resolution
enhancement factor was therefore 1.5. Extraction of spectral data was
conducted using in-house software generated with Matlab (Mathworks Inc.
Natick, MA, USA).

2.2.9.4

Transmission Electron Microscopy

Aβ42 peptide pre-incubated with SPE fractions (Section 2.2.2) and
MBP/MBP-Aβ

fusion

microscopy (TEM).

protein

were

analysed

by

transmission

electron

The samples were diluted to a final concentration of

0.01mg/ml with de-ionised, filtered (0.2 µm) water before applying to carboncoated 400-mesh copper grids, which had been glow discharged in nitrogen.
After 1 min adsorption time excess sample was wicked off with filter paper and
the sample stained with 2–3 drops of 2% aqueous uranyl acetate. The grids
were air-dried and examined in a Tecnai 12 Transmission Electron Microscope
(FEI, Eindhoeven, The Netherlands) operating at 120 KV. Micrographs are
recorded using a Megaview III CCD camera running under AnalySiS imaging
software (Olympus Australia, Mt Waverley, Australia).

2.2.10

Inducing stationary phase in yeast

Yeast cells were stored on YEPD agar plates at 4ºC. A single yeast colony
from stock agar plates (Candida glabrata or Saccharomyces cerevisiae
BY4743) was inoculated in 5ml YNB+2%glucose or YNB+2%glucose (-trp)
respectively and incubated with shaking at 30ºC overnight. For inducing
stationary phase, the overnight culture was washed in sterile water and
resuspended in YNB+ different carbon sources including 2% maltose or 2%
glycerol or 2% ethanol or 0.1% glucose media at a starting dilution of 0.2 optical
density (OD) at 600nm and incubated for 7h at 30°C. For normal growth the
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overnight culture was incubated in YNB+2%glucose or YNB+2%glucose (-trp)
for Candida glabrata or Saccharomyces cerevisiae BY4743 respectively. The
growth was determined every hour for 7h by measuring the OD at 600nm.
Flow cytometric analysis of yeast cells (Candida glabrata) was done in
Beckman Coulter EPIC flow cytometer. The size distribution of actively growing
cells (exponential phase) in YNB+2%glucose and starved cells (stationary
phase) in YNB+2%maltose were studied by forward scatter (FSC) analysis
(Tzur et al., 2011). Data was analysed using CellQuest analysis software. To
determine budding, the cells were analysed by light microscopy.

2.2.11

Aβ treatment of stationary phase yeast cells

The stationary phase yeast cells were treated with Aβ42 peptide similar to
treatment in exponential phase cells described above (Section 2.2.2.3). Cell
proliferation was determined by plating aliquots of the cell suspensions onto
YEPD agar plates to measure the number of colony-forming units (CFU) after
incubation at 30°C for 2 days. Cell proliferation following Aβ treatment was
calculated from the CFU count and represented as percent change from vehicle
treated.
2.2.12

Construction of GFP-Aβ42 (19:34) mutant in p416 plasmid

The yeast shuttle plasmid, p416.GPD (Mumberg et al., 1995) was used to
express GFP, GFP-Aβ42 and the mutant GFP-Aβ42 (19:34) in yeast. It is a
centromeric plasmid stably maintained at one or two copies per cell, and has
the strong constitutive GPD promoter to direct heterologous gene expression
throughout the yeast life cycle. Standard molecular biology techniques were
used for the construction of recombinant plasmids. Briefly, a GFP coding
fragment was isolated from pAS1N (Prescott et al., 1997) and inserted into
p416.GPD. The GFP-Aβ42 fragment was obtained from pAS1N.GFP-Aβ42 from
the previous work (Caine et al., 2007a).
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The GFP-Aβ42 (19:34) mutant was constructed in p416 (Figure 1) by Sonia
Sankovich, CSIRO. To create the GFP-Aβ42 (19:34) mutant, site-directed
mutagenesis was carried out on a sub-fragment cloned into pBluescript to avoid
spurious changes in coding sequences. The changes effected were F19S,
L34P, with numbering referring to Aβ amino acid residue number. Sequencing
was carried out to confirm that the required changes had been effected and that
no additional mutations were introduced into the Aβ coding sequence. Mutated
fragments were subsequently cloned back into p416.GPD.

Figure 1: The p416 is a shuttle vector with low copy number. It has the
ampicillin resistance selectable marker (AmpR) and uracil synthesis selectable
marker (URA3) genes. (Adapted from www.atcc.org)

2.2.13

Yeast Transformation:

Yeast cells were transformed with p416 (GFP/GFP-Aβ expressing) and
pRS306 (GFP-Atg8p expressing) using electroporation. A single colony of the
untransformed yeast strain was inoculated in 5ml YEPD media and incubated at
30ºC overnight with shaking. The overnight culture was transferred into fresh
YEPD media and grown until mid-exponential phase (OD at 600nm, 1). Cells
were washed in ice-cold sterile water two times and then in 1M sorbitol. The
cells were then resuspended in 1M sorbitol. A 50µl aliquot of the yeast
80

suspension was mixed with ~5µg plasmid DNA in a pre-chilled electroporation
cuvette (0.2cm) and pulsed once at V=1.5kV, 25µF, 200Ohms. A 1M sorbitol
(500µL) was added to the yeast suspension and plated out on selective media
agar plates (YNB+2%glucose –ura for p416 and pRS306 expression). The
plates were then incubated at 30ºC for 5-6 days. Yeast colonies from the
transformant plates were then re-streaked onto fresh selective media agar
plates (YNB+2%glucose –ura) and stored at 4ºC after formation of yeast
colonies.

2.2.14

cDNA synthesis and Real Time PCR:

Starting culture (OD 0.2) of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34)
expressing yeast cells (KVY55) were grown in selective YNB+2%glucose (-ura)
media till exponential phase (OD 0.6). Untransformed cells (KVY55) grown in
YEPD media were also collected (OD 0.6). Total cell number and viability was
measured by Vi-CELL XR cell counter. The cDNA from the frozen pellets (~1-3
X 106 cells) was synthesized using CellSure cDNA kit (Bioline). A 1uL aliquot of
the cDNA template was mixed with KAPA SYBR® FAST universal qPCR 2X
mix, primers for GFP (L, R: 5µM final) and DNase free water to a final volume of
15µl. The samples were run on the iQ5 real-time PCR detection system. Using
the LinRegPCR (version 2009) software the threshold Ct values and the mean
PCR efficiencies were calculated. GFP transcript levels/106 cells was calculated
by using the comparative Ct method with slight modifications, The transcript
levels were expressed as levels/106 cell = 106 * (relative 2-(∆Ct) value/total
number of cells) (Schmittgen and Livak, 2008).

2.2.15

Agarose gel electrophoresis:

The PCR products (from rtPCR reaction described above, Section 2.2.14)
were analysed by agarose gel electrophoresis and observed under UV
transillumination. Agarose (1.5%) was prepared in 1 x TAE (0.04M Tris-acetate,
0.001M EDTA, pH 8.3) by boiling in a microwave. The dissolved agarose was
cooled to ~60°C and then poured into a gel tray to set, with combs positioned to
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produce sample wells. Set gels were placed in tanks (Bio-Rad), which were
then filled with 1XTAE buffer. Ethidium bromide (stock solution 10mg/ml) was
added to give a final concentration of 1 μg/mL in the cooled gel before pouring.
Sample loading dye was added to samples and loaded into the wells. Gels were
run at 70 Volts for 45 minutes to an hour, then visualised under UV light in the
Bio-Rad Gel DocTM UV transilluminator system.

2.2.16

Analysis of GFP fluorescence by microscopic imaging:

GFP/GFPAβ expressing yeast cells were stored on YNB+2%glucose (-ura)
agar plates at 4ºC. A single yeast colony from stock agar plates was inoculated
in 5ml YNB+2%glucose (-ura) and incubated with shaking at 30ºC overnight.
The overnight culture was resuspended in fresh YNB+2%glucose (-ura) to an
initial cell density (OD at 600nm) of 0.2 and incubated at 30°C with shaking.
Yeast cell suspensions were collected at different points of growth from early
exponential phase till late log phase for microscopic analysis and GFP
fluorescence quantification. Following washing in distilled water, a total of 4-5µL
of the suspension was loaded on microscopic slide for imaging using oil
immersion at 100X magnification. Images were taken using similar fluorescence
and bright field exposure levels using Olympus DP71 digital camera. GFP
fluorescing cells were counted relative to the total number of cells in the frame
to determine the levels of the GFP/GFP-Aβ protein in the cell population. A
number of 10 image frames each containing approximately 50 cells were
quantified for each sample.

2.2.17

Preparation of cell extracts from GFP/GFPAβ expressing

yeast
Yeast cell suspensions of GFP/GFPAβ expressing yeast were collected at
different points of growth from early exponential phase till late log phase as
described above. Total cell protein extracts from yeast were used for
immunoblotting. Frozen cell pellets were resuspended in 150μl cold lysis buffer
(50mM Tris pH 8, 1mM EDTA, 150mM NaCl, 1mM DTT, 2% SDS) with freshly
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added 1XPI and then incubated at 70ºC for 15-20min. Following centrifugation
at 18000g for 10min, the supernatant was collected and protein concentration of
each sample was measured using the Micro BCA protein assay kit as described
above (Section 2.2.1.3). A total of 50µg protein of each sample was studied by
SDS-PAGE and western blot analysis as described previously as described
above (Section 2.2.1.2).

2.2.18

Assessing autophagy in yeast

Autophagy was assessed by FM 4-64 staining, vacuolar alkaline
phosphatase activity: Pho8 assay and by GFP-Atg8p transport assay as
described below.
2.2.18.1 FM 4-64 staining:
Vacuolar membrane specific lipophilic dye, FM 4-64 staining in yeast was
performed as described in (Journo et al., 2008). Saccharomyces cerevisiae
(KVY55, and atg8Δ) yeast cells were cultured to mid exponential phase in
YEPD media. The cells were later washed in 50mM HEPES (pH 7) twice and
resuspended in YNB+2%glucose (complete) or YNB (-N) media containing
1mM PMSF. Latrepirdine or rapamycin treatment was done in YNB+2%glucose
(-trp) media. Following 6h incubation at 30ºC, the cells are washed and
resuspended in YNB (-trp) media containing 10mM sodium citrate (pH 4.3). FM
4-64 stain was added to the cells to a final concentration of 1µM. The solutions
were incubated for 30min at RT. The cells were washed and resuspended in
YNB+2%glucose (-trp) media containing 10mM sodium citrate (pH 4.3) and
observed under the fluorescence microscope. A total of 4-5µL of the suspension
was loaded on microscopic slide for imaging using oil immersion at 100X
magnification. Images were taken using similar fluorescence and bright field
exposure levels for all samples using Olympus DP71 digital camera
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2.2.18.2 Vacuolar Alkaline phosphatase activity: Pho8 assay
Vacuolar alkaline phosphatase activity in yeast cell lysates were measured
as described in (Noda and Klionsky, 2008).

Saccharomyces cerevisiae

(KVY55, atg8Δ) yeast cells were cultured to mid exponential phase in YEPD
media. The cells were later washed in sterile water twice and resuspended in
YNB+2%glucose (complete) media or YNB (-N) media. Latrepirdine or
rapamycin treatment were done in YNB complete) media. Following 6h
incubation at 30ºC, the cells are washed and re-suspended in ice-cold assay
buffer (250mM; Tris-HCl, pH 9.0; 10mM MgSO4, and 10mM ZnSO4). The cells
were lysed using glass beads vortexing for 3 X 2min on ice. The samples were
centrifuged at 14000g for 5min. The supernatant was used for the assay.
Protein concentration of each sample was measured using Micro BCA protein
assay kit as described before (Section 2.2.1.3). A total of 100µg of cell lysate
was incubated with 55mM α-naphthyl phosphate disodium salt for 20min at
30ºC and diluted in the lysis buffer to a final volume of 0.5ml. The reaction was
stopped by adding 0.5mL stop buffer (2M glycine-NaOH, pH 11). The
fluorescence was measured at 345nm excitation and 470nm emission
wavelengths. After correcting for blank, the activity was calculated as Units/µg
of sample.
2.2.18.3 GFP-Atg8p transport assay:
The atg8Δ cells were transformed with pRS306 (GFP-Atg8p expressing)
plasmid as described in section 2.2.9.2). For the GFP-Atg8p processing assay
(Yen et al., 2007), yeast strains harbouring the GFP-Atg8 plasmid were grown
to mid exponential phase in YNB+2%glucose (-ura). Cells were then treated
with latrepirdine, rapamycin or nitrogen starved for 6h at 30ºC. Following
incubation the samples were collected for fluorescence microscopy. Following
washing in distilled water, a total of 4-5µl of the suspension was loaded on
microscopic slide for imaging using oil immersion at 100X magnification. Images
were taken using similar fluorescence and bright field exposure levels using
Olympus DP71 digital camera. Intravacuolar GFP fluorescence in cells relative
to the total number of cells in the frame was determined as an indicator of
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activation of autophagy in the cell population. The intravacuolar green
fluorescence indicates GFP-Atg8p transport to vacuole and cleavage of GFP
into vacuole. A number of 10 image frames each containing approximately 50
cells were quantified for each sample.
2.2.19

Aβ clearance in APOE knockout mice:

The Aβ peripheral clearance experiment in mice were performed by Dr
Ian Martins, Kevin Taddei, Mike Morici and Linda Wijaya from our laboratory.
APOE knockout mice (B6.129P2 ApoE−/−), were originally obtained from the
Jackson Laboratory, Bar Harbor, Maine. All mice were bred and maintained at
the Animal Resources Centre (ARC, Perth,Western Australia). Mice were
housed 5–6 per cage in a controlled environment at 22°C on a 12h day/night
cycle (light from 0700 to 1900 h). A standard laboratory chow diet (Rat and
Mouse Cubes, Specialty Feeds Glen Forrest,WA, Australia) and water were
consumed ad libitum. This study was conducted in accordance with the
Australian code of practice for the care and use of animals for scientific
purposes as specified by the National Health and Medical Research Council
(NHMRC). The experimental protocols were approved by the University of
Western Australia Animal Ethics Committee.

Stock Aβ42 was prepared by dissolving the Aβ42 peptide in DMSO to a
concentration of 1mg/ml. The stock was diluted in sterile isotonic saline solution
(0.9% w/v NaCl) immediately before experimentation to a concentration of 20μg
in 50μL. The ApoE4 lipid emulsions were prepared as described in (Sharman et
al., 2010). The composition of the remnant like emulsions was triolein
45.8%±3.2%, total cholesterol and cholesterol oleate 21.5% ± 3.2% and egg
yolk phosphatidylcholine 32.7% ± 2.5%. The remnant like emulsion particles
had a mean diameter of 133nm ± 17.6nm as measured by laser light scattering
using the Malvern Instruments particle Zetasizer (Malvern Instruments,
Worcestershire, United Kingdom). Partially lipidated human recombinant ApoE4
(Invitrogen, Madison, WI, USA) was freeze dried, resuspended in isotonic saline
and then lipidated by incorporation into lipid emulsion particles that were
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prepared by sonication and purified by ultracentrifugation as described
previously (Hone et al., 2003; Yang et al., 1999b).

To determine the role of latrepirdine in the peripheral clearance of Aβ42
12monthold APOE knockout mice were anaesthetized with an intraperitoneal
injection of Ketamine/Xylazine (75/10 mg/kg). APOE knockout mice were
injected with lipidated recombinant ApoE4 (75μg) plus Aβ42 (20μg/50μl) preincubated with latrepirdine (3.5mg/kg) or vehicle (saline). Blood samples were
taken from the retroorbital sinus using 1.0mm diameter heparinised haematocrit
tubes at 2.5, 5 and 15 min postinjection for Aβ analysis by immunoblotting (3µl
of plasma) as described in Section 2.2.19. Injected mice were sacrificed by
decapitation and liver tissues were collected at similar time points (2, 5 and
15min). Tissue samples were homogenised in TBS (pH 7.4) containing 5μg/ml
aprotinin, 0.1mMPMSF and 5μg/ml leupeptin followed by Aβ immunoblotting
analysis (100µg of total protein of total homogenate) as described in Section
2.2.1.2.

2.2.20

Statistical Analysis:

Student t-tests and one-way ANOVA tests were used for statistical
analysis and p-value analysis. All graphs were made in Microsoft ExcelTM. All
data were represented as Data±SEM (Standard error of mean).
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Chapter 3
Toxicity and Cellular
localization of Oligomeric Aβ42
in Yeast
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3.1

Introduction:

Soluble oligomer Aβ42 is a key mediator of neuronal dysfunction and toxicity
in the AD brain. As described in Chapter 1, Aβ can affect a wide array of
neuronal functions and thereby may lead to neurodegeneration [reviewed in
(Bharadwaj et al., 2009)]. Aβ42 mediated toxicity has been found to be
associated with disruption of mitochondrial activity (Butterfield et al., 2001 ;
Dyrks et al., 1992; Lustbader et al., 2004a; Palmblad et al., 2002), receptormediated functions (Bhaskar et al., 2009; Fuentealba et al., 2004; Pereira et al.,
2004; Wei et al., 2002 ; Yaar et al., 1997), disruption of Ca2+ homeostasis
(Hartmann et al., 1994; Mattson et al., 1993) and oxidative damage of
membranes (Butterfield et al., 2002; Müller et al., 2001; Verdier et al., 2004).
The natural occurrence of multiple structural entities of Aβ42 in the brain and
the complexity of detecting specific isoforms in cellular compartments have
confounded the study of oligomer Aβ-mediated toxicity in neuronal cell models.
Although, the toxicity of exogenously-added oligomeric Aβ42 peptide compared
to other forms has been well established in neurons, the cellular localization and
target of oligomeric Aβ42 by which it mediates the cascade of events leading to
cell death are unclear. A growing body of evidence indicates that membrane
mediated cytotoxicity is an inherent property of protein oligomers including Aβ
(Glabe, 2006; Glabe and Kayed, 2006). Since the majority of Aβ42 produced is
secreted into the extracellular lumen, it is thought that it can have a major
impact on neuronal functions and viability by interacting with the cell surface
membranes (Talaga and Quere, 2002; Verdier and Penke, 2004; Verdier et al.,
2004). A recent study has also shown that increased Aβ levels in membraneassociated and intracellular fractions isolated from the temporal neocortex of
AD patients to be more closely related to AD symptoms than other measured
Aβ species (extracellular soluble and extracellular insoluble) (Steinerman et al.,
2008).

Aβ-mediated toxicity has been studied in other non-mammalian models
including Caenorhabditis elegans (worm) (Link, 1995) and Drosophila
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melanogaster (fly) (Finelli et al., 2004). However these models are largely
based on transgenic overexpression of Aβ/APP and are complex systems
compared to yeast cells. Moreover, yeast is a well established model organism
for studying toxic proteins involved in neurodegenerative diseases (Bharadwaj
et al., 2010; Braun et al., 2010; Winderickx et al., 2008). Yeast cells combine a
high level of conservation in cellular processes with mammalian cells with
added advantages of fast cell division, simple growth requirements and an
abundance of experimental tools (Hughes, 2002; Mager and Winderickx, 2005;
Simon and Bedalov, 2004).
Recently, I developed a novel method for determining toxicity of different Aβ
isoforms in yeast (Bharadwaj et al., 2008). In this study, oligomeric Aβ treatment
was shown to be more toxic compared to fibrillar Aβ, consistent with previous
observations in neuronal cells (Dahlgren et al., 2002; Stine et al., 2003). The
yeast model of oligomeric Aβ toxicity (Bharadwaj et al., 2008) therefore
represents a simple cellular model for studying Aβ toxicity and uptake. In this
chapter, I have extended the work to compare the toxicity of oligomeric Aβ42
and a non-oligomeric Aβ42 (19:34) peptide in yeast and neuronal cells. Further I
have investigated the cellular localization and binding of Aβ peptide to the yeast
plasma membrane to provide potential mechanisms of oligomer Aβ42 mediated
toxicity in yeast cells.

3.2

Aims:

1.) Compare the toxicity of oligomeric Aβ42 and non-oligomeric Aβ42 (19:34)
peptides in yeast and in M17 neuroblastoma cells.
2.) Determine the uptake and cellular localization of oligomeric Aβ42 and nonoligomeric Aβ42 (19:34) peptide in yeast.

3.3

Materials and Methods:

Aβ42 and Aβ42 (19:34) peptide solutions were prepared as described in
Section 2.2.4.1. The peptide solutions were characterized by SDS-PAGE
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followed by western blotting analysis. The toxicity of the peptides were tested in
yeast (Candida glabrata) and M17 neuroblastoma cells by colony count and
MTT assays respectively as described in Section 2.2.4.3 and Section 2.2.4.4.
Uptake of exogenously added Aβ42 in yeast was studied by immunoblotting
analysis (with WO2, an anti Aβ antibody) of cell extracts (soluble and
membrane-associated) as described in Section 2.2.5.1. Sub-cellular localization
was analysed using Leica TCS NT (upright confocal microscope) by 2 channel
fluorescence imaging of yeast cells treated with FITC-labelled Aβ42 (green
channel) for 6h followed by staining with lipophilic membrane stain (FM4-64, red
channel). Yeast cells treated with Aβ42 (6h) were also analysed by
immunoelectron microscopic analysis as described in Section 2.2.5.3. Plasma
membrane fractions of Aβ42-treated yeast cells were delipidated and analysed
by electrospray ionization-mass spectrometry (ESI-MS) as described in Section
2.2.7. Aβ42 peptides were co-incubated with crude plasma membrane fractions
and assayed for vanadate sensitive H+ATPase (ATP hydrolysing) activity as
described in Section 2.2.8.

3.4

Results:

3.4.1 Toxicity of oligomeric and fibrillar Aβ42 peptides in yeast:
In neuronal cells, fibrillar Aβ42 is less toxic compared to oligomeric Aβ42
peptide (Dahlgren et al., 2002). In the previous work, I showed that similar to
neuronal cells, fibrillar Aβ42 was less toxic to yeast cells (Figure 1A), whereas
oligomeric Aβ42 treatment caused a dose-dependent loss of cell viability in
yeast (Figure 1B). Significant cell death was observed from concentrations of
1µM with complete loss of cell viability at higher concentrations of 30µM
(Bharadwaj et al., 2008).

Due to its heterogeneous nature and advanced aggregation state, fibrillar
Aβ42 would be an inappropriate control to compare cellular uptake and
localization. Instead a non-aggregating, monomeric form of Aβ would be better
suited. Aβ42 is difficult to be maintained in a monomeric form due to its
hydrophobic nature and tendency to aggregate under physiological conditions.
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Besides, a control would need to be prepared under the same conditions.
Therefore, an Aβ42 peptide modified at positions F19S and L34P [Aβ42
(19:34)] with reduced tendency to aggregate was chosen for this work (Ahmed
et al., 2010; Hughes et al., 1996; Luhrs et al., 2005; Wurth et al., 2002).

Cell Survival (%)

A

**

B

Cell Survival (%)

*

**
**
0

0.5

1

30

100 (µM)

Figure 1: Toxicity of oligomeric and fibrillar Aβ42 peptides in yeast (Bharadwaj
et al, 2008)
Toxicity of oligomeric and fibrillar Aβ peptide preparations were tested in yeast
cells. Exponentially growing yeast cells (Candida glabrata) were treated with
5μM oligomeric, fibrillar Aβ42 peptide or vehicle buffer alone for 20h at 30ºC
(A). Cell viability was determined by counting the number of colonies formed
and expressed as a percentage of vehicle treated control. Compared to vehicle
treated cells, cell viability was significantly reduced (** p<0.01) in cells treated
with oligomeric Aβ42. No significant loss of viability was observed with fibrillar
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Aβ42 treatment. Dose response of oligomeric Aβ42 (0.5, 1, 5. 30 and 100µM)
peptide in yeast (B) Compared to vehicle treated cells, cell viability was
significantly reduced with oligomeric Aβ42 peptide in a dose dependent manner
(* p<0.05, ** p<0.01). All data are expressed as mean ± SEM (n=4).

3.4.2

Oligomerization and toxicity of Aβ42 and Aβ42 (19:34)

peptides:
Firstly, oligomer Aβ42 and non-aggregating Aβ42 (19:34) peptide were
characterized by SDS-PAGE electrophoresis followed by coomassie staining
and western immunoblotting analysis (Figure 2A). Aβ42 peptide was observed
as monomers (4.5kDa) and SDS stable oligomers in the 7-17kDa range,
indicative of low-n oligomers (dimers, trimers, tetramers) by both coomassie
staining and Aβ immunoblotting using WO2 (Figure 2A, lanes 1, 3). However in
Aβ42 (19:34) peptide, only monomeric species (4.5kDa) was detectable by both
methods (Figure 2A, lanes 2, 4). Supporting the (Wurth et al., 2002) study, this
result shows that Aβ42 (19:34) had reduced tendency to form oligomers
compared to Aβ42.
Further the toxicity of oligomeric Aβ42 and non-oligomeric Aβ42 were
tested in yeast and M17 neuroblastoma cells. Oligomeric Aβ42 treatment
caused a 75-90% cell death at concentrations of 5-10μM as measured by viable
counts. However Aβ42 (19:34) treatment showed less than 5% cell death at
similar concentrations (Figure 2B). The toxicity of Aβ peptides at similar
concentrations was also tested in human M17 neuroblastoma cell lines by
determining the ability of cells to reduce MTT to purple formazan after treatment
(Mosmann, 1983) (Figure 2C). 5-10μM of oligomeric Aβ42 treatment caused
~75-95% decrease in cell viability, whereas Aβ42 (19:34) caused only ~5%
decline in MTT reduction (Figure 2C). Overall the results showed that Aβ42
(19:34) had reduced tendency to form oligomers and was less toxic in yeast and
neuronal cells compared to oligomeric Aβ42. This result supports previous
studies indicating that oligomerization is essential for Aβ mediated toxicity in
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cells [reviewed in (Bharadwaj et al., 2009)]. Further, the uptake and localization
of Aβ42 and Aβ42 (19:34) peptides in yeast cells was studied.
A

1

2

3

4

Aβ oligomers
Aβ monomers
WB: WO2

Coomassie

B
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Figure 2: Toxicity of Aβ42 and Aβ42 (19:34) in yeast and M17 neuroblastoma
cells
The Aβ42 and Aβ42 (19:34) peptides were prepared as described Section
2.2.4.1. The peptide solutions were size fractionated by SDS-PAGE
electrophoresis (4-12% Bis-Tris gels) (A). 100ng of Aβ42 (lane 1) and Aβ42
(19:34) (lane 2) were analysed by immunoblotting (anti-Aβ, WO2). 5μg of Aβ42
(lane 3) and Aβ42 (19:34) (lane 4) of the same peptide stock were analysed by
coomassie staining. Exponentially growing yeast cells (Candida glabrata) were
treated with Aβ42 or Aβ42 (19:34) peptide (5μM and 10μM) for 20h at 30ºC.
Cell viability was determined by counting the number of colonies formed and
expressed as a percentage of untreated control (B). Compared to untreated
cells, cell viability was significantly reduced (**, p<0.01) in cells treated with 5 or
10µM Aβ42. Treatment with Aβ42 (19:34) did not significantly alter cell viability.
M17 neuroblastoma cells plated in Opti-MEM were treated with Aβ42 or Aβ42
(19:34) peptide (5μM and 10μM) for 48h at 37°C. Cell viability was measured by
MTT assay as described in Section 2.2.4.4 and expressed as a percentage of
untreated control (C). Similar to yeast cells, Aβ42 treatment caused significant
loss of viability at concentrations 5 and 10µM (**p<0.01), whereas treatment
with Aβ42 (19:34) did not significantly alter cell viability in M17 neuroblastoma
cells. All data are expressed as mean ± SEM (n=4).
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3.4.3

Uptake and toxicity of Aβ42 and Aβ42 (19:34) peptides in

yeast:
The uptake of exogenously added Aβ peptides in yeast was first determined
by fluorescent microscopy of cells treated with fluorescein isothiocyanate
(FITC)-labelled Aβ peptides. FITC labelling of Aβ42 and Aβ42 (19:34) peptides
was performed as described in Section 2.2.4.2. Exponentially growing yeast
cells were treated with FITC-labelled Aβ peptides for 6h at 30°C and observed
under the microscope. Cells treated with FITC-Aβ42 showed a strong intense
green fluorescence around the cell surface (Figure 3A). Cells treated with FITCAβ42 (19:34) also showed a similar pattern but lower intensity of fluorescence
around the cell surface (Figure 3C). No internalization of Aβ peptide (both Aβ42
and Aβ42 (19:34)) was observed at 6h incubation. To determine if Aβ
internalizes with longer incubation, yeast cells were treated with FITC labelled
Aβ for 20h. However, even with longer incubation times no intracellular
fluorescence could be observed. This suggested that Aβ42 was largely
associated with the cell surface.
Aβ peptide uptake was also studied by western immunoblotting analysis in
yeast cells. Soluble (cytosolic) and insoluble (membrane associated, 1% SDS
solubilised) extracts of yeast cells treated with Aβ42 and Aβ42 (19:34) peptides
for 3, 7 and 20h were analysed by Aβ immunoblotting (WO2). Both Aβ42 and
Aβ42 (19:34) were detected in the insoluble extracts (lanes 5, 6, 10 and 11) and
undetectable in the soluble extract (lanes 7, 8, 12 and 13) (Figure 3G, H and I).
Also, cells treated with Aβ42 showed increased uptake with longer incubation
times (7, 20h) compared to Aβ42 (19:34) treatment. At 3h, only monomeric
Aβ42 (4.5kDa) was detectable, but with 7 and 20h incubation, Aβ42 oligomers
(7-17kDa range and 50-200kDa range) were evident in the insoluble extract
(Figure 3G, H, I: lanes 5 and 6). However with Aβ42 (19:34) peptide treatment,
only monomeric forms were detectable and no significant increase in levels of
uptake was observed (Figure 3G, H, I: lanes 10 and 11). These results
indicated that Aβ42 had increased affinity to cell surface membrane compared
to Aβ42 (19:34). It was notable that both the Aβ peptides were undetectable in
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the soluble cytosolic lumen of the cell, even with longer incubation times. The
increased uptake of Aβ with longer incubation times was evident in Aβ42 but
not in Aβ42 (19:34) treatment. One explanation is that Aβ42 is more
hydrophobic and prone to self-aggregation than Aβ42 (19:34) and as a result
shows increased association with the cell surface membrane.
To determine if there is a correlation of Aβ42 uptake with toxicity, cell
viability of yeast cells treated with oligomer Aβ42 (5µM) was determined at
different incubation times (0, 3, 7 and 20h) (Figure 3J). Compared to vehicle
treated cells, cell viability was significantly reduced with increasing incubation
time with 5µM Aβ42. Cell death was significant from 3h incubation with Aβ42
(~20%) and was found to increase to ~60% at 7h and ~75% at 20h. This
indicated that toxicity of oligomer Aβ42 was dependent on the incubation period.
Together with the immunoblotting analysis, the result suggested a correlation of
detection of Aβ42 oligomers with toxicity in yeast cells. With Aβ42 treatment at
3h, only monomeric forms were detectable with a cell death of ~20%. Whereas
at 7h and 20h, Aβ42 oligomers (7-17kDa range and 50-200kDa range) were
detected comparing to increased cell death of up to ~60-75% (compare Figure
3G, H, I with J).
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Figure 3: Analysis of the uptake and toxicity of Aβ42 and Aβ42 (19:34) peptides
in yeast cells
Uptake of Aβ42 in yeast cells was analysed by microscopic analysis of FITC
labelled Aβ treated yeast. Fluorescent and bright-field images of exponentially
growing yeast cells (Candida glabrata) treated with FITC-Aβ42 (A, B) and FITCAβ42 (19:34) (C, D) for 6h and 20h at 30°C are shown here. Cells treated with
FITC-Aβ42 showed a strong intense fluorescence around the cell surface. Cells
treated with FITC-Aβ42 (19:34) exhibited a similar pattern but lower intensity of
fluorescence. Vehicle buffer treatment showed no fluorescence at similar
exposure levels (E, F). Yeast cells incubated with unlabelled Aβ42 or Aβ42
(19:34) peptides were collected for western immunoblotting analysis (WO2) at
3h (G), 7h (H) and 20h (I). Soluble (cytosolic) proteins were isolated by glass
bead lysis in lysis buffer and insoluble (membrane) proteins were extracted
using 1% SDS/200mM Na2CO3/2M urea in lysis buffer. Samples (in duplicates)
were size fractionated by SDS-PAGE electrophoresis (4-12% Bis-Tris gels) and
analysed by Aβ immunoblotting (anti Aβ-WO2) (G, H). Lanes are- vehicle
treated: insoluble (1, 2), soluble (3, 4), Aβ42 treated: insoluble (5, 6), soluble (7,
8) and Aβ42 (19:34) treated insoluble (10, 11), soluble (12, 13) including 100ng
loading standards of Aβ42 (9) and Aβ42 (19:34) (14). Both Aβ42 and Aβ42
(19:34) were detected in the insoluble extracts and undetectable in the soluble
extracts. Cell viability of yeast cells treated with oligomer Aβ42 (5µM) was
determined at different incubation times (0, 3, 7 and 20h) and expressed as a
percentage of vehicle treated control (J). Compared to vehicle treated cells, cell
viability is significantly reduced (*, p<0.05, **, p<0.01) with increasing incubation
time (from 3h) with 5µM Aβ42. Data are expressed as mean ± SEM (n=4).
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3.4.4

Cellular localization of Aβ42 in yeast

FITC-Aβ and western blot analysis in yeast showed that Aβ42 bound to the
cell surface membrane and was undetectable in the soluble cytosolic lumen of
the cell. The data suggested that Aβ42 was associated with the cell surface and
not internalized into the cells. To further study the sub-cellular localization of
Aβ42, cells were analysed by fluorescent imaging confocal microscopy. To
determine whether Aβ42 associated with the plasma membrane, cells were
treated with FITC-Aβ42 for 6h followed by staining with FM4-64 stain for 15 min
at 30°C (Figure 4A-C). FM4-64 stain is a lipophilic styryl dye which binds to
cellular membranes. The fluorescence of FM4-64 dye is quenched in aqueous
state, but when inserted into membranes it fluoresces. It is ideally used for
analysis of endocytosis and as a plasma membrane marker (Fischer-Parton et
al., 2000). Co-localization analysis of FITC (green channel) and FM4-64
fluorescence (red channel) showed association of FITC-Aβ42 with FM4-64
staining (Figure 4D). To determine the levels of co-localization, a region of
interest (ROI) across the diameter of the cell was chosen and fluorescence
intensities was measured across the red (FM4-64) and the green (FITC-Aβ42)
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channels (Figure 4D). Significant overlap of the red and green channels
indicated the association of FITC-Aβ42 with FM4-64 fluorescence. Although
FITC-Aβ42 and FM4-64 fluorescence were not completely overlapping, the
result indicated a strong association of Aβ42 with the yeast plasma membrane.
For enhanced image resolution and sensitivity of Aβ detection, yeast cells
treated with oligomeric Aβ42 were analysed by immunoelectron microscopy
(Mulholland and Botstein, 2002; Wright, 2000) as described in Section 2.2.5.3.
Aβ localization was detected by WO2 (anti-Aβ) probing followed by incubation
with gold conjugated secondary antibody. The yeast sections were then stained
with uranyl acetate and Reynolds‟s citrate solution for imaging by electron
microscopy. Aβ immunoreactivity was indicated by the appearance of distinct
dark spots. Cells treated with Aβ42 showed dark spots associated with the cell
surface, whereas no such spots were observed within the cell. The dark spots
were mainly found populated on the cell wall and also in the outer leaflet of the
yeast plasma membrane (Figure 4F). Vehicle treated cells showed no dark
spots associated with the cell (Figure 4E). Overall the data from co-localization
analysis (with plasma membrane marker FM4-64) and immunoelectron
microscopy showed that Aβ42 binds to the yeast cell surface and supported the
previous data where intracellular uptake of Aβ was absent in yeast (Section
3.4.3).
To provide insight into specific Aβ oligomeric forms associated with the
yeast plasma membrane, crude fractions of yeast plasma membranes were
isolated from cells treated with Aβ42 and Aβ42 (19:34) peptide (5µM, 6h) and
analysed by electrospray ionization mass spectrometric analysis (ESI-MS)
(Figure 5). Distinct species with mass/charge ratio of 4514.09, 9027.61 and
13539.88, indicating Aβ42 monomer, dimer and trimer respectively were
detected in the crude membrane fractions of cells treated with Aβ42 (Figure
5A). Crude membrane fractions isolated from cells treated with Aβ42 (19:34)
(5µM) for 6h showed no detectable levels of Aβ (Figure 5B). The peaks
observed in the Figure 5B represent the yeast plasma membrane proteins. This
was absent in the crude membranes isolated from Aβ42 treated cells (Figure
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5A) because the levels of Aβ42 detected was ~10 fold higher than the yeast
membrane proteins. Due to this, the graphs are represented in different Y-axis
range [(relative abundance): highest point of 2X10 4 in figure 5B and 9.5X105 in
figure 5A]. Overall, the result supported the earlier observations showing that
Aβ42 has increased affinity to the plasma membrane compared to Aβ42
(19:34).
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FM 4-64
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Figure 4: Aβ42 associates with the yeast plasma membrane
Cellular localization of Aβ42 in yeast was analysed by confocal and
immunoelectron microscopic analysis of Candida glabrata cells treated with
Aβ42. Cells were analysed by dual channel fluorescence imaging (Leica TCS
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NT confocal microscope) after treatment with FITC labelled Aβ42 (A, green
channel) for 6h and staining with FM4-64 stain for 15 min (B, red channel) at
30°C. Images were recorded using Olympus DP70 camera. Image overlay (C)
and co-localization of FITC-Aβ42 and FM4-64 staining across the region of
interest (ROI) was done using Leica LASAF software image analysis.
Fluorescence intensities (arbitrary units) of FITC-Aβ42 (green), FM4-64 (red)
and overlay (orange) across the ROI is represented by the green, purple and
orange dotted lines respectively (D). A significant association of FITC-Aβ42 with
FM4-64 staining was observed. Cells treated with vehicle (E) or unlabelled
Aβ42 (6h) (F) were fixed, permeabilized and prepared on gold grids for electron
microscopic imaging. The grids were probed with WO2 (anti-Aβ) followed by
incubation with gold conjugated anti-mouse secondary antibody. The samples
were observed by negative staining using 2% aqueous uranyl acetate and
Reynold‟s lead citrate and micrographs were recorded using a Megaview III
CCD camera. Cells treated with Aβ42 showed dark circular spots around the
cell surface, indicative of Aβ42 associating with the yeast plasma membrane (F)
(indicated by black arrows). No distinct dark spots were observed with the
untreated sample. Overall, the data suggested that Aβ42 localized on the yeast
plasma membrane. However, Aβ42 was not detected in the intracellular lumen
of yeast.
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Figure 5: Mass spectrometric (ESI-MS) analysis of plasma membrane fractions
of Aβ42 treated yeast cells
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Mass spectrometric (ESI-MS) analysis of plasma membrane fractions of
Aβ42 treated yeast cells: Plasma membrane fractions of yeast cells treated with
Aβ42 (5µM) (A) and Aβ42 (19:34) (B) were isolated and analysed by mass
spectrometry (ESI-MS). The crude plasma membrane (CPM) fractions from the
cells were delipidated using chloroform/methanol/water extraction. The protein
from the aqueous layer was recovered using acetone precipitation and air dried.
The protein pellet was dissolved in 70% acetonitrile, 0.1% TFA and analysed in
an Agilent QTOF 6510 mass spectrometer (mass range of 4-100kDa). Distinct
species with mass/charge ratio of 4514.09, 9027.61 and 13539.88, indicating
Aβ42 monomer, dimer and trimer respectively were detected in cells treated
with oligomer Aβ42 as shown in the ESI-MS spectra here. However, no species
representative of Aβ was identified in cells treated with Aβ42 (19:34). The
graphs are represented in different Y-axis range (relative abundance: highest
point of 2X104 in figure 5B and 9.5X105 in figure 5A).

3.4.5

Effects of Aβ42 and Aβ42 (19:42) peptides on plasma

membrane H+ATPase activity
Cellular localization analysis of Aβ42 and Aβ42 (19:34) uptake in yeast
clearly showed that exogenously added Aβ42 is localized to the cell surface,
strongly associated with the plasma membrane. It was suggested that Aβ42
caused cell death in yeast is possibly mediated by plasma membrane
associated toxicity. In neuronal cells, Aβ42 is known to disrupt membrane
associated proteins and related functions contributing to its ability to induce cell
death. One of these targets for Aβ42 that has been suggested is the Na+/K+
ATPase, which is critically important for osmotic balance and cell volume
maintenance. Decreased overall Na+/K+ ATPase enzyme activity is observed in
the hippocampus of the APP+PS1 mice (Dickey et al., 2005). Reports have
shown that Aβ42 can mediate disruption of cellular homeostasis via inhibition of
Na+/K+ ATPase activity in neurons (Dickey et al., 2005; Mattson et al., 1993).
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In yeast, the proton (H+)-transporting plasma membrane protein (H+ATPase) is mainly responsible for maintenance of cellular homeostasis and
viability (Ambesi et al., 2000). It is also a member of the P2-ATPase family in
eukaryotes and a functional homolog of the Na+/K+ ATPase. The H+-ATPase is
the most abundant plasma membrane protein in yeast cells (Ambesi et al.,
2000) and also an important target for anti-fungal drugs implying its essential
role in cell survival (Billack et al., 2010; Manavathu et al., 1999).
To determine if oligomeric Aβ42 can damage the yeast H+-ATPase, in vitro
plasma membrane H+-ATPase (vanadate sensitive ATP hydrolysis) activity was
determined in crude membrane fractions incubated with Aβ peptides (Figure 6).
ATPase activity measurement was performed as described in Section 2.2.8.
Following Aβ pre-incubation for 15-20min, the crude membranes were tested for
plasma membrane ATPase activity. The assay was done in presence of
ammonium molybdate and sodium nitrate to prevent residual effects of
nonspecific phosphatase, and mitochondrial ATPase activities. Pre incubation
with oligomeric Aβ42 was found to cause a dose-dependent inhibition of H+ATPase activity of yeast plasma membranes. A ~70% and ~95% loss of
ATPase activity was observed when 15μg of total yeast membrane suspension
was incubated with 1 and 1.5μM of Aβ42, respectively. However, treatment with
similar amounts of Aβ42 (19:34) did not alter the ATP hydrolysing activity. The
result suggested that inhibition of H+-ATPase activity was mediated by
oligomeric Aβ42 and not by non-oligomeric Aβ42 (19:34).
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(µM)
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Figure 6: Oligomeric Aβ42 inhibits H+-ATPase activity in yeast plasma
membrane fractions
Crude plasma membranes (CPM) were prepared from exponentially growing
yeast.

The

CPM

fractions

(15μg)

was

pre-incubated

with

different

concentrations (0-1.5µM) of oligomeric Aβ42 or the non-aggregating Aβ42
(19:34) peptide for 15-20 min followed by addition of ATP assay buffer
containing 10mM ATP and reaction at RT for 45-60 min. The ATP hydrolysing
property of the plasma membrane H+-ATPase was determined from the
phosphate released, which was measured colorimetrically at (630nm) using
ammonium molybdate stop buffer. Activity (%) was measured by subtracting the
Abs (630nm) of vanadate-treated CPM fractions and normalized using
phosphate standard curve. A significant inhibition of H+-ATPase activity was
observed with Aβ42 pre-incubation (**, p<0.01), but not with Aβ42 (19:34). Data
are expressed as mean ± SEM (n=4).
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3.5

Discussion:

3.5.1 Modified Aβ42 (19:34) exhibited reduced aggregation and
toxicity
It is well established that the toxicity of Aβ is associated with its ability to
oligomerize and aggregate. A number of mammalian models have been used to
study mechanisms of Aβ mediated toxicity. A major advantage of using yeast
cells for Aβ toxicity is the ability to perform the assay in water. Unlike
mammalian cells which require osmotic and nutrient support, yeast cells can
survive in water for several days with minimal loss of viability (Bharadwaj et al.,
2008). Since Aβ42 has an increased tendency to form heterogeneous
aggregates in the presence of salts under physiological conditions (Stine et al.,
2003), studies of oligomer Aβ specific toxicity in mammalian cell models can be
problematic. Using yeast cells for oligomer Aβ42 toxicity in water therefore can
overrule the influence of the salts on Aβ aggregation. In this chapter, I have
extended my previous finding where I showed that oligomeric Aβ was more
toxic than fibrillar Aβ (Figure 1). The major aim of this study was to investigate
the uptake and localization of oligomeric Aβ42 in yeast cells.
Due to the heterogeneous nature of Aβ fibrillar preparations, an Aβ42
peptide modified at positions F19S and L34P [Aβ42 (19:34)] (Wurth et al., 2002)
with reduced tendency to aggregate was chosen as a control for oligomeric
Aβ42 in this study. In vitro structural modelling and yeast two hybrid analysis
indicate that positions 19 (phenylalanine) and 34 (leucine) in Aβ42 sequence
play an important role in self interaction of the peptide monomers (Ahmed et al.,
2010; Hughes et al., 1996; Luhrs et al., 2005). Size fractionation analysis by
SDS-PAGE showed that Aβ42 (19:34) peptide was completely monomeric,
compared to the stable low-n oligomers (7-17kDa range) observed with
oligomeric

Aβ42

preparations

(Figure

2A).

In

both

yeast

and

M17

neuroblastoma cells, oligomeric Aβ42 caused significant loss in cell viability
(Figure 2B, C). Approximately 75% cell death was observed at concentrations
of 5μM of Aβ42 in both yeast and M17 neuroblastoma cells, compared to less
than 5% cell death at similar concentrations of Aβ42 (19:34). As expected,
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these results showed that oligomeric Aβ42 was more toxic than the nonoligomerizing Aβ42 (19:34). This data supports the previous studies in
mammalian cells indicating that soluble oligomeric form of Aβ42 is the main
toxic species responsible for cell death (Dahlgren et al., 2002; McLean et al.,
1999; Shankar et al., 2007; Shankar et al., 2008).
3.5.2 Accumulation of Aβ42 in the yeast plasma membrane
Due to its hydrophobic nature, Aβ has an inherent nature to associate with
biological membranes. The ability to interact with membranes is therefore an
important feature of oligomer Aβ mediated toxicity to cells. The cellular
localization of the oligomeric Aβ42 and the non-oligomeric Aβ42 (19:34) was
determined by fluorescence microscopy (Figure 3A-F) and Aβ immunoblotting
of cell extracts (Figure 3G-H) showed that both Aβ peptides bound the cell
surface. However, oligomeric Aβ42 displayed an increased binding affinity
compared to the modified Aβ42 (19:34) (Figure 3). Also, an increased level of
Aβ42 oligomers (7-17kDa range and 50-200kDa range) in the insoluble
membrane fraction was evident with longer incubation periods (Figure 3G, H
and I: lanes 5 and 6). However no increase in levels of the modified Aβ42
(19:34) was observed with longer incubation times (Figure 3G, H and I: lanes 10
and 11). The hydrophobic nature of Aβ42 and its ability to oligomerize may
explain its accumulation in the insoluble membrane fraction, which was clearly
reduced with Aβ42 (19:34) treatment. It is likely that the decreased ability of the
Aβ42 (19:34) peptide to self associate (Hughes et al., 1996; Wurth et al., 2002)
may contribute to its low affinity and accumulation in the cell compared to
oligomeric Aβ42.
Importantly, the progressive accumulation of Aβ and the appearance of Aβ
oligomers (7-17kDa range and 50-200kDa range) in the insoluble membrane
fraction showed correlation with increased loss of viability in yeast with longer
incubation times (compare lanes 5, 6 Figure 3G-I with 3J). This observation
supports previous reports indicating that increased binding to the plasma
membrane can enhance the neurotoxic property of Aβ (Ciccotosto et al., 2004;
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Crouch

et

al.,

2008).

Further,

confocal

microscopic

analysis

and

immunoelectron microscopy clearly showed that oligomeric Aβ42 was largely
populated on the cell surface, strongly associated with the cell wall and the
outer leaflet of the plasma membrane of the yeast cell. The crude plasma
membranes of Aβ42 and modified Aβ42 (19:34) peptide treated cells were
analysed by ESI-MS (Figure 5A). Aβ42 treated cells revealed monomer and
oligomeric forms (dimer and trimer). However, the membrane fractions isolated
from cells treated with modified Aβ42 (19:34) showed no detectable levels of Aβ
(Figure 5B). It is likely that Aβ42 (19:34) was stripped during the delipidation
process of sample preparation for ESI-MS, due to its weak binding to the yeast
cell surface membranes (cell wall and plasma membrane). This suggests that
the modification at residues 19 and 34 of the Aβ sequence affects not only the
self interaction of the Aβ42 (19:34) peptides, but its nature of membrane
interaction. Furthermore the results suggested that the reduced affinity of Aβ42
(19:34) peptide to the cell surface could be one of the reasons for its decreased
cytotoxicity. However, it could be argued that the lack of detection of the
modified Aβ42 (19:34) peptide in the crude plasma membrane fractions may be
due to its vulnerability to degradation compared to Aβ42 because of its inability
to form oligomers.
The binding dynamics of Aβ42 to membranes is complex. Aβ42 has a long
hydrophobic C-terminus which can insert into the lipid bilayer membranes of cell
surfaces. Studies suggest that these cell surfaces can catalyse amyloid
aggregate nucleation, perhaps in a different mechanism from that observed in
solution state (Sethuraman and Belfort, 2005; Stefani, 2007). Cellular surfaces
can also accelerate amyloidogeneis and possibly impact the structural integrity
and functions of membranes (Porat et al., 2003). Aβ can bind a variety of
cofactors on the plasma membrane including ion channels proteins, receptor
complexes, lipid and sterol molecules which can impact its binding and also
contribute to cellular dysfunction and death. The results presented in this
chapter provide evidence in support of the idea that binding to the plasma
membrane plays an important role in oligomer Aβ mediated cell death.
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3.5.3 Inhibition of H+-ATPase in vitro activity by oligomeric Aβ42

Ion motive ATPases are vital plasma membrane protein complexes
responsible for the active transport of ions across the plasma membrane and
maintenance of cellular homeostasis (Skou, 1982). Decreased Na+/K+ ATPase,
Cl--ATPase activity and protein levels has been observed in APP +PS1 double
transgenic mice (Dickey et al., 2005) and also in the AD brains (Hattori et al.,
1998). Reduced activity of the Na+/K+-ATPase and Cl--ATPase has been
associated with elevated intracellular Ca+, Na+, swelling of neurons, increased
vulnerability to excitotoxic stress, accumulation of reactive oxygen species
(ROS) and apoptotic cell death in AD (Dickey et al., 2005; Mark et al., 1995).
Moreover decreased activity of Na+/K+-ATPase proteins has been observed to
be associated with amyloid deposition in the hippocampus of APP+PS1 mice
(Dickey et al., 2005). In addition, reports suggest that disruption of Na+/K+
ATPase and Cl- ATPase activity by Aβ can result in neuronal cell death in AD
(Bores et al., 1998; Mark et al., 1995; Yagyu et al., 2001).
Aβ42 toxicity in yeast was found to be mediated by its binding to the plasma
membrane. Oligomeric Aβ42 was toxic to cells and showed increased affinity to
the plasma membrane compared to the modified Aβ42 (19:34) which had
reduced binding to the plasma membrane (Section 3.4.3). Furthermore oligomer
Aβ42 was found to inhibit the H+ATPase activity in isolated yeast plasma
membranes whereas the modified non-oligomerizing Aβ42 (19:34) did not affect
the activity. Approximately a 70-95% decrease in activity with 1-1.5μM of
oligomeric Aβ42 treatment was observed compared to only a 5% decrease with
Aβ42 (19:34) at similar concentrations (Figure 6). Collectively the data indicated
that inhibition of the plasma membrane H+-ATPase as one of the possible
mechanisms of oligomer Aβ42 mediated cell death. This finding was consistent
with the data obtained from neuronal cells.

Previous studies report decreased Na+/K+ ATPase and Cl--ATPase activity
in plasma membranes isolated from Aβ42 peptide treated hippocampal cells
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(Bores et al., 1998; Mark et al., 1995; Xiao et al., 2002). It is however difficult to
distinctly associate the effect of Aβ42 peptide to the inhibition of the ion-motive
ATPase activity. Aβ42 induced disruption of membrane integrity, lipid
peroxidation and other affected cellular functions may also contribute to the
decreased activity. It has also been shown that mRNA for the Na+/K+ ATPase
αIII subunit is consistently down-regulated in the hippocampus ridden with
amyloid deposition (Dickey et al., 2003). Alternative pathways involving
interactions of Aβ with membrane proteins leading to modulation of signal
transduction cascades can also contribute to the decreased expression of
Na+/K+ ATPase. A study showing that Lyn, a tyrosine kinase can phosphorylate
Na+/K+ ATPase leading to its reduced expression levels (Bozulic et al., 2004)
further supports this idea. However, Aβ peptide treatment [both oligomer Aβ42
and non-oligomeric Aβ42 (19:34)] was performed in isolated wild type yeast
plasma membranes. Moreover, the assay was done in the presence of
ammonium molybdate and sodium nitrate to prevent residual effects of
nonspecific phosphatase, and mitochondrial ATPase activities. This suggested
that oligomer Aβ42 specifically inhibited the ATP hydrolysing property of the
yeast plasma membrane H+-ATPase. Overall the data from the toxicity, cellular
localization of Aβ peptides and the isoform specific effects on the H+-ATPase
activity suggested that inhibition of plasma membrane H+-ATPase activity can
be one of the main causes of cell death mediated by oligomeric Aβ42 in yeast.

3.6 Summary:
The results presented in this chapter have confirmed the toxicity of
oligomeric Aβ42 to yeast cells. In addition I have shown that oligomeric Aβ42
binds the yeast plasma membrane where it can alter the activity of the plasma
membrane proton pump H+ATPase. This may be one mechanism by which
oligomeric Aβ can impact cellular homeostasis and cause cell death. Preventing
the formation or disrupting oligomeric structures of Aβ has shown to inhibit
toxicity (Yang et al., 1999a; Yang et al., 2005). In the next chapter, I determine
the effects of dairy derived peptides in modulating Aβ structure and toxicity in
yeast and neuronal cells.
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Chapter 4
Suppression of Aβ42
Oligomerization prevents
Toxicity in Yeast and Neuronal
cells
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4.1

Introduction

Preventing the formation or disrupting the specific Aβ toxic oligomer
structures that cause neuronal dysfunction in the brain has been proposed as a
therapeutic strategy for AD (Klein, 2007; Zimecki, 2008). A wide range of
inhibitors and modulators of Aβ42 aggregation, including peptide, protein and
small molecular classes of natural and synthetic origin (Estrada and Soto, 2007;
Gordon et al., 2002; Kokkoni et al., 2006) have been shown to regulate toxicity
of Aβ42 both in vitro and in vivo (Amijee et al., 2009; Bastianetto et al., 2008;
Dumery et al., 2001; Findeis, 2002; Nerelius et al., 2009). A major challenge in
designing such Aβ inhibitors is to specifically target the toxic form of Aβ and
identify potent compounds with low cytotoxicity.
Inhibitors of Aβ aggregation from natural food products or dietary intake has
been of interest in AD therapeutics. Milk proteins are well known for chaperone
activity. The micellar structure of the bovine milk caseins represents a
thermodynamically stable architecture that accommodates the amphiphillic
casein proteins and colloidal calcium phosphate components of milk (Ferrandini
et al., 2005). Two of the four proteins of the casein micelle, -casein (Cn) and
S2 casein on isolation readily form fibrils under either reducing or nonreducing conditions, respectively (Thorn et al., 2008; Thorn et al., 2005a) but
this behaviour is suppressed by αS1-casein and β-casein, present in
stoichiometric excess, in fresh milk (Thorn et al., 2008; Thorn et al., 2005a).
Anti-fibril properties have been previously demonstrated in milk protein
hydrolysates (Bennett et al., 2009). Anti-fibril and other bioactivities have also
been extensively characterised in a peptide extract from ovine colostrum
(Schuster et al., 2005) and also shown to improve learning and memory in rats
(Popik et al., 1999). The chaperoning activity of milk proteins implicates them as
interesting candidates for targeting Aβ oligomerization and associated toxicity.
Toxicity of oligomeric Aβ42 has been recently established in a yeast cell
model [(Bharadwaj et al., 2008), (Chapter 3)]. In addition to its high level of
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conservation in cellular processes with mammalian cells, yeast cells present
added advantages of simple growth requirements, fast cell division, and a
robust nature making it a very attractive cellular model for drug screening
(Hughes, 2002; Mager and Winderickx, 2005; Simon and Bedalov, 2004). The
yeast model for oligomer Aβ toxicity is therefore well suited for characterizing
the effects of Aβ structure modifying compounds. In this chapter, the dosedependence effects of a whey protein-derived peptide hydrolysate (SPE product
series) on Aβ42 structure were characterized using circular dichroism, fourier
transform infrared spectroscopy (FTIR), transmission electron microscopy
(TEM) and by size fractionation (SDS-PAGE). To determine the effects of SPE
mediated modulation of Aβ42 structure, the toxicity of pre-incubated SPE-Aβ42
mixtures were studied in yeast and further validated in neuronal cell models.

4.2

Aims:

1.) Preparation and amino acid analysis of SPE hydrolysate fractions from
bovine whey protein isolate
2.) Study the effects of SPE fractions on Aβ42 secondary structure and
oligomerization
3.) Investigate the effects of SPE fractions on Aβ42 toxicity

4.3

Materials and Methods:

Preparation and amino acid analysis of SPE fractions recovered from dairy
whey protein hydrolysate was done as described in Section 2.2.2 (Louise
Bennett, CSIRO). Aβ42 solutions were prepared and incubated with different
concentrations of SPE fractions. The SPE-Aβ42 mixtures were then analysed
by circular dichroism (CD), Fourier transform infrared spectroscopy (FTIR,
Rabia Sarroukh, Université Libre de Bruxelles, Belgium) for determining the
secondary structure constitution as described in Section 2.2.9.2 and Section
2.2.9.3. The mixtures were also studied by transmission electron microscopy
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(TEM) and size fractionation (SDS-PAGE, Aβ immunoblotting) for analysis of
Aβ oligomerization. Cellular toxicity of the pre-incubated SPE-Aβ42 solutions
were studied in yeast by CFU (colony forming units) count and in SH-SY5Y
human neuroblastoma cells by LDH and MTS assays as described in Section
2.2.4.5.
4.4

Results:

4.4.1 Characterization of Whey Peptide SPE Product

The dairy whey protein hydrolysate was fractionated by preparative SPE and
fractions recovered in either 40% acetonitrile (SPE40) followed by 100%
acetonitrile (SPE100) elution, or a „total‟ fraction recovered in 100% acetonitrile
(SPE) were studied. HPLC profiles indicated significant retention of peptides by
the C18 SPE media and overlap between SPE40 and SPE100 peptide
assemblages (Figure 1A). However, the SPE40 contained a relatively higher
proportion of species eluting in the 15 to 22 min range (Figure 1A).

The amino acid composition of the SPE product was compared with
Colostrinin, which is a proline rich peptide complex derived from ovine
colostrums, reported to exhibit many functional properties of relevance to
bioactivity of the bovine whey SPE product (Boldogh and Kruzel, 2008; Kruzel
et al., 2001; Zimecki, 2008). Colostrinin has also shown to inhibit Aβ oligomer
mediated toxicity (Schuster et al., 2005), regulate levels of reactive oxygen
species (ROS) and immunomodulatory functions (Boldogh et al., 2008; Boldogh
and Kruzel, 2008). A significant correlation was observed between the amino
acid contents of the two products (Pearson Product Moment correlation
coefficient was 0.604 and P=0.013, Figure 1B). Colostrinin was significantly
richer in mole percentage of Glu+Gln and Proline whereas SPE was relatively
richer in the non-polar amino acids: Alanine and Leucine.

Dairy derived peptides have previously shown to have anti-fibril and protein
chaperoning properties (Bennett et al., 2009; Thorn et al., 2005b), however its
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effects on Aβ42 structure and aggregation has not been studied before. To
study the effects of SPE fractions on Aβ42 secondary structure and
oligomerization, pre-incubated mixtures of Aβ42 with different concentrations of
SPE were studied by circular dichroism, Fourier transform infrared spectroscopy
(FTIR), transmission electron microscopy (TEM) and by size fractionation (SDSPAGE).
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Figure 1: Preparation and characterization of SPE fractions from dairy whey
protein hydrolysate
Reverse phase HPLC profiles of sub-fractions of dairy peptide hydrolysate
showing solid phase extraction (SPE) cartridge non-binding void plus wash
fraction (pooled) and products eluted with 40% and 100 % acetonitrile,
designated SPE40 and SPE100, respectively. The ratio of SPE40 to SPE100
present in SPE-total was approximately 19:1 and profiles have been
standardised for mass of solids analysed. (A). Amino acid analysis of total SPE
retentate of dairy hydrolysate was compared with ovine colostral „Colostrinin‟
(Georgiades, 2004). The Pearson Product Moment correlation coefficient for
colostrinin with the SPE total was 0.604 and P=0.013 (B).
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4.4.2 Effect of SPE on Aβ42 secondary structure

Aβ42 peptide solutions (0.05 mg/ml; 11µM), pre-incubated with different
concentrations of SPE40 and SPE100 (final concentrations: 0.005, 0.05 & 0.25
mg/ml in de-ionised water) were analysed by CD spectrometer. The mean
residue ellipticities of samples were recorded across the far UV range (190-260
nm). Spectra of SPE products alone at appropriate concentrations were
subtracted from respective profiles of Aβ42+SPE product, but were otherwise
unsmoothed. The beta sheet content of Aβ42 in the presence of increasing
concentrations of SPE40 and SPE100 was analysed using the CD spectra
generated (Figure 2). The ratio of Aβ42 molarity per mg of SPE product was
2200 down to 44, from 0.005 to 0.25 mg/ml, respectively. Inhibition of β-sheet
development of Aβ42 (peak at 215 nm) was evident at a ratio of 44 (0.25 mg/ml)
and not above 220 (0.05 or 0.005 mg/ml). The suppression of β-sheet was also
accompanied by progressive apparent loss of alpha helix (190-200 nm, Figure
2). The results showed that the SPE product was able to interfere with
assembly of β-sheet structures in Aβ42.
Modulation of Aβ42 secondary structure in the presence of increasing
concentrations of SPE product was further studied using FTIR spectroscopy.
FTIR characteristics of SPE product indicated that SPE did not absorb in
designated β-sheet regions at either 1695 or 1629 cm -1. FTIR analysis also
showed no change in SPE peptide secondary structure over the concentration
range studied. After incubation for 20h at 30°C in the absence of the SPE
product, Aβ42 exhibited anti-parallel β-sheet structure associated with the
presence of oligomers as previously shown (Cerf et al., 2009). Similar to CD
data (Figure 2), modulation of Aβ42 secondary structure by the SPE product
was evident by FTIR spectroscopy. The SPE product induced FTIR spectral
changes in the Amide I region (1700-1600 cm-1) reflecting its effects on the
extent of Aβ42 self-assembly (Figure 3). Specifically, curve fitting indicated that
SPE-concentration-dependent structural changes occurred in the β-sheet
(1613-1629 and 1695 cm-1) and to a lesser extent, in the α-helix and/or random
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coil structure regions, clustering between 1620 and 1705 cm -1. Difference
spectra produced after subtraction of SPE product at each concentration
permitted evaluation of „pure‟ Aβ42 FTIR spectra (Figure 3A). The ratio of
1695/1630 cm-1 allowed the ratio of anti-parallel to total β-sheet to be quantified,
and detect the effect of SPE product specifically on formation of oligomeric
Aβ42.

By this method, the oligomer content of Aβ42 was found to be

significantly lowered by the SPE product in a concentration-dependent manner
(Figure 3B). Overall, these results suggested that the SPE product
progressively inhibited the self-assembly of Aβ42 into oligomers and reversed
existing β-sheet structures. To further study the effect of SPE mediated β-sheet
inhibition of Aβ, pre-incubated Aβ42+SPE mixtures were examined by TEM and
SDS-PAGE analysis.
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Aβ42 + SPE40
Aβ42 + SPE40
Aβ42 + SPE40
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Aβ42 + SPE100
Aβ42 + SPE100
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Figure 2: CD spectroscopy of Aβ42+SPE mixtures
The absorption bands of Aβ42 peptide solutions (11 µM), pre-incubated with
different concentrations of SPE40 and SPE100 were analysed by Jasco J-810
CD Spectropolarimeter. The mean residue ellipticities of samples were recorded
across the far UV range (190-260 nm), using a 0.1 cm path-length quartz
cuvette, at room temperature, monitoring at 0.1 nm intervals. Concentration122

dependent effects of SPE40 (A) and SPE100 (B) on Aβ42 peptide (11 M),
following 24 hr incubation at 22ºC was determined. Spectra of SPE products
alone at appropriate concentrations were subtracted from respective profiles of
Aβ42+SPE product. Individual data sets (n=3) acquired were averaged over 3
scans. At higher concentrations (0.25mg/ml) SPE fractions (40 and 100)
reduced total beta sheet content in Aβ42 solutions, as indicated by the changes
in the 210-230nm band region.
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Figure 3: FTIR spectroscopy of Aβ42+SPE mixtures
Infra red (IR) spectra of

Aβ42 solution pre-incubated with different

concentrations of SPE fraction (total) were measured using an Equinox 55
infrared spectrophotometer. Spectral subtraction was applied between 4000
and 800 cm-1 and changes mainly reflected effects of SPE-total on Aβ42
secondary structure in the Amide I band region (1700-1600 cm-1). Fourier selfdeconvolution was applied to increase the resolution of spectra in the amide I
region, which is that most sensitive to protein secondary structure. The FTIR
data was preprocessed, baseline corrected and normalized for equal area
between 1700-1500 cm−1as described in (Goormaghtigh et al., 1999). ATRFTIR spectra of Aβ42 incubated at 30C for 20h in the presence of (a) 0, (b)
0.001, (c) 0.005, (d) 0.01, (e) 0.05, (f) 0.1 mg/ml of SPE-total, after subtraction
of SPE-total controls (A). Ratio of 1695/1630 cm−1 intensities normalized to
control Aβ42 (100%) is plotted as a function of the concentration of SPE-total
(B).

Each spectrum represents the mean of 128 repetitions recorded at a

resolution of 2 cm-1 and further averaged across triplicate independent sample
preparations.

Increasing

concentrations

absorbance intensity at 1695/1630 cm

−1

of

SPE

reduced

the

relative

band region, indicating decrease of

anti-parallel β-sheet structures

4.4.3 Effect of SPE on Aβ42 oligomerization

The oligomerization of Aβ42 is initiated by a conformational change from
random coil or α-helix into a β- sheet maximized by cross linking hydrophobic
interactions, quite similar to prion and other amyloidogenic proteins (Lansbury
Jr, 1996; Tycko, 2003). Previously it was shown that increasing concentrations
of SPE showed significant inhibition of β-sheet structures in Aβ42 (Figure 2, 3).
To study the effects of SPE induced β-sheet inhibition on Aβ42 structure and
oligomerization, pre-incubated Aβ42-SPE100 mixtures (11µM Aβ42+0.1 mg/ml
SPE100) were observed by transmission electron microscopy or analysed by
Aβ immunoblotting.
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Aβ42 alone exhibited globular oligomeric (50-60nm in diameter) and protofibrillar structures (100-150nm in length, Figure 4A) as observed by TEM
analysis. However, Aβ42 co-incubated with SPE also comprised small globular
structures (10-20nm in diameter, Figure 4B) similar to the SPE100 control, and
was devoid of larger oligomeric and fibrillar structures. The SPE product alone
was characterised by small globular particles of approximately 10 nm diameter
(Figure 4C). It is notable, that TEM analysis showed visible aggregates (10nm
diameter) in SPE100 fraction, whereas CD and FTIR analysis of pure SPE
fractions contained less hydrophobic peptides and showed no detectable
aggregation. The TEM images of Aβ42 incubated with the SPE100 reflected
strong suppression of oligomer/protofibril development (Figure 4B) compared to
Aβ42 only (Figure 4A).
Freshly prepared Aβ42 was incubated with increasing concentrations of
SPE100 and aliquots were collected for SDS-PAGE/Aβ immunoblotting analysis
at 0h, 24h and 48h time points. Aβ42 showed increasing levels of higher-order
oligomers (~50-110 kDa) with increasing incubation time (0, 24 and 48h), with
no noticeable change in lower-order oligomers (dimer, trimer, tetramer) (Figure
5). Higher mass oligomeric Aβ42 (~50-110 kDa range) products were
suppressed with increasing concentrations of SPE product (Figure 5). However,
no change was observed with the levels of low mass Aβ42 oligomer (~7-20 kDa
range) and monomer bands.

Overall, the data from secondary structure analysis (CD, FTIR), showed
clear evidence for suppression of total β-sheet content and anti-parallel βsheets associated with Aβ42 oligomerization by SPE products. TEM and
western blotting analysis further supported the data from CD and FTIR showing
that SPE inhibited formation of Aβ oligomers. Further the toxicity of the Aβ42SPE mixtures were determined in yeast and validated in neuronal cells.
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Figure 4: Electron micrographs of Aβ42+SPE mixtures
Aβ42 solutions (11µM) pre-incubated with SPE100 (0.1 mg/ml in 10% ethanol)
or vehicle (10% ethanol) for 20 h at 22C were applied to glow discharged
carbon-coated 400-mesh copper grids. The excess sample is removed and the
grids are stained with 2–3 drops of 2% aqueous uranyl acetate (Sigma). The
grids were air-dried and examined by Tecnai 12 Transmission Electron
Microscope operating at 120 KV. Micrographs of Aβ42 alone (A), Aβ42 preincubated with SPE100 (B) and SPE100 alone (C) were recorded using a
Megaview III CCD camera. Oligomer Aβ42 preparations showed oligomeric
structures (50-60 nm in diameter) and proto-fibrillar structures (100-150 nm in
length), which were undetectable in pre-incubated SPE100-Aβ42 samples and
SPE100 samples.

128

Aβ42
PO147(0.05mg/ml)
(0.1mg/ml) +
PO147 (0.1mg/ml)

0h

1

2

3

48h

24h

4

5

1

2

3

4 5

1

2

3

4

5

Figure 5: SDS-PAGE western blotting analysis of Aβ42+SPE mixtures
Aliquots from pre-incubated Aβ42 (10µM) with increasing concentrations of
SPE100 (lanes 1-5 are 0, 0.005, 0.01, 0.05, 0.1 mg/ml) at different time points
(0h, 24h and 48h) were analysed by western blot analysis. The samples were
separated by electrophoresis using a 4-12% Bis-Tris gel with MES buffering
system. The protein was transferred to nitrocellulose membrane and probed
with WO2 antibody (anti-Aβ) and developed on films using enhanced
chemiluminiscence (ECL). SPE100 inhibited the formation of higher Aβ
oligomers (50-110kDa) in a dose dependent manner.
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4.4.4 Modulation of Aβ42 toxicity

Aβ42 oligomerization is strongly associated with toxicity to both yeast and
neuronal cells [Chapter 3, (Bharadwaj et al., 2008)]. Compounds which inhibit
Aβ oligomerization have shown to protect cells from toxicity (Amijee et al., 2009;
Findeis, 2002). The previous data showed suppression of Aβ42 oligomerization
by SPE (Figure 2-5). To correlate the reduced oligomer content with toxicity to
cells, SPE products were tested in Aβ42 toxicity assays with both yeast and
neuronal cells. Oligomeric Aβ42 peptide was toxic to both yeast and neuronal
cells in a dose-dependent manner (Figure 6A) with the concentration of 10µM
chosen for subsequent experiments.
Pre-incubated Aβ42 (10µM) +SPE (0.001-0.1mg/ml) mixtures were treated
with yeast cells for 20h followed by viability analysis using colony forming unit
(CFU) count. A dose-dependent increase in yeast cell viability was observed
with increasing concentrations of SPE in the Aβ42+SPE mixtures (Figure 6B).
Protection against Aβ toxicity was evident at higher concentrations of 0.05 and
0.1mg/ml concentrations. Aβ42 only (10µM) caused ~50% cell death compared
to ~40% with 0.05mg/ml SPE100 and complete reversal of toxicity at 0.1mg/ml
SPE100. Interestingly, at lower concentrations of SPE (0.001-0.01mg/ml), cell
death was increased compared to Aβ42 only (by 10%). Yeast toxicity
experiments indicated that SPE100 was more protective than SPE40 at 0.05
and 0.1 mg/ml (Figure 6B) and subsequent studies with neuronal cells focussed
on effects of SPE100.
SHSY5Y cells were treated with pre-incubated Aβ42 (10µM) +SPE100
(0.01-0.1mg/ml) mixtures for 3days followed by viability analysis by LDH and
MTS assays as described in Section 2.2.4.5. Similar to yeast, the SPE100
product exhibited concentration-dependent rescue of Aβ toxicity, measured by
either decreased release of LDH or enhanced reduction of MTS reagent in cells
(Figure 6C). A 50% loss of viability as measured by MTS assay was seen with
Aβ42 treatment (10µM). Increased viability of ~65% with SPE concentrations of
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0.01mg/ml was observed which further improved to ~80% with 0.1mg/ml of
SPE100. A similar pattern of rescue was observed with LDH release in cells.
Aβ42 only treatment induced ~35% cell death whereas the cell death decreased
to 20-15% with SPE100 concentrations of 0.01-0.1mg/ml. Overall, the data from
the toxicity analysis of Aβ42+SPE mixtures in yeast and neuronal cells showed
that SPE inhibited Aβ42 induced toxicity at higher concentrations. Together with
the effects of SPE on Aβ42 structure and oligomerization, the results indicated
that suppression of Aβ42 oligomerization inhibited its toxicity in both yeast and
neuronal cells.
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Figure 6: Toxicity of Aβ42+SPE mixtures in yeast and neuronal cells
Dose response of Aβ42 treatment on viability in yeast (by colony forming units
count, CFU) and SHSY5Y cells (by LDH and MTS methods) (A). Dose
response effects of Aβ42 pre-incubated with SPE100 (0.01 to 0.1 mg/ml) on
viability of exponentially growing yeast cells incubated at 30˚C for 20h (B). Dose
response effects of Aβ42 pre-incubated with SPE100 (0.01 to 0.1 mg/ml) on
viability of SHSY5Y cells (C). Cell viability was determined by the ratio of colony
numbers in the absence and presence of SPE samples, and reported by LDH
and MTS assay methods. At higher concentrations, SPE fractions significantly
reduced Aβ42 toxicity in yeast and SHSY-5Y cells. However, at lower
concentrations, SPE40 and SPE100 enhanced Aβ42 toxicity in yeast but not in
SHSY-5Y cells.

Results represent

the mean

and

SEM of

triplicate

determinations at each concentration with significance of differences to control
(*, P<0.05; **, P<0.01; #, P<0.05; ##, P<0.01) determined by Students t test.

4.5

Discussion:

The self-assembly of proteins into fibrillar structures based on cross β-sheet
„laminae‟ of amyloidogenic polypeptides represents a common folding pathway
of many proteins (Krebs et al., 2008). Furthermore, „amyloid‟ structuring of
proteins has been described as a detoxification strategy to mask the
promiscuous surface of the oligomeric building block (Carrell et al., 2008).
Studies have also identified novel biological functions for amyloidogenic protein
fibrils in bacteria, fungi and even mammals (Kelly and Balch, 2003). Supporting
evidence from a range of studies in several neurodegenerative disease
including AD correlate soluble protein oligomers in the brain as the indicator of
cognitive decline rather than insoluble fibrillar deposits (Ferreira et al., 2007;
Glabe and Kayed, 2006; Popik et al., 1999).
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Aβ42 fibrils are assembled from a planar „laminate‟ of up to six parallel sheets, stacking and elongating the fibril perpendicular to the laminate plane
(Burkoth et al., 2000). However, formation of meta-stable oligomeric Aβ42
represents an early competing folding pathway (Necula et al., 2007)
characterised by anti-parallel β-sheet structure (Sarroukh et al., 2010). Widely
differentiated behaviour in propensities for self-aggregation into oligomers and
fibrils is observed in naturally-secreted forms of Aβ (e.g., Aβ37-42, Aβ40) and
also in forms of Aβ generated by mutations of APP in the brain (Tomiyama et
al., 2008) (Bharadwaj et al., 2009; Peralvarez-Marin et al., 2009). Underlying
these effects is the key role of primary Aβ sequence in permitting β-sheet
organisation.

Studies have also identified key amino acids involved in Aβ

structural morphology. For example, deletion of E22-glutamate from Aβ42
permitted assembly of dimers and trimers but not ThT-binding fibrils (Tomiyama
et al., 2008) whereas substitution of Phe19 to Pro19 in Aβ42, prevented ability
to form oligomers and fibrils (Bernstein et al., 2005). Also, modification of Phe19
to Ser19 and Leu34 to Pro34 in Aβ42 showed decreased aggregation (Wurth et
al., 2002) and was less toxic compared to oligomeric Aβ42 in yeast and
neuronal cells (Chapter 3). Apart from its natural tendency to self-associate via
multiple folding pathways sequence, several environmental factors and binding
partners can alter Aβ aggregation in the brain. Studies implicate that Aβ
structures in the brain can be heterogeneous (Bibl et al., 2006), and associate
with chaperone like species that may affect its morphology and regulate
proteostasis (Voisine et al., 2010). Actually, increased chaperone levels have
shown to be associated with longer lifespan (Tatar et al., 1997) and also protect
cells from the toxic proteins (Balch et al., 2008; Zhou et al., 2001).
Chaperones that facilitate or prevent assembly of either the β-sheet laminate
or the intra-laminate assembly are likely to catalyse or inhibit, respectively, the
self-assembly of Aβ42. The development of peptide-based inhibitors of Aβ42
aggregation has focussed significantly on active domains of chaperone
proteins. For example, transgenically-expressed human Aβ42 in C. elegans
elicited the expression of known heat shock „chaperone‟ proteins that were
subsequently immunoprecipitated with Aβ42 (Fonte et al., 2002) (Fonte et al.,
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2008), and which regulated the folding of Aβ42 towards less toxic pathways.
Similarly, α1-anti-chymotrypsin (ACT), which is present in AD brain plaque,
drives Aβ42 along either amorphous aggregation or fibril pathways, depending
on the molar ratio (Janciauskiene et al., 1998). A peptide fragment of the
chaperone protein α-crystallin also inhibited aggregation of Aβ42 (Raman et al.,
2005) and its toxicity to PC12 cells (Santhoshkumar and Sharma, 2004). By
analogy, mixture studies with different ratios of Aβ42 in the presence of Aβ40,
show that the presence of Aβ40 can inhibit mature fibril development when
Aβ40 approaches equimolar ratios to Aβ42, with corresponding attenuation of
cell toxicity (Jan et al., 2008). Also, compounds which dissociate intact cross βsheet structures (β-sheet „breakers‟) have been successfully designed from
peptoid and retro-peptoid analogues of an amyloidogenic peptide such as
amylin (Elgersma et al., 2007). Chaperone-mediated interactions can alter the
morphology and toxicity of amyloid proteins (Fonte et al., 2002) and supports
that aggregation pathways can be strategically manipulated by exogeneous
„chaperone‟ agents.

In this study, the chaperoning like effects of whey derived peptide
hydrolysate (SPE) on beta-amyloid protein (Aβ42) folding pathways and cellular
toxicity was demonstrated. The SPE product bioactivity described follows the
precedent reported for proline-rich complex „Colostrinin‟ (Kruzel et al., 2001)
and other mammalian sources of colostrum (Sokolowska et al., 2008). Peptides
with capacity for fibril regulation, derived from bovine dairy sources including
whey, casein and lactoferrin, have also been reported (Bennett et al., 2009).
The colostrinin peptide complex was shown to inhibit and disrupt β-sheets of
amyloid aggregates (Schuster et al., 2005) and exert several other bioactive
properties including neuroprotection in AD (Bilikiewicz and Gaus, 2004). It is
suggested that other exogenous peptides, perhaps dietary sources, with
aggregate inhibition capacity might be also be protective against AD and other
amyloidogenic diseases (Balch et al., 2008; Powers et al., 2009). The SPE
product prepared from bovine whey proteins described in this study appears to
be of very similar but not identical composition to Colostrinin (Figure 1B),
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probably reflecting differences in respective host materials and the processing
method used to produce the SPE product.

4.5.1 Inhibition of Aβ42 oligomerization and toxicity by SPE

CD and FTIR spectroscopy were used for studying the modulation of
secondary structure of Aβ42, with FTIR results permitting evaluation of the ratio
of anti-parallel (oligomer) to parallel (fibril) β-sheet content (Cerf et al., 2009)
(Sarroukh et al., 2010). FTIR monitoring of Aβ42 self-assembly in the presence
of SPE product indicated that the Aβ42-SPE mixtures contained structures of
net lower β-sheet content and specifically lower anti-parallel β-sheet (Figure 3).
Analysis by TEM (Figure 4) and Western blot analysis (Figure 5) clearly showed
that SPE inhibited Aβ42 oligomerization, supporting previous data from CD and
FTIR studies.

The concomitantly protective effects against Aβ42 toxicity in

yeast and neuronal cells (Figure 6B, C), were clearly evident. The pattern of
loss of high mass oligomers of Aβ42 and associated toxicity was very similar to
that seen in the presence of curcumin (Yang et al., 2005). Low mass ratio of
SPE to Aβ42 showed enhanced toxicity in yeast (Figure 6B). However, the
„promotion of toxicity‟ was not present for neuronal cell studies or detected by
CD or FTIR studies. This observation reflects the sensitivity of the methods and
the possibility that different Aβ isoforms might possess differentiated toxicity
profiles in yeast compared with neuronal cells. There is a possibility that the
„enhanced‟ toxicity observed (Figure 6B), is a result of SPE (at lower
concentrations) induced formation of „off pathway‟ toxic soluble complexes with
Aβ42.
Overall, a positive correlation between suppression of β-sheet content and
oligomerization by SPE fractions (Figures 2-5) and protection against Aβ42mediated toxicity to both yeast and neuronal cells (Figure 6) was observed.
Collectively, these results provide important evidence that suppression of antiparallel β-sheet structures can prevent formation of oligomeric structures linked
with toxicity. The lack of toxicity of a mutant form of Aβ12-28 (Peralvarez-Marin
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et al., 2009), in contrast to Aβ25-35 and related variants (Pike et al., 1995) , in
spite of the presence of aggregates characterised by having β-sheet secondary
structure, further supports these observations.
The Aβ structure modulating properties of the dairy derived peptides (SPE
fractions) demonstrated in this study implicate them as interesting candidates
for identifying novel inhibitors of Aβ oligomerization and toxicity. Further
characterization of the SPE product mixture aided by cleaner and better
resolved preparations is necessary to isolate specific peptides which are
responsible for anti-Aβ activity. However for future therapeutic application, it will
be essential to determine whether these dietary peptide preparations can
survive gut enzymatic degradation and if they will be able to cross the blood
brain barrier.

4.6 Summary:

A number of molecular species have been shown to act as chaperones and
thereby regulate the folding pathway of Aβ42. In many cases, the toxicity of
products is differentiated from unchaperoned Aβ42, usually attenuated. Thus,
„chaperones‟ of Aβ42 represent obvious molecules for development into
disease-modifying therapeutics, if in vitro bioactivities can translate to protective
effects in vivo.

These results demonstrate the important finding that

suppression of anti-parallel β-sheet structures is specifically required for
regulation of oligomer toxicity to cells. In addition to inhibition and disruption of
Aβ42 oligomers, the SPE dairy peptide product may display other useful
neuroprotective properties as shown for Colostrinin. It is unknown the extent to
which dietary factors already play a role in chaperone-mediated modulation of
Aβ42 toxicity in vivo, if at all, however, based on in vitro properties, it is possible
that a wide range of adequately bio-available dietary peptides and
phytochemicals might contribute to neuroprotection by chaperone-mediated
activity.
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Chapter 5
Oligomerization and Toxicity of
MBP-Aβ fusion proteins
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5.1

Introduction:

A substantial amount of structural and functional information of Aβ comes
from studies using synthetically derived Aβ produced by solid phase peptide
synthesis (SPPS). Although synthetic Aβ has been widely used for variety of
experimental purposes, the preparation and handling of the peptide solutions
have not been very straightforward. In addition to its intrinsic heterogeneous
and variable nature, substantial compositional differences and intrinsic
impurities in Aβ produced by SPPS resulting in experimental irreproducibility
has been reported (Dobeli et al., 1995; Howlett et al., 1995; Simmons et al.,
1994; Soto et al., 1995a; Soto et al., 1995b; Zagorski et al., 1999). In addition,
aggregation kinetics and toxicity of synthetic Aβ have been reported to fluctuate
between different batches and also with storage and solubilisation conditions
(Soto et al., 1995b).
The in-vitro solubility and aggregation properties of the Aβ peptide are
found to be dependent on the pH environment, temperature, peptide
concentration, incubation times (Burdick et al., 1992; Stine et al., 2003),
hydrostatic pressure (Foguel et al., 1999) and other local interacting factors
including metals, lipids and other proteins [reviewed in (Bharadwaj et al., 2009)].
However, the precise molecular interaction leading to the formation of the toxic
Aβ oligomers have not been completely understood. Several papers report
methods to produce Aβ oligomers from synthetic Aβ (Barghorn et al., 2005;
Lambert et al., 1998; Lambert et al., 2001; Stine et al., 2003) but the
preparations differ in the sizes of oligomers, and stability and even
reproducibility can be an issue (Brining, 1997).
In addition to synthetic Aβ (SPSS derived), recombinantly produced Aβ
proteins have also been reported. Recombinantly–derived Aβ present
significant advantages comparing SPSS synthesized Aβ mainly for the reason
that primary structure changes are rare because of the high fidelity of the
cellular expression systems and the physiological conditions under which these
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operate. Moreover recombinant production is more cost effective than SPSS
synthesis for large scale manufacture. There are several studies reporting
methods for recombinant production of Aβ in different cellular systems (Dobeli
et al., 1995; Hortschansky et al., 2005; Lee et al., 2005; Li et al., 2009; Luhrs et
al., 2005; Sharpe et al., 2005; Subramanian and Shree, 2007; Walsh et al.,
2009; Wiesehan et al., 2007). However, most of the existing methods either
yield low amounts or require enormous efforts for purification. More importantly,
a majority of these studies have not established the toxic properties of the
recombinantly derived Aβ. Caine et al 2007 described a novel method for
producing Aβ as an N-terminal fusion to maltose binding protein (MBP). In this
methods, the maltose binding protein tagged Aβ42 (MBP-Aβ42) fusion protein
could be stably produced in large quantities, purified easily using affinity
columns and showed properties (binding to Cu and Zn) similar to Aβ peptide
(Caine et al., 2007b). However, the toxic properties of these MBP-Aβ fusions
have not been determined.
Toxicity of synthetically derived Aβ oligomers has been established in
yeast cells (Bharadwaj et al., 2008). In chapter 3 it was shown that oligomeric
Aβ was more toxic than the non-oligomerizing Aβ peptide in yeast and neuronal
cells. In chapter 4, it was shown that inhibition of Aβ oligomerization using dairy
derived peptides (SPE fraction) suppressed its toxicity both in yeast and
neuronal cells. In this chapter, the MBP-Aβ fusion proteins were studied in the
yeast model where their toxicity was demonstrated. Furthermore the toxicity of
the MBP-Aβ fusion proteins was also observed in neuronal cells.

5.2

Aims:

1.) Purification and characterization of MBP-Aβ fusion proteins
2.) Determine the toxicity of MBP-Aβ fusion proteins in yeast and neuronal cells.
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5.3

Materials and Methods:

Purification of MBP, MBP-Aβ16 and MBP-Aβ42 fusion proteins were done as
described in Section 2.2.3. The MBP fusion proteins were harvested in bacteria
followed by purification via affinity chromatography using an amylose column
and analysis by size exclusion chromatography (superdex-200 gel filtration
column) as described in Section 2.2.3. The purified fusion proteins were
characterized using SDS-PAGE followed by western blotting analysis and
coomassie staining. Volume analysis of the protein gel bands was done using
the Quantity-1D analysis software. The fusion proteins were studied using
Transmission electron microscopy (TEM) and Dynamic light scattering (DLS)
(Jo Caine, CSIRO) as described in Section 2.2.9. Toxicity of purified MBP,
MBP-Aβ16 and MBP-Aβ42 fusion proteins were tested in yeast cells and
primary mouse cortical cells by colony count and CCK-8 assays respectively as
described in Section 2.2.4.3 and Section 2.2.4.6 respectively.

5.4

Results:

5.4.1 Purification and characterisation of MBP-Aβ42 fusion protein

MBP fusion variants were expressed and purified from E. coli and
analysed by SDS-PAGE followed by coomassie staining (Figure 1A) and
western blot analysis using anti-Aβ (WO2) (Figure 1B) and anti-MBP (Figure
1C). The molecular mass estimated from the SDS PAGE analysis were found to
be to be 39.6 kDa for MBP, 42.6 kDa for MBP-Aβ16, and 45.7 kDa for MBPAβ42. In addition, the proteins exhibited no breakdown products. The MBPAβ42, under non-reducing conditions, demonstrated additional higher molecular
weight bands, corresponding to sizes ~97 kDa (dimer), ~135 kDa (trimer), ~160
kDa (tetramer), and ~235kDA (hexamer) (Figure 1B, C). Volume analysis of
these bands showed the monomeric band to be the major species on the gel
(~71% of the total protein) followed by tetramers, hexamers, dimers and trimers
(~19%, 6%, 3% and 1% of total protein respectively). The shorter MBP-Aβ16
fusion shows ~94% of the total protein in the lane made up of a monomeric
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band at 42 kDa and a faint dimer band (~6%) (Figure 1B, C).
The MBP-Aβ fusion proteins were further studied by size exclusion
chromatography using a superdex-200 gel filtration column (performed by Jo
Caine). The gel filtration profile of the concentrated peaks eluted from the
amylose affinity column showed two major peaks plus a small peak for MBPAβ42 (Figure 1D). The S200 profile of MBP-Aβ16 protein showed one main
peak and a small peak (Figure 1E). Interestingly, purified peaks collected and
left at 4oC for 1 week or more reproduced the original profile of three peaks
when re-run on the S200 column. The results from the SDS-PAGE western
blotting and size exclusion chromatograph showed that MBP-Aβ42 formed
higher oligomeric structures compared to MBP-Aβ16. To further analyse their
structure, the MBP-Aβ proteins were observed by transmission electron
microscopy (TEM).
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Figure 1: SDS-PAGE Western blotting and gel filtration profiles of MBPAβ42 and MBP-Aβ16.
MBP-Aβ samples (5µg) were run on a 4-12% Bis-Tris gel in a MES buffering
system and coomassie stained (A).

For immunoblotting, MBP-Aβ samples

(0.5µg) were run on identical gels, transferred to nitrocellulose membranes and
probed with anti-Aβ (WO2) (B) and anti-MBP (C) antibodies and visualised
using chemiluminescence. Lane loadings as follows: Lane 1 = molecular weight
markers, Benchmark (A) and Precision Western C (B and C); Lane 2 = MBP;
Lane 3 = MBP-Aβ16 and Lane 4 = MBP-Aβ42. Samples from the amylose
affinity column were concentrated on a spin concentrator (10kDa MWCO) and
fractionated using Superdex-200 gel filtration column equilibrated in 50mM Tris
pH8.0 at 0.5ml/min. Absorbance was monitored at 280nm. The plots of the
S200 gel filtration profile show profiles of MBP-Aβ42 (D) and MBP-Aβ16 (E).
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5.4.2 Transmission electron microscopy of MBP-Aβ fusion
proteins
Samples from the MBP-Aβ fusion proteins (MBP, MBP-Aβ16 and MBPAβ42) were analysed by TEM (Figure 2). The electron micrographs showed that
the MBP control and MBP-Aβ16 proteins had small globular structures of 5-9nm
in diameter (Figure 2A and 2B respectively). However, MBP-Aβ42 showed large
amorphous globular structures ranging from 11-16 nm in diameter in addition to
globular structures of 5-9nm in the TEM (Figure 2C). However no fibrillar
structures were seen in any of the fusion protein preparations. TEM analysis of
the MBP-Aβ fusion proteins showed that MBP-Aβ42 formed larger amorphous
structures compared to smaller globular structures found in MBP-Aβ16 and
MBP solutions. The results supported the previous observations from SDSPAGE immunoblotting and size exclusion chromatography analysis indicating
that MBP-Aβ42 can form higher oligomeric structures (Figure 1). To determine
the size distributions of these oligomeric structures, the MBP-Aβ fusion proteins
were analysed by dynamic light scattering (DLS).
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Figure 2: Electron micrographs of MBP-Aβ solutions.
The MBP-Aβ fusion proteins (MBP, MBP-Aβ16 and MBP-Aβ42) were applied to
carbon coated copper grids which were glow-discharged in nitrogen. After the
application of uranyl acetate, the grids were examined by TEM. MBP (A) and
MBP-Aβ16 (B) contain species mainly 5-9nm in size; whereas MBP-Aβ42 (C)
contains species 11-16 nm in size and 5-9nm range.

5.4.3 Dynamic light scattering analysis of MBP-Aβ fusion proteins
The size distribution of MBP-Aβ fusion proteins (MBP and MBP-Aβ42) in
solution were analysed by Dynamic light scattering (DLS) (performed by Jo
Caine). DLS of MBP and MBP-Aβ42 (~0.8mg/ml) proteins were performed
using the DynaProTM NanoStar plate reader at laser wavelength 830nm. The
particle size of MBP and MBP-Aβ42 fusion proteins in solution were
represented as hydrodynamic radii (Rh) and radius of gyration (Rg) which were
calculated as described in Section 2.2.9.1. The size distributions of the particles
were determined on the basis of modality and dispersity. Modality refers to the
number of „peaks‟ in the size distribution and dispersity is a measure of
heterogeneity or homogeneity of the species comprising the population.

MBP was found to be a monomodal monodispersed species with an
average hydrodynamic radius (Rh) of 2.8 ± 0.3 nm (Figure 3A). The radius of
gyration for MBP calculated from the available crystal structure was found to be
Rg = 2.07 nm. This would be converted to an Rh =Rg/0.77=2.69 nm which was
very close to the experimental Rh value for MBP. The DLS data collected for
MBP-Aβ42 showed that the sample was monomodal polydispersed, indicating
the presence of different forms of MBP-Aβ42. The Rh for the most abundant
species of MBP-Aβ42 was determined to be 8.8 ± 0.5 nm (Figure 3B) with a
range of radii between 3-100 nm. The polydiversity of the MBP-Aβ42 peaks
indicated that there is a range of oligomeric species present. This result
supported the previous data from SDS-PAGE, size exclusion chromatography
(Figure 1) and TEM analysis (Figure 2) indicating that MBP-Aβ42 forms
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oligomers whereas the MBP alone remained largely monomeric in physiological
aqueous solutions.

A

B

Radius (nm)
Figure 3: DLS measurements of MBP & MBP-Aβ42
The dynamic light scattering plot is representative of the average of 40
individual 5 sec DLS collections for 3 separate dilutions of the MBP (A) and
MBP-Aβ42 (B). The results indicate a monomodal monodisperse species in
MBP with hydrodynamic radii of 2.8 ± 0.3 and monomodal polydisperse in MBPAβ42 (B) with a hydrodynamic radii range 3–100 nm with a peak at 8.8 ± 0.5.
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5.4.4 Toxicity of MBP-Aβ fusion proteins in yeast and neuronal
cells:
The previous data showed that MBP-Aβ42 formed oligomers whereas
MBP alone and MBP-Aβ16 remained largely monomeric. Further, the toxicity of
these fusion proteins were determined in yeast and subsequently validated in
mouse primary cortical neuronal cultures. The toxic effects of the MBP-Aβ
fusion proteins was determined using a colony forming unit (CFU) count assay
after treatment in yeast (Bharadwaj et al., 2008). The full length MBP-Aβ42 was
significantly toxic while MBP-Aβ16 and MBP alone were not. At a concentration
of 22µM, MBP-Aβ42 caused 50% loss of yeast cell viability, compared to less
than 5% cell death with MBP-Aβ16 treatment, while MBP alone was not toxic
(Figure 4A). Untreated yeast cells were exposed to 10mM maltose/20mM
Tris/HCl vehicle buffer alone. In addition, the MBP-Aβ42 protein mediated
toxicity was dose dependent with 25% cell death seen at 10μM and a 3-fold
higher 75% cell death measured at concentration of 44μM (Figure 4B).
Having confirmed that the MBP-Aβ42 fusion protein was toxic in yeast,
the toxicity of the MBP-Aβ fusion proteins was determined in mouse primary
cortical neuronal cultures treated with 30µM of different isoforms of MBP-Aβ for
4 days. Cell viability was determined by CCK-8 assay. The CCK-8 assay uses a
tetrazolium dye (WST-8, 2-(2-methoxy-4-nitrophenyl)-3- (4-nitrophenyl)-5-(2,4disulfophenyl)-2H-tetrazolium, monosodium salt) which is reduced to a yellow
colored product (formazan) by dehydrogenases in cells. The amount of the
formazan dye generated was determined to measure viability following
treatment (Zhang et al., 2010a). Vehicle treated cells were exposed to 10mM
maltose/20mM Tris/HCl buffer alone. Treating the cortical cultures with MBPAβ42 caused a significant reduction (25% loss) in cell viability (Figure 4C). In
contrast, the MBP-Aβ16 fusion and MBP control proteins did not display any
neurotoxicity at the same concentration tested (Figure 4C). Overall the data
showed that MBP-Aβ42 was more toxic than MBP and MBP-Aβ16 proteins in
both yeast and neuronal cells.
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Figure 4: Toxicity of MBP-Aβ proteins in yeast and neuronal cells
Yeast cells were treated with 22µM MBP, MBP-Aβ16 and MBP-Aβ42 proteins.
Untreated cells were exposed to 10mM maltose/20mM Tris/HCl vehicle buffer
alone.

Following treatment, cell viability was determined by counting the

number of colonies formed (A). 22µM MBP-Aβ42 caused significant loss of
yeast cell viability (50%, **p<0.0001) compared to less than 5% cell death with
MBP-Aβ16 treatment, while MBP alone was not toxic. Yeast cells were treated
with increasing concentrations of MBP-Aβ42 fusion protein (5-44µM) (B). A
dose dependent increase in cell death was seen with MBP-Aβ42 treatment
(**p<0.0001, *p<0.01). Primary cortical neurons were treated with 30µM MBP,
MBP-Aβ16 and MBP-Aβ42 proteins for 4 days (C). Vehicle treated cells were
exposed to 10mM maltose/20mM Tris/HCl buffer alone. Following treatment,
cell viability was determined by CCK-8 assay.

30µM MBP-Aβ42 caused

significant loss of cell viability (25%, *p<0.01) while MBP-Aβ16 and MBP were
not toxic. Data is presented as mean +/- SEM, n=4 per treatment group.
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5.5

Discussion:

Similar to naturally derived forms, Aβ42 prepared from synthetic lyophilized
peptides have shown to form multiple forms ranging from monomeric,
oligomeric, fibrillar and many more other multimeric structures and show
neurotoxic properties. Various methods are also available to prepare oligomeric
Aβ from synthetic Aβ peptides including filtration using low molecular weight
cut-off filters (Bitan and Teplow, 2005), treatment of lyophilized Aβ with strong
acids and bases to disrupt pre-formed aggregates (Stine et al., 2010; Zagorski
et al., 1999), photo-induced crosslinking (Bitan et al., 2003), density gradient
centrifugation (Ward et al., 2000) and size exclusion chromatography (SEC)
(Lambert et al., 1998; Walsh et al., 1997).
However, the above methods for preparing Aβ oligomers involve tedious
purification work and high costs for pure lyophilized peptides stocks. Although
well suited for studies involving physiological level analysis (requiring
nanomolar concentrations), such methods for Aβ oligomer preparations are not
suitable for larger scale purposes required for physicochemical and structural
analysis. Therefore recombinantly produced Aβ can be beneficial for such high
throughput screening methods. It is however essential to characterize the
structural and functional properties of such recombinantly derived Aβ.
Previously, (Caine et al., 2007b) described a method for producing large
quantities of soluble MBP tagged Aβ fusion protein using a bacterial expression
system. In this chapter, the oligomerization and the toxicity of these
recombinantly produced MBP-Aβ fusion proteins were studied to enable further
characterization of these fusion proteins. The structural characteristics of the
MBP-Aβ fusion proteins were studied using a variety of techniques. Further, the
toxicity of the MBP-Aβ fusion proteins was determined in yeast and neuronal
cells.
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5.5.1 Oligomerization of MBP-Aβ42
The structural characteristics of MBP-Aβ fusions were studied using SDSPAGE, size exclusion, TEM and DLS analysis. The MBP-Aβ42 fusion protein
was shown to form SDS stable higher molecular weight oligomeric structures
corresponding to dimers (~97 kDa), trimers (~135 kDa) tetramers (~160 kDa),
and hexamers (~ 235 kDa) (Figure 1). MBP-Aβ16 solutions were found to
contain a faint band at ~97kDa which also corresponded to the small peak
found by size exclusion (gel filtration analysis) (Figure 1). This indicated the
presence of a possible dimer species, which formed ~6% of the total protein, as
measured by band volume analysis (Figure 1). However, no higher molecular
weight structures (trimers, tetramers and hexamers) could be found in MBPAβ16 solutions similar to that present in MBP-Aβ42. TEM and DLS analysis
further showed that the particle sizes present in the MBP-Aβ42 solutions were
bigger and morphologically different compared to those in MBP and MBP-Aβ16
proteins (Figure 2, 3). DLS analysis also showed that the size ranges of the
particles in MBP-Aβ42 solutions are monomodal polydispersed. This showed
that MBP-Aβ42 contained a mixture of particles derived from a single
monomeric form, which suggested that the solutions contained a mixture of
monomeric and oligomeric forms (Figure 3). However MBP had a monomodal
monodispersed population indicating that the majority of the solution contained
monomers. Overall the data indicated the presence of oligomeric forms in MBPAβ42 solutions.
In addition to its nature of forming oligomers, the MBP-Aβ42 fusion was
stable. Size exclusion, TEM and DLS results indicated that this fusion protein
does not form fibrils but small oligomers which maintain species equilibrium on
the removal of higher oligomers. The major SDS stable oligomeric species from
the gel electrophoresis and DLS measurements appear to be multimeric
species up to hexamers. In the literature, the toxic state of the Aβ peptide has
been variously ascribed to multimers ranging from dimers to dodecamers
(Barghorn et al., 2005; Singh et al., 2002; Walsh et al., 2002a). The absence of
152

higher molecular weight (greater than hexamers) or fibrillar forms in MBP-Aβ42
may be due to lower self-association propensity of MBP-Aβ42 compared to
Aβ42 due the attached MBP fusion protein. Higher oligomers of the MBP-Aβ42
are prevented from forming most likely due to steric clashes from the much
larger globular part of the fusion protein. This has been clearly shown in the
crystallographic study of MBP fusion with a T-cell leukemia virus type 1 gp21
ectodomain (Kobe et al., 1999) where the 31 amino acid gp21 fusion peptide
forms a trimer while possible higher oligomers were prevented from forming due
to the close proximity of the globular MBP protein.

5.5.2 Toxicity of MBP-Aβ42

The toxicity of these different fusions was determined in yeast and also in
neuronal cells to establish their functional nature. MBP-Aβ42 was found to be
significantly more toxic than MBP-Aβ16 and MBP in both yeast and neuronal
cells. Moreover MBP-Aβ42 showed a dose-dependent response on yeast
viability (Figure 4). However, MBP-Aβ42 was found to be less toxic compared to
Aβ42 peptide in mammalian cell lines (Hung et al., 2008) and also in yeast
[Chapter 3, (Bharadwaj et al., 2008)]. It is likely that the steric hindrance from
the much larger globular part of the fusion protein (MBP) may contribute to
reduced toxicity. The inability to form higher molecular weight structures
(greater than hexamer) may also contribute to its reduced toxicity compared to
Aβ42 in cells.
Although it is widely accepted that soluble oligomeric forms of Aβ42 are the
main toxic species in the AD brain, no particular Aβ species has been identified
as the main cause of neuronal dysfunction and death. (Lesne et al., 2006) study
implicated a unique and a novel Aβ isoform (Aβ*56: 56-kD soluble Aβ42
assembly, dodecamer) as the key neurotoxic Aβ42 species responsible for
cognitive decline. However, a more recent study (Shankar et al., 2008) has
identified Aβ dimers from the soluble extract of AD cerebral cortex tissues as
the main toxic isoform. Both Lesne et al and Shankar et al studies identify
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different toxic Aβ species (dimer or Aβ*56), which might reflect differences in
the Aβ detection techniques employed. Alternatively, it is also suggested that an
array of soluble oligomeric Aβ species (ranging from dimers to dodecamers)
may have neurotoxic properties associated with memory impairment in AD. The
MBP-Aβ42 toxicity data shown here supports the notion that oligomer Aβ42
mediated cell death can be a collective contribution of a variety of toxic isoforms
and not mediated by a single isoform. Compared to Aβ42, MBP-Aβ42 solutions
lacked higher oligomeric forms (greater than hexamers) which only reduced its
toxicity and did not rescue it completely. The reduced toxicity of MBP-Aβ42
solutions could therefore represent the absence of the toxic higher oligomeric
forms. In addition, due to its MBP fusion partner, it is also quite likely that the
oligomers formed by MBP-Aβ42 are structurally different compared to the
natural Aβ42 oligomers which further suggests that different oligomeric
structures of Aβ42 can be toxic. Due to its nature of maintaining species
equilibrium, it was difficult to unequivocally attribute the toxicity to the oligomeric
MBP-Aβ42 isoforms. Further investigation using stable cross-linking analysis of
the MBP-Aβ42 oligomeric species can provide a better idea of the contribution
of different isoforms to toxicity and cell death.

5.6 Summary
Overall the data presented here shows that MBP-Aβ42 forms oligomers
and is a stable protein. The oligomer forming MBP-Aβ42 protein was also found
to be toxic in yeast and neuronal cells. It is therefore a well suited model for
structural elucidation and physicochemical studies of smaller Aβ oligomers
(Caine et al., 2011). The MBP-Aβ42 fusion protein could also be a potential tool
for analysing the toxicity of Aβ42. In addition, it provides the opportunity of
developing assays for screening potential inhibitors of Aβ oligomer induced
toxicity.
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Chapter 6
Effect of Aβ42 Induced Cell
Division in Yeast is Restricted
to Stationary Phase
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6.1

Introduction:

There is now strong evidence to show abnormal activation of cell cycle
events in the regions of the brain that are susceptible to neurodegeneration in
AD (Husseman et al., 2000; Yang et al., 2003). Increased levels of cell cycle
proteins (Ding et al., 2000; Vincent et al., 2001) and mitotic signalling
phosphoepitopes (Chang et al., 2002; Li et al., 2005; Li et al., 2004) have also
been observed in degenerating hippocampal neurons of AD brains.
A number of studies have shown that Aβ42 treatment (both fibrillar and
oligomer) can induce neuronal cell cycle events via mTOR/MAP kinase
pathways in neurons (Bhaskar et al., 2009; Frasca et al., 2004; Malik et al.,
2008; Varvel et al., 2008; Wu et al., 2000) and associated toxicity via activation
of protein kinase R (PKR) through calcium signalling and caspase 8 activation
(Suen et al., 2003). A recent study also showed that long-term inhibition of
mTOR by rapamycin prevented AD-like cognitive deficits and lowered levels of
Aβ42 in the PDAPP transgenic mouse model (Spilman et al., 2010).

In contrast, other studies show a significant decrease in p-mTOR and pp70S6K (serine/threonine kinase) levels in differentiated neuroblastoma cells
(N2a. SH-SY5Y cells) treated with Aβ42 (Lafay-Chebassier et al., 2005; LafayChebassier et al., 2006). A recent study also showed correlation between the
inhibition of mTOR signalling and impairment in synaptic plasticity in
hippocampal slices from an AD mouse model and also with Aβ42 treatment (Ma
et al., 2010b). One possible explanation for the conflicting findings observed
with modulating mTOR signalling by Aβ42, is that neurons have different
response patterns to Aβ42 treatment depending on their cell cycle and
availability of neurotrophic factors. However it is unclear whether Aβ induced
growth or toxic effects in neurons are dependent on the cell cycle.
Investigating Aβ42 induced cell cycle events in neurons can be problematic
and unreliable. One problem is that neurons of the adult brain are terminally
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differentiated and lack the capacity to divide in vivo and in vitro, (McShea et al.,
1999). Also, re-activation of cell cycle machinery in post-mitotic neurons can
lead to cell loss (Feddersen et al., 1992; Park et al., 2007). Moreover Aβ42 is a
known neurotoxic protein. Therefore this poses a challenge to dissect the toxic
and trophic properties of Aβ42 in neurons. A particular advantage of studying
cell cycle in yeast cells compared to neurons is their robust nature. Cell cycle
can be physiologically modulated effectively by nutrient limitations without loss
of viability and they can survive prolonged periods in starvation, which makes it
a very useful model for studying Aβ induced effects (Lillie and Pringle, 1980).
Moreover, Aβ42 has been shown to be toxic in yeast cells [Chapter 3,
(Bharadwaj et al., 2008)] which will enable differentiating the biphasic properties
of Aβ42.
In the studies presented in this chapter, I determined whether Aβ42 can
induce cell division in yeast cells within the stationary phase of the cell cycle
and assessed the role of mTOR signalling in this process.

6.2

Aims:

1) Induce entry of yeast cells into the stationary phase of cell growth by nutrient
starvation
2) Determine if Aβ42 can promote proliferation of cells within the stationary
phase of cell growth and whether this can be blocked by inhibition of mTOR by
rapamycin.

6.3 Materials and Methods:
Candida glabrata cells and Saccharomyces cerevisiae (BY4743) grown in
YNB+2% glucose (no amino acids) and YNB+2%glucose (-Trp) respectively
were used for this study. For inducing stationary phase, cell division was
inhibited via starvation in media lacking essential nutrients (non-fermentable
carbon source) as described in Section 2.2.10. Aβ42 peptide was prepared as
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described in Section 2.2.4.1 and used to treat yeast cells as described in
Section 2.2.11. Stationary phase cells were treated with Aβ42 (in the presence
or absence of 0.2µM rapamycin).

6.4

Results:

6.4.1 Starvation induced entry of yeast cells into a stationary
growth phase:
To induce starvation, yeast cells (Candida glabrata) were incubated in
YNB+2% or 0.1% glucose or starved in non growing media (YNB+ nonfermentable carbon source i.e. 2% ethanol, 2% maltose, 2% Glycerol) for 6-7h
at 30°C. Following incubation, the cell density (OD at 600nm) at different time
points was measured. In addition, the morphology of the cells was studied by
flow cytometry using forward scatter (FSC) analysis (Tzur et al., 2011) and light
microscopy. These results are shown in Figure 1. An increase in cell density
was observed in cells incubated in YNB+2%glucose compared to YNB+ other
non-fermentable carbon sources (Figure 1A). Forward scatter analysis for cell
volume showed that cells incubated in YNB+2% glucose showed increased cell
volume (Figure 1B) indicative of active metabolism. Also the actively growing
cells were distributed across a size range of 3-8μm (Figure 1C). Whereas cells
incubated in YNB+2% maltose showed no increase in cell volume (Figure 1D)
and were distributed over a size range of 2-4μm (Figure 1E). Microscopic
analysis of cells incubated in YNB+2% glucose showed active budding [(Figure
1F), indicative of cell division in yeast] (Mortimer and Johnston, 1959) whereas
cells incubated in YNB+2% maltose showed no budding (Figure 1G). Overall
the data showed that starvation in non-growing media induces entry into
stationary phase in yeast. Cells in exponentially and stationary phase were
used for subsequent experiments
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Figure 1: Nutrient starvation inhibits cell division and induces stationary phase
in Candida glabrata cells. Exponentially growing Candida glabrata cells in YNB+
2% glucose were washed and incubated in YNB containing different carbon
sources (2% glucose, 0.1% glucose, 2% ethanol, 2% maltose or 2% glycerol).
Cell density at 600 nm was measured at different time points (0-7 h) (A). Cells
incubated in YNB+2% glucose and YNB+2% maltose were analysed by forward
scatter analysis (B, D) and size distributed (C, E) using flow cytometry (FACS).
The cells were also analysed by bright field microscopy (F, G). Cells incubated
in YNB+2% glucose showed increasing cell density and active budding
indicating growth, however, cells incubated in other carbon sources showed no
increase in cell density, no budding and reduced cell size indicating entry into
stationary phase.

6.4.2 Aβ42 induced cell division in starved cells:
To determine the effects of Aβ42 on cell growth, Candida glabrata cells in
stationary phase and exponential phase were treated with Aβ42. Candida
glabrata cells incubated in YNB+ 2% glucose and YNB+ 2% maltose for 7h
were treated with vehicle or 5μM Aβ42 for 20h at 30°C. Following treatment the
cells were spread on YEPD media plates. Images of media plates from the
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viable count assay are showed in Figure 2A-D. Aβ42 induced cell death in
exponential phase cells (grown in YNB+2% glucose) is indicated by the
decrease in the number of colonies compared the untreated (Figure 2A, B). In
contrast, Aβ42 induced growth in stationary phase cells (incubated in YNB+2%
maltose) is indicated by the increase in the number of colonies compared to the
vehicle treated (Figure 2C, D).
Quantitative analysis of Aβ42 induced cell division in stationary phase cells
was determined by colony forming unit (CFU) count. Candida glabrata cells
incubated in YNB+ different carbon sources (2% glucose, or 0.1% glucose, 2%
maltose or 2% glycerol) for 7h were treated with vehicle or 5μM Aβ42 for 20h at
30°C. Exponential phase cells (YNB+2% glucose) showed marked loss of
viability (25-30% viable) with Aβ42 treatment, compared to vehicle (Figure 2E).
This level of reduction is similar to that shown in Chapter 3 and as previously
reported (Bharadwaj et al., 2008). However, treating cells in stationary phase
(YNB+0.1% glucose, 2% maltose or 2% glycerol) with Aβ42 caused a
significant increase in the number of colonies (200-250%) indicating an increase
in cell division (Figure 2E).
To determine if lower doses of Aβ42 could significantly increase cell division,
cells in stationary or exponential growth phases were treated with vehicle or
0.1-5µM of Aβ42. Cells were also treated with 20 and 50µM of Aβ42 to
determine if higher levels were toxic. The results are shown in Figure 2F. A
dose-dependent decrease in the number of colonies with Aβ42 treatment was
observed in exponential phase cells indicating loss of viability. In stationary
cells, a significant increase in the number of colonies was observed from
concentrations of 100nM (~150%) up to a maximum of ~200-250% increase at
2-5μM. However at, higher concentrations of Aβ42 (≥20μM), cell viability
decreased in both exponential growing and stationary phase cells (Figure 2F).
These results indicate that Aβ42 can promote proliferation only in cells that are
in the stationary phase at doses that are otherwise toxic to exponentially
growing cells. Overall the data above indicates that Aβ42 may induce mitotic
cell division in Candida glabrata promoting cell proliferation. An essential
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pathway for cell cycle progression and proliferation in eukaryotes is the mTOR
signalling pathway (Hay and Sonenberg, 2004). To determine if this signalling
pathway has a role in Aβ42 induced cell division stationary phase growing cells
were treated with Aβ42 in the absence or presence of mTOR inhibitor,
rapamycin.
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Figure 2: Aβ42 induces cell division in stationary phase yeast cells
Candida glabrata cells incubated in YNB+ 2% glucose and YNB+ 2% maltose
for 7h were treated with vehicle or 5μM Aβ42 for 20h at 30°C. Following
treatment the cells were spread on YEPD media plates. Images of yeast media
plates showing Aβ42 caused cell death (decrease in number of colonies) in
exponentially growing cells (YNB+2% glucose) (A, B) and cell division (increase
in number of colonies) in stationary phase cells (YNB+2% maltose) (C, D) after
a 20h treatment at 30°C are shown. Quantitative analysis of Aβ42 induced cell
division in stationary phase cells was determined by colony forming unit (CFU)
count. Exponentially growing Candida glabrata cells were incubated in YNB+
different carbon sources (2% glucose, or 0.1% glucose, 2% maltose or 2%
glycerol) for 7h followed by Aβ42 (5µM) treatment for 20h. Cell viability was
measured by the number of colonies (CFU) and expressed as percent change
compared to untreated control (E). Aβ42 caused significant cell death in yeast
grown in YNB+2% glucose (**p<0.001). However, a significant increase in cell
division with Aβ42 treatment was observed in cells grown in other carbon
sources (0.1% glucose, 2% maltose or 2% glycerol, ##p<0.001). To determine
effects of low concentrations of Aβ42, cells incubated for 7h in YNB+2%
glucose and YNB+2% maltose were treated with increasing concentrations of
Aβ42 (0.05-5μM). A dose-dependent effect of Aβ42 induced loss of viability in
cells grown in YNB+2% glucose and increased cell division in cells grown in
YNB+2% maltose was observed (F) (*p<0.05, **p<0.001, ##p<0.001). However,
at very high concentrations, Aβ42 was toxic in cells grown in YNB+2% maltose
(**p<0.001). All data are represented as mean ± SEM (n=4).

164

6.4.3 Rapamycin suppressed Aβ42 induced cell division in yeast:
Rapamycin is a macrolide which binds to FK-binding protein 12 (FKBP12)
and inhibits the complex formation with mTORC1 thereby suppressing the
downstream growth signalling pathway (Brown et al., 1994). It has been shown
to inhibit G1 cell cycle progression via mTOR pathway in a variety of cell types
including yeast at concentrations from 0.1-0.2µM (Heitman et al., 1991). To
determine whether inhibition of mTOR signalling affects Aβ42 induced cell
division, stationary phase yeast (Candida glabrata) cells were treated with
increasing doses of Aβ42 (0.1-5µM) in the absence or presence of rapamycin
(0.2µM) for 20h at 30°C followed by colony count.
Compared to vehicle treated cells, treating cells with Aβ42 in the absence of
rapamycin induced a dose-dependent increase in the number of colonies in
stationary phase Candida glabrata cells (Figure 3). The number of colonies
increased by ~125-150% on treatment with 0.1-0.5µM A reaching a maximum
of ~200-250% increase at 2-5µM. However, in cells treated with Aβ42 in the
presence of rapamycin, a significant decrease in the number of colonies
compared to Aβ42 per se was observed (Figure 3). The inhibition of Aβ42
induced cell division by rapamycin was significant at all concentrations of Aβ42
tested (0.1-5µM). At lower concentrations of Aβ42 (0.1-0.5 µM) co-incubated
with rapamycin, the number of colonies decreased to 80-90% compared to
~125-150% with Aβ42 per se. However this decrease in cell number [Aβ42 (0.10.5μM) +0.2μM rapamycin] was not significant compared to the untreated
control (Figure 3). Overall rapamycin suppressed Aβ42 induced cell division in
stationary phase yeast cells. To gain a better insight into the Aβ42 induced
growth effect, Aβ42 peptide treatment was assessed in genetically diverse
species Saccharomyces cerevisiae and Candida glabrata.
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Figure 3: Rapamycin treatment inhibited Aβ42-induced cell division in yeast
Exponentially growing Candida glabrata cells were incubated in YNB+ 2%
maltose for 7h to inhibit cell division and induce stationary phase. The stationary
cells are co-incubated with rapamycin (0.2µM) and different concentrations of
Aβ42 (0-5µM) for 20h at 30°C. Aβ42 induced cell division was determined by
colony forming unit (CFU) count and expressed as percent change compared to
untreated control. A dose-dependent increase in number of colonies was
observed with Aβ42 treatment without rapamycin (##p<0.01, #p<0.05).
However in the presence of rapamycin, a significant decrease in the number of
colonies compared to Aβ42 alone was observed (*p<0.05, **p<0.01). All data
are represented as mean ± SEM (n=4).
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6.4.4 Aβ42 does not induce cell division in Saccharomyces
cerevisiae cells
Candida glabrata and Saccharomyces cerevisiae cells represent the main
models in

evolutionary yeast

biology.

Candida

glabrata

cells

shows

considerable genomic diversity in growth signalling pathways compared to
Saccharomyces cerevisiae (Bowman et al., 1992; Walsh et al., 2002b).
Although the gene expression patterns in Candida glabrata and Saccharomyces
cerevisiae are highly conserved, significant diversity is observed in the
signalling and regulatory networks (Lelandais et al., 2008). Therefore, to gain
insight into the mechanism of Aβ42 induced cell division, stationary phase
Candida glabrata and Saccharomyces cerevisiae cells were treated with Aβ42
peptide.
Candida glabrata cells were initially used for studying Aβ42 induced growth
effects mainly for its faster growth rates compared to Saccharomyces cerevisiae
(Lelandais et al., 2008). Aβ42 induced growth effects were studied in stationary
phase Saccharomyces cerevisiae and Candida glabrata cells. Similar to
Candida glabrata, Saccharomyces cerevisiae cells (BY4743) were subjected to
starvation in YNB+2% maltose (Figure 4A) to induce stationary phase.
Saccharomyces cerevisiae cells (BY4743) showed increased cell density with
time in YNB+2% glucose (-Trp), however no increase was seen in YNB+2%
maltose for both cell types indicating entry into stationary phase. As expected,
Saccharomyces cerevisiae cells (BY4743) showed a slower growth rate
compared to Candida glabrata in normal media (Figure 4A).
Next, Aβ42 induced growth effect was also tested in Saccharomyces
cerevisiae yeast cells alongside Candida glabrata (Figure 4B). Stationary phase
induced Candida glabrata and Saccharomyces cerevisiae (BY4743) cells were
treated with increasing concentrations of Aβ42 (0.5-5µM) (Figure 4B) for 20h at
30°C. As seen before in Section 6.4.2 and 6.4.3, a dose dependent increase in
the number of colonies was observed with Aβ42 treatment in Candida glabrata
cells. A maximum of ~150-200% increase in colonies at 2-5µM Aβ42 was
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observed. No increase in the number of colonies was seen at lower Aβ42
concentrations (0.5 and 1µM) in Saccharomyces cerevisiae cells. Interestingly,
at higher Aβ42 concentrations (2-5µM), a significant decrease in the number of
colonies in Saccharomyces cerevisiae cells was observed indicating cell death
(by ~20-25%, Figure 4B). The results showed that stationary phase
Saccharomyces cerevisiae cells were unresponsive to Aβ42 induced growth
effects. The effect of Aβ42 to induce cell division with longer incubation times
was then assessed considering the slower growth rate of Saccharomyces
cerevisiae compared to Candida glabrata cells.
To determine growth effects at longer incubation times, Aβ42 (2µM) was
incubated with stationary phase Candida glabrata and Saccharomyces
cerevisiae cells for 12, 24 and 36h followed by colony count analysis (Figure
5A, B). Aβ42 treatment induced a significant increase in the number of colonies
(~200%) at 12-24h incubation in Candida glabrata. However, the number of
colonies started to decline (~150%) with longer incubations (36h) (Figure 5A).
No change in number of colonies was observed in Saccharomyces cerevisiae
cells treated with Aβ42 for 12h. Indeed, at 24 and 36h incubation times Aβ42
treatment caused a significant decrease in the number of colonies (~20-25%),
indicating cell death (Figure 5B).
Overall the results showed that Aβ42-induced growth effects were absent in
Saccharomyces cerevisiae cells. As previously discussed, Candida glabrata
and Saccharomyces cerevisiae have considerable differences in genomic
structure and cellular make-up (Bowman et al., 1992; Walsh et al., 2002b),
which is the most likely factor responsible for the differential effects of Aβ42.
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Figure 4: Concentration dependent Aβ42 growth effects in Candida glabrata
and Saccharomyces cerevisiae.
Candida glabrata and Saccharomyces cerevisiae (BY4743) cells grown in
YNB+ 2% glucose and YNB+ 2% glucose (-Trp) respectively were washed and
incubated in fresh growth media [YNB+ 2% glucose or YNB+ 2% glucose (-Trp)]
or in YNB+ 2% maltose to induce stationary phase. Cell density at 600 nm was
measured at different time points (0-7h) (A). Similar to Figure 1, Candida
glabrata cells showed increased cell density in YNB+ 2% glucose and no
growth in YNB+ 2% maltose. Similarly, Saccharomyces cerevisiae (BY4743)
cells showed growth in YNB+ 2% glucose (-Trp), but absent in YNB+ 2%
maltose. Wild type Candida glabrata cells and Saccharomyces cerevisiae
(BY4743) were grown in YNB+2% glucose and YNB+2% glucose (-Trp)
respectively followed by starvation in YNB+2% maltose for 7 h. The starved
cells were then treated with different concentrations of Aβ42 (0-5μM) for 20h at
30°C. Colony forming units (CFU) were counted and expressed as percent
change compared to untreated control (B). A dose-dependent increase in
number of colonies was observed in Candida glabrata with Aβ42 treatment
(##p<0.01). No change in number of colonies was seen in Saccharomyces
cerevisiae cells (BY4743) at lower Aβ42 concentrations (0.5-1µM). At higher
concentrations (2-5µM), Aβ42 showed a significant decrease in number of
colonies in Saccharomyces cerevisiae cells (BY4743) (*p<0.05).
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Figure 5: Time dependent Aβ42 growth effects in Candida glabrata and
Saccharomyces cerevisiae.
Candida glabrata and Saccharomyces cerevisiae (BY4743) cells grown in
YNB+ 2% glucose and YNB+ 2% glucose (-Trp) respectively were washed and
incubated in fresh growth media [YNB+ 2% glucose or YNB+ 2% glucose (-Trp)]
or in YNB+ 2% maltose to induce stationary phase. Aβ42 (2µM)-induced growth
effect at different incubation time points (12h, 36h and 48h) was also measured
in starved Candida glabrata cells (A) and Saccharomyces cerevisiae (BY4743)
cells (B). Aβ42 treatment induced a significant increase in the number of
colonies from 12h incubation in Candida glabrata (**p<0.01). But, no change in
the number of colonies was observed in Saccharomyces cerevisiae cells
(BY4743) at 12h incubation with Aβ42. However, at 24h and 36h incubation
times, Aβ42 showed significant decrease in the number of colonies in
Saccharomyces cerevisiae cells (BY4743) (*p<0.05). All data are represented
as mean ± SEM (n=4).

6.5

Discussion

6.5.1 Aβ42 mediated growth or toxicity is dependent on cell cycle
stage
The neurotoxic property of Aβ42 is thought to play a key role in mediating
neurodegeneration in AD. In contrast to its toxic nature, Aβ42 can also possess
mitogenic properties and has shown to enhance cell survival in neurons (Luo et
al., 1996a; Whitson et al., 1989). However, the relationship between the
mitogenic properties of Aβ and AD pathology is poorly understood. It is
hypothesized that the biphasic nature of Aβ-induced toxic or proliferative effects
may depend on the cell cycle.
In this chapter, the effects of Aβ42 within different cell cycles (exponential
and stationary phase) of yeast growth were determined. Yeast cells were
starved in non-growth media to induce stationary phase (G0) or incubated in
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normal media to maintain exponential growth phase (Figure 1) prior to Aβ42
treatment. In exponentially growing yeast cells, Aβ42 caused a dose-dependent
loss of viability as previously observed [Chapter 3, (Bharadwaj et al., 2008).
However in the stationary phase cells, low concentrations of Aβ42 (0.1-5µM)
induced cell division up to a maximum of ~250%, but at higher concentrations
(≥20µM) the cell viability decreased, indicating toxicity (Figure 2). The results
showed that Aβ42 can promote proliferation only in cells that are in the
stationary phase and induce cell death in exponentially growing cells (Figure 2).
The Aβ-induced growth and toxic effects within different cell cycles in yeast is
comparable to the initial report showing that Aβ can enhance survival in freshly
plated undifferentiated hippocampal cells (Yankner et al., 1990), but toxic in
aged differentiated cultures. Studies showing Aβ42 mediated cell death in
neurons expressing particular cell cycle-related elements (cyclin dependent
kinases, Cdk4/6, Cdk5) (Giovanni et al., 1999; Liu et al., 2004), and in G1 cell
cycle stage (Simakova and Arispe, 2007) further supported the notion that Aβ42
mediated toxicity or growth is dependent on the cell cycle. The data presented
here also indicated that Aβ42 induced growth effect happens at a much lower
concentration range (0.1-5µM) compared to its toxicity which is significant only
at higher concentrations (>5µM).
It was also evident from the data that induction of stationary phase in yeast
increased resistance to Aβ42 toxicity. At concentrations of 5-20µM, Aβ42
treatment caused 50-75% cell death in exponential phase cells whereas at the
same concentrations Aβ42 induced cell proliferation in stationary phase cells
(~200%). Toxicity of Aβ42 in stationary phase cells was observed only at
concentrations as high as 50µM. Induction of stationary phase in yeast is
featured by enormous cellular transformation including development of a thick
cell wall, sharp decline in metabolic rates, increased lipid, glycogen and
trehalose storage, resistance to a variety of toxic insults, stimulated catabolic
pathways like autophagy and repression of high energy consumers like ion
channel proteins and proton pumps (Herman, 2002; Werner-Washburne et al.,
1993). The rate of protein synthesis falls ~300 fold in stationary phase cells and
only a low level of protein synthesis (less than 10%) essential for stationary
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phase survival is maintained (Paz and Choder, 2001; Werner-Washburne et al.,
1996). It is therefore possible that one or many of these featured changes in the
cell may contribute to the increased resistance to Aβ42 toxicity. Of particular
interest are the ion channel proteins and cell surface receptors expressed or
repressed during the stationary phase, since Aβ42 was found to be largely
localized in the yeast plasma membrane and inhibited the activity of the proton
pump H+ATPase (Chapter 3). Whether repression of H+ATPase expression
during stationary phase is directly associated with decreased Aβ42 toxicity
remains to be determined.
Collectively the data raises a wide range of possibilities on the nature of
Aβ42 interaction with the cell and the potential receptor coupled pathways that
maybe associated with the distinct effects observed in this chapter. The Aβ42induced growth effect is observed within a physiological concentration range
(starting from 100nM) compared to its toxicity (>5µM), suggesting that Aβ42mediated cell division involves a high-affinity receptor. Since Aβ42-induced
effects are dependent on the cell cycle stage, a broad array of proteins and
receptors associated with metabolism, stress, transcription factors and
intracellular growth signalling pathways are potential candidates involved with
the response to Aβ treatment.

6.5.2 Inhibition of mTOR signalling suppressed Aβ42 induced
growth effects
The cell cycle is a tightly regulated process with several checkpoints that
ensure normal development when appropriate nutritional and trophic signals are
present. Neurons of the adult brain are terminally differentiated and do not show
mitotic cell division. Also, differentiated neurons lack the capacity to divide in
vivo and in vitro, possibly due to lack of components necessary to complete the
cell division process (McShea et al., 1999). However in AD, studies show
increased levels of cell cycle related proteins and abnormal entry into mitosis in
areas vulnerable to neurodegeneration in AD (reviewed in (Bonda et al., 2010;
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Lee et al., 2009). It is suggested that in AD, the neurons may be attempting to
initiate the early phases of mitosis (Zhu et al., 2008). Studies have shown that
re-activation of cell cycle machinery in post mitotic neurons can lead to cell loss
and degeneration (Feddersen et al., 1992; Park et al., 2007). It is believed that
in AD, the incomplete transition of the neuronal cells into M phase makes them
vulnerable to reactive oxygen species, excitotoxic stress and apoptosis (Park et
al., 2000).
mTOR is an eukaryotic cell signalling pathway essential for cell cycle
progression,

and proliferation. Reports show increased levels of mTOR

pathway components (p-eIF4E, p-mTOR and p-4E-BP1) in AD brains (Li et al.,
2005; Li et al., 2004) and it is believed that Aβ42 induced cell cycle events in
neurons are closely associated with mTOR signalling. However studies in
neuronal cell cultures and animal models have yielded contradictory results as
previously discussed (Ma et al., 2010b; Pei and Hugon, 2008; Spilman et al.,
2010). In this Chapter, the role of mTOR signalling in Aβ42 mediated growth
effects was determined. Aβ42 treatment induced a dose-dependent increase in
cell division in stationary yeast cells (Figure 3). But when co-incubated with
rapamycin, an mTOR inhibitor, the increase in cell division was significantly
repressed (Figure 3). Overall the result showed that rapamycin suppressed
Aβ42-induced cell division in stationary phase yeast cells. It suggested that
mTOR is one pathway by which Aβ42 can stimulate growth effects in the yeast
cell. mTOR signalling can be initiated by extracellular membrane bound sensors
and transporters of growth factors and nutrients in eukaryotic cells. Yeast cells
possess several nutrient-sensing systems localized in the plasma membrane
that are associated with growth signalling. Importantly, some of the plasma
membrane sensors include the amino acid permease Ssy1p-Ptr3p-Ssy5p family
(SPS) and the glucose transporters Gpa2p, Snf3p and Rgt2p which are also
members of highly conserved nutrient-transport protein families involved with
TOR signalling (Cardenas et al., 1999; Cutler et al., 1999; Forsberg et al., 2001;
Forsberg and Ljungdahl, 2001a, b). Immunoelectron and confocal microscopy
analysis showed that Aβ42 was localized in the yeast plasma membrane
(Chapter 3). It is therefore likely that Aβ42 may induce growth via interaction
175

with one or more of these transmembrane receptors involved with mTOR
pathway.
6.5.3 Aβ42 induced growth effect was absent in Saccharomyces
cerevisiae
Aβ42 induced growth effect was evident in stationary phase Candida
glabrata cells and was suppressed by mTOR inhibitor, rapamycin (Figure 2, 3).
Interestingly, the increased cell division with Aβ42 treatment was absent in
Saccharomyces cerevisiae cells (Figure 4). No evidence of cell division was
seen at lower Aβ42 concentrations (0.5-1µM) or even with extended periods of
treatment (Figure 4). In fact at concentrations of 2-5µM, Aβ42 caused cell death
(20-25%) in Saccharomyces cerevisiae cells compared to increased cell
division (~200%) in Candida glabrata (Figure 4). It is well accepted that Candida
glabrata

cells

have

considerable

genomic

diversity

compared

to

Saccharomyces cerevisiae, which is probably the most likely explanation for this
phenomenon. It is notable that Saccharomyces cerevisiae cells showed a
slower growth rate compared to Candida glabrata, which is a widely accepted
phenomenon among yeast biologists.

One important difference between the species is the supplements required
for growth. Candida glabrata is a prototrophic strain, which indicates that it has
wild-type characteristics of a naturally-occurring fungal cell capable of growth in
media depleted of amino acids (YNB+2% glucose media without amino acids
for Candida glabrata). However, Saccharomyces cerevisiae is an auxotrophic
laboratory strain which needs amino acid supplements for growth (YNB +2%
glucose+ histidine+ alanine+ uracil+ leucine for Saccharomyces cerevisiae
BY4743). It is therefore a possibility that Candida glabrata expresses high
affinity amino acid transporters (amino acid permeases) compared to
Saccharomyces cerevisiae which enables it to survive in amino acid depleted
conditions (Yadav and Bachhawat). It is likely that Aβ42 could bind to such high
affinity amino acid transporters to induce growth in Candida glabrata. It also
explains the absence of the Aβ42 induced growth effect in Saccharomyces
176

cerevisiae, which could be attributed to the lack or repressed expression of
such receptors. However further investigation of other fungal species using
mutational analysis is required to confirm this interesting notion.

6.6 Summary:
Aβ42 was found to induce cell division in stationary phase yeast cells, but
was toxic in exponential phase cells at similar concentrations. The effect of
mTOR inhibition by rapamycin in blocking Aβ42-growth effects was also
studied. Rapamycin suppressed the Aβ growth effect, indicating that Aβinduced cell division is possibly mediated via mTOR signalling. Interestingly, the
Aβ42-induced growth effect was observed only in Candida glabrata cells and
not in Saccharomyces cerevisiae cells. Overall, the data has provided a greater
understanding of the interplaying roles of the cell cycle and mTOR signalling in
the Aβ42-induced growth in yeast cells.
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Chapter 7
Yeast Model for Intracellular
Aβ42 Expression and
Accumulation
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7.1

Introduction:

In the previous chapters, the effects of exogenously added Aβ (as a peptide
and fusion protein) were studied in yeast. Oligomerizing Aβ42 peptide was
significantly more toxic compared to the non-aggregating isoform Aβ42 (19:34)
in yeast and also in neuronal cells. Localization analysis in yeast showed that
both Aβ peptides bound the cell surface but were undetectable in the
intracellular lumen. Oligomer Aβ42 showed increased affinity to the plasma
membrane compared to non-aggregating Aβ42 (19:34) peptide and data
suggested the plasma membrane H+ATPase as a possible target of oligomeric
Aβ42 mediated cell death in yeast (Chapter 3).
Although extracellular Aβ deposition and neuronal cell death are key
pathological events in AD, growing evidence indicate that the clinical
manifestations of the disease could be a collective contribution of numerous
other pathological events associated with intraneuronal Aβ accumulation;
reviewed in (LaFerla et al., 2007 ). Apart from uptake of secreted Aβ from the
extracellular media, several reports indicate that Aβ can be generated
intracellularly by APP processing in the trans-Golgi network (Xu et al., 1995),
endoplasmic reticulum (ER), endosomal, lysosomal compartments (Kinoshita et
al., 2003; Nixon et al., 2005; Yu et al., 2005) and mitochondrial membranes
(Mizuguchi et al., 1992). Studies have reported accumulation of Aβ within
neurons in post-mortem AD and transgenic mouse brains (Gouras et al., 2000;
Nagele et al., 2002). Studies also indicate that the build-up of intracellular Aβ
may be an early event in the pathogenesis of AD, preceding the formation of
extracellular Aβ deposits (Gouras et al., 2000; Mori, 2002). It is thought that
neurodegeneration and synaptic loss in AD could be the direct result of
defective clearance mechanisms leading to intracellular Aβ accumulation and
toxicity (Boland et al., 2008; Lee et al., 2010; Nixon, 2007). However, the
contribution of various intracellular clearance pathways in the degradation of Aβ
aggregates is not completely understood. In the following chapters, I have used
yeast as a model to investigate the intracellular clearance of Aβ42 aggregates.
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In chapter 3, I showed that Aβ42 was largely localised to the plasma
membrane and was undetectable in the cytosolic lumen. Thus a model where,
Aβ42 is expressed intracellularly would be more amenable for investigating
clearance pathways. Yeast models expressing pathogenic proteins as green
fluorescent protein (GFP) tagged fusion partners including α-synuclein (Cooper
et al., 2006; Soper et al., 2008; Zabrocki et al., 2008; Zabrocki et al., 2005) have
been engineered to reduce targeting for proteolysis in yeast cells and therefore
enable real time monitoring of the protein of interest. Recently, a yeast model
expressing GFP-Aβ42 was developed in Prof Macreadie‟s laboratory (Caine et
al., 2007a). The expression of GFP-Aβ42 expression in yeast was shown to
induce growth stress and heat shock response (Caine et al., 2007a). Also, GFPAβ42 was found to localize into inclusion like structures compared to diffuse
cytosolic expression of GFP in yeast. Overall, these findings suggest that GFPAβ42 was misfolded and subsequently gets accumulated into amorphous
inclusions inside the cell.
In the following chapters, I have employed the GFP-Aβ42 expressing yeast
model for investigating intracellular Aβ accumulation and degradation and
evaluated the efficacy of agents that enhance clearance of intracellular Aβ
aggregates. In the current chapter, a GFP-fusion Aβ42 (19:34) expression
vector was generated and used to express the non-aggregating Aβ42 mutant in
yeast. This chapter characterises intracellular expression and localisation of the
mutant Aβ42 and native Aβ42 within yeast cells, prior to utilising these cells to
investigate clearance pathways in subsequent chapters.

7.2

Aim:

Characterise localization and expression of GFP, GFP-Aβ42 and GFP-Aβ42
(19:34) fusion proteins in yeast cells.
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7.3

Materials and Methods:

Wild type yeast cells (Saccharomyces cerevisiae, KVY55) transformed with
p416 plasmids harbouring GFP/GFPAβ fusion protein construct and a URA
selectable marker for growth in selective media (YNB+2% glucose –ura) was
used in this work. GFP-Aβ42 (19:34) mutant was constructed from GFPAβ42:p416 by site directed mutagenesis as described in Section 2.2.12 (the
construct was made by Sonia Sankovich, CSIRO, Parkville). GFP levels and
localization in GFP/GFPAβ expressing yeast grown in YNB+2% glucose (–ura)
was analysed throughout the growth phase (early exponential till late log phase)
by fluorescent microscopy as described in Section 2.2.16. Also the levels of
GFP/GFPAβ protein in yeast cell lysates were analysed using immunoblotting
with anti-GFP or anti-Aβ (WO2) as described in Section 2.2.17. The mRNA
levels of GFP transcript were quantified in the GFP/GFPAβ expressing cells by
real time q-PCR and comparative Ct analysis as described in Section 2.2.14.
Cell viability of GFP/GFPAβ yeast transformants at different stages of growth
was also determined using the Vi-Cell Cell viability analyser (Beckman Coulter).

7.4

Results:

7.4.1 Intracellular expression of GFP tagged Aβ42 fusion protein in
yeast:
Yeast is a widely used model for expression of neurotoxic proteins (Braun et
al., 2010; Winderickx et al., 2008). Wild type yeast cells (Saccharomyces
cerevisiae) constitutively expressing GFP-Aβ42 protein (Caine et al., 2007a)
were utilized as a model for intracellular Aβ expression. Cells were transformed
with a plasmid construct harbouring either the GFP or GFP-Aβ42 sequence with
a uracil synthesis gene (URA3) (Figure 1A, B) for selective growth in media
lacking uracil [YNB+2%glucose (-ura)], thus allowing for only stable
transformants to be selected. To determine the localization of the fusion
proteins within the cells, GFP and GFP-Aβ42 expressing yeast were studied by
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fluorescent and immunoelectron microscopy. GFP expressing cells showed a
diffuse green pattern of fluorescence compared to a punctate form of
fluorescence in GFP-Aβ42 expressing cells (Figure 1C, D). The levels of
fluorescence in GFP-Aβ42 expressing cells were also low compared to GFP
alone. Immunoelectron microscopy using anti-GFP and anti-Aβ antibodies
showed that GFP had a cytosolic distribution, whereas GFP-Aβ42 seemed to be
localized into amorphous bodies (Figure 1E, F).
This punctate fluorescence pattern and localization within inclusion like
structures in yeast was reminiscent of an unfolded protein response in the cell
(UPR) (Mori, 2009). GFP-Aβ42 expression also induced a heat shock response
and growth stress (~5%) in the cell compared to GFP only (Caine et al., 2007a).
Overall the data suggested that Aβ42 evoked a stress response in the cell,
however it was unclear whether it was specific to the aggregating and toxic
nature of Aβ42. To address this, a GFP tagged modified Aβ42 (19:34) isoform
was generated for expression in yeast cells.
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Figure 1: Expression of GFP-Aβ42 in yeast cells
Sequence of the full length Aβ42 (A), Schematic diagram of the yeast
centromere plasmid p416 harbouring the GFP–Aβ fusion protein gene (B).
Fluorescent images of mid log phase yeast (w303-1a) cells grown in
YNB+2%glucose (-ura) expressing GFP (C) or GFP-Aβ42 (D). GFP expressing
cells show bright diffuse green fluorescence compared to punctate staining
observed in GFP-Aβ42. Immunoelectron micrographs of yeast transformants
expressing GFP (E) and GFP-Aβ42 (F) are shown here. Antibody to GFP was
gold-labelled and probed against cells expressing GFP or GFP-Aβ42. Cells
expressing GFP showed cytosolic localization as indicated by the black dots.
However cells expressing GFP-Aβ42 showed localization in inclusion like
structures. Note the labelling (black arrows) of amorphous structures (adapted
from (Caine et al., 2007a).

7.4.2 Generation of yeast cells expressing GFP-Aβ42 (19:34):
Aβ42 peptide modified at positions F19S and L34P [Aβ42 (19:34)] has been
shown to have reduced tendency to aggregate (Ahmed et al., 2010; Hughes et
al., 1996; Luhrs et al., 2005; Wurth et al., 2002). In chapter 3, I showed that
compared to native Aβ42 the Aβ42 (19:34) mutant remained largely monomeric,
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and did not form SDS stable oligomers (dimers, trimers and tetramers).
Extracellular treatment in yeast and neuronal cells further showed that the nonaggregating Aβ42 (19:34) mutant did not induce cell death compared to
oligomeric Aβ42 (Section 3.4.2).
Yeast cells expressing the GFP tagged non-aggregating Aβ42 (19:34) fusion
protein was generated and its expression and localization pattern was
compared to cells expressing GFP only or GFP-Aβ42. As described above,
GFP-Aβ42 was found to localize into punctate like patterns (Figure. 2A) within
the cell compared to the diffuse cytosolic localisation in cells expressing GFP
only (Figure. 2C). Cells expressing GFP-Aβ42 (19:34) showed a similar diffuse
pattern of expression to those expressing GFP only (compare Figure. 2B with
2C). The GFP fluorescence patterns in the cells expressing the GFP/GFPAβ
fusions suggested that GFP-Aβ42 was packaged and compartmentalized into
inclusion bodies, whereas, GFP, GFP-Aβ42 (19:34) was mainly localized in the
cytoplasm.
From the qualitative analysis of localisation it was noted that the
fluorescence intensity was markedly less throughout the growth phase in cells
expressing GFP-Aβ42 compared to those expressing GFP-Aβ42 (19:34) or
GFP. To provide a more quantitative measure of expression and if it was altered
through cell growth, the expression pattern and levels at early, intermediate and
late stages of cell growth were assessed.
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Figure 2: Localization of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) in yeast.
GFP/GFP-Aβ yeast (Saccharomyces cerevisiae, KVY55) transformants were
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single
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yeast colony from stock agar plates was inoculated in 5ml YNB+2%glucose (ura) and incubated with shaking at 30ºC overnight. The overnight culture was
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. Aliquots
at

mid-late

log

phase

(OD

of

1-1.6)

in

selective

minimal

media

(YNB+2%glucose, -ura) were collected and observed under the fluorescent and
bright field microscope. Localization of GFPAβ42 (A, D), GFPAβ42 (19:34) (B,
E) and GFP (C, F), expressed in wild-type yeast was investigated.

7.4.3 Assessment of expression levels of GFP, GFP-Aβ42 and GFPAβ42 (19:34) over the yeast growth phase
The expression levels of GFP/GFPAβ fusions in the cells were monitored
throughout different growth phases. A single yeast colony of GFP/GFP-Aβ
expressing yeast transformants from stock agar plates was inoculated in 5ml
YNB+2%glucose (-ura) and incubated with shaking at 30ºC overnight. The
overnight culture was resuspended in fresh YNB+2%glucose (-ura) media to an
initial cell density (OD at 600nm) of 0.2 and incubated at 30°C. Following,
sample aliquots throughout different growth phases starting from early
exponential till mid-late log phase (cell density OD 600nm, 0.4-1.6) were
collected for microscopy and immunoblotting analysis
The percentage of green fluorescing cells was estimated in all cells from the
starting point (initiation at cell density 0.2), through the early exponential phase
(6-9 hours after initiation of the culture- cell density 0.4 and 0.7) till mid-late log
growth phase of cells (10-12 hours after initiation; cell density 1 and 1.6) (Figure
3). In the cells expressing GFP only, the percentage of fluorescent cells (~95%)
remained stable throughout the growth phase. However, in cells expressing the
GFP-Aβ42, only a maximum of ~15-20% of cells were fluorescent at the
exponential phase and mid-late log phase (OD=1) of growth. In cells expressing
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GFP-Aβ42 (19:34), ~70% cells were fluorescent in the exponential phase and
mid-late log phase. A comparison of the percentage fluorescing cells between
those cells expressing GFP-Aβ42 and those expressing GFP-Aβ42 (19:34),
showed almost 50% less cells expressing GFP-Aβ42 (Figure 3). The
percentage of fluorescing cells in GFP-Aβ42 expressing cells declined sharply
during the mid-late log phase and was almost undetectable (less than 5%) at
OD>1.6. However the percentage of GFP fluorescing cells were unchanged in
GFP and GFP-Aβ42 (19:34) and remained at ~95% and ~70% respectively
(Figure 3).
As a more quantitative measure of the levels of these fusion proteins in the
cells, extracts of the yeast transformants at different stages of the cell growth
phase [early exponential phase (0.4) till mid-late log growth phase of cells (1.6)]
was analysed by western immunoblotting with anti-Aβ and anti-GFP (Figure 4).
Samples at the initiation point (0.2) were not collected for immunoblotting, due
to lack of cell growth for protein extraction and analysis. Similar to the
fluorescence quantification, the levels of GFP-Aβ42 (Figure 4A) was
significantly lower than GFP-Aβ42 (19:34) (Figure 4B) and GFP (Figure 4C)
throughout the growth phase (Figure D). Also GFP-Aβ42 protein levels sharply
reduced and became undetectable at OD>1.6, compared to GFP and GFPAβ42 (19:34) levels which were unchanged. Viability at different points of the
growth phase was determined in all the transformants. No significant change in
viability of the yeast GFP/Aβ transformants was observed throughout the cell
cycle indicating that decreased levels of GFP-Aβ42 compared to GFP and GFPAβ42 (19:34) was not due to cell death (Figure 4E).
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Figure 3: GFP fluorescence levels in cells expressing GFP, GFP-Aβ42 and
GFP-Aβ42 (19:34).
GFP/GFP-Aβ yeast (Saccharomyces cerevisiae, KVY55) transformants were
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single
yeast colony from stock agar plates was inoculated in 5mL YNB+2%glucose (ura) and incubated with shaking at 30ºC overnight. The overnight culture was
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. The
percentage of cells expressing green fluorescence in cells expressing GFP,
GFPAβ42 and GFPAβ42 (19:34) fusion proteins were quantified at different
phases of growth starting from early exponential phase (OD: 0.4) till late-log
phase (OD: 1-1.6) as described in Section 2.2.16 (A). The percentage of
fluorescing cells was significantly reduced in cell expressing GFP-Aβ42 (**,
p<0.001), compared to those expressing GFP and GFP-Aβ42 (19:34)
throughout the growth phase. The percentage of GFP fluorescence was
significantly reduced in cell expressing GFP-Aβ42 (19:34) (**, p<0.001#,
p<0.05), compared to those expressing GFP throughout the growth phase Data
is expressed as mean ± SEM (n=4).
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Figure 4: Expression levels of GFP-Aβ42, GFP-Aβ42 (19:34) and GFP proteins
in yeast
GFP/GFP-Aβ yeast (Saccharomyces cerevisiae, KVY55) transformants were
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single
yeast colony from stock agar plates was inoculated in 5mL YNB+2%glucose (ura) and incubated with shaking at 30ºC overnight. The overnight culture was
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. Aliquots
at different cell densities were collected for western blot analysis. Total protein
extracts (50µg) from wild-type cells expressing GFPAβ42 (A), GFPAβ42 (19:34)
(B) and GFP (C) throughout the growth phase (early exponential phase till mid
log phase) were probed with anti-Aβ (WO2) or anti-GFP. Immunoreactive bands
were quantified by densitometric analysis and expressed as arbitrary units (D).
The protein levels of GFP-Aβ42 was significantly lower compared to GFP and
GFP-Aβ42 (19:34) throughout the growth phase (**p<0.001). Cell viability of
yeast transformants (GFP, GFP-Aβ42 and GFP-Aβ42 (19:34)) at different
stages of growth in YNB+2%glucose (-ura) media at 30ºC was also measured
(E). Data represented as mean ± SEM, n=3. No significant change in cell
viability was observed among the different clones.
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7.4.4 GFP transcription analysis using real time RT-PCR:
To rule out the possibility that transcription levels of GFP-tagged Aβ genes
were altered, GFP transcription was quantified by real time RT-PCR using
comparative Ct method (Schmittgen and Livak, 2008). Equal number of yeast
cells (~1-3 X 106 cells) expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34)
were collected at exponential growth phase (OD of 0.6). cDNA was synthesized
from the frozen pellets and used for the real time PCR amplification targeting
the GFP transcript. The PCR products were analysed by 1.5% agarose gel
electrophoresis and observed by UV transillumination. A ~90bp size band,
representing GFP, was observed in all the transformants, but absent in
untransformed and no-cell control (Figure 5A). This indicated the presence of
the GFP mRNA transcripts in the yeast transformants. The levels of the
transcripts were quantified from the Ct (threshold cycle) values. The Ct value
represents the number of cycles required for the amplified PCR product (GFP)
to reach the saturation threshold. The GFP mRNA levels were measured from
the Ct values as described in Section 2.2.14 and were found to be similar in
cells expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) (Figure 5B).
In summary, I have characterised the localisation and expression of GFP,
GFP-Aβ42 and Aβ42 (19:34) fusion proteins expressed in yeast. Compared to
cells expressing GFP, or the non-aggregating GFP-Aβ42 (19:34), cells
expressing GFP-Aβ42 showed punctate fluorescence staining. The expression
levels of GFP-Aβ42 were markedly reduced, despite equal levels of transcript
generated, indicating that transcription of the different GFP fusion proteins were
not altered.
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Figure 5: Transcription of GFP is not altered in yeast expressing GFP, GFPAβ42 or GFP-Aβ42 (19:34).
GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) expressing yeast cells (KVY55) were
grown in selective YNB+2%glucose (-ura) media till exponential phase (OD
0.6). Untransformed cells (KVY55) grown in YEPD media were also collected
(OD 0.6). cDNA from the frozen pellets (~1-3 X 106 cells) was used for the real
time PCR. The PCR products were analysed by 1.5% agarose gel
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electrophoresis and observed under UV transillumination. Lanes (from left) are
1) 100bp DNA ladder, 2) no cells control, 3) Untransformed cells, 4, 7) GFP, 5,
8) GFP-Aβ42, 6, 9) GFP-Aβ42 (19:34) (A). A ~90bp size band, representing
GFP, was observed in all the transformants, but absent in untransformed and
no-cell control. The fold change in GFP transcription/106 cells using the
comparative Ct method was measured as described previously (Schmittgen and
Livak, 2008) (B). Levels of GFP transcript were similar in all cell lines. Data is
expressed as mean ± SEM, n=3.

7.5

Discussion:

7.5.1 Yeast model for studying intracellular Aβ

The budding yeast Saccharomyces cerevisiae has proven to be a valuable
model organism for studying fundamental cellular processes and pathways
involved in aggregation and toxicity of pathogenic proteins in neurodegenerative
diseases (Bharadwaj et al., 2010; Braun et al., 2010; Winderickx et al., 2008).
Yeast models have been extensively used for expression of misfolding proteins
including α-synuclein (α-synucleinopathies) (Brandis et al., 2006; Cooper et al.,
2006; Flower et al., 2005; Franssens et al., 2009; Lee et al., 2008; Oien et al.,
2009; Outeiro and Lindquist, 2003; Sharma et al., 2006; Willingham et al., 2003;
Zabrocki et al., 2005), Huntington protein (polyglutamine disorders) (Gokhale et
al., 2005; Krobitsch and Lindquist, 2000; Meriin et al., 2002; Sokolov et al.,
2006), Tau (tauopathies) (Vandebroek et al., 2006; Vandebroek et al., 2005;
Vanhelmont et al., 2010), TDP-43 (Frontotemporal dementia and Amyotrophic
lateral sclerosis)(Armakola et al., 2010; Johnson et al., 2008; Kryndushkin et al.,
2011) and Aβ42 (Alzheimer‟s disease) (Bagriantsev and Liebman, 2006; Caine
et al., 2007a; von der Haar et al., 2007). The Aβ expression model as
developed in Prof. Ian Macreadie‟s laboratory by Caine and colleagues (2007)
was the model of choice, since it was fused to green fluorescent protein (GFP)
for much easier tractability as compared to the models developed by
Bagriantsev and colleagues (2006) and von der Haar and colleagues (2007)
who utilized Aβ fused to Sup35p prion proteins.
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Initial attempts at expressing native Aβ42 in yeast using a copper
inducible system was unsuccessful (Caine et al., 2007a). This study showed
that native expression of Aβ42 in yeast was undetectable, which was similar to
findings from other attempts at generating yeast models of protein aggregates
such as α-synuclein (Outeiro and Lindquist, 2003). It was suggested that using
native expression, led to a rapid proteolysis of the protein of interest within the
cell (Outeiro and Lindquist, 2003). Expression of native human proteins as GFP
tagged fusions is known to reduce targeting for proteolysis in yeast cells and
also enables real time monitoring of the protein of interest (Caine et al., 2007a;
Outeiro and Lindquist, 2003). Thus, Caine and colleagues developed a yeast
model expressing GFP-tagged fusion Aβ42 protein. The findings from this
chapter have further characterised the localisation and expression of GFP-Aβ42
in this model.
The original study by Caine and colleagues showed that GFP-Aβ42 induced
a heat shock response and a slight growth stress. It could be argued that this
may alter cell growth or viability, or reduce expression of the labelled protein.
However, the findings in Figure 4 show that cell viability is not altered by
intracellular Aβ42 and that equal amount of transcript was generated in all cell
lines. However, extracellular treatment of yeast cells with oligomeric Aβ42
caused significant loss of viability and cell death [Chapter 3, (Bharadwaj et al.,
2008)]. It is notable that toxicity in wild type yeast cells was associated only with
specific isoforms (oligomeric) and supraphysiological levels of Aβ42 treatment
(micromolar). It is most likely that expression levels of GFP-Aβ42 intracellularly
would therefore be too low to cause any significant toxicity. Further, the
markedly reduced levels of GFP-Aβ42, compared to levels of the nonaggregating, non-toxic GFP-Aβ42 (19:34) mutant and GFP alone, indicate that
the cell can deal with the intracellular over-expression of Aβ42. The expression
levels coupled with the previously reported heat shock response in the cell
suggests that GFP-Aβ42 may be activating intracellular degradation pathways
which may account for its decreased levels detected in the yeast cell.
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Immunoelectron microscopy showed that GFP-Aβ42 is localized into
vesicles reminiscent of autophagic bodies or endosome like structures ((Caine
et al., 2007a), Figure 1). Reports showing that Aβ accumulates in
vesicular/lysosomal structures in neurons of a variety of AD mouse models
(Oddo et al., 2006; Wirths, 2001), human AD brains (Gouras et al., 2000; Nixon
et al., 2005) and in neuronal cells treated with extracellular Aβ42 (Hu et al.,
2009) collectively supports the idea that GFP-Aβ42 may be accumulating in
such vesicles in yeast.

7.5.2 Altered localization of non aggregating Aβ42 (19:34) isoform
in yeast
Aβ42 is known to attain multiple isoforms in physiological conditions
[reviewed in (Bharadwaj et al., 2009)]. The pathological basis of Aβ42 in AD is
dependent on its ability to oligomerize and accumulate leading to cellular
dysfunction. In addition to its intrinsic self associating nature, several
environmental factors and binding partners can also affect Aβ aggregation and
toxicity (Burdick et al., 1992; Holtzman, 2001; Stine et al., 2003). In chapter 3,
synthetic derived Aβ42 was shown to form SDS stable low-n oligomers
compared to monomeric Aβ42 (19:34) peptide. Although GFP-Aβ42 localized
into punctate patterns within the cell indicated aggregation, oligomeric forms of
GFP-Aβ42 were not observed by immunoblotting analysis. It is also suggested
that identifying intracellular Aβ oligomers can be difficult due to their strong
association with membranes (LaFerla et al., 2007 ).
Therefore, expressing the non aggregating Aβ42 (19:34) as a GFP tagged
fusion protein in yeast was beneficial in addressing whether the aggregating
nature of Aβ affects the localization and expression levels of the GFP-Aβ fusion
proteins in yeast. The modified form of Aβ42 (19:34) did not exhibit a punctate
pattern like GFP-Aβ42, but rather had a cytoplasmic distribution similar to cells
expressing GFP only. Recent findings also showed that expression of GFPAβ42 (19:34) induced a markedly weak heat shock response compared to GFP196

Aβ42 in yeast, as measured by β-galactosidase activity (Antony, 2008). Along
with the aggregation/toxic properties of synthetically derived Aβ42 and Aβ42
(19:34) peptides (Section 3.4.2), the distribution patterns of GFP-Aβ42 and
GFP-Aβ42 (19:34) in yeast suggested that GFP-Aβ42 is misfolded/aggregated
and is sequestered into vesicular structures (diagrammatic representation in
Figure 6). The sequestering of GFP-Aβ42 into these vesicles may indicate a
potential mechanism in yeast by which it could be targeted for degradation by
the yeast vacuole. This is further investigated in chapters 7 and 8.
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Figure 6: Schematic of GFP/GFPAβ fusion expression in yeast
A diagrammatic representation of localization of GFP-Aβ42 (A), GFP- Aβ42
(19:34) (B) and GFP (C) expression in yeast, GFP-Aβ42 protein is selectively
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sequestered into inclusions, whereas GFP-Aβ42 (19:34), a non aggregating
Aβ42 isoform and GFP are localized in the cytosol.

7.5.3 Reduced expression levels of GFP-Aβ42 in yeast

Apart from the distinct localization patterns in the cells, the levels of GFPAβ42 were markedly reduced throughout different stages of cell growth
compared to GFP or GFP-Aβ42 (19:34) (Figure 4). Interestingly, the levels of
GFP-Aβ42 were dramatically reduced and became almost undetectable during
the mid-late log phase of growth, whereas GFP and GFP-Aβ42 (19:34) levels
remained unchanged. Similar levels of GFP transcript in all three cell lines
indicate transcription of the GFP fusion construct was not altered and therefore
could not account for the marked reduction in percentage of cells expressing
GFP-Aβ42. Further, cell viability was not significantly altered by expression of
GFP-Aβ42 (Figure 4E).

Overall the results from fluorescence quantification and immunoblotting
analysis in GFP/GFPAβ transformants indicate that GFP-Aβ42 was degraded
rapidly throughout the growth phase (exponential till late log phase) compared
to GFP and GFP-Aβ42 (19:34) in yeast. The expression levels of GFP-Aβ42
were consistently low compared to GFP and GFP-Aβ42 (19:34) during the
exponential growth phase (OD 0.4-1.2), and further declined sharply during the
mid-late log phase (>1.2) (Figure 3, 4). One possible explanation is that Aβ42 is
degraded continuously during the growth phase, but during the late-log phase,
there is an additional boost to the degradation possibly by activation of catabolic
pathways. Notably the late-log phase indicates point of nutrient limitation and
entry into starvation, where pathways like autophagy are stimulated. The results
therefore indicate that Aβ42 can be degraded via distinct pathways in the cell
depending on the different phases of growth.
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7.6

Summary

Overall this chapter has characterised a novel yeast model of
intracellular Aβ42 accumulation, where Aβ42 was localised in a punctate
pattern and expression was reduced over the growth phase of the cells. These
findings provide evidence in support of Aβ42 being sequestered into
cytoplasmic inclusion bodies/ vesicles which may be targeted for degradation.
In the subsequent chapter, I report on the use of this model to investigate two
intracellular clearance pathways, the ubiquitin-proteasome and the autophagylysosome pathways and their contribution to the reduction of GFP-Aβ42
expression observed in this model.
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Chapter 8
Clearance mechanisms of
intracellular Aβ42 aggregates in
Yeast
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8.1

Introduction:

Intraneuronal accumulation of beta amyloid (Aβ) protein in the brains of
AD patients and transgenic mouse models has been widely reported previously
(LaFerla et al., 1997; Nagele et al., 2002). Levels of Aβ rise substantially in
endosomal-lysosomal compartments (Cataldo et al., 2004; Takahashi et al.,
2004) and cognitive deficits have been reported in AD models in which
intracellular Aβ levels are elevated in the absence of plaque deposition
(Koistinaho et al., 2001; LaFerla et al., 2007 ). Impaired clearance of Aβ from
the CNS, rather than overproduction has been suggested to be the main
contributor to accumulation of this peptide in the brains of sporadic AD patients
(Bates et al., 2009; Mawuenyega et al., 2010). In addition to Aβ degrading
enzymes, changes in efflux of Aβ from CNS into the periphery can influence
cerebral Aβ accumulation and clearance. Another Aβ clearance mechanism is
via the two main intracellular degradation/recycling pathways

Firstly, the ubiquitin-proteasome system (UPS) which is responsible for
the degradation of short lived peptides (Hochstrasser, 1996), and secondly, the
autophagy-lysosome system which regulates longer lived proteins and
organelles [reviewed in (Martinet et al., 2009)] are the two pathways which
maintain protein homeostasis in cells. In AD, both autophagy-lysosome system
and the UPS have been implicated to play important roles in regulating the
levels of intracellular Aβ. Autophagy has been shown to be an active pathway
for turning over APP and generating the Aβ peptide (Nixon, 2007) and impaired
clearance of autophagic vesicles are observed in AD mice models and AD brain
(Nixon et al., 2005; Yu et al., 2005; Yu et al., 2004). Suggestions have been
made that in AD, deficiences in autophagy and impaired clearance of
autophagic vesicles could contribute to the accumulation of Aβ-containing
autophagic vesicles within affected neurons (Nixon et al., 2005; Yu et al., 2005)
(Boland et al., 2008). Apart from extensive involvement of autophagic
processes in the AD brain, studies have also shown selective decrease of
proteasomal activity in specific regions (Keck et al., 2003; Keller et al., 2000)
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and accumulation of ubiquitin in plaques and tangles of AD brains (Mori et al.,
1987; Morishima-Kawashima et al., 1993; Perry et al., 1987; Tabaton et al.,
1991). Reports also suggest that Aβ oligomers can inhibit proteasomal function
(Oh et al., 2005; Tseng et al., 2008). Although defective clearance by
autophagy-lysosome and the ubiquitin-proteasome pathways are associated
with increased Aβ accumulation in the brain, their exact roles and contributions
of the various components involved in the degradation of Aβ aggregates inside
the cell still remain unclear.
In chapter 7, the GFP tagged Aβ expression system (Caine et al., 2007a)
in yeast was utilized for studying intracellular Aβ accumulation. GFP-Aβ42 was
found to be sequestered into amorphous inclusions, whereas GFP and GFPAβ42 (19:34) showed diffuse cytosolic localization in the cell. Also compared to
cells expressing GFP or GFP-Aβ42 (19:34), the levels of GFP-Aβ42 were
markedly reduced throughout different stages of cell growth. Together with
differences in distribution and levels of GFP fusion proteins, the results
indicated that compared to non-aggregating GFP-Aβ42 (19:34) mutant, GFPAβ42 aggregates are efficiently cleared from yeast. Also, the data supported the
idea that GFP-Aβ42 is sequestered into cytoplasmic inclusion bodies/vesicles
which may be targeted for degradation by autophagy or the proteasome in the
cell.

In this chapter, I describe the use of this yeast model in an attempt to
understand the roles of autophagic vesicle (AV) transport, vacuolar protease
activity and proteasomal chymotrypsin activity in clearance of GFP-Aβ42
aggregates inside the cell. To achieve this objective, expression levels and
distribution of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) fusion proteins were
studied in mutants deficient in AV synthesis (atg8Δ), vacuolar proteases
associated with autophagy (pep4Δ and cvt1Δ) and 26 proteasome subunits
essential for chymotrypsin activity (pre1Δ and pre1-2Δ).
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8.2

Aims:

1.) Comparative analysis of the expression levels and localization of
GFP/GFPAβ fusion proteins in wild type and AV synthesis mutant (atg8Δ)
transformants.
2.) Comparative analysis of the expression levels and localization of
GFP/GFPAβ fusion proteins in wild type and vacuolar protease deficient
mutants (pep4Δ and cvt1Δ) transformants.
3.) Comparative analysis of the expression levels and localization of
GFP/GFPAβ fusion proteins in wild type and proteasomal activity deficient
mutants (pre1Δ and pre1-2Δ) transformants.

8.3

Materials and Methods:

GFP/GFPAβ fusion protein constructs were transformed into wild type, AV
synthesis mutant (atg8Δ), vacuolar protease deficient mutants (pep4Δ and
cvt1Δ) and proteasomal activity deficient mutants (pre1Δ and pre1-2Δ) yeast
mutants cells. As described in Section 2.2.16 and Section 2.2.17, expression
levels and localization of GFP/GFPAβ fusion proteins were studied by
fluorescent microscopy and immunoblotting in all the yeast transformants.

8.4

Results:

In chapter 7, using a GFP tagged Aβ expressing yeast model, it was shown
that compared to non-aggregating GFP-Aβ42 (19:34) mutant, levels of GFPAβ42 were markedly reduced, suggesting clearance of Aβ aggregates. This
was also supported by the punctate staining of GFP-Aβ42, compared to GFPAβ42 (19:34) indicating sequestration of Aβ42 aggregates into cytoplasmic
inclusion bodies/ vesicles, which may be targeted for degradation. This chapter
reports on the contribution of autophagy and proteasomal activity in the
degradation of GFP-Aβ42 in yeast.
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8.4.1 Localization

and

expression

levels

of

GFP/GFPAβ

in

autophagic vesicle (AV) synthesis mutant (atg8Δ)

A pathway that has been implicated in clearing/ degrading intracellular
aggregated proteins is autophagy. Autophagy is a catabolic process initiated by
the formation of an autophagic vesicle (AV) which sequesters and transports
the bulk of the cytoplasmic material for degradation in the lysosome (vacuole in
yeast) by acid hydrolases. To determine the role of AV transport in GFP-Aβ42
degradation in yeast, the distribution and expression levels of GFP/GFPAβ
fusion proteins were determined in yeast cells deficient of a protein Atg8p
(homolog of human LC3) essential for AV synthesis (atg8Δ).

GFP, GFP-Aβ42 or the GFP-Aβ42 (19:34) transformants were generated
in atg8Δ mutant cells and corresponding background wild type strain
(Saccharomyces cerevisiae, KVY55). The distribution of GFP fluorescence in
wild-type and atg8Δ cells expressing the GFP/GFPAβ fusion proteins was
assessed. As described in chapter 7, in wild-type cells expressing GFP-Aβ42,
fluorescence was found to localize into punctate like patterns (Figure. 1A) within
the cell compared to diffuse cytosolic fluorescence in those expressing GFP
only (Figure. 1C) or GFP-Aβ42 (19:34) (Figure. 1B). In atg8Δ mutant cells, the
localization of GFP and GFP-Aβ42 (19:34) was diffuse and similar to that
observed in wild type cells (compare Figure.1E, F with 1B, C). In atg8Δ cells
expressing GFP-Aβ42, fluorescence was more diffuse and cytosolic compared
to the punctate staining observed in wild-type cells expressing GFP-Aβ42
(compare Figure. 1D with 1A) during the mid-late log phase (OD>1). The diffuse
fluorescence in atg8Δ cells expressing GFP-Aβ42 suggested that the mutant
had reduced ability to sequester the GFP-Aβ42 aggregates, possibly due to the
lack of AV synthesis. Next, the expression levels of the GFP/GFPAβ fusion
proteins in wild type and atg8Δ cells were determined.
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Figure 1: Localization of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) in wild type and
atg8Δ yeast transformants.
GFP/GFP-Aβ transformants were generated in wild type and atg8Δ cells
(Saccharomyces cerevisiae, KVY55), and stored on selective minimal
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at mid-late log
phase (OD of 1-1.6) of growth in selective minimal media (YNB+2%glucose, ura) were observed under the fluorescent microscope. Localization of GFPAβ42
(A, D), GFPAβ42 (19:34) (B, E) and GFP (C, F) in wild-type and atg8Δ cells
respectively were investigated.
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To determine if deficiency of AV synthesis in atg8Δ cells altered the
levels of the fusion proteins, the percentage of green fluorescent cells were
estimated for the transformant cell lines (Figure 2). A similar profile of
percentage of GFP expressing cells to that shown in the previous chapter
(Chapter 7, Figure 3) was observed for the wild-type transformant cells. Cells
expressing GFP showed ~90% fluorescent cells throughout the growth phase
compared to a maximum of only ~15-20% fluorescence (exponential to mid-late
log phase) in cells expressing GFP-Aβ42. And, in cells expressing GFP-Aβ42
(19:34), ~70% cells were fluorescent in the exponential phase and mid-late log
phase. In atg8Δ cells expressing GFP and GFP-Aβ42 (19:34), the profile was
similar to that seen in wild-type cells. However, compared to wild-type cells, a
two-fold increase (up to ~40%) in fluorescent cells was observed from the early
exponential growth phase in atg8Δ mutant cells expressing GFP-Aβ42 (Figure
2). Also the levels were found to remain stable after mid-late log phase, even at
cell density OD>1, whereas fluorescence was almost undetectable in wild-type
cells at similar growth phase.

To specifically determine the levels of these fusion proteins in the cells,
extracts of the wild type (i) and atg8Δ (ii) yeast transformants at different time
points in the growth phase was analysed by SDS-PAGE western blotting
(Figure 3). Western immunoblotting of cell extracts for Aβ showed similar results
to fluorescence data. No significant changes in the levels of GFP and GFPAβ42 (19:34) was observed between wild type and atg8Δ cells (Figure 3B and
C). It is noted that compared to cells expressing GFP-Aβ42, cells expressing
GFP-Aβ42 (19:34) exhibit higher levels of the modified Aβ42. Compared to wildtype cells, GFP-Aβ42 levels were increased in atg8Δ cells during mid-late log
phase of growth (OD>0.6) (Figure. 3A). Also the GFP-Aβ42 levels remained
unchanged in the atg8Δ even at OD>1.6, whereas it was markedly reduced at
OD=1.2 and undetectable at OD=1.6 in the wild type (Figure 3A).
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The overall differences in GFP-Aβ42 levels and distribution between
wild-type and atg8Δ mutant yeast cells suggested that disruption of AV
synthesis lead to increased accumulation of GFP-Aβ42 in the mutant compared
to the wild type.
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Figure 2: GFP fluorescence levels in GFP, GFP-Aβ42 or GFP-Aβ42 (19:34)
expressing wild type and atg8Δ yeast transformants.
GFP/GFP-Aβ transformants were generated in wild type and atg8Δ cells
(Saccharomyces cerevisiae, KVY55), and stored on selective minimal
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at different cell
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densities were collected and observed under the fluorescent microscope. The
percentage of cells expressing green fluorescence in wild type and atg8Δ cells
expressing GFP, GFPAβ42 and GFPAβ42 (19:34) fusion proteins were
quantified at different phases of growth starting from initiation (OD: 0.2) till latelog phase (OD: 1-1.6) (A). The percentage of fluorescing cells was significantly
reduced in wild type cells expressing GFP-Aβ42 (**, p<0.001), compared to
those expressing GFP and GFP-Aβ42 (19:34) throughout the growth phase.
The percentage of fluorescing cells was significantly higher in atg8Δ cells
expressing GFP-Aβ42 (#, p<0.005) compared to wild type GFP-Aβ42. Data is
expressed as mean ± SEM (n=4).
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Figure 3: Expression levels of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) proteins
in wild type and atg8Δ yeast transformants.
GFP/GFP-Aβ transformants were generated in wild type and atg8Δ cells
(Saccharomyces cerevisiae, KVY55), and stored on selective minimal
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YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
agar plates was inoculated in 5ml YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at different cell
densities were collected for immunoblotting analysis. Cell extracts (50µg) from
wild-type (i) or atg8Δ mutant (ii) cells expressing GFPAβ42 (A), GFPAβ42
(19:34) (B) and GFP (C) were probed using anti-Aβ (WO2) and anti-GFP
antibodies.
8.4.2 Localization and expression levels of GFP/GFPAβ in vacuolar
protease mutants (pep4Δ and cvt1Δ)

Vacuolar proteases are a family of acid hydrolases in yeast which operate
as the key enzymes essential for degradation of cytoplasmic material
transported to the vacuole (Klionsky and Emr, 2000). In yeast, pep4p ([homolog
of human cathepsin D (Ammerer et al., 1986; Jones et al., 1982)], yscA) and
cvt1p

[(member

of

subtilisin

family),

yscB]

are

the

main

vacuolar

endopeptidases (Teichert et al., 1989). To determine the contribution of
vacuolar proteases in the degradation of GFP-Aβ42 in yeast, the distribution
and expression levels of GFP/GFPAβ fusion proteins in mutant cells deficient of
enzymes pep4p (pep4Δ) and cvt1p (cvt1Δ) was determined.
GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) transformants were generated in
pep4Δ, cvt1Δ mutant cells and corresponding background wild type strain
(Saccharomyces cerevisiae, BY4743). The distribution of GFP fluorescence in
wild-type, pep4Δ, and cvt1Δ cells expressing GFP/GFPAβ fusion proteins was
assessed (Figure 4). The distribution of GFP fluorescence in wild-type cells
expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) were similar to previous
observations as described in chapter 7. In pep4Δ and cvt1Δ cells, the
localization of GFP and GFP-Aβ42 (19:34) were diffuse and was similar to that
in observed in wild type cells (compare Figure 4D-F and Figure 4G-I). In pep4Δ
and cvt1Δ cells expressing GFP-Aβ42 the fluorescence was punctate similar to
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wild type expressing GFP-Aβ42. However both pep4Δ and cvt1Δ cells
expressing GFP-Aβ42 showed increased number of punctate staining
compared to the wild type during the mid-late log phase (OD>2) (compare
Figure 4A with 4B, C). This result suggested an increased accumulation of
GFP-Aβ42 in pep4Δ and cvt1Δ compared to the wild type during starvation
periods.
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Figure 4: Localization of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) in wild type,
pep4Δ and cvt1Δ yeast transformants.
GFP/GFP-Aβ transformants were generated in wild type, pep4Δ and cvt1Δ cells
(Saccharomyces cerevisiae, BY4743), and stored on selective minimal
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
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agar plates was inoculated in 5ml YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at mid-late log
phase (OD of 2-2.5) of growth in selective minimal media (YNB+2%glucose, ura) were observed under the fluorescent microscope. Localization of GFPAβ42
(A-C), GFPAβ42 (19:34) (D-F) and GFP (G-I), in wild-type, pep4Δ, and cvt1Δ
cells respectively were investigated.
To determine if lack of the vacuolar proteases (pep4p and cvt1p) altered the
levels of the fusion proteins, the percentage of green fluorescent cells were
estimated for the transformant cell lines (Figure 5). A similar profile of
percentage of fluorescing cells to that shown in Chapter 7 (See Figure. 3) was
observed for the wild-type transformant cells. Also, the levels of GFP
fluorescence in pep4Δ, cvt1Δ cells expressing GFP and GFP-Aβ42 (19:34)
were similar to that of the wild type (Figure 5A, B). Comparing the wild type, the
percent of fluorescing cells were increased in GFP-Aβ42 expressing cvt1Δ and
pep4Δ cells during the mid-late log phase (OD 1.5-3). In pep4Δ-GFP-Aβ42
cells, the percent of fluorescing cells were similar (~25%) to the wild type up to
the mid-log phase (OD~1-1.5). However during the late log phase (>1.5), the
decrease in percent fluorescing cells was significantly slow in pep4Δ cells
compared to the wild type (~5% in wt compared to ~20% in pep4Δ) (Figure 5A).
Interestingly, a similar trend was also observed in cvt1Δ-GFP-Aβ42 (~5% in wt
compared to ~30% in cvt1Δ) (Figure 5B).
Immunoblotting analysis for all transformant cell lines was also done (Figure 6).
Similar to wild-type cells, the levels of GFP and GFP-Aβ42 (19:34) were
unchanged throughout the growth phase in pep4Δ, cvt1Δ cells (Figure 6B, C).
The GFP-Aβ42 protein levels were reduced markedly after OD>1.6 (late log
phase) in the wild type cells. However in pep4Δ and cvt1Δ cells, the GFP-Aβ42
protein levels do not reduce until OD 3.3. Unlike the atg8Δ mutant expressing
GFP-Aβ42, the protein levels are not higher than the wild type during the early
stages of growth (OD 0.4-1.6) (Figure 6A). Overall, the differences in GFP-Aβ42
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levels and distribution between wild-type and the vacuolar protease mutants
showed that, deficiency in acid hydrolases (pep4p, cvt1p) can result in
increased accumulation of GFP-Aβ42, especially during the late log phase of
growth (OD>1.6).
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Figure 5: GFP fluorescence levels in GFP, GFP-Aβ42 or GFP-Aβ42 (19:34)
expressing wild type, pep4Δ and cvt1Δ yeast transformants.
GFP/GFP-Aβ transformants were generated in wild type, pep4Δ and cvt1Δ cells
(Saccharomyces cerevisiae, BY4743), and stored on selective minimal
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at different cell
densities were collected and observed under the fluorescent microscope. The
percentage of cells expressing green fluorescence in wild type compared
individually to pep4Δ (A), cvt1Δ (B) cells expressing GFP, GFPAβ42 and
GFPAβ42 (19:34) fusion proteins were quantified at different phases of growth
starting from early exponential phase (OD: 0.2) till late-log phase (OD: 3.3) The
percentage of fluorescing cells `is significantly reduced in wild type cells
expressing GFP-Aβ42 (**, p<0.001), compared to those expressing GFP or
GFP-Aβ42 (19:34) throughout the growth phase. The percentage of fluorescing
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cells was similar in wild type, pep4Δ, and cvt1Δ cells expressing GFP and GFPAβ42 (19:34). Comparing the wild type, % fluorescing cells was increased (#,
p<0.05) in GFP-Aβ42 expressing cvt1Δ and pep4Δ cells during the mid-late log
phase (OD 1.5-3). Data is expressed as mean ± SEM (n=4).
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Figure 6: Expression levels of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) fusions
in wild type pep4Δ, and cvt1Δ yeast transformants
GFP/GFP-Aβ transformants were generated in wild type, pep4Δ, and cvt1Δ
cells (Saccharomyces cerevisiae, BY4743), and stored on selective minimal
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
agar plates was inoculated in 5ml YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at different cell
densities (OD 600nm, 0.4-3.3) were collected for immunoblotting analysis. Cell
extracts (50µg) from wild-type (i), pep4Δ (ii), and cvt1Δ (iii) mutant cells
expressing (A) GFPAβ42 (B), GFPAβ42 (19:34) and (C) GFP were probed
using anti-Aβ (WO2) or anti-GFP antibodies.

8.4.3 Localization

and

expression

levels

of

GFP/GFPAβ

in

proteasomal mutants (pre1Δ and pre1-2Δ)

The data from Chapter 7 (see Figure 3) and current chapter (Figure 2 and
5) in wild type yeast clearly shows that apart from the late log phase, GFP-Aβ42
levels are significantly low throughout the exponential phase compared to wildtype yeast expressing GFP and GFP-Aβ42 (19:34). This shows that levels of
GFP-Aβ42 are tightly controlled during the entire growth phase (exponential
phase till log phase). Under conditions of normal growth, the bulk of protein
degradation occurs via the ubiquitin proteasomal system (UPS) (Hershko and
Ciechanover, 1998). To determine the role of UPS activity in the degradation of
GFP-Aβ42, the distribution and expression levels of GFP/GFPAβ fusion
proteins were determined in yeast strains bearing mutations in genes coding for
two proteolytic proteasome subunits responsible for chymotrypsin like activity:
β4 (PRE1) and β5 (PRE2) (pre1Δ and pre1-2Δ) (Egner et al., 1995; Kragt et al.,
2005).
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GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) transformants were generated in
pre1Δ, pre1-2Δ cells and corresponding background wild type strain
(Saccharomyces cerevisiae, Wcg4a). The distribution of GFP fluorescence in
wild-type, pre1Δ and pre1-2Δ cells expressing GFP/GFPAβ fusion proteins was
assessed (Figure 7). The distribution of GFP fluorescence in wild-type cells
expressing GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) were similar to previous
observations in chapter 7. In pre1Δ and pre1-2Δ cells, the localization of GFP
and GFP-Aβ42 (19:34) were diffuse and was similar to that in wild type
(compare Figure 7D, E, F and Figure 7G, H, I). However, pre1Δ and pre1-2Δ
cells expressing GFP-Aβ42 showed increased levels of punctate staining
compared to wild type (Figure 7A-C). The increased punctuate fluorescence in
pre1Δ and pre1-2Δ cells comparing wild type suggested an increased
accumulation of GFP-Aβ42 within the cell.
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Figure 7: Localization of GFP, GFP-Aβ42 or GFP-Aβ42 (19:34) in wild type,
pre1Δ and pre1-2Δ.
GFP/GFP-Aβ transformants were generated in wild type, pre1Δ and pre1-2Δ
cells (Saccharomyces cerevisiae, Wcg4a), and stored on selective minimal
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at mid-late log
phase (OD of 2-2.5) of growth in selective minimal media (YNB+2%glucose, ura) were observed under the fluorescent microscope. Localization of GFPAβ42
(A-C), GFPAβ42 (19:34) (D-F) and GFP (G-I), in wild type, pre1Δ and pre1-2Δ
cells respectively were investigated.
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The percentage of green fluorescent cells was estimated for the
transformant cell lines (Figure 8). A similar profile of percentage of GFP
expressing cells to that shown in the previous chapter (Chapter 7, Figure. 3)
was observed for the wild-type transformant cells. The percent of fluorescing
cells in pre1Δ and pre1-2Δ cells expressing GFP and GFP-Aβ42 (19:34) were
similar to that of the wild type (Figure 8A, B). However, percent of fluorescing
cells were ~2 fold higher throughout the growth phase (OD 0.7-3) in GFP-Aβ42
expressing pre1Δ and pre1-2Δ cells compared to wild type (Figure 8A, B). Also,
pre1-2Δ cells showed increased percent of fluorescing cells (~40%) compared
to pre1Δ cells (~30%) during late log phase (OD 3.3), which was markedly
higher than the wild type (~5%) at the same growth phase.

Immunoblotting analysis for all transformant cell lines was also performed
(Figure 9). Similar to wild-type cells, levels of GFP and GFP-Aβ42 (19:34) were
unchanged throughout the growth phase in pre1Δ and pre1-2Δ cells (Figure 9B,
C). However, GFP-Aβ42 levels in pre1Δ and pre1-2Δ were consistently high
throughout the growth phase (OD 0.4-3.3) compared to the wild type (Figure
9A). At the late-log phase of cells growth (OD 3.3), levels of GFP-Aβ42 were
undetectable in wild-type cells (Figure 9A). Similar to the fluorescence data,
pre1-2Δ cells showed increased GFP-Aβ42 levels compared to pre1Δ cells
during late log phase (OD 3.3), whereas undetectable in wild type. The data has
shown that decreased chymotrypsin activity of the proteasome resulted in
increased levels of GFP-Aβ42 in the cell throughout the growth phase of yeast
(from exponential till the late log phase).
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Figure 8: GFP fluorescence levels in GFP, GFP-Aβ42 or GFP-Aβ42 (19:34)
expressing wild type, pre1Δ and pre1-2Δ yeast transformants
GFP/GFP-Aβ transformants were generated in wild type, pre1Δ and pre1-2Δ
cells (Saccharomyces cerevisiae, Wcg4a), and stored on selective minimal
YNB+2%glucose (-ura) agar plates at 4ºC. A single yeast colony from stock
agar plates was inoculated in 5mL YNB+2%glucose (-ura) and incubated with
shaking at 30ºC overnight. The overnight culture was resuspended in fresh
YNB+2%glucose (-ura) media to an initial cell density (OD at 600nm) of 0.2.
The culture was then incubated at 30ºC with shaking. Aliquots at different cell
densities were collected and observed under the fluorescent microscope. The
percentage of cells expressing green fluorescence in wild type compared
individually to pre1Δ (A) and pre1-2Δ (B) cells expressing GFP, GFPAβ42 and
GFPAβ42 (19:34) fusion proteins were quantified at different phases of growth
starting from early exponential phase (OD: 0.2) till late-log phase (OD: 3.3) The
percentage of GFP fluorescence is significantly reduced in wild type cells
expressing GFP-Aβ42 (**, p<0.001), compared to those expressing GFP or
GFP-Aβ42 (19:34) throughout the growth phase. The percentage of GFP
fluorescence was similar in wild type, pre1Δ and pre1-2Δ cells expressing GFP
and GFP-Aβ42 (19:34). Comparing the wild type GFP fluorescence was
increased (##, p<0.05) in GFP-Aβ42 expressing pre1Δ and pre1-2Δ cells
throughout the growth phase (OD 0.7-3). Data is expressed as mean ± SEM
(n=4).

221

GFP-Aβ42

A

(i)
30kDa -

(ii)
30kDa -

(iii)
30kDa -

0.4

0.7

1.1

1.6

2.4

3.3

2.4

3.3

GFP-Aβ42 (19:34)

B

(i)
30kDa -

(ii)
30kDa -

(iii)
30kDa -

0.4

0.7

1.1

1.6

GFP

C

(i)
30kDa -

(ii)
30kDa -

(iii)
30kDa -

0.4

0.7

1.1

1.6

2.4

3.3

Cell Density (OD, 600nm)

Figure 9: Expression levels of GFP, GFP-Aβ42 and GFP-Aβ42 (19:34) fusions
in wild type, pre1Δ and pre1-2Δ yeast transformants
GFP/GFP-Aβ transformants were generated in vacuolar protease deficient
yeast mutants (Saccharomyces cerevisiae Wcg4a, pre1Δ and pre1-2Δ), and
stored on selective minimal YNB+2%glucose (-ura) agar plates at 4ºC. A single
yeast colony from stock agar plates was inoculated in 5mL YNB+2%glucose (222

ura) and incubated with shaking at 30ºC overnight. The overnight culture was
resuspended in fresh YNB+2%glucose (-ura) media to an initial cell density (OD
at 600nm) of 0.2. The culture was then incubated at 30ºC with shaking. Aliquots
at different cell densities (OD 600nm, 0.4-3.3) were collected for immunoblotting
analysis. Cell extracts (50µg) from wild-type (i), pre1Δ (ii) and pre1-2Δ (iii) cells
expressing (A) GFPAβ42 (B), GFPAβ42 (19:34) and (C) GFP were probed
using anti-Aβ (WO2) or anti-GFP.

8.5

Discussion:

In chapter 7, the GFP tagged Aβ expressing system was utilized as a model
for studying the intracellular accumulation of Aβ42. This system allowed the
study of the various degradation pathways involved in the clearance of Aβ
aggregates in the cell, without any loss of viability. Intracellular degradation
pathways like autophagy and ubiquitin-proteasome have been comprehensively
studied in yeast cells (Abeliovich and Klionsky, 2001; Hilt et al., 1996; Hilt and
Wolf, 1996; Hochstrasser, 1995; Jentsch, 1992a, b; Nair and Klionsky, 2005;
Yang and Klionsky, 2009). In addition, a variety of mutants deficient in specific
processes of these pathways are available which can be used to dissect the
mechanism and the various elements associated with Aβ42 trafficking and
degradation inside the cell.

8.5.1 Disruption of autophagic vesicle (AV) synthesis reduced
GFP-Aβ42 trafficking and degradation
The localization and expression of GFP-Aβ42 was determined in the mutant
deficient of AV synthesis (atg8Δ). The Atg8p protein (and human homologue
LC3) is essential for the formation of AV‟s that deliver intracellular components
to the vacuole for degradation (Kabeya et al., 2000). Compared to the punctate
inclusion pattern of localization in wild type GFP-Aβ42, the atg8Δ cells showed
a more diffuse form of distribution. In addition the atg8Δ cells increased levels of
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GFP-Aβ42 during late log phases of growth (Figure 1, 2, 3). Overall, the data
suggested that the disruption of AV synthesis lead to a reduced ability to
sequester the GFP-Aβ42 resulting in increased accumulation of GFP-Aβ42 in
the mutant compared to the wild type.

The function of Atg8p protein in yeast autophagy is well characterized.
Atg8p undergoes conjugation to phosphatidylethanolamine forming the Atg8pPE complex. The Atg8p-PE complex plays an important role in the expansion of
the autophagic membrane vesicle (phagophore) and in the formation of the
autophagosome/AV (Huang et al., 2000; Xie et al., 2008). Atg8 gene expression
is induced at least 10-fold in response to starvation (Gasch et al., 2000; Kirisako
et al., 1999). In wild-type cells, GFP-Aβ42 is markedly reduced during late log
phases of growth (Figure 3) which is a period of starvation in yeast. However
compared to the wild type cells, the levels remain unchanged in the atg8Δ
mutant throughout all stages of cell growth, most likely due to the inability to
generate autophagosomes (AV), despite the initial signal by cell starvation to
induce an autophagic response. Indeed, the atg8Δ mutants have been shown
previously to have a low resistance to starvation conditions due to inability to
form AV‟s and undergo autophagy (Xie et al., 2008). Interestingly, in wild-type
cells only GFP-Aβ42 was reduced whereas GFP and GFP-Aβ42 (19:34) levels
remained relatively stable during the late log phases. As GFP-Aβ42 (19:34) is
unable to aggregate, these findings suggest that autophagy has a role in
clearing Aβ42 aggregates and its up-regulation during the late stages of cells
growth can enhance the clearance of these aggregates.

The homolog of Atg8p in mammals belongs to a multigene family, consisting
of GATE16 (GABA-A receptor-associated protein like protein), GABARAP
(GABA-A receptor-associated protein), and LC3 (microtubule associated protein
1) (Amar et al., 2006; Behrends et al., 2010; Hemelaar et al., 2003). Reports
show co-localization of Aβ with LC3-II indicating that internalized Aβ can
associate with autophagosomes (AV) (Hung et al., 2009). Also, a recent study
showed that APP over-expressing mice with beclin1 (an autophagy related
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protein, Atg6p in yeast) deficiency (APP+Becn1+/–) had reduced levels of LC3
associated

with

intraneuronal

accumulation

of

Aβ

and

AD

like

neurodegeneration and pathology (Pickford et al., 2008). These findings clearly
showed that the disruption of neuronal autophagy can contribute to AD
pathology. There are more than 30 autophagy-related (ATG) proteins identified
so far in yeast. Analysis of yeast mutants deficient in ATG proteins can
therefore help understanding the pathway of intracellular Aβ clearance and
identify potential targets for intervention. A recent study has shown that cells
deficient in Atg5p show increased levels of Aβ and altered metabolism (Tian et
al., 2011). It is notable that Atg5p is a highly conserved protein which binds to
Atg12p, and is involved in Atg8p lipidation and autophagosome (AV) synthesis
(Mizushima et al., 1998; Mizushima et al., 2001).

8.5.2 Vacuolar proteases mediate GFP-Aβ42 degradation during
late log phase:

Previous studies of AD brain revealed a marked up-regulation of
lysosomal activity, including extensive involvement of various acid hydrolases
and proteases such as cathepsins B and D with Aβ protein deposits (Cataldo et
al., 1995; Cataldo et al., 1996; Dreyer et al., 1994; Evin et al., 1995; Nixon and
Cataldo, 1993; Tagawa et al., 1991). Several lines of evidence indicate that
autophagy in AD is predominantly a cause of defective lysosomal proteolysis
(Nixon and Yang, 2011). In yeast, proteinases pep4p (yscA, homolog of
cathepsin D) and cvt1p (yscB, member of subtilisin family) are the vital
endopeptidases which are responsible for activation of most of the proteases
which operate in the vacuolar (lysosomal) lumen under nutritional stress
conditions and autophagy (Nair and Klionsky, 2005; Teichert et al., 1989).
Unlike the atg8Δ mutant which showed diffuse fluorescence, GFP-Aβ42
showed increased punctate fluorescence in the vacuolar protease deficient cells
(pep4Δ and cvt1Δ). These findings suggest that although the GFP-Aβ42 can be
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sequestered into AVs, the lack of vacuolar proteases prevent its degradation,
leading to the accumulation of Aβ42 containing vesicles. This notion is
supported by the findings that compared to wild-type cells, the pep4Δ and cvt1Δ
mutants showed accumulation of GFP-Aβ42 levels during late log phase (Figure
4, 5, 6), suggesting that degradation by the vacuole is impaired at these stages
of growth. These findings are in line with others that show vacuolar hydrolase
activity of pep4p and cvt1p are required for degradation of autophagic bodies
(Xie et al., 2008) and are also associated with targeted degradation of misfolded
proteins in the vacuole (Hong et al., 1996). A similar pattern of AV accumulation
and neuritic dystrophy is also observed in the brain when lysosomal
degradation is inhibited by deletion of cathepsins (pep4p in yeast) (Felbor et al.,
2002; Koike et al., 2000; Koike et al., 2005) or by lysosomal enzyme inhibitors
(Bednarski et al., 1997; Boland et al., 2008; Ivy et al., 1989; Takeuchi and
Takeuchi, 2001; Yang et al., 2008). Cathepsin mutations are also associated
with lysosomal storage disorders coupled with severe neurodegeneration
(Tyynela et al., 2000). Interestingly, compared to wild-type yeast, in the pep4Δ
and cvt1Δ mutants the levels of GFP-Aβ42 expression during the active growth
phase (OD 0.2-1.1, Figure 5) were unaltered. These results indicate that the
proteases pep4p and cvt1p are not involved in actively degrading GFP-Aβ42
during the active growth phase of yeast. Unlike pep4Δ and cvt1Δ, the levels of
GFP-Aβ42 were increased during the active growth phase in atg8Δ mutant
compared to the wild type. This indicates that low levels of autophagy can
operate in the cell during the active growing stage. Atg8p is also known to be
involved in the formation of vesicles required for the cytoplasm to vacuole (CVT)
pathway which operates constitutively under growing conditions (Kirisako et al.,
2000; Nair and Klionsky, 2005). Therefore this result suggests that Aβ42
degradation

maybe

targeted

via

the

CVT

pathway

in

addition

to

macroautophagy as both pathways involve Atg8p.
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8.5.3 Decreased

proteasomal

activity

increases

GFP-Aβ42

accumulation:
Overall data from the GFP-Aβ42 expression in autophagosome/AV
synthesis deficient (atg8Δ) cells and vacuolar protease deficient (pep4Δ, cvt1Δ)
cells suggests that apart from catabolic mechanisms like autophagy operating
during starvation, degradation of GFP-Aβ42 can also occur constitutively during
the growth phase. Another pathway that can be active during cell growth and
can actively degrade proteins is the ubiquitin-proteasome pathway. Apart from
short lived proteins, the 26S proteasome is also responsible for degradation of
damaged, misfolded proteins (Cohen et al., 2008; Hilt and Wolf, 1996;
Hochstrasser, 1996; Loayza and Michaelis, 1998; Werner et al., 1996). Studies
also reveal interactions between UPS and autophagy suggesting a coordinated
and complementary relationship between these degradation systems which is
critical during periods of cellular stress (Nedelsky et al., 2008).
The expression of GFP/GFPAβ was studied in yeast strains (pre1Δ and
pre1-2Δ) bearing mutations in genes coding for two proteolytic proteasome
subunits responsible for chymotrypsin like activity: β4 (PRE1) and β5 (PRE2)
(Egner et al., 1995; Kragt et al., 2005). The pre1-2Δ mutant has been shown to
have lower chymotrypsin activity than pre1Δ (Heinemeyer et al., 1991).
Compared to wild-type cells, GFP-Aβ42 accumulated throughout the growth
phases in pre1Δ and pre1-2Δ mutant cells (Figure 7, 8 and 9). This result
indicates that in yeast, these proteolytic proteasomal subunits can degrade
Aβ42. At the later stages of cell growth (OD3.3) GFP-Aβ42 expression was
undetectable in wild-type yeast but also reduced in pre1Δ and pre1-2Δ mutant
cells. These results indicate that at later stages of cell growth, autophagy is the
prominent pathway that is responsible for the reduction in Aβ42 levels.
Differences in GFP-Aβ42 degradation in pre1Δ and pre1-2Δ cells were apparent
only during the late log phase (OD 3.3) (Figure 8, 9). This may suggest that
autophagy maybe compensating for the differences in chymotrypsin activity
between pre1Δ and pre1-2Δ during the growth phase.
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Herein this chapter, I showed that levels of Aβ42 can be regulated by both
autophagy and the proteasome pathways in the cell. Since Aβ42 has a strong
tendency to self-aggregate, it is likely that a variety of GFP-Aβ42 isoforms (lown oligomer to aggregates) maybe be present in the cell. It is possible that
different GFP-Aβ42 forms are degraded differently by autophagy and the
proteasome in the cell as it is widely accepted that the proteasome and
autophagy have distinct differences in substrates for degradation (Rubinsztein,
2007). It is possible that smaller misfolded oligomeric forms of GFP-Aβ42 are
degraded by the proteasome and the larger aggregated forms are degraded by
autophagy. This might also explain the different patterns of GFP-Aβ42
expression levels in autophagy-lysosomal pathway and ubiquitin-proteasome
deficient mutants.

8.6 Summary
In this chapter the GFP-Aβ expressing yeast model was used for
characterizing the role of important pathways involved in the intracellular
degradation of Aβ42 aggregates. Mutants deficient in vesicular transport of
autophagic vesicles (atg8Δ), acid hydrolases involved in degradation in the
vacuole (pep4Δ, cvt1Δ) and proteasomal activity (pre1Δ and pre1-2Δ) have
provided insight into some of the pathways involved in the clearance of Aβ42
aggregates inside the cell. Modulation of these cellular degradation pathways to
enhance clearance of protein aggregates is gaining interest as a therapeutic
strategy in many neurodegenerative diseases particularly AD where the majority
of cases are defective in clearing A. Similar to other yeast models for studying
protein aggregates such as huntington poly Q aggregates (Sokolov et al., 2006)
or α-synculein aggregates (Zabrocki et al., 2005) the GFP-Aβ42 yeast model
can also be used to identify/screen agents that can enhance Aβ42 intracellular
clearance. In the next chapter, the use of this yeast model to determine the
ability of known autophagy enhancer rapamycin in GFP-Aβ clearance is
presented. In addition, the molecular action of the AD drug latrepirdine in
enhancing autophagy and promoting GFP-Aβ clearance has been assessed.
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Chapter 9
The Role of Latrepirdine in
Enhancing Aβ42 Clearance
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9.1

Introduction:

In chapter 8, the role of the intracellular degradation/clearance pathways
(autophagy-lysosome and ubiquitin-proteasome) on distribution and levels of
GFP-Aβ42 in yeast was studied. The expression levels and distribution of
GFP/GFPAβ fusion proteins were analysed in yeast cells deficient in AV
synthesis (atg8Δ), vacuolar proteases (pep4Δ and cvt1Δ) or proteasomal
activity (pre1Δ and pre1-2Δ). Overall, the data showed that GFP-Aβ42
accumulated in yeast mutant cells that lacked autophagy or proteasomal
activity, indicating that disruption of these intracellular degradation pathways
impaired the clearance of GFP-Aβ42 in the cell.

Modulating cellular degradation pathways to enhance clearance of
protein aggregates is gaining interest as a therapeutic strategy in many
neurodegenerative diseases (Rubinsztein et al., 2007). However, stimulating
proteasomal activity as a therapeutic approach can have serious undesirable
effects because many key short-lived intracellular regulators, which are
essential for the normal functioning of the cell, are also degraded. Therefore upregulating autophagy is considered to be more safer and tractable alternative as
its substrates are generally long lived proteins and are not believed to be
selectively degraded (Rubinsztein, 2006). Enhancing autophagy has been
suggested as a treatment strategy for Huntington‟s Disease (HD) (Ravikumar et
al., 2004; Sarkar et al., 2007b; Williams et al., 2008) and α-synucleinopathies
such as Dementia with Lewy Bodies (DLB; (Crews et al., 2010)). Currently the
commonly used pharmacological agent for up-regulating autophagy in neurons
is rapamycin (Rubinsztein et al., 2007; Williams et al., 2008). This agent is
known to activate autophagy by inhibiting mTOR and has been shown to
enhance clearance of Huntington protein and α-synuclein aggregates in various
cell and animal models (Crews et al., 2010; Ravikumar et al., 2004). It has also
been shown to protect SH-SY5Y cells from Aβ42 toxicity (Hung et al., 2009),
and recently been shown to improve cognition and reduce cerebral amyloid load
in a mouse model of AD (Spilman et al., 2010). A recent study has also shown
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that a small molecule enhancer of rapamycin (SMER28) decreases levels of Aβ
via Atg5 dependent autophagy in neuronal cells (Tian et al., 2011).

Another agent which has received considerable attention recently as a
result of successful phase II clinical trials for HD (Kieburtz et al., 2010) and AD
(Doody et al., 2008) is latrepridine (Dimebon, dimebolin). Like rapamycin,
latrepridine also shows neuroprotective activity (Bachurin et al., 2001;
Lermontova et al., 2001; Wu et al., 2008; Zhang et al., 2010b). A study of
synucleinopathy in a mouse model has found that latrepirdine reduced levels of
-synuclein protein deposits and associated neurodegeneration, suggesting
enhanced clearance of protein deposits (Bachurin et al., 2009). It has also been
shown to modulate Aβ secretion and metabolism in neuronal cells and promote
the secretion of Aβ42 into the interstitial fluid of AD mice (Steele et al., 2009).
Recent studies have also reported latrepirdine‟s cognitive enhancing properties
in wild-type and AD transgenic mice, although the mechanism of action
responsible for improving memory functions is unclear (Giorgetti et al., 2010;
Vignisse et al., 2011). It is conceivable that latrepirdine may have multiple
targets that may account for its neuroprotective functions; however the studies
from Bachurin et al., (2009) and Steele et al., (2009) in particular, suggest a role
for latrepirdine in the removal of protein aggregates or preventing the formation
through enhancing clearance. This may represent an underlying mechanism for
latrepirdine‟s

benefits

in

neurodegenerative

disease

characterised

by

accumulation of misfolded or aggregated proteins. In this chapter, I employed
the GFP-Aβ42 expressing yeast model to investigate whether enhancing
autophagy can reduce levels of Aβ aggregates. I investigated whether
latrepirdine (DimebonTM) upregulates autophagy similar to that observed for
established activators rapamycin or nitrogen starvation. Latrepirdine‟s ability to
alter GFP-Aβ42 levels and protect against oligomer Aβ toxicity in the yeast
model was also assessed.
The clearance of Aβ42 from the periphery is thought to play an important
role in preventing the accumulation of Aβ in the brain (see introduction Section
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1.9.1). Our laboratory has developed an in vivo model in which the clearance of
peripherally injected human Aβ42 is followed over a period of time (Hone et al.,
2003; Sharman et al., 2010). We have used this model to show APOE genotype
specific effects on the peripheral clearance of Aβ42, in which the presence of
APOEε4 results in impaired clearance from the blood and the major peripheral
organ to degrade Aβ, the liver (Sharman et al., 2010). Using this model, the
ability of latrepirdine to enhance clearance of Aβ42, in the presence of APOE ε4
was also determined.
9.2 Aims:
1.) Assess the levels of GFP-Aβ42 in wild-type and autophagy deficient (atg8Δ)
mutant yeast cells following treatment with rapamycin.
2.) (i) Determine if latrepirdine can induce autophagy by evaluating vacuolar
uptake of FM4-64 dye, Pho8 activity and Atg8p localization in latrepirdine
treated wild type and atg8Δ yeast cells and (ii) compare activity with those
observed for the known activators of autophagy in yeast, nitrogen starvation
and rapamycin treatment.
3.) Assess the cellular distribution and levels of GFP-Aβ42 in wild-type and
autophagy deficient (atg8Δ) mutant yeast cells following activation of autophagy
via latrepirdine.
4.) Determine if enhancing autophagy can protect yeast cells from oligomer
Aβ42 induced toxicity.
5.) Determine if latrepirdine can enhance the peripheral clearance of Aβ42, in
vivo, in the presence of APOE ε4.

9.3

Materials and Methods:

Non transformant or GFP-Aβ42/ GFP-Aβ42 (19:34) expressing (wild type
and atg8Δ) yeast cells treated with rapamycin (0.1-0.2μM), latrepirdine (1-5μM)
or incubated in nitrogen depleted media were analysed by anti-Aβ (WO2)
immunoblotting and assays for measuring autophagy as described in Section
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2.2.18. Aβ42 mediated loss of cell viability in yeast (Candida glabrata) cells
following pre-treatment with latrepirdine, rapamycin or nitrogen starvation was
measured by colony count assay as described in Section 2.2.4.3.
APOE KO mice were injected with Aβ42 (20µg) +ApoE4 lipid emulsions
in the absence or presence of latrepirdine (3.5mg/kg). Following injections, the
animals were sacrificed at different time points (2.5, 5 and 15 min) and the
levels of Aβ42 in the blood plasma and liver tissues were determined by
immunoblotting analysis as described in Section 2.2.19. The peripheral
clearance experiments in mice were performed by Dr Ian Martins, Kevin Taddei,
Mike Morici and Linda Wijaya from our laboratory.

9.4

Results:

9.4.1 Rapamycin treatment in GFP-Aβ expressing wild type and
atg8Δ yeast cells
To determine if activation of autophagy would reduce levels of
intracellular Aβ42 in yeast, actively growing (OD 0.7) wild type and autophagy
deficient mutant (atg8Δ) cells expressing GFP-Aβ42 and wild type cells
expressing GFP-Aβ42 (19:34) were treated with rapamycin. Rapamycin inhibits
mTOR signalling and activates autophagy by binding to FK-binding protein 12
(FKBP12) and preventing the complex formation with mTORC1. It is also a
widely used compound for enhancing autophagy in yeast cells (Klionsky, 2010;
Nair and Klionsky, 2005). Following rapamycin treatment for 1h at 30°C, cells
were collected for fluorescence quantification, Aβ immunoblotting and cell
viability.
The GFP fluorescence images of untreated and rapamycin treated
(0.2μM) wt-GFP-Aβ42, atg8Δ-GFP-Aβ42 and wt-GFP-Aβ42 (19:34) expressing
cells are shown in Figure 1A-F.The distribution of the GFP fusion proteins in
wild-type and atg8Δ cells are similar to that described in chapter 8 (Section
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8.4.1). Rapamycin treatment did not appear to alter the distribution of GFP
fluorescence but instead in wild-type cells expressing GFP-Aβ42, appeared to
reduce the amount of punctate/ diffuse fluorescence. To provide a quantitative
assessment, the percentage of green fluorescent cells was estimated following
treatment (Figure 1G). Compared to vehicle, rapamycin treatment (0.1 and
0.2μM) resulted in significant reduction in the percentage of cells expressing
GFP. However, wild-type cells expressing GFP-Aβ42 were more sensitive to
rapamycin where treatment resulted in an 80-95% decrease in Aβ42 levels.
Rapamycin treatment of atg8Δ mutant yeast, resulted in a 55-80% decrease in
fluorescence levels, whilst treatment of wild type cells expressing non
aggregating GFP-Aβ42 (19:34) resulted in a 40-75% decline (Figure 1G).
As a more quantitative measure of levels of the GFP-Aβ proteins after
rapamycin treatment, aliquots of cells were collected for Aβ immunoblotting
analysis (Figure 2). Compared to vehicle treatment, rapamycin treatment (0.1,
0.2µM) resulted in a significant reduction in Aβ42 levels in all cell lines (Figure
2A, B). In addition, to enhancing autophagy, rapamycin is a potent inhibitor of
mTOR which is an important pathway for cell growth and protein synthesis. To
rule out the possibility that the reduction in GFP-Aβ42 in wild-type and mutant
cells was due to impaired cell growth, percentage cell viability was estimated
following treatment. The results (Figure 2C) show that rapamycin treatment did
not

alter cell viability indicating that

the decrease in

Aβ levels following

rapamycin treatment was not due to a reduction in the percentage of viable cells
(Figure 2C). However, it cannot be ruled out that the non-specific effects of
rapamycin on protein synthesis contributed to the reduction in GFP-Aβ42 levels
in treated wild-type and atg8Δ cells.
The reduction of Aβ42 levels was more prominent in wild-type yeast cells
expressing GFP-Aβ42, compared to mutant cells expressing GFP-Aβ42 or wildtype cells expressing GFP-Aβ42 (19:34). Wild-type cells expressing GFP-Aβ42
were more sensitive to rapamycin where treatment resulted in an 80-95%
decrease in Aβ42 levels. Rapamycin treatment of atg8Δ mutant yeast, resulted
in a 65-80% decrease in Aβ42 levels, whilst treatment of wild type cells
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expressing non- aggregating GFP-Aβ42 (19:34) resulted in a 40-80% decline in
GFP-Aβ42 levels (Figure 2B). These results indicate that although rapamycin
led to non-specific background effects in yeast, its ability to induce autophagy
resulted in a reduction in intracellular GFP-Aβ42. I next investigated if similar to
rapamycin; latrepirdine induced autophagy and reduced the intracellular
accumulation of GFP-Aβ42 aggregates.
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Figure 1: Rapamycin treatment in GFP-Aβ42 and GFP-Aβ42 (19:34)
expressing wild type and atg8Δ cells: percentage of fluorescing cells
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were
grown overnight in 5ml YNB+2%glucose (-ura) media. Cells were resuspended
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After
incubation at 30ºC, at OD of 0.7, the cells were treated with rapamycin (0, 0.1
and 0.2μM) for 1h. Following treatment the cells were collected for microscopic
analysis. GFP fluorescence images of untreated and rapamycin treated (0.2μM)
wt-GFP-Aβ42 (A, D), atg8Δ-GFP-Aβ42 (B, E) and wt-GFP-Aβ42 (19:34) (C, F)
expressing cells are shown here. The percentage of cells expressing green
fluorescence following treatment was estimated as described in the Section
2.2.16 (G). Compared to untreated control, the percentage of cells expressing
green fluorescence were significantly reduced in all cell lines treated with
rapamycin (#, p<0.01). Compared to wild-type cells expressing GFP-Aβ42
(19:34) or atg8Δ mutant cells expressing GFP-Aβ42, the fluorescence levels
were significantly reduced in wild-type cells expressing GFP-Aβ42 (*, p<0.01 at
0.1 and 0.2µM rapamycin treatment). Data is represented as mean ± SEM
(n=3).
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Figure 2: Rapamycin treatment in GFP-Aβ42 and GFP-Aβ42 (19:34)
expressing wild type and atg8Δ cells: Levels of GFP-Aβ fusion proteins
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were
grown overnight in 5mL YNB+2%glucose (-ura) media. Cells were resuspended
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After
incubation at 30ºC, at OD of 0.7, the cells were treated with rapamycin (0, 0.1
and 0.2μM) for 1h. Following treatment the cells were collected for
immunoblotting and viability analysis. Cell extracts (100µg) from untreated and
rapamycin treated (0.1μM or 0.2μM) wild-type and atg8Δ mutant cells
expressing GFP-Aβ42 or wild-type cells expressing GFP-Aβ42 (19:34) were
prepared and probed with anti-Aβ (WO2) (A). Expression levels of Aβ42
(immunoreactive bands) were quantified and expressed as a percentage of
untreated control and data represented as mean ± SEM (n=3) (B). Compared to
untreated control, levels of Aβ42 were significantly reduced in all cell lines
treated with rapamycin (#, p<0.01). Compared to wild-type cells expressing
GFP-Aβ42 (19:34) or atg8Δ mutant cells expressing GFP-Aβ42, Aβ42 levels
were significantly reduced in wild-type cells expressing GFP-Aβ42 (*, p<0.05 **,
p<0.01 at 0.1 and 0.2µM rapamycin treatment). Cell viability was estimated in
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all untreated and treated cell lines and expressed as a percentage of untreated
control (C). Rapamycin treatment did not significantly alter the viability of cells.

9.4.2 Autophagy in nitrogen starved, rapamycin or latrepirdine
treated wild type and atg8Δ yeast cells
Latrepirdine‟s ability to enhance autophagy was compared to known
activators of autophagy in yeast. Incubating cells in growth media depleted of
any form of nitrogen source or treating with rapamycin are well known methods
of inducing autophagy in yeast (Cheong and Klionsky, 2008). Exponentially
growing wild-type and atg8Δ mutant cells (OD 0.7) were either nitrogen starved,
treated with various doses of latrepirdine or 0.2M rapamycin for 6h. Autophagy
was then monitored by following the bulk transport of cytosolic material for
degradation in the vacuole using a vacuolar specific lipophilic dye FM 4-64
(Journo et al., 2008) and by measuring increased vacuolar alkaline
phosphatase (Pho8) activity in cell extracts using the fluorimetric α-naphthyl
phosphate assay (Noda and Klionsky, 2008).
Cells that either underwent nitrogen starvation or treated with rapamycin
(0.2μM) or latrepirdine (2.5μM) were stained with FM 4-64 (Figure 3). Activation
of autophagy was indicated by intravacuolar staining and multivesicular bodies
as shown in wild-type cells treated with rapamycin or nitrogen starved (Figure
3B, C) indicating transport of cytosolic material for degradation. However, in the
absence of autophagy in either untreated wild-type cells or atg8Δ mutant cells,
staining of the vacuole perimeter was observed (Figure. 3A, I-L). The
percentage of cells showing intravacuolar staining was estimated and shown in
Figure 3Q. As expected, nitrogen starvation and rapamycin treatment resulted
in almost 90% of cells showing intravacuolar staining, indicating strong
activation

of

autophagy.

Although

latrepirdine

treatment

also

showed

significantly increased intravacuolar staining (up to ~40% cells, Figure 3D, Q,
p<0.01), it was ~2 fold less than nitrogen starvation and rapamycin treatment.
As expected nitrogen starvation, rapamycin or latrepirdine treatment of atg8Δ
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mutant cells did not result in significant intravacuolar staining, consistent with
the inability of these cells to undergo autophagy.
Similar results were obtained when vacuolar alkaline phosphatase
(Pho8) activity was assessed. Compared to untreated wild-type cells, nitrogen
starvation and rapamycin treatment resulted in a 4-5 fold increase in alkaline
phosphatase activity (Figure. 4A). Treatment of cells with latrepirdine also
resulted in an increase in alkaline phosphatase activity (Figure. 4B). However,
Latrepirdine was less potent than either rapamycin or nitrogen starvation (eg.
activity for nitrogen starvation = 4.5 U/g, highest activity for latrepirdine =1.7
U/g). Treatment of atg8Δ mutant cells did not result in any increase in vacuolar
phosphatase activity. To investigate a more specific autophagic marker, I
studied the localization of Atg8p, an essential autophagic protein involved in
autophagosome formation which is up-regulated and transported to vacuole
during autophagy (Xie et al., 2008).
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Figure 3: N-starvation, rapamycin and latrepirdine treatment induces vacuolar
uptake of FM 4-64 dye.
Wild type and atg8Δ yeast were grown overnight in 5mL YEPD media. Cells
were resuspended in fresh YEPD to a cell density (OD at 600nm) of 0.2-0.3.
After incubation at 30ºC, at OD of 0.7, the cells were washed in sterile water
and resuspended in minimal media (YNB complete) containing rapamycin
(0.2µM) or latrepirdine (ltp) (1µM, 2.5µM) or in YNB (-N) media for 6h. Following
treatment cells were stained with FM 4-64 as described in the material and
methods. FM 4-64 staining was observed by fluorescence microscopy in wild
type (A-H) and atg8Δ (I-P) cells. The number of cells showing intravacuolar
staining and multivesicular morphology were counted as percentage of total cell
population (Q). Untreated cells showed minimal (<10%) of intravacuolar or
multivesicular staining. Significant increase in intravacuolar or multivesicular
staining was observed in wild-type cells compared to atg8Δ mutant cells that
underwent N-starvation, rapamycin treatment (0.2μM) or latrepirdine treatment
(1µM, 2.5µM) (**, p<0.01). Data represents mean ±SEM (n=4).
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Figure 4: N-starvation, rapamycin and latrepirdine treatment increases vacuolar
Alkaline Phosphate (Pho8) activity.
Wild type and atg8Δ yeast were grown overnight in 5mL YEPD media. Cells
were resuspended in fresh YEPD to a cell density (OD at 600nm) of 0.2-0.3.
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After incubation at 30ºC, at OD of 0.7, the cells were washed in sterile water
and resuspended in minimal media (YNB complete) containing rapamycin
(0.2µM) or latrepirdine (0.25µM, 0.5µM, 1µM, 2.5µM and 5µM) or in YNB (-N)
media for 6h. Vacuolar alkaline phosphatase activity was measured in cell
extracts and expressed as U/μg of total protein in the cell extract (A). Alkaline
phosphatase activity was significantly increased (**, p< 0.01, n=3) in wild type
compared to atg8Δ cells that underwent N-starvation or treatment with 0.2μM
rapamycin. Cells treated with latrepirdine exhibited ~4 fold lesser activity than
those that underwent N-starvation or rapamycin treatment and thus activities
were represented on separate graphs (B). Activity was significantly increased
dose dependently in wild type compared to atg8Δ cells treated with latrepirdine
(**, p<0.01, n=3). atg8Δ mutant cells that underwent latrepirdine treatment
showed similar levels of activity as untreated wild-type cells in accordance with
the inability of this cell line to undergo autophagy. Data is represented as mean
± SEM (n=4).

A GFP-Atg8p expressing yeast was used to examine the transport of Atg8p to
the vacuole (Yen et al., 2007). atg8Δ cells were transformed with GFP-Atg8p
plasmid (pRS306). Starting at OD 0.2 yeast culture (wt, atg8Δ) was cultured
until exponential phase (OD 0.7) and then treated with rapamycin (0.2µM)
(Figure 5B, F), nitrogen starved (Figure 5C, G) or latrepirdine (2.5µM) (Figure
5D, H) for 6h. Following treatment, the cells were observed by fluorescent
microscopy. With activation of autophagy, the GFP-Atg8p is transported to the
vacuole for degradation. While the Atg8p is recycled, the GFP moiety remained
intact in the vacuole showing diffuse green fluorescence which was used to
monitor autophagic flux (Kim et al., 2001a). Compared to vehicle treated cells,
rapamycin, nitrogen starvation and latrepirdine treated cells showed significant
increase in cells with diffuse GFP fluorescence. With 2.5µM latrepirdine
treatment ~25% of the cell population exhibited diffuse GFP fluorescence
compared to ~90% with nitrogen starvation or rapamycin treatment (Figure 5I),
indicating activation of autophagy. Overall, employment of three different
244

markers of the autophagy-vacuolar pathway indicates that although not a very
strong inducer of autophagy compared to nitrogen starvation or rapamycin,
latrepirdine induces autophagic like characteristics in yeast. Next I determined if
similar to rapamycin, latrepirdine enhanced autophagy contributes to a
reduction in GFP-Aβ42 levels.
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Figure 5: N-starvation, rapamycin and latrepirdine treatment enhances
transport of GFP-Atg8p to the vacuole.
atg8Δ cells were transformed with GFP-Atg8p plasmid with URA selectable
marker. The transformants were stored on YNB+2%glucose (-ura) agar plates
at 4ºC. A single yeast colony from stock agar plates was inoculated in 5mL
YNB+2%glucose (-ura) and incubated with shaking at 30ºC overnight. The
overnight culture was resuspended in fresh YNB+2%glucose (-ura) media to a
cell density (OD at 600nm) of 0.2. At cell density of 0.7, the cells were treated
with rapamycin (0.2µM) (B, F), Nitrogen starved (C, G) or latrepirdine (2.5µM)
(D, H) for ~6h till OD 0.8. Following treatment, the cells were observed by
fluorescent

microscopy.

The

number

of

cells

showing

diffuse

green

fluorescence was counted as a percentage in the total cell population (I) as
described in the materials and methods. Data is represented as mean ± SEM
(n=4). Rapamycin (0.2µM), Nitrogen starved or latrepirdine treatment (2.5µM)
significantly increased the levels of diffuse GFP fluorescence (**, p<0.01, n=3)
indicating the increased transport of GFP-Atg8p to the vacuole.
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9.4.3 Latrepirdine treatment in GFP-Aβ expressing wild type and
atg8Δ yeast cells
To determine if activation of autophagy by latrepirdine reduced GFPAβ42 levels, wild type and autophagy deficient mutant (atg8Δ) cells expressing
GFP-Aβ42 and wild type yeast expressing GFP-Aβ42 (19:34) were treated with
latrepirdine. Exponentially growing yeast cells (OD 0.7) were treated with
different concentrations of latrepirdine ranging from 1-5µM. After incubating at
30°C till OD 0.8 for ~4-5h, aliquots were collected for fluorescence
quantification, Aβ immunoblotting and cell viability.
GFP fluorescence images of untreated and latrepirdine treated (5μM) wtGFP-Aβ42, atg8Δ-GFP-Aβ42 and wt-GFP-Aβ42 (19:34) expressing cells are
shown in Figure 6A-F. The distribution of the GFP fusion proteins in wild-type
and atg8Δ cells are similar to that described in chapter 8 (Section 8.4.1).
Latrepirdine treatment did not appear to alter the distribution of GFP
fluorescence but instead in wild-type cells expressing GFP-Aβ42, appeared to
reduce the amount of punctate/ diffuse fluorescence. To provide a quantitative
assessment, the percentage of green fluorescent cells were estimated following
treatment (Figure 6G). Compared to vehicle, latrepirdine treatment resulted in a
significant reduction in percent of green fluorescent cells in wild type expressing
GFP-Aβ42 (Figure 6G). A decrease of ~10% with 1µM up to ~40-50% with 2.55µM was observed with latrepirdine treatment in wild type expressing GFPAβ42 (Figure 6G). However, latrepirdine treatment did not significantly alter the
percentage of fluorescence wild-type yeast cells expressing GFP-Aβ42 (19:34)
or atg8Δ mutant cells expressing GFP-Aβ42 (Figure 6G).
As a more quantitative measure of the levels of the GFP-Aβ proteins
after

latrepirdine

treatment,

aliquots

of

cells

were

collected

for

Aβ

immunoblotting analysis (Figure 7). Compared to vehicle, latrepirdine treatment
resulted in a significant reduction in GFP-Aβ42 protein levels in wild-type cells
as measured by densitometric analysis of the Aβ immunoreactive bands (Figure
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7A and B). A decrease of ~20% with 2.5µM up to ~40% with 5µM was observed
with latrepirdine treatment in wild type expressing GFP-Aβ42 (Figure 7B).
However, latrepirdine treatment did not significantly alter the Aβ levels of wildtype yeast cells expressing GFP-Aβ42 (19:34) or atg8Δ mutant cells expressing
GFP-Aβ42 (Figure 7A and B). In addition, latrepirdine treatment did not alter cell
viability (Figure 7C).
Overall, the data indicated that latrepirdine can reduce the levels of GFPAβ42 in wild type cells expressing GFP-Aβ42. Unlike rapamycin, latrepirdine
treatment reduced Aβ levels only in the wild type GFP-Aβ42 expressing cells
and not in atg8Δ GFP-Aβ42 and wild type -GFP-Aβ42 (19:34) cells (compare
Figure 6, 7 with 1, 2). Both rapamycin and latrepirdine have shown
neuroprotective functions against Aβ toxicity in neurons. I further determined
whether rapamycin and latrepirdine pre-treatment enhanced survival against Aβ
toxicity in wild type and atg8Δ cells.
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Figure 6: Latrepirdine treatment in GFP-Aβ42 and GFP-Aβ42 (19:34)
expressing wild type and atg8Δ cells: percentage of fluorescing cells
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were
grown overnight in 5mL YNB+2%glucose (-ura) media. Cells were resuspended
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After
incubation at 30ºC, at OD of 0.7, the cells were treated with latrepirdine (0, 1,
2.5, 5μM) for 6h. Following treatment the cells were collected for microscopic
analysis. GFP fluorescence images of untreated and latrepirdine treated (5μM)
wt-GFP-Aβ42 (A, D), atg8Δ-GFP-Aβ42 (B, E) and wt-GFP-Aβ42 (19:34) (C, F)
expressing cells are shown here. The percentage of cells expressing green
fluorescence following treatment was quantified as described in the materials
and methods (G). Compared to untreated cells, latrepirdine treatment resulted
in significant reduction in fluorescence levels in the wild type-GFP-Aβ42
(*p<0.05). However no significant change in fluorescence levels was observed
in wild type expressing GFP-Aβ42 (19:34) and atg8Δ expressing GFP-Aβ42.
Data is represented as mean ± SEM (n=3).
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Figure 7: Latrepirdine treatment in GFP-Aβ42 and GFP-Aβ42 (19:34)
expressing wild type and atg8Δ cells: Levels of GFP-Aβ fusion proteins
Wild type and atg8Δ Saccharomyces cerevisiae (KVY55) yeast cells were
grown overnight in 5mL YNB+2%glucose (-ura) media. Cells were resuspended
in fresh YNB+2%glucose (-ura) to a cell density (OD at 600nm) of 0.2-0.3. After
incubation at 30ºC, at OD of 0.7, the cells were treated with latrepirdine (0, 1,
2.5, 5μM) for 6h. Following treatment the cells were collected for
immunoblotting and viability analysis. Cell extracts (50µg) from untreated and
latrepirdine treated (1-5μM) wild-type and atg8Δ mutant cells expressing GFPAβ42 or wild-type cells expressing GFP-Aβ42 (19:34) were prepared and
immunoblotted with WO2 (A) Expression levels of Aβ42 (immunoreactive
bands) were quantified and expressed as a percentage of untreated control (C)
and data represented as mean ± SEM (n=3). Compared to untreated cells,
latrepirdine treatment resulted in significant reduction in Aβ levels wild typeGFP-Aβ42 (*p<0.05, **p<0.01). However no significant change in fluorescence
levels was observed in wild type expressing GFP-Aβ42 (19:34) and atg8Δ
expressing GFP-Aβ42. Cell viability was estimated in all untreated and treated
cell lines and expressed as a percentage of untreated control. Latrepirdine
treatment did not significantly alter the viability of cells.
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9.4.4 Aβ42 toxicity in yeast cells pre-treated with rapamycin,
nitrogen starvation or latrepirdine
Both rapamycin and latrepirdine have been shown to protect cerebellar
neuron cultures against Aβ induced toxicity, modulate Ca+ channels (Bachurin
et al., 2001; Lermontova et al., 2001; Wu et al., 2008) and enhance
mitochondrial function in the absence or presence of cell stresses (Zhang et al.,
2010b). Thus, I next determined whether enhancing autophagy by rapamycin,
latrepirdine or nitrogen starvation can reduce Aβ42 mediated toxicity in yeast.
Exponentially growing Saccharomyces cerevisiae (KVY55) wild type cells
(OD 0.7) were incubated with rapamycin (0.2μM), latrepirdine (1-5μM) or
nitrogen depleted media for 6h. After treatment, cells were treated with oligomer
Aβ42 (2μM) for 20h. Cell viability was measured by viable colony count and
represented as percent of untreated (Figure 8). Aβ42 (2µM) treatment caused
significant cell death (~80%) in vehicle treated wild type cells. However in
nitrogen starved or rapamycin pre-treated wild type cells, Aβ42 caused only
~30-40% cell death. Similarly with latrepirdine pre-treatment (2.5 and 5µM) of
wild type cells, Aβ42 caused only 40-50% cell death. The data showed that
rapamycin, latrepirdine or nitrogen starvation pre-treatment reduced Aβ42
mediated toxicity in wild type yeast (Figure 8A).

To determine whether activation of autophagy induced protection against
Aβ42, autophagy deficient (atg8Δ) cells pre-treated with rapamycin (0.2μM),
latrepirdine (1-5μM) or nitrogen starved were treated with Aβ42 similar to the
wild type cells. Interestingly, atg8Δ cells showed increased cell viability
compared to wild type cells with Aβ42 treatment (see Figure 8B, A). Treatment
of cells with 2μM Aβ42 caused cell death of only ~40% (~60% survival) in the
atg8Δ cells compared to ~80% (~20% survival) in the wild type. However unlike
wild type, the cell survival did not increase in atg8Δ cells pre-treated with
rapamycin (0.2μM), latrepirdine (1-5μM) or nitrogen starved following Aβ42
treatment. This showed that rapamycin, latrepirdine or nitrogen starvation did
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not affect Aβ42 mediated toxicity in atg8Δ cells (Figure 8B).

Overall the data showed that pre-treatment with known activators of
autophagy, rapamycin and nitrogen starvation enhanced survival against Aβ42
toxicity. In a similar fashion, latrepirdine pre-treatment also enhanced survival
against Aβ42 toxicity. The increase in cell survival with rapamycin, nitrogen
starvation or latrepirdine pre-treatment was evident only in wild type cells and
was absent in the autophagy deficient mutant (atg8Δ). This result indicated that
stimulation of autophagy in wild type cells increased its resistance against Aβ42
toxicity, whereas due to the lack of autophagy atg8Δ cells did not show any
increase in cell survival with rapamycin, nitrogen starvation or latrepirdine.
Supporting this data is the previous observations where atg8Δ cells did not
show any increase in autophagy with rapamycin, nitrogen starvation or
latrepirdine treatment (Figure 3, 4 and 5). Interestingly, the atg8Δ cells
displayed an increased resistance to Aβ42 toxicity (Figure 8). Whether this
phenomenon is associated with a deficiency in autophagy in the mutant or due
to a secondary effect of Atg8 gene deletion remains to be determined.
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Figure 8: Oligomer Aβ42 toxicity in wild type and atg8Δ cells pre-treated with
rapamycin, nitrogen starvation or latrepirdine
Exponentially growing Saccharomyces cerevisiae (KVY55) wild type were
incubated with rapamycin (0.2μM), nitrogen depleted media or increasing
concentrations of latrepirdine (1-5μM) for 6h. After treatment, cells were treated
with oligomer Aβ42 (2μM) for 20h. Cell viability was measured by viable colony
count and represented as percent of untreated (A). Aβ42 treatment caused
significant loss of viability in vehicle treated cells (#, p<0.001). However cell
viability following Aβ42 treatment was significantly higher in nitrogen starved,
rapamycin treated or latrepirdine (2.5 and 5μM) treated wild type cells
compared to vehicle treated (*, p<0.05 **, p<0.01). Similarly, exponentially
growing Saccharomyces cerevisiae (KVY55) atg8Δ cells were incubated with
rapamycin (0.2μM), nitrogen depleted media or increasing concentrations of
latrepirdine (1-5μM) for 6h. After treatment, cells were treated with oligomer
Aβ42 (2μM) for 20h. Viability was represented as percent of untreated (B).
Aβ42 treatment caused significant loss of viability in vehicle treated cells (#,
p<0.001). No significant change in cell viability following Aβ42 treatment was
observed in nitrogen starved, rapamycin treated or latrepirdine (2.5 and 5μM)
treated atg8Δ cells compared to vehicle treated. All data expressed as mean±
SEM (n=5).

9.4.5 Latrepirdine enhanced the peripheral clearance of Aβ42 in
vivo.
A recent study has shown that latrepirdine stimulates secretion of Aβ in cell
culture and also into the interstitial fluid of AD mouse brains (Steele et al.,
2009), suggesting that latrepirdine may promote the secretion/efflux from
neuronal cells/brain. The efflux of Aβ42 from the CNS into the periphery and
subsequent clearance/degradation by peripheral tissues is thought to be an
important mechanism to regulate Aβ levels within the brain (basis of the
peripheral sink hypothesis: see introduction section 1.9.1). Using an in vivo
model developed by our laboratory to assess the clearance of Aβ42 in the
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periphery, latrepirdine‟s ability to enhance clearance was evaluated.
The clearance of peripherally injected human Aβ42 in plasma and
subsequent degradation by peripheral organs was assessed as described in
Section 2.2.19. Our laboratory has demonstrated that Aβ is rapidly removed
from the plasma by the liver and kidney and the rate of its clearance is affected
by ApoE in C57BL/6J and APOE knockout mice (Hone et al., 2003). Recently
our laboratory showed that peripheral clearance of Aβ42 was impaired by the
presence of ApoE4 (Sharman et al., 2010). This was shown in mice expressing
human APOE ε4 (APOE ε4 targeted replacement (TR) mice) and also in APOE
knockout mice injected with Aβ42 and lipidated ApoE4. To determine whether
latrepirdine can promote clearance of Aβ42 in the periphery in the presence of
ApoE4, APOE knockout mice were injected via the lateral tail vein with Aβ42
(20µg) + lipidated ApoE4 in the absence or presence of latrepirdine. Mice were
sacrificed at 2.5, 5 and 15 mins and blood plasma and liver tissues were
collected. The levels of Aβ42 in blood plasma and liver were determined by
immunoblotting analysis (Figure 9).
Aβ42 levels were significantly decreased in the plasma of mice injected with
Aβ42+latrepirdine compared to Aβ42+saline at 2.5 and 5 minute time points
(Figure 9A, B). At 2.5-5 minutes, the plasma Aβ42 levels were 50-65% less with
latrepirdine injections compared to saline (Figure 9B). At 15 minutes, a trend
towards a reduction in Aβ42 levels was observed between the two groups but
this was not statistically significant. To further determine whether the reduced
levels of Aβ42 in the plasma were associated with increased uptake in the liver,
total protein extracts from the liver tissue homogenates were analysed by Aβ
immunoblotting at similar time points (Figure 9A, C). A significant increase in
the levels of Aβ42 was observed in the liver homogenates of Aβ42+latrepirdine
injected mice compared to that of Aβ42+saline (Figure 9C). The increase in
Aβ42 levels was significant only at the initial time point of 2.5 minutes. However
no significant increase was observed at 5 and 15 minutes. Overall the data
showed that in the presence of ApoE4, compared to saline, latrepirdine reduced
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the levels of intravenously injected Aβ42 in the plasma. This reduction in blood
plasma corresponded with an accumulation in Aβ42 in the liver at an early time
point, possibly indicating that latrepirdine mediates the rapid transport of Aβ42
from the plasma to the liver.
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Figure 9: Peripheral Aβ42 Clearance in APOE KO mice administered ApoEε4
and Aβ42 in the presence or absence of latrepirdine.
Saline (S) or latrepirdine (L; 3.5mg/Kg) was co-incubated with Aβ42 (20μg) for
3h prior to combining with ApoEε4 lipid emulsion and injecting into the tail vein
of APOE KO mice. Mice were sacrificed at 2.5, 5 and 15 min after injection and
Aβ clearance assessed by immunoblotting plasma and liver homogenates (A).
In the presence of latrepirdine, more Aβ is cleared from the plasma (B),
particularly at 2.5 and 5 min, with a corresponding increased uptake by the liver
at 2.5 min (C). Data represents means ±SEM, n=4 in saline (S) group, n=5 in
latrepirdine (L) group. Plasma Aβ levels are significantly reduced in mice
injected with latrepirdine+Aβ42 compared to saline + Aβ42 injected ones (*,
p<0.05; ** p<0.01). Liver Aβ levels was significantly increased in mice injected
with latrepirdine+Aβ42 compared to saline + Aβ42 injected ones (#, p<0.05).
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9.5

Discussion:

The ubiquitin-proteasome and autophagy-lysosome pathways are the main
intracellular degradation pathways for protein and organelle clearance in
eukaryotic cells. Dysfunction of these pathways resulting in the accumulation of
aggregate prone and toxic proteins in cells contributes to the pathology of
several neurodegenerative diseases including AD. Modulating these cellular
degradation pathways to enhance clearance of protein aggregates is gaining
interest as a therapeutic strategy. In chapter 8, I showed that the proteasome
had a greater contribution to reducing intracellular Aβ42 levels in yeast than
autophagy, particularly at early stages of cell growth. However, at late log phase
of cell growth, autophagy was the major contributor to reducing Aβ42 as cells
enter a nutrient starvation stage. It is suggested that enhancing the autophagylysosome pathway is a more favourable target to promote clearance of protein
aggregates compared to the ubiquitin-proteasome system (Rubinsztein, 2006).
One reason is the substrate limitations for proteasome mediated degradation.
The proteasome degrades proteins that are ubiquitin tagged and only unfolded
proteins which can enter the proteasomal core. By contrast, autophagy has the
capacity to degrade folded proteins, large aggregates and even entire
organelles. Upregulating autophagy is also considered to be safer and a more
attractive alternative compared to enhancing the proteasomal activity as
discussed previously in the introduction to this chapter (Section 9.1). Studies
from a variety of models have shown that up-regulation of autophagy; both
pharmacologically and physiologically can promote clearance of protein
aggregates and attenuate neurodegeneration (Berger et al., 2006; Mizushima et
al., 2008; Ravikumar et al., 2004; Sarkar et al., 2007b; Williams et al., 2008).
In chapters 7 and 8, the GFP-Aβ expressing yeast model was used to
investigate intracellular Aβ accumulation and degradation pathways involved in
clearance of Aβ. Disruption of both ubiquitin-proteasome and autophagylysosome pathway resulted in increased accumulation of GFP-Aβ42 compared
to the wild type in the yeast cell. The use of this model to determine the effect of
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rapamycin, a known activator of autophagy, in the clearance of GFP-Aβ42 in
yeast cells has been presented here. Further, the ability of latrepirdine in
activating autophagy, promoting clearance of GFP-Aβ42 and protecting cells
from Aβ42 toxicity provides a novel mechanism of action for this promising drug
for AD.

9.5.1 Rapamycin reduced intracellular GFP-Aβ42 levels in yeast

The typical pathway for modulating autophagy is via mTOR, a protein kinase
that is central to nutrient-sensing signal transduction, regulation of translation
and cell-cycle progression (Klionsky et al., 2005; Noda and Klionsky, 2008).
mTOR can be inhibited by rapamycin and related molecules, which belongs to a
family of lipophilic macrolide antibiotics that form a complex with the
immunophilin FK506-binding protein 12 (FKBP12), which then binds to and
inactivates mTOR, leading to an up-regulation of autophagy. Inhibition of mTOR
by rapamycin has been widely reported to enhance clearance of aggregateprone proteins (Berger et al., 2006; Ravikumar et al., 2004; Sarkar and
Rubinsztein, 2008). In mammalian AD models, rapamycin induced activation of
autophagy have been shown to be neuroprotective and confer cognitive
benefits (Hung et al., 2009; Spilman et al., 2010).
Rapamycin treatment of GFP-Aβ42 expressing wild-type cells resulted in a
reduction in GFP-Aβ42 levels (Figure 1). It is noted that rapamycin also led to a
reduction in levels of GFP-Aβ42 expressed in atg8Δ mutant cells and the levels
of the GFP-Aβ42 (19:34) expressed in wild-type cells. This may be due to
rapamycin‟s action as a potent inhibitor of mTOR signalling, which is an
important pathway for growth and cell cycle progression. Also rapamycin has
been demonstrated to attenuate cell growth and inhibit protein synthesis in
many cell lines (Hay and Sonenberg, 2004; Heitman et al., 1991). Results
presented in Figure 1C show that cell viability was not significantly altered,
however inhibition of protein synthesis cannot be ruled out which may have
contributed to the decreased Aβ levels in

atg8Δ cells. Moreover,
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macroautophagy is largely a non-specific process which sequesters bulk
cytoplasmic material for degradation in the vacuole (Nair and Klionsky, 2005)
and thus, apart from aggregate proteins, soluble cytosolic proteins and
organelles are also degraded which may account for the reduction in levels of
the non-aggregated GFP-Aβ42 (19:34). Nevertheless, it was shown that
rapamycin mediated reduction in intracellular Aβ42 levels were more
pronounced in the wild type cells expressing GFP-Aβ42 (Figure 1) compared to
those expressing GFP-Aβ42 (19:34) and atg8Δ mutant cells expressing GFPAβ42. The results suggest that rapamycin enhanced autophagy contributes to
the removal of aggregated forms of Aβ. However, as is seen by the reduction in
Aβ levels in cells that are unable to undergo autophagy, other non-autophagy
related effects must be taken into consideration.

Its effects on mTOR signalling cell growth, proliferation and protein synthesis
(Hay and Sonenberg, 2004) and its known immunosuppressant effects
(Abraham, 1998) indicates that rapamycin can have multiple cellular targets,
some undesirable. Synthetic small molecule derivatives of rapamycin have
been shown to have benefits at reducing toxicity induced by Huntington protein
aggregates whist minimising its adverse effects (Floto et al., 2007; Ravikumar et
al., 2004). A recent study has also shown that small molecule enhancer of
rapamycin (SMER28) decreased levels of Aβ and APP-CTF via Atg5 dependent
autophagy in neuronal cells (Tian et al., 2011). Further, derivatives of known
agents shown to have benefits in AD models, such as resveratrol, have been
developed and shown to modulate mTOR signalling and facilitate autophagy
and Aβ clearance (Vingtdeux et al., 2010).

Autophagy can also be induced by an mTOR-independent route by
physiological stress, such as starvation or by 1) lowering myo-inositol-1,4,5triphosphate (IP3) levels (lithium, sodium valproate and carbamezapine) 2) Ltype Ca2+ channel antagonists (e.g. verapamil), 3) calpain inhibitors (e.g.
calpastatin and calpeptin) and 4) Gsα inhibitors (such as NF449) (Zhang et al.,
2007) (Fornai et al., 2008; Sarkar et al., 2005). Trehalose, an mTOR
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independent autophagy activator has also shown to enhance clearance of
protein aggregates in HD and PD models (Sarkar et al., 2007a). As discussed
below, the results presented in this chapter provide evidence in support of
latrepirdine‟s ability to induce autophagy and reduce intracellular Aβ levels,
without exhibiting the non-autophagy related effects observed for rapamycin.

9.5.2 Latrepirdine induced autophagy and reduced intracellular
levels of GFP-Aβ42
Latrepirdine (Dimebon™; dimebolin) is a neuroactive compound with
antagonist activity at histaminergic, α-adrenergic, and serotonergic receptors
(Wu et al., 2008). Latrepirdine is another small molecule that appears to
mediate a number of activities associated with receptor inhibition (Grigorev et
al., 2003), enhancing cognitive function (Lermontova et al., 2000), promoting
neuronal survival (Bachurin et al., 2001; Zhang et al., 2010b), intracellular Ca+2
stabilisation (Lermontova et al., 2001), Aβ secretion and metabolism (Steele et
al., 2009) and clearance of α-synuclein protein aggregates (Wu et al., 2008;
Yamashita et al., 2009). Some recent studies have also reported latrepirdine‟s
cognitive enhancing properties (Giorgetti et al., 2010; Vignisse et al., 2011). In
the current study an additional function for latrepirdine in enhancing autophagy
was demonstrated. Latrepirdine was shown to induce autophagy by three
independent methods, including morphological detection of autophagic bodies
using FM 4-64 staining, measuring the autophagic flux by determining Pho8
enzyme activity and by monitoring the vesicle delivery into the vacuole using a
GFP-Atg8p expressing yeast (Figure 2, 3 and 4).

The FM 4-64 dye belongs to a group of cationic amphiphilic styryl dyes that
fluoresce in the presence of a hydrophobic environment (Betz et al., 1992).
Under normal conditions the FM 4-64 dye is associated with the biological
membrane and with longer incubations they are internalized and concentrate
onto the vacuolar membranes. During starvation conditions, autophagic bodies
accumulate in the cell and are transported into the vacuole for degradation.
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When the breakdown of the autophagic bodies in the vacuole is inhibited by
protease inhibitor (PMSF), intravacuolar bodies are observed accumulating in
the vacuole marked by intense FM 4-64 staining inside the vacuole (Takeshige
et al., 1992). Known activators of autophagy like nitrogen starvation and
rapamycin induced accumulation of autophagic bodies associated with strong
intravacuolar staining of FM 4-64 in yeast (Figure 2B, C). Latrepirdine treatment
induced a similar phenotype in yeast indicating an increased accumulation of
autophagic bodies in the vacuole (Figure 2D). Latrepirdine treatment (1-2.5µM)
induced intravacuolar FM 4-64 uptake in approximately 40% of cells compared
to ~90% in N-starved and rapamycin treated. However in the atg8Δ cells, where
autophagy is impaired, such morphology was absent with nitrogen starvation,
rapamycin and latrepirdine treatment (Figure 2I-L).

Measurement of the activity of autophagy is referred to as autophagic flux.
The Pho8 assay is a commonly used quantitative monitoring system of yeast
autophagic flow based on the measurement of the enzyme activity during
stimulation of autophagy (Noda and Klionsky, 2008). PHO8 is the gene
encoding the sole vacuolar alkaline phosphatase in yeast. It is a type II
transmembrane protein containing an N-terminal cytosolic tail with the active
site and the C-terminus are located within the vacuolar lumen (Klionsky and
Emr, 1989). During autophagy, the C terminal pro-peptide is cleaved off by
vacuolar proteases resulting in the generation of the active form. Pho8 activity
was measured using a specific substrate (α-naphthyl phosphate) using a
fluorimetric assay. Latrepirdine increased the Pho8 activity in a dose dependent
fashion at concentrations (0.25-5µM) (Figure 3). Similar to the FM 4-64 staining,
latrepirdine treatment stimulation of Pho8 activity was markedly less than
nitrogen starvation and rapamycin treatment. No increase in activity with
latrepirdine, nitrogen starvation or rapamycin treatment was observed in atg8Δ
cells, indicating that AV synthesis and Atg8p were essential for latrepirdine
induced alkaline phosphatase activity.
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The Atg8p molecule is an ubiquitin-like protein which conjugates to
phosphatidylethanolamine (PE) and associates with the autophagosome/AV
membrane during autophagy (Huang et al., 2000; Xie et al., 2008). After
delivery to the vacuole, the Atg8p–PE complex is cleaved from the outer
surface of the sequestering vesicle, but the GFP tag (in the GFP-Atg8p
transformant) located on the inside of the vesicle remains trapped and was
used as a functional marker for monitoring delivery of vesicles to the vacuole
(Kim et al., 2001a). The released GFP moiety remains relatively stable from
vacuolar hydrolysis, whereas Atg8p is rapidly degraded. Nitrogen starvation and
rapamycin treatment induced a vacuolar GFP fluorescence phenotype in ~90%
of cells, whereas latrepirdine treatment (2.5µM) induced a similar phenotype in
~25% (Figure 4).

Although not as efficient as rapamycin or N-starvation, latrepirdine promoted
uptake of the vacuole stain FM 4-64, increased activity of the vacuolar alkaline
phosphatase and up-regulation of GFP-Atg8p. Overall the data indicated that
latrepirdine can promote autophagy in yeast cells. The lack of activation of
autophagy in cells deficient in Atg8p may suggest that latrepirdine mediated
autophagy in yeast was Atg8 dependent. However the exact mechanism of
action is unclear.

The concentrations needed to induce autophagy for

latrepirdine in yeast is around 1-5µM, which is approximately 5-50 times (by
molarity) more than rapamycin (0.1-0.2µM). This probably suggests that
latrepirdine may be a weak inhibitor of TOR, targeting a downstream signalling
molecule of mTOR pathway or even mTOR independent. Isolating yeast
mutants resistant to latrepirdine stimulated autophagy can assist in the
identification of the potential mechanism of latrepirdine induced autophagy. In
addition, analysis of other mutants lacking particular genes in the autophagic
pathway, such as Atg1 (protein kinase required for vesicle formation) or Atg5
(formation and transport of autophagosome) may provide further insight into
potential targets for latrepirdine in the autophagic-vacuolar pathway in yeast.

Latrepirdine significantly reduced GFP-Aβ42 levels expressed in wild-type
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yeast cells but not in atg8Δ mutant cells, indicating the involvement of
autophagic-vacuolar pathways. Similar to the activity observed in the
autophagic assays, latrepirdine mediated decrease in GFP-Aβ42 levels in yeast
was significantly lower compared to rapamycin treatment [40% decrease with
5µM latrepirdine compared to ~95% with 0.2µM rapamycin (compare Figure 5
and 1)]. The decreased ability of latrepirdine to stimulate autophagy compared
to rapamycin may account for this. Assessing GFP-Aβ42 clearance in yeast
cells deficient in essential components involved in the initiation of the pathway
(through inhibition of mTOR), autophagosome formation and transport or
autophagosome-vacuolar fusion, will provide further insight into possible targets
for latrepirdine. Once identified this would require further validation in
mammalian neuronal cells.

9.5.3 Activation of autophagy protects yeast cells from Aβ42
toxicity
Activation of autophagy has been shown to be protective against a variety of
stresses to cells (Levine and Kroemer, 2008; Mizushima et al., 2008). The prosurvival function of autophagy has been demonstrated in cells and animal
models during nutrient and growth factor deprivation, endoplasmic reticulum
stress, development, microbial infection, and diseases characterized by the
accumulation and toxicity of protein aggregates (Lum et al., 2005; Yorimitsu and
Klionsky, 2007).

Stimulation of autophagy by rapamycin and latrepirdine was shown to
reduce the levels of GFP-Aβ42 aggregates in yeast cells (Section 9.5.1 and
9.5.2). Therefore, I further determined whether activation of autophagy reduced
toxicity of oligomeric Aβ42 using the colony count viability assay in yeast
(Bharadwaj et al., 2008). Wild type and autophagy deficient atg8Δ cells were
pre-treated with rapamycin, latrepirdine or nitrogen starved followed by oligomer
Aβ42 treatment (Figure 8). The data showed that activation of autophagy by
rapamycin, latrepirdine and nitrogen starvation enhanced survival against Aβ42
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toxicity. The increase in cell survival was evident only in wild type cells and was
absent in the atg8Δ cells. This result indicated that stimulation of autophagy in
wild type cells increased its resistance against Aβ42 toxicity, whereas due to the
lack of autophagy atg8Δ cells did not show any increase in cell survival. The
observations that atg8Δ cells do not respond to rapamycin, nitrogen starvation
or latrepirdine treatment (Figure 3, 4 and 5) further supported the notion that
activation of autophagy enhanced survival against oligomer Aβ42 toxicity.

Interestingly, under normal conditions (without any pre-treatment) atg8Δ
cells displayed an increased resistance to Aβ42 toxicity compared to the wild
type (compare Figure 8A with 8B). Ideally, the atg8Δ mutant would have
expected to be more susceptible to oligomeric Aβ42 treatment due to its inability
to undergo autophagy. However in the yeast Aβ42 toxicity assay, atg8Δ cells
showed almost ~2 fold increase in cell survival comparing the wild type. Studies
indicate that autophagic related (ATG) genes can act both in cellular protection
and also in cell death (Levine and Kroemer, 2008; Mizushima et al., 2008).
Notably, many examples of ATG-gene dependent death occur in mammalian
cells (Levine and Yuan, 2005; Pattingre et al., 2005). Whether Aβ42 mediated
cell death in yeast is associated with Atg8 gene expression in cells is yet to be
determined. Another likely possibility is that the knock-out of Atg8 gene in yeast
may be associated with effects beyond autophagy which may contribute to this
phenomenon. It is therefore unclear whether the increased resistance of atg8Δ
cells to oligomer Aβ42 toxicity is autophagy dependent or a result of a
secondary effect of Atg8 gene deletion. Investigation of oligomer Aβ42 toxicity
in other ATG gene knock out mutants including Atg1, Atg5, Atg8, and Atg9 can
provide a better insight into this effect.

9.5.4 Latrepirdine promotes peripheral clearance of Aβ42 in the
presence of ApoE4
In addition to intracellular degradation pathways like autophagy, one of
the important mechanisms of action with respect to clearance of Aβ from the
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brain is the “peripheral sink” hypothesis (DeMattos et al., 2001). The main basis
of this hypothesis is that Aβ is transported out of the brain, into the periphery
where proteins in the circulation can sequester Aβ and deliver it to peripheral
tissues like liver and kidney for clearance. Plasma Aβ levels in the periphery are
typically low (Gandy et al., 2001), indicating that metabolic process facilitates
rapid clearance of this protein in the periphery. Earlier studies (DeMattos et al.,
2001; DeMattos et al., 2002) have shown that Aβ can be cleared to the plasma
from the brain by the use of anti-Aβ antibodies. In addition, work by Matsuoka et
al. (Matsuoka et al., 2003) has showed that peripheral treatment with an agent
having a high affinity for Aβ reduced brain levels of Aβ.

While the yeast studies clearly provide valuable insight into the
mechanism of action of latrepirdine in clearing A its clinical significance
requires an in vivo model. Latrepirdine was therefore assessed for its ability to
promote Aβ42 clearance in the periphery using APOE knockout mice injected
with Aβ42+ lipidated ApoE4 (Figure 9). Substantial differences in the expression
levels of total plasma ApoE has been observed in different APOE (ε2, ε3, and
ε4) knock-in mice (APOE-targeted replacement (TR) mice) (Knouff et al., 1999;
Sullivan et al., 1998). Therefore, to control for the differeing levels of plasma
ApoE across genotypes, the peripheral clearance of Aβ42 was evaluated in the
APOE knockout mouse model utilizing lipidated recombinant ApoE isoforms
(Sharman et al., 2010). Regardless of the model used (APOE-TR mice or
APOE KO mice +lipidated ApoE4), Sharman and colleagues showed that the
presence of ApoE4 impaired the peripheral clearance of injected human Aβ42.
The results presented in this chapter show that latrepirdine, compared to the
saline control, can markedly improve the clearance of Aβ42 from the blood
plasma and promote uptake by the liver, (Figure 9), in the presence of ApoE4.
The reasons for these marked effects of latrepirdine on the peripheral clearance
of Aβ42 are unclear. A possible explanation is that latrepirdine interacts with
Aβ42; either preventing its further aggregation (thus promoting more effective
clearance of Aβ monomers) or this interaction may promote its uptake (possibly
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receptor mediated) and clearance/degradation by the liver. Steele et al., (2009)
study reported increased Aβ levels in ISF of mice treated with latrepirdine. It is
conceivable that as part of latrepirdine‟s overall effect, it enhances clearance of
Aβ from the ISF and the CNS into the periphery where it is rapidly cleared.

The findings presented in this chapter have provided initial evidence for a
novel mechanism of action for latrepirdine in promoting the clearance of Aβ, in
vivo. Further investigation into whether latrepirdine could modulate the
aggregation and degradation of Aβ in mammalian in vitro and in vivo systems
would be required.

9.6 Summary

Overall the data presented in this chapter has established the use of the
yeast model for screening compounds which can reduce intracellular
accumulation of Aβ, by possibly enhancing its clearance. A novel mechanism of
action has also been identified for the AD drug latrepirdine. Latrepirdine was
shown to enhance autophagy and promote Aβ clearance in cells. Although
latrepirdine has shown mixed results in AD clinical trials, more recent studies
are reporting its cognitive benefits in animal models. The ability of latrepirdine to
stimulate autophagy in the yeast model can be used to develop analogues with
increased potency and lesser toxicity. While rapamycin is the most widely used
autophagy stimulating drug, growing evidence has emphasized the need for
more specific and potent agents/small molecules to replace this first generation
autophagy promoting drug. The identification of novel compounds which can
specifically inhibit particular elements of autophagy combined with genetic
screens can be resourceful to understand the pathways and the proteins
involved with the clearance of intracellular aggregates. Besides its ability to
modulate autophagy, in vivo studies showed that latrepirdine can promote
peripheral Aβ42 clearance and also increase uptake into liver. In general, the
data presented in this chapter have suggested that latrepirdine may operate by
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multiple

mechanisms

to

promote

Aβ

clearance

thereby

reducing

its

accumulation and toxicity. How and which of these effects relate to drug-related
changes in cognition and behaviour will need to be elucidated in order to
selectively modify this promising drug candidate and thus develop more potent
related molecules that are tailored to effectively treat AD.
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Chapter 10
Conclusions and Future
Directions
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General Discussion: Cellular models are essential for studying the
underlying pathology of a disease and designing novel techniques for drug
discovery. Yeast has been used as a model for several neurological disorders
characterized by protein misfolding and aggregation: reviewed in [(Braun et al.,
2010; Winderickx et al., 2008)]. In addition to its conserved nature, yeast cells
are robust and have better tractability and reduced complexity compared to
other mammalian cells which makes it a resourceful model for studying disease
pathways and drug mechanisms. The work presented in my thesis has primarily
focussed on establishing yeast models for investigating the toxicity and
intracellular clearance pathways of beta amyloid (Aβ), a peptide central to the
pathogenesis of Alzheimer‟s disease (AD). In this thesis, I have also
demonstrated the use of the yeast model in investigating novel agents which
can attenuate Aβ toxicity or enhance its clearance.
10.1

Oligomer Aβ Toxicity

10.1.1 Membrane associated toxicity of Oligomeric Aβ42

AD is characterized by extensive neuronal loss associated with senile
amyloid plaques in the brain. There is considerable evidence to clearly indicate
that the soluble oligomeric forms of Aβ protein are the main toxic species which
are responsible for the pathology of the disease. Aβ is an intramembrane
cleavage product of APP and is largely secreted into the extracellular lumen. It
can therefore have a major impact on neuronal functions and viability by
interacting with cell surface membranes (Talaga and Quere, 2002; Verdier and
Penke, 2004; Verdier et al., 2004). Due to its hydrophobic nature, Aβ has an
inherent ability to associate with biological membranes. The ability to interact
with membranes is therefore an important feature of oligomer Aβ mediated
toxicity to cells.
In earlier work I had demonstrated that Aβ was shown to be toxic to yeast
cells (Bharadwaj et al., 2008). I now show in chapter 3 of this thesis the
significance of Aβ42 binding to the plasma membrane in causing cell death in
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yeast. The uptake of the Aβ42 peptide by yeast and its localisation indicated
that oligomeric Aβ42 mediated cell death was associated with binding to the
plasma membrane. Taken together with previous reports in neuronal cells
(Ciccotosto et al., 2004; Hung et al., 2008), the data supports the notion that
reduced binding to the plasma membrane is associated with decreased toxicity.
In yeast, oligomeric Aβ42 was shown to alter the activity of the plasma
membrane proton pump H+ATPase (Section 3.4.5, Chapter 3), a functional
homolog of the mammalian Na+/K+ ATPase. This data is consistent with
previous reports from a non-yeast model which showed decreased Na+/K+
ATPase and Cl--ATPase activity in plasma membranes isolated from Aβ42
peptide treated hippocampal cells (Bores et al., 1998; Mark et al., 1995; Xiao et
al., 2002). This may be one mechanism by which oligomeric Aβ42 can impact
cellular homeostasis and cause cell death. Further investigation is required to
determine how oligomer Aβ42 inhibits the H+ATPase and whether modulating
the activity of H+ATPase can rescue Aβ mediated cell death.

10.1.2

Suppression of Aβ42 Oligomerization prevented Toxicity

Preventing the formation or disrupting the specific toxic oligomer structures
to reduce Aβ caused neuronal dysfunction in the brain has been proposed as a
therapeutic strategy in AD (Klein, 2007; Kruzel et al., 2001). In my study, the
effect of dairy peptides on Aβ oligomerization and toxicity was determined using
the yeast model. Dairy peptides lowered the net β-sheet content and more
specifically the anti-parallel β-sheet content in Aβ42 thereby inhibiting
oligomerization. Studies indicating the essential role of anti-parallel β-sheets in
the formation of Aβ oligomers further supported this data (Cerf et al., 2009). The
concomitant reduction in the toxicity of the Aβ42 peptides with reduced
oligomerization was clearly evident in both yeast and neuronal cells. The
pattern of loss of high mass oligomers (Figure 5, Chapter 4) of Aβ42 and
associated toxicity was very similar to that seen in the presence of curcumin
(Yang et al., 2005). It appears that the high mass oligomers represent the main
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toxic species involved in cell death. However, their exact structural nature is
unclear and needs further investigation. Overall, a positive correlation between
suppression of β-sheet content and oligomerization by dairy peptides (Figures
2-5, Chapter 4) and protection against Aβ42-mediated toxicity to both yeast and
neuronal cells (Figure 6, Chapter 4) was observed. The results presented in this
chapter 4 established the application of the yeast model for screening
compounds which can affect Aβ oligomerization and toxicity. Comparing
neuronal cell cultures, the use of yeast cells for screening such compounds can
be cost effective and is more amenable to developing a rapid in vitro screening
tool for agents targeting oligomeric Aβ mediated toxicity.

10.1.3

MBP-Aβ42 fusion protein: A model for oligomeric Aβ

The majority of the assays used for identifying compounds which bind Aβ or
target oligomerization and toxicity are based on using synthetic Aβ preparations
[derived from solid phase peptide synthesis (SPSS)]. As discussed in Chapter
5, the preparation of oligomeric Aβ peptide solutions from synthetic Aβ is
expensive and can be unsuitable for large scale studies. As a result, an
increasing number of studies are adopting methods for recombinant production
of Aβ (Dobeli et al., 1995; Hortschansky et al., 2005; Lee et al., 2005; Li et al.,
2009; Luhrs et al., 2005; Sharpe et al., 2005; Subramanian and Shree, 2007;
Walsh et al., 2009; Wiesehan et al., 2007). The maltose binding protein tagged
Aβ42 (MBP-Aβ42) fusion protein reported by Caine et al. (2007) is a
recombinant protein which can be stably produced in large quantities, purified
easily using affinity columns and also showed properties (binding to Cu and Zn)
similar to Aβ peptide (Caine et al., 2007b). The work presented in this thesis
investigated the structural properties and toxicity of MBP-Aβ fusion proteins in
yeast and neuronal cells (Caine et al., 2011).

Overall the data provided clear evidence that MBP-Aβ42 formed oligomers
in solution and was more toxic compared to the truncated MBP-Aβ16 (Chapter
5). However compared with the Aβ42 peptide, the MBP-Aβ42 fusion protein
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showed reduced ability to form higher oligomeric structures (greater than
hexamer) and also fibrillar forms. Consequently, the MBP-Aβ42 also showed
decreased toxicity compared to Aβ42 peptide in yeast

and neuronal cells

[Chapter 3, (Bharadwaj et al., 2008)]. The reduced toxicity of the MBP-Aβ42
solutions could be attributed to the absence of higher oligomeric structures
which are observed with Aβ42. The data supported the notion that oligomer
Aβ42 mediated cell death is caused collectively by an array of soluble
oligomeric Aβ species with neurotoxic properties (Haass and Selkoe, 2007).
Further investigation using stable cross-linking analysis of the different MBPAβ42 species may provide greater insight into the individual contributions of the
different isoforms to toxicity and cell death.

Although MBP-Aβ42 may not be a naturally occurring form, it can have
multiple applications based on its structural and toxic properties demonstrated
in this thesis. Due to its relatively cheap manufacturing costs and high stability,
it is a well suited model for large unbiased screening methods for structural
elucidation and physicochemical studies for identifying Aβ binding ligands and
compounds which can affect Aβ oligomerization. Moreover, it provides the
opportunity for developing assays for identifying potential inhibitors of Aβ
peptide toxicity in yeast.

10.1.4

Cell cycle dependent effects of Aβ

In addition to its toxic effects, reports have also demonstrated neurotrophic
properties of Aβ peptides (Chan et al., 1999; Koo et al., 1993; Luo et al., 1996a;
Whitson et al., 1989; Yankner et al., 1990). Studies indicate that the
neurotrophic effects of Aβ reflect its role in neuronal development. But why a
certain population of neurons become susceptible to Aβ42 mediated
neurodegeneration in the AD brain is uncertain. Data presented in this thesis
provides evidence that Aβ42 mediated toxicity or growth effects is dependent on
the cell cycle which may explain the selective vulnerability of neurons in AD.
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The results showed that Aβ42 can promote proliferation only in cells that are
in the stationary phase and induce cell death in exponentially growing cells
(Chapter 6). The Aβ-induced growth and toxic effects within different cell cycles
in yeast is comparable to the initial report showing that Aβ can enhance survival
in freshly plated undifferentiated hippocampal cells (Yankner et al., 1990), but
toxic in aged differentiated cultures. Studies showing Aβ42 mediated cell death
in neurons expressing particular cell cycle-related elements (Giovanni et al.,
1999; Liu et al., 2004), and in G1 cell cycle stage (Simakova and Arispe, 2007)
further supported the notion that Aβ42 mediated toxicity or growth is dependent
on the cell cycle. mTOR is one important eukaryotic cell signalling pathway
associated with Aβ induced growth effects. It was shown that rapamycin; an
mTOR inhibitor, suppressed Aβ42-induced cell division in stationary phase
yeast cells. This data supported the previous reports showing that mTOR
inhibitors block Aβ42 induced neuronal cell cycle events (Bhaskar et al., 2009;
Frasca et al., 2004; Malik et al., 2008; Varvel et al., 2008; Wu et al., 2000).

However, the exact role of mTOR signalling in AD is contentious as some
studies have shown increased levels of p-mTOR in the AD brain (Chang et al.,
2002; Li et al., 2005; Li et al., 2004), whereas a significant decrease in p-mTOR
levels has also been reported (Lafay-Chebassier et al., 2005). A recent study
showed that long-term inhibition of mTOR by rapamycin reduced Aβ levels in
the brain and prevented AD-like cognitive deficits (Spilman et al., 2010). In
contrast, another recent study showed correlation between the inhibition of
mTOR signalling and Aβ induced impairment of synaptic plasticity (Ma et al.,
2010b). It is evident that Aβ42 and mTOR are closely associated in AD
pathology and can regulate each other. However, further investigation is
required to determine the exact role of mTOR signalling and its association with
Aβ42 mediated neurodegeneration in AD.
Data presented in this work has suggested a significant role of Aβ42 in
mediating both growth and toxicity which can be associated with essential
signalling pathways in the cell like mTOR. The strong association of Aβ42 on
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the yeast plasma membrane (Section 3.4.4) suggests that the peptide mediated
effects could be a result of its interaction with cell surface receptors. The
reduced toxicity in stationary phase cells compared to the actively growing cells
and the levels required for Aβ42 induced toxicity (micromolar) and cell
proliferation (nanomolar) suggests that diverse receptors or their varied
expression levels depending on the cell cycle may influence the Aβ42 mediated
effects (Section 6.5.1). Interestingly, Aβ42 induced growth effect was observed
only in Candida glabrata and was absent in Saccharomyces cerevisiae cells
(Section 4.4.4). This observation is particular intriguing and further investigation
of other fungal species using mutational analysis would provide a greater
understanding of the pathways and receptor molecules involved in Aβ mediated
proliferation and cell cycle events.

10.2

Intracellular Aβ42 Accumulation

10.2.1 Aβ clearance pathways in the cell
Data presented in chapters 7 and 8 of this thesis employ a GFP tagged Aβ
expressing yeast model (Caine et al., 2007a) for investigating intracellular
clearance pathways involved in the degradation of Aβ42. Further in chapter 9,
enhancing autophagy to promote clearance of intracellular Aβ42 was
investigated.
GFP-Aβ42 was found localized into vesicles reminiscent of autophagic
bodies or endosome like structures [(Caine et al., 2007a), Chapter 7]. Reports
showing that Aβ accumulates in vesicular/lysosomal structures in neurons of a
variety of AD mouse models (Oddo et al., 2006; Wirths, 2001), human AD
brains (Gouras et al., 2000; Nixon et al., 2005) and in neuronal cells treated with
extracellular Aβ42 (Hu et al., 2009) supports the idea that GFP-Aβ42 may
accumulate in such vesicles. The reduced levels and the punctate staining of
GFP-Aβ42 observed in yeast indicated that Aβ42 is sequestered into these
vesicles and targeted for degradation (Chapter 7). The results suggested that
expression of GFP-Aβ42 in the cell elicited a degradative response and that it
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can be cleared via distinct pathways. Autophagy-lysosome and ubiquitin
proteasome system (UPS) are the main protein degradative mechanisms in
cells. Data presented in Chapter 8 provided evidence for Aβ clearance by both
the UPS and autophagic pathways.

10.2.2
and

Lack of autophagic vesicle synthesis, vacuolar hydrolases
proteasomal

activity

elevates

intracellular

Aβ42

accumulation

The morphology of neurons and the plasticity of synapses impose unique
challenges on the cellular machinery for both protein synthesis and degradation
(Steward and Schuman, 2003). Therefore post-mitotic differentiated neurons in
the adult brain are highly vulnerable to accumulation of protein aggregates
which is a main feature in several neurodegenerative diseases including AD.
Hence disruption of protein homeostasis or imbalance in synthesis/clearance
can be a major contributing factor of neuronal dysfunction.
It was shown that disruption of autophagy (atg8Δ) or vacuolar hydrolase
(pep4Δ, cvt1Δ) activity elevated total GFP-Aβ42 levels and accumulation of
GFP-Aβ42 containing vesicles in the yeast cell especially during the starvation
periods of growth (Chapter 8). Baseline levels of autophagy during the active
growth phase also contributed to the clearance of GFP-Aβ42 in yeast. The
accumulation of Aβ has been reported in the absence of other autophagy genes
such as Atg5p, Beclin1 and Ulk1 (Pickford et al., 2008; Tian et al., 2011).
Accumulation of autophagic vesicles with loss of cathepsins (hydrolases) has
also been previously reported. (Felbor et al., 2002; Koike et al., 2000; Koike et
al., 2005). Besides autophagy, the UPS also showed a significant contribution
towards the degradation of GFP-Aβ42 especially during the active growth
phase. Interestingly, autophagy was shown to partially compensate for Aβ
clearance during the growth phase in the proteasomal mutant (pre1-2Δ) lacking
chymotrypsin activity (Chapter 8). This indicates that Aβ accumulation in AD
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brain may be a collective contribution of aberrant degradation mechanisms. The
findings presented in the work showed that both autophagy and the proteasome
are actively involved in regulating the levels of Aβ42 aggregates and disruption
of these functions leads to increased Aβ42 accumulation in the cell. The study
of these pathways in yeast as presented in this thesis has provided evidence for
the use of this in vitro model to screen compounds which can reduce
intracellular accumulation of Aβ.

10.2.3

Stimulating Autophagy and a novel mechanism of action for

Latrepirdine in Enhancing Aβ42 Clearance

Although less potent compared to the known autophagy activator rapamycin,
the findings presented in this thesis have provided, for the first time, a novel
mechanism of action for latrepirdine on enhancing autophagy and promoting the
clearance of GFP-Aβ42 in yeast cells. Notably, rapamycin mediated reduction
of GFP-Aβ42 levels was associated with pleotropic effects including inhibition of
protein synthesis in cells (Heitman et al., 1991). In contrast, latrepirdine did not
show such effects and was found to be dependent on the activity of the Atg8
gene, which is essential in the formation of autophagosomes which is a critical
step prior to the fusion with the vacuole to release its contents for degradation.
The ability of latrepirdine to stimulate autophagy in yeast model can be used to
develop analogues with increased potency and lesser toxicity. Besides its ability
to modulate autophagy, in vivo studies showed that latrepirdine can promote
peripheral Aβ42 clearance and also increase its uptake into liver. Overall the
data showed that latrepirdine may operate via multiple mechanisms both
indirectly (via stimulation of intracellular degradation pathways) and directly
(transport and clearance in the periphery) to promote Aβ clearance. It is also
possible that latrepirdine modulates Aβ structure and aggregation to promote
these effects. Further investigation is required to determine how these
mechanisms explain the overall effects of latrepirdine on cognitive and memory
function.
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10.3

Future Directions

The work presented in this thesis has provided evidence for the use of yeast
in studying pathological mechanisms underlying Aβ toxicity and clearance and
its utilization as a model to screen novel agents which can attenuate toxicity or
enhance Aβ clearance. One direction for future research is to identify pathways
and putative receptors involved in Aβ42 mediated cell proliferation in yeast
cells. The Aβ growth effect can be systematically designed to be tested in a
wide range of selected yeast species with diverse genomic backgrounds to
determine the various pathways and associated receptor protein complexes
involved with this action of A. Another important course for future research is
to establish a mutation screen in yeast for dissecting the various autophagic
genes involved in degradation of intracellular Aβ42. More than 30 ATG
(autophagy related) genes have been identified in yeast. Expression of GFPAβ42 in each of the 30 ATG gene deletion mutants followed by quantitative Aβ
immunoblotting assays and localization analysis can be done to identify the
mechanism and the genes directly involved in the degradation process of Aβ
aggregates. A similar screen can be used for identifying the mechanism of
latrepirdine induced autophagy and Aβ clearance. It will also be useful to
determine the global effects of latrepirdine in cells using DNA microarray
analysis to assess the possible influence of other non-autophagic genes and
regulatory proteins in the modulation of degradation pathways. However, it is
important to demonstrate that the findings in yeast are replicated in neuronal
cells.
10.4

Conclusion

This study has established and broadened the application of yeast models
for investigating toxicity and intracellular clearance mechanisms of Aβ. Using
the yeast model for oligomer Aβ toxicity, this work has identified protective
functions for dairy derived peptides and established recombinant MBP-Aβ
fusion proteins as a model for studying Aβ oligomers. Furthermore using the
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GFP-Aβ expressing yeast, the degradation pathways involved in clearance of
Aβ aggregates was investigated and a novel mechanism identified for a drug
currently in clinical trials, latrepirdine, in enhancing autophagy and promoting
clearance of intracellular Aβ.
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